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 ß-Keto- and ß-hydroxy-α,α-difluorosulfonamides are both underexplored classes of 
molecules. There is only one report of each class of molecules in the literature, however very 
similar molecules are well known and are biologically active therefore we expect ß-Keto- and ß-
hydroxy-α,α-difluorosulfonamides to be useful inhibitors of enzymes, especially proteases.  
 We have developed an efficient synthesis of ß-hydroxy-α,α-difluorosulfonamides via 
electrophilic fluorination of ß-ketosulfonamides which are derived from the reaction of N-
protected α-amino acid methyl esters and methanesulfonamide carbanions. Both steps proceed in 
high yield without epimerization. Several protecting groups were investigated for the 
sulfonamide nitrogen and both dimethoxybenzyl and diphenylmethyl groups could be removed 
cleanly under mild conditions.  
 A new synthesis of difluoromethanesulfonamides has been developed which does not 
rely on expensive ozone depleting reagents. An investigation of difluoromethanesulfonamide 
carbanions revealed a dramatic dependence of stability on the cation with potassium and sodium 
salts being more stable than lithium. Difluoromethanesulfonamide carbanions reacted with 
aldehydes and ketones to give ß-hydroxy-α,α-difluorosulfonamides. Yields were high with 
nonenolizable substrates and lower with enolizable carbonyls. Excellent yields were obtained 
using 9-phenyl-9-fluorenyl protected α-amino aldehydes and, by using doubly protected N-
benzyl-N-9-phenyl-9-fluorenyl-α-aminoaldehydes, excellent dr could be obtained. The reaction 
was extremely rapid and was complete within a few minutes, even at -128 °C. 
 The above synthesis required the use of the 9-phenyl-9-fluorenyl protecting group. 
However, we found that literature methods for the introduction of this group were unsatisfactory 





using a combination of phenylfluorenyl chloride, silver nitrate, and N-methylmorpholine which 
gave excellent yields of protected amines within 1 hour. By using TMS protecting groups the 
reaction could be extended to free amino acids. This approach also gave high yields rapidly with 
alcohols and carboxylic acids. Meanwhile thiols, sulfonamides, and amides reacted better with a 
mixture of 9-phenyl-9-fluorenyl alcohol and BF3·Et2O.  
 The IgA1 protease is an important virulence factor which contributes to diseases caused 
by a diverse group of bacteria. We investigated the synthesis of a series of chromogenic 
substrates that may be used to assay this enzyme and are derived from its natural substrate. We 
also investigated a series of peptidomimetics bearing C-terminal ß-keto- and ß-hydroxy-α,α-
difluorosulfonamides, trifluoromethyl ketones and alcohols, and boronic acids, which we expect 
to be inhibitors of the enzyme. These inhibitors may lead to new to antivirulence therapies for 
the global fight against antibiotic resistance.  
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Chapter 1 — Synthesis of ß-keto-α,α-difluorosulfonamides.  
1.1 — Introduction  
1.1.1 — ß-Keto-α,α-difluorosulfonamides: an underexplored class of molecules  
 Sulfa drugs, introduced in the 1930’s, were the first major class of antibiotics used 
clinically and were also the first major class of drugs bearing a sulfonamide group.1 Since then, 
many compounds containing the sulfonamide group have been developed into clinically useful 
drugs to treat a variety of medical conditions such as bacterial and viral infections, cancer, 
glaucoma, inflammation and dandruff. These have been reviewed by Supuran et al. in 2003 and 
2013 and by Gulçin and Taslimi in 2018.2-5 The sulfonamide group is one of the most important 
pharmacophores in medicinal chemistry. There were 72 FDA-approved drugs bearing the 
sulfonamide group as of 2018.6 The majority of these molecules were aryl sulfonamides; 
however, a few have been alkyl sulfonamides. For example, sumatriptan and naratriptan are used 
to treat migraines while the methane sulfonamides: dofetilide, ibutilide, and sotalol are all used 
as anti-arrhythmia agents.3  
 Of the approved sulfonamides, 12 contain one or more fluorine atoms but none of these 
are α to the sulfonamide moiety.6 Nevertheless, sulfonamides bearing α-fluorines are known in 
the literature and many are biologically active (Figure 1.1). Examples include inhibitors of 
Clostridium histolyticum collagenase (ChC),7 matrix metaloproteases (MMP),8 steroid sulfatase 





fluorosulfonamides have herbicidal properties and the commercially available herbicide 
pyrimisulfan contains a difluoromethane sulfonamide moiety.13,14 The N-H of primary 
sulfonamides become approximately 1.5 pKa units more acidic with for each fluorine atom α-to 
the sulfonamide and a coincident increase in lipophilicity is observed.15 This can have a 
profound impact on bioavailability and interactions with enzymes. The CF2 moiety can also be 
viewed as a non-hydrolysable replacement for an oxygen atom with similar electronic 
properties.16  
 
Figure 1.1. Structures of selected biologically active α-difluorosulfonamides. 
 
There has been very little work done on ß-keto-α,α-difluorosulfonamides. Indeed, we are 
aware of only one report describing the synthesis of these molecules. This was the synthesis of 
sulfonamide 1.5 (Figure 1.2) by Vannada et al. in 2006 which is discussed below.17 On the other 
hand, other closely related ß-keto-α-fluoro compounds are well represented in the literature, and 






Figure 1.2. Structure of ß-keto-α,α-difluorosulfonamide prepared by Vannada et al. 
 
1.1.2 — α-Fluorocarbonyls as enzyme inhibitors  
 Carbonyl compounds bearing one, two, or three fluorine atoms adjacent to the carbonyl 
are known to be inhibitors of serine hydrolases. This is due in part to the tendency of these 
carbonyls to exist in a tetrahedral state. The tetrahedral state mimics the tetrahedral intermediate 
of amide hydrolysis this may be a hydrate or a hemiketal that is covalently bonded to the active 
site serine (Figure 1.3a). Some of the earliest examples of this are inhibitors of acetyl 
cholinesterase, which catalyzes the hydrolysis of the ester acetylcholine to acetate and choline 
(Figure 1.3b).18,19  However, when the α-fluorocarbonyl 1.6 encounters the enzyme, hemiketal 
1.7 is formed which is stabilized by the fluorine atoms and the reaction cannot proceed forward 
due to the lack of a suitable leaving group (Figure 1.3c).18 Since this report, there have been 
many investigations into the use of fluorinated carbonyls as inhibitors of serine proteases and 
esterases, and while the specific structure will vary depending on the enzyme in question, the 






Figure 1.3. α-Fluorocarbonyls are transition state analog inhibitors of serine hydrolases. (a) 
Hydrated ketones resemble the tetrahedral intermediate of peptide hydrolysis; (b) Catalytic 
cycle of acetylcholinesterase; (c) The mechanism of an acetylcholinesterase inhibitor. 
 
 Many other α-fluorocarbonyls are also known enzyme inhibitors including ß-keto-α,α-
difluoro esters,20 and phosphonates.21-25 ß-ester, and ß-amide α,α-difluorosulfonamides have also 
been reported,11,26 as well as biologically active nonfluorinated ß-ketosulfonamides.27 While 
there is only a single report on ß-keto-α,α-difluorosulfonamides, the most closely related class of 
molecules, the ß-keto-α,α-difluoroamides, are well studied. These include a number of 
peptidomimetics that are low or sub nanomolar inhibitors of important enzymes such as the 
aspartyl proteases pepsin19 and renin,28 as well as serine proteases such as chymase29 and elastase 





removal of the fluorines from amides 1.8 and 1.9 results in a 930- and 65-fold loss of potency, 
respectively. 
 
Figure 1.4. ß-Keto-α,α-difluoroamide containing enzyme inhibitors. 
 For the synthesis of ß-keto-α,α-difluorosulfonamide 1.5, Vannada et al. first prepared the 
nonfluorinated ß-ketosulfonamide precursor 1.14 by reacting the dianion of N-Boc-protected 
methane sulfonamide 1.12 with methyl ester 1.13 (Scheme 1.1a).17 The reaction required three 
equiv of base because both the methyl and sulfonamide N-H protons of 1.12 are acidic and the 
product, 1.14, contains an additional acidic methylene proton which is lost to produce an enolate. 
The formation of this enolate prevents double addition. This dianion approach has also been used 
by others to prepare ß-ketosulfonamides.27,31-33 Several other routes to ß-ketosulfonamides are 
also known (Scheme 1b-d). Sulfamyl chlorides, 1.15, when in the presence of a base can react 
with enamines34 or with TMS enol ethers35 to give ß-ketones of type 1.16 after a hydrolytic 
workup (Scheme 1.1b and c). These approaches proceed through the in situ formation of a 
sulfonylimine (1.16) and are, therefore, limited to monoalkyl sulfonamides. ß-ketosulfonamides 





amines. This reaction presumably proceeds through a sulfene intermediate (Scheme 1.1d).36,37 
This approach allows access to tertiary sulfonamides (1.18).  
 
Scheme 1.1. Literature methods for preparing ß-ketosulfonamides. 
 
 To obtain ß-keto-α,α-difluorosulfonamide 1.5, Vannada et al. alkylated 1.14 under 
Mitsunobu conditions to give 1.20 which was subjected to electrophilic fluorination using 
Selectfluor and sodium hydride to give 1.21 (Scheme 1.2).17 It is noteworthy that less than 2 
equiv of base was used in the fluorination step because 1-(chloromethyl)-DABCO is produced as 







Scheme 1.2. Electrophilic fluorination of a ß-ketosulfonamide. 
 Selectfluor is one of many reagents that are available for electrophilic fluorination. The 
simplest reagent for this purpose is molecular fluorine but it is too hazardous and nonselective 
for most applications. All electrophilic fluorination reagents involve a weak fluorine bond, 
usually with nitrogen, but electrophilic fluorinating agents in which the fluorine is bonded to 
oxygen,38 hypervalent iodine,39 or xenon40 are also known. Several groups have sought to 
quantify the fluorinating ability of N-F based electrophilic fluorinating agents.41-43 Selectfluor is 
among the most powerful and practical of these and has been used extensively for the α-
fluorination of carbonyl compounds including ß-ketophosphonates,22-23 ß-ketosulfones,44 ß-
ketoesters,45 ß-ketoamides,45 and 1,3 dicarbonyls.43 Selectfluor also has the advantage of being 
an easily handled non-hygroscopic solid which is relatively inexpensive, and the byproducts 
readily partition into the aqueous layer. 
1.1.3 — Research objective  
 The primary objective of the research described in this chapter is to examine electrophilic 
fluorination as a means to prepare ß-keto-α,α-difluorosulfonamides of type 1.22 (Figure 1.5), 
which are derived from amino acids, with or without alkyl groups on the sulfonamide nitrogen. 





appropriate sulfonamide and Nα protecting groups and optimization of the electrophilic 
fluorination and deprotection conditions. 
 
Figure 1.5. General structure of ß-keto-α,α-difluorosulfonamides derived from amino acids. 
1.2 — Results and Discussion 
 
 Of the methods used to prepare ß-ketosulfonamides that were described in Scheme 1.1, 
the reaction with methyl esters (Scheme 1.1a) is the most appealing because methyl esters of N-
protected amino acids are commercially available. Therefore, we began our studies using this 
approach and using methyl benzoate as a model ester. We were pleased to find that acylation of 
sulfonamide 1.23 with methyl benzoate using 3.1 equiv LDA occurred smoothly to give 1.24 and 
no over acylation at the sulfonamide nitrogen was observed (Scheme 1.3a). Under very similar 
conditions, the dianion derived from sulfonamide 1.25 reacted with Boc-Pro-OMe to give ß-
ketone 1.26 in 66% yield (Scheme 1.3b). However, under the same conditions, methane 
sulfonamide, which contains no N-alkyl groups, did not produce the desired product 1.27 
(Scheme 1.3c). Further difficulties were encountered if the amino acid included a carbamate 
proton. For example, using 3 equiv of the sulfonamide dianion, ß-ketone 1.28 was produced in 
very low yields from the reaction of Boc-homophenylalanine methyl ester and the dianion of 
1.23. Even when the amount of dianion was increased to 4 equiv only a 30% yield was obtained 






Scheme 1.3. Initial investigations on the acylation of methane sulfonamide dianions. 
 
 We anticipated that further difficulties might be encountered upon fluorination of these 
ketones because the sulfonamide nitrogen is prone to fluorination.46 This might yield N-fluoro-ß-
keto-α,α-difluorosulfonamides 1.29 (Scheme 1.4). Such compounds would be expected to have 
high reactivity, similar to the known N-fluoro-trifluoromethane sulfonamides.47 We concluded 
that the sulfonamide nitrogen would need to be fully protected in order to obtain sulfonamides of 






Scheme 1.4. Potential undesired over-fluorination of an unprotected sulfonamide nitrogen. 
 
1.2.1 — Selection of protecting groups 
 N-alkyl sulfonamides have previously been protected using common carbamate type 
protecting groups such as Boc, Cbz, Alloc,48 and Fmoc.49 Bis protection using common 
carbamate type protecting groups has been used occasionally;50-53 however, sulfonamides 
protected in the way are highly labile. For example, both bis(Boc) sulfonamides and bis(Cbz) 
sulfonamides are labile to Mg(ClO4)2 or very low concentrations of TFA,
51 and the bis Boc 
sulfonamides could also be cleaved by amines.52 Furthermore, we suspected that the anions 
derived from N,N-bis(alkoxycarbonyl)methanesulfonamides 1.30 might be prone to ß-
elimination producing sulfene and anion 1.31. For these reasons, we chose not to investigate 
carbamate protecting groups. 
 
Scheme 1.5. E2 elimination of a biscarbamate protected sulfonamide. 
 Several alkyl groups have been used for the bis protection of the sulfonamide nitrogen. 





paramethoxybenzyl (PMB) group which is removed using high concentrations of TFA or by 
oxidation with CAN,10 and the 2,4-dimethoxybenzyl (DMB) group which can be removed with 
lower concentrations of TFA.9  
 Additional alkyl groups used for bis sulfonamide protection include t-butyl,10,54 prenyl,55 
and TMSE56 groups, However, these have drawbacks. The TMSE group is removed by fluoride 
treatment which we expect to be incompatible with our fluorination conditions when TBAF or 
CsF is used as a base (vide infra). Prenyl groups are removed using very high temperatures and 
expensive silver salts, and t-butyl groups are removed under similar conditions to DMB groups, 
but bis-t-butyl is difficult to install. It is noteworthy that N,N-bis(benzyl)sulfonamides are readily 
prepared, but the benzyl group cannot be removed by the usual methods of hydrogenolysis or 
strong acids.10  
 The diphenylmethyl (DPM) group has also been used for sulfonamide protection and is 
removed by hydrogenolysis.31 To the best of our knowledge this group has only been used for 
mono protection, possibly because N,N-bis(diphenylmethyl)sulfonamides would be too sterically 
demanding. However, we decided to pursue the DPM group because it is more acid stable than 
the DMB and PMB groups. 
1.2.2 — Preparation of methane sulfonamides 
 The first step was to prepare the N,N-dialkyl methanesulfonamides, which was 
accomplished in two ways. N-alkyl methane sulfonamides were prepared by allylation of the 
commercially available N-methyl or N-ethyl methanesulfonamides using allyl bromide to give 
1.32 and 1.33 (Scheme 1.6). Sulfonamides 1.32 and 1.33 were prepared by Professor Scott 






Scheme 1.6. Allyl protection of N-alkyl methane sulfonamides. 
 
 In the other approach, methanesulfonamides 1.34-1.39 were prepared by mesylation of 
the appropriate amine (Table 1.1). The yields were generally high and sulfonamides 1.33, 1.34, 
and 1.35 were purified by distillation, while 1.37, 1.38, and 1.39 were purified by crystallization, 
and sulfonamides 1.32 and 1.36 by chromatography. This provided us with methanesulfonamides 
which could be deprotected under reductive, oxidative, acidic, or palladium-catalyzed conditions.  
Table 1.1. Preparation of methane sulfonamides by mesylation of amines. 
 
Entry R1 R2 Solvent Temperature Time Product Yield (%) 
1 Et Et THF 66 °C 2 h 1.34 89 
2 Allyl Allyl THF 66 °C 2 h 1.35 90 
3 DMB DMB THF 66 °C 2 h 1.36 81 
4 PMB PMB DCM 0 °C 16 h 1.37 75 
5 Ph2CH H THF -20 ° to rt 16 h 1.38 92 
6 -(CH2)4- DCM 0 °C 16 h 1.39 63 
 
1.2.3 — Preparation of ß-ketosulfonamides derived from methyl benzoate 
 We selected methyl benzoate as a model ester since this molecule is inexpensive and non-
enolizable. The reaction was performed by first generating the carbanion of sulfonamide 1.33-
1.37 using n-BuLi at low temperatures followed by addition of methyl benzoate (Scheme 1.7). 





the product ß-ketone are acidic. With the exception of 1.43, the reaction proceeded in high yield; 
however, the methanesulfonamide starting materials were often difficult to separate from the 
product which made the preparation of these ketones on a multigram scale labor intensive.  
 
Scheme 1.7. Acylation of methane sulfonamides using methyl benzoate. 
 
 Theoretically, it should be possible to use equimolar quantities of the 
methanesulfonamides and methyl benzoate while using a two-fold excess of the base. 
Unfortunately, these attempts were not successful using n-BuLi or LDA.  
 We were surprised to find that the reaction was unsuccessful using the DMB-protected 
1.36. We initially suspected that the desired anion was not being formed on treatment with n-
BuLi. We performed a control experiment in which the sulfonamide was treated with n-BuLi for 
30 min at -78 °C and then quenched with D2O (Figure 1.6). Complete deuterium exchange was 
observed as determined by examination of the 1H NMR of the crude reaction mixture; the singlet 







Figure 1.6. Deuterium exchange experiment with sulfonamide 1.36.  (a) 1H NMR spectrum of 
1.36; (b) 1H NMR spectrum of the crude product. The peak at 2.7 ppm corresponds to the SCH3 
or SCH2D group which undergoes partial deuterium exchange. The peak at 4.35 ppm 
corresponds to the four benzylic protons. 
 
 The acylation of 1.36 was successful using the Weinreb amide of benzoic acid as shown 
in Scheme 1.8, where ketone 1.43 was obtained in 66% yield. It is unclear what role the amide 
plays in the reaction which makes it a more suitable substrate than an ester. 
 






1.2.4 — Preparation of ß-ketosulfonamides derived from amino acids 
 Next, we turned our attention to ß-ketosulfonamides derived from amino acids. We 
selected the allyl-protected 1.33 as our model sulfonamide and chose a selection of amino acid 
methyl esters protected with either Boc or Cbz groups. We employed the same conditions as 
those used in Scheme 1.7 except an extra equivalent of the sulfonamide carbanion was required 
for substrates with an acidic carbamate proton (Table 1.2). The ketones in Table 1.2 were 
prepared in collaboration with Edmond Chiu and Professor Scott Taylor.  
Table 1.2. ß-Ketosulfonamides from N-protected α-amino acids methyl esters. 
 
Entry Sulfonamide R Amino acid ester Product Yield (%) er 
1 1.33 Me Boc-Val-OMe 1.45 97 >99:1 
2 1.33 Me Boc-Phe-OMe 1.46 93 ND 
3 1.33 Me Boc-Ala-OMe 1.47 84 >99:1 
4 1.33 Me Boc-Met-OMe 1.48 74 96:4 
5 1.33 Me Cbz-Val-OMe 1.49 65 >99:1 
6 1.33 Me Cbz-Ile-OMe 1.50 71 ND 
7 1.33 Me Cbz-Leu-OMe 1.51 83 ND 
8 1.33 Me Cbz-Tyr(tBu)-OMe 1.52 68 ND 
9a 1.33 Me Boc-Pro-OMe 1.53 95 ND 
10 1.32 Et Boc-hPhe-OMe 1.54 92 >99:1 
a2 equiv of BuLi and 2 equiv of 1.33 were used. 
 
  ß-Keto-sulfonamides 1.45-1.54 were obtained in good to excellent yields. For 1.45, 1.47, 
1.48, 1.49, and 1.54 the enantiomeric ratio (er) was determined by preparing their enantiomers 
using the D-amino acid esters. The enantiomers were separable by chiral HPLC and in most 





was detected. The ee determinations were performed by Ryan Chung and Professor Jason E. 
Hein at the University of British Colombia.  
 Next, we examined DMB-protected methanesulfonamide 1.36 as a substrate for the 
reaction with amino acids. Unfortunately, 1.36 did not react with the methyl ester of Boc alanine 
but did react with the analogous Weinreb amide 1.55 (Table 1.3). It is well known that Weinreb 
amides react with carbon nucleophiles to give ketones because the tetrahedral intermediate does 
not break down at low temperatures.57 In principle, the reaction should proceed to completion 
using 2 equiv of sulfonamide and n-BuLi (entry 2) or using 1 equiv of sulfonamide and 2 equiv 
of LDA (entry 6). To our surprise, three equiv of 1.36 and n-BuLi were required for full 
conversion to ketone 1.56 by TLC (entry 3) suggesting that, under these conditions, the 
tetrahedral intermediate is not well stabilized and decomposes to give 1.56. Equimolar amounts 
of 1.36 and 1.55 with 3 equiv of LDA also gave 1.56 in moderate yield (entry 7). It is unclear 
what role the Weinreb amide functional group plays that makes it a more suitable substrate than 





Table 1.3. Optimization of the synthesis of ketone 1.56. 
 
Entry 1.36 (equiv) Base equiv Yield 
1 1.0 n-BuLi 1.0 4%a 
2 2.0 n-BuLi 2.0 47%a 
3 3.0 n-BuLi 3.0 92%a(87%b) 
4 4.0 n-BuLi 4.0 97%a  
5 1.0 LDA 1.0 6%a 
6 1.0 LDA 2.0 18%a 
7 1.0 LDA 3.0 67%a (64%b) 
8 1.0 LDA 4.0 59%a 
a Yield was determined by HPLC. b Isolated Yield 
 
 Boc- and Cbz-protected ketones 1.57 and 1.58 were prepared in good yield from PMB-
protected sulfonamide 1.37 and Boc- or Cbz-protected proline methyl ester (Scheme 1.9). As 
these proline substrates lack a carbamate proton, the reaction required less than three equiv of 
sulfonamide anion. 
 
Scheme 1.9. Preparation of PMB-protected ß-ketosulfonamides derived from proline. 
 
 The DPM-protected sulfonamide 1.38 has an sulfonamide proton and so will react as a 
dianion; therefore, based upon the reactions of mono-alkyl sulfonamides 1.23 and 1.25 (Scheme 
1.3), we expected that good yields would only be achieved with substrates lacking a carbamate 





electrophile (Table 1.4). When we applied our normal conditions (entry 1), none of the desired 
1.59 was isolated. A modest yield was obtained by increasing the relative concentration of the 
electrophile (entry 2) and a slightly better yield was obtained when LDA was used instead of n-
BuLi. In a literature example, sulfonamide 1.38 gave satisfactory results when reacted with a 
Weinreb amide if the anion was generated using n-BuLi-LiCl complex at -40 °C.31 The influence 
of lithium chloride on the outcome of organometallic reactions is well documented, and may be 
related to the ability of LiCl to catalyze degradation of oligomers.58 These conditions improved 
the yield of 1.59 (entry 5). Using LiBr, which is less hydroscopic and more soluble in THF than 
LiCl, resulted in a reduced yield (entry 6). The reaction also proceeded well when anhydrous 
lithium chloride was generated in situ by including an extra equivalent of n-BuLi and anhydrous 
HCl (entry 7). The increase in temperature, from -78 °C to -40 °C, was necessary to prevent 
precipitation of LiCl. It was not necessary to use a Weinreb amide, and proline methyl esters also 
gave 1.59 and 1.60 in satisfactory yields when the reaction was conducted at – 40 °C in the 









Base (equiv) Temp (°C) Additive 
(equiv) 
Electrophile (equiv) Product Yield 
1 2.1 n-BuLi (4.2) -78 - Boc-Pro-OMe (1) 1.59 NDa 
2 1 n-BuLi (2) -78 - Boc-Pro-OMe (1) 1.59 30% 
3 2.1 LDA (4.2) -78 - Boc-Pro-OMe (1) 1.59 40% 
4 1 n-BuLi (2) -100 - Boc-Pro-OMe (1) 1.59 15% 
5 2.5 n-BuLi (5) -40 LiCl (2.5) Boc-Pro-N(Me)OMe (1) 1.59 83% 
6 2.5 n-BuLi (5) -40 LiBr (2.5) Boc-Pro-N(Me)OMe (1) 1.59 36% 
7 2.5 n-BuLi (7.5) -40 HCl (2.5) Boc-Pro-N(Me)OMe (1) 1.59 85% 
8 2.5 n-BuLi (7.5) -40 HCl (2.5) Boc-Pro-OMe (1) 1.59 80% 
9 2.5 n-BuLi (7.5) -40 HCl (2.5) Alloc-Pro-OMe (1) 1.60 66% 
aA complex mixture was obtained. 
 
1.2.5 — Electrophilic fluorination of ß-ketosulfonamides 
 We first attempted a fluorination reaction using the conditions of Vannada et al. (Scheme 
1.2), which involved quantitative generation of an enolate using sodium hydride followed by 
cannulation into a solution of Selectfluor (Scheme 1.10). When we applied these conditions to ß-
ketone 1.45, very little reaction occurred. When the base was increased to 2.6 equiv and 
Selectfluor to 3 equiv, then a 70% yield of monofluorinated 1.61 was obtained but the desired 
1.62 was observed in only trace amounts, even after stirring overnight.  
 
Scheme 1.10. Fluorination of ß-ketone 1.45 according to literature conditions.   
 We did not want to further increase the amount of sodium hydride for fear of epimerizing 






59 Therefore, we examined weaker bases CsF, Cs2CO3, DBU, and 
TBAF, using MeOH, CH3CN, and DMF as solvents and the reactions were evaluated by TLC 
and 19F NMR. Using DBU, the reactions were sluggish and incomplete after 24 h in all cases, 
Cs2CO3 in DMF or CH3CN gave rapid difluorination within 15 min albeit with a significant 
amount of minor unidentified byproducts. Using MeOH as the solvent led to a cleaner reaction 
with Cs2CO3 within 1 h, while using TBAF or CsF in DMF even fewer side products; however, 
to drive the reaction to completion four equiv of Selectfluor and base were required. Isolated 
yields of 1.62 were 84% using CsF and 78% using TBAF (Table 1.5). These conditions were 
applied to several other ß-ketones and the difluorinated products were obtained in reasonable to 
excellent yield with the exception of methionine derivitive 1.65. The sulfide moiety of 1.65 
would be expected to react with Selectfluor giving α-fluorination through the intermediacy of a 
fluorosulfonium ion.60,61 Similar yields were obtained using either CsF or TBAF (compare entries 
1 and 2 and entries 15 and 16). Secondary sulfonamides were also tolerated, although with DPM 
the yields were lower (entries 15 to 18). None of the N-Fluorinated products of type 1.29 were 
observed from these reactions, either because it does not occur or because the nitrogen fluorine 
bond is hydrolyzed on workup.  
 The er values of 1.62 and 1.66 were determined by preparing the enantiomers of these 
amino acid derivitives, which were separable by chiral HPLC and the undesired isomer was not 
detected. The compounds in Table 1.5 were prepared in collaboration with Edmond Chiu and 
Professor Scott Taylor and the enantiomers were separated by chiral HPLC by Ryan Chung and 





Table 1.5. Fluorination of ß-ketosulfonamides using Selectfluor and fluoride bases. 
 
 
Entry Substrate Pg R1 R2 Amino acid side chain Base Product Yield er 
1 1.45 Boc Me Allyl Val CsF 1.62 84% >99:1 
2 1.45 Boc Me Allyl Val TBAF 1.62 78%  
3 1.46 Boc Me Allyl Phe CsF 1.63 84%  
4 1.47 Boc Me Allyl Ala CsF 1.64 76%  
5 1.48 Boc Me Allyl Met CsF 1.65 0  
6 1.49 Cbz Me Allyl Val CsF 1.66 93% >99:1 
7 1.50 Cbz Me Allyl Ile CsF 1.67 90%  
8 1.51 Cbz Me Allyl Leu CsF 1.68 82%  
9 1.52 Cbz Me Allyl Tyr(OtBu) CsF 1.69 74%  
10 1.53 Boc Me Allyl Pro CsF 1.70 69%  
11 1.54 Boc Et Allyl hPhe CsF 1.71 85%  
12 1.56 Boc DMB DMB Ala TBAF 1.72 64%  
13 1.57 Boc PMB PMB Pro CsF 1.73 87%  
14 1.58 Cbz PMB PMB Pro CsF 1.74 89%  
15 1.28 Boc Et H hPhe CsF 1.75 68%  
16 1.28 Boc Et H hPhe TBAF 1.75 74%  
17 1.59 Boc DPM H Pro TBAF 1.76 50%  
18 1.60 Alloc DPM H Pro CsF 1.77 47%  
 
 In some cases side reactions occurred which ultimately led to oxidation of the α-amino 
ketones to fluorinated 1,2-iminoketones.61 This occurred in some cases if Cs2CO3 was used as 
the base as shown in Scheme 1.11. The most likely mechanism involves difluorination of the 
methylene group which increases the acidity of the α-proton. Enolization at the α-carbon by 
Cs2CO3 leads to fluorination at the α-position. Finally, an E2 elimination by deprotonation of the 
amine yields the imine. It is also possible that fluorination occur at the amino acid nitrogen 
followed be loss of the α proton and ß-elimination. This occurred with 1.46, 1.47, and 1.54 





1.50, or 1.51 where the side chain side chain was derived from Val, Ile and Leu, presumably 
because the α-carbon of the latter amino acid derivitives is more hindered and does not quickly 
react with Selectfluor. Ketones 1.78-1.80 all existed in the hydrated state (as determined by 
13C{1H} NMR ) even in CDCl3. In contrast to 1.62-1.77 which all existed as ketones. The 
compounds in Scheme 1.11 were prepared by Professor Scott Taylor. 
 
Scheme 1.11. Fluorination in the in the presence of Cs2CO3 leading to oxidation. 
 When we attempted the fluorination of 1.42 we found that the conditions used in Table 
1.5 gave incomplete fluorination and a lower yield of 1.81 (Table 1.6, entry 1). We screened 
several bases and solvents, and the highest yield was achieved by using 4 equivalent each of 
TBAF and Selectfluor in DMF and by reducing the temperature to -10 °C (entry 15). This 
resulted in complete conversion to the difluorinated ketone with no side products detectable in 
the 19F NMR of the crude reaction mixture. The reaction should require just 2 equiv of 
Selectfluor and base, unfortunately, lower yields were obtained with less than 4 equiv (entries 13 





Table 1.6. Optimization of the fluorination conditions for 1.42. 
 
Entry Base (equiv) Selectfluor equiv Solvent Temp Time Yield(%)a 
1 CsF (4) 4 DMF rt 3 h 57b,c 
2 TBAF (4) 4 DMF rt 1 h 70 
3 TBAF (4) 4 MeOH rt 6 h 11 
4 Cs2CO3 (4) 4 MeOH rt 6 h 50 
6 NaOMe (4) 4 MeOH rt 6 h 10 
7 TBAF (4) 4 CH3CN rt 8 h 46 
8 TBAF(4) 4 Dioxane rt 8 h 0 
9 TBAF (4) 4 Water rt 8 h 0 
10 TBAF (4) 4 THF rt 8 h 0d 
11 TBAF (4) 4 DMSO rt 8 h 0d 
12 TBAF (4) 4 DMF 60 °C 1 h 40 
13 TBAF (2) 2 DMF -10 °C 2 h 50c 
14 TBAF (3) 3 DMF -10 °C 2 h 80c 
15 TBAF (4) 4 DMF -10 °C 2 h 100 
(88c) 
a
Yield determined by 1H NMR using a 3-fluorotoluene internal standard.  
b27% of monofluorinated material was also isolated.  
cIsolated Yield.  
dSome monofluorinated product was obtained. 
 
 The optimized conditions were also applicable to the other benzoyl methanesulfonamides 
(Scheme 1.12), although the yields were somewhat lower. Unlike most of the ß-keto-α,α-
difluoromethanesulfonamides, DMB protected sulfonamide 1.83 appeared to form a hemiketal in 
methanol which was observed as a set of AB doublets in fluorine NMR. This persisted after 
being concentrated by rotary evaporation and redissolved in CDCl3 twice, but was completely 






Scheme 1.12. Fluorination of ß-ketosulfonamides derived from methyl benzoate. 
 
1.2.6 — Sulfonamide deprotection 
 With the protected ß-ketosulfonamides in hand we set about investigating the conditions 
for deprotection. All the protecting groups that we have employed here have been used 
previously for sulfonamide protection, but none specifically for protection of ß-keto-α,α-
difluorosulfonamides. 
 Deallylation of sulfonamides 1.62, and 1.63 could be achieved using Pd(PPh3)4 and 
DMBA to give the secondary sulfonamides of 1.85 and 1.86. Although the yields were good, the 
reaction required 24 h at 100 °C. This led to significant epimerization and the er of 1.85 was only 
3:2 (Scheme 1.13). Once again this was determined by comparing the chiral HPLC trace of 1.85 
and its enantiomer. Other deallylation methods for sulfonamides are known which proceed at 
room temperature. One approach uses DIBAL in the presence of a nickel catalyst, however this 
would also reduce the ketone group.62,63 A metal-free method using ultraviolet light has been 
reported, but this can also cleave nitrogen sulfur bonds.64 We did not pursue these methods. The 
separation of enantiomers was performed by Ryan Chung and Professor Jason E. Hein at the 








Scheme 1.13. Deprotection of allyl protected sulfonamides. 
 
 Removal of the diphenylmethyl group in 1.59 and 1.76 was accomplished via 
hydrogenation with Pearlman’s catalyst and Hünig’s base in ethanol-THF (Scheme 1.14).31 The 
DPM group in 1.59 was removed more slowly than 1.76, and after 36 h 60% of 1.27 was isolated 
and 14% of 1.59 was recovered.  
 
Scheme 1.14. Hydrogenolysis of diphenylmethane protecting groups. 
 
 PMB groups are typically removed from sulfonamides using TFA; however, Blackburn 
observed that TFA-mediated PMB deprotection of sulfonamides was slower and lower yielding 
when one or two fluorines were added to the α-position.10 This is due to the low basicity of the 
sulfonamide nitrogen, and we expect the situation to be even worse with ß-keto-α,α-
difluoromethanesulfonamides due to the additional electron withdrawing ketone moiety. The 
same study also used CAN for PMB deprotection. When we employed this reagent for the 
deprotection of sulfonamide 1.74 a number of unidentified side products were observed and the 





due to the presence of the ketone since these deprotection conditions were effective on the ß-
hydroxy-α,α-difluoromethanesulfonamides discussed in Chapter 2.  
 
Scheme 1.15. Oxidative deprotection of sulfonamide 1.74. 
 DMB protecting groups have previously been removed in good yield from α-fluorinated 
sulfonamides using TFA.9 These conditions were also effective for sulfonamide 1.83 giving 
benzoyl difluoromethanesulfonamide 1.89 in 79% yield (Scheme 1.16). 
 
Scheme 1.16. Acid-mediated deprotection of a DMB protected sulfonamide. 
1.3 — Conclusions and future studies 
 In the project described in this chapter, a series of ß-keto-α,α-difluorosulfonamides were 
prepared by the reaction of the lithiated methane sulfonamide with the methyl ester of an amino 
acid or methyl benzoate. The previously reported literature protocol for this transformation 
employed the dianion of N-alkyl methane sulfonamides, however, this reaction gives poor results 
with amino acid methyl esters that contain a carbamate proton. We have shown that the 
monoanion of N,N-dialkyl methanesulfonamides is effective with these methyl esters giving our 
method a superior substrate scope over the literature method.  
 We prepared ß-ketosulfonamides containing a variety of N-alkyl groups including allyl, 
ethyl, PMB, DMB and DPM groups. The reaction with methyl esters proceeded smoothly with 





DPM protected 1.38. These were overcome by reacting 1.36 with Weinreb amides rather than 
methyl esters (Table 1.3). It remains unclear what role the Weinreb amide plays in this reaction 
that makes it a more suitable substrate. To shed light on this reaction it may be useful to 
investigate the acylation of 1.36 with other ester derivatives such as anhydrides, acyl chlorides, 
or Pfp esters.  
 The DPM protected 1.38 reacts as a dianion; therefore, we only investigated the reaction 
of this compound with proline derivatives since these lack a carbamate proton. Still, difficulties 
were encountered (Table 1.4), and this reaction only gave satisfactory yields with methyl esters 
in the presence of lithium chloride. Again, it may be useful to employ more powerful acylating 
agents such as anhydrides, acyl chlorides, or Pfp esters to expand the substrate scope using this 
protecting group which may allow amino acids other than proline to be employed. 
 Conditions for electrophilic fluorination were optimized which avoid over fluorination or 
oxidation at the amino acid α-carbon. These conditions were effective using N,N-dialkyl 
sulfonamides, as well as the mono N-alkyl sulfonamides 1.28, 1.59, and 1.60 which reacted 
smoothly without noticeable nitrogen fluorination. It may be interesting to investigate these 
conditions using primary sulfonamides, such as 1.87, which may or may not undergo nitrogen 
fluorination. The fluorination failed using a methionine derivative, presumably due to the 
reaction between the sulfide moiety and Selectfluor. It should be possible to carry out this 
transformation by first protecting the sulfide as a sulfoxide, however this was not attempted.  
 Deprotection of the ß-keto-α,α-difluorosulfonamides was investigated with all four 
protecting groups. Difficulties were encountered with PMB deprotection and unknown side 
reactions occurred. DMB and DPM groups were both removed cleanly by treatment with acid or 





studies with these ß-ketones should focus on these protecting groups. This underscores the 
potential value in investigating more powerful acylating agents in order to broaden the substrate 
scope.  
 Allyl deprotection could be achieved by a Tsuji–Trost reaction using a palladium catalyst 
and DMBA as an allyl scavenger. However, the reaction required elevated temperatures and 
resulted in some degree of epimerization. Recently, Panigrahi et al., have published the 
deprotection of allyl groups from α-difluoro phosphonates under extremely mild conditions using 
ruthenium catalyst 1.90 (Scheme 1.17).65 If these conditions are also effective for the 
deprotection of ß-keto-α,α-difluorosuolfonamides, then the allyl group would be superior to 
DMB and DPM in terms of atom economy and ease of removal. 
 
Scheme 1.17. Mild ruthenium catalyzed Deallylation by the Berkowitz group. 
1.4 — Experimental  
1.4.1 — General experimental 
 All reagents and solvents were purchased from commercial suppliers and used without 
purification unless stated otherwise.  
 DMF was distilled from CaH2 under reduced pressure and stored over activated 4 Å 
molecular sieves. THF was distilled from sodium metal in the presence of benzophenone under 
nitrogen. Acetonitrile was distilled from CaH2 under nitrogen. Diisopropylamine was distilled 





sieves. All 13C{1H} NMR spectra were proton decoupled. Chemical shifts (δ) for 1H NMR 
spectra run in CDCl3 are reported in ppm relative to the standard tetramethylsilane (TMS). 
Chemical shifts for 13C{1H} NMR spectra run in CDCl3 are reported in ppm relative to the 
solvent residual carbon (δ 77.0 for central peak). Chemical shifts (δ) for 19F NMR spectra run in 
CDCl3 or DMSO-d6 are reported in ppm relative to CFCl3 (δ 0.0, external standard). Chemical 
shifts (δ) for 1H NMR spectra run in or DMSO-d6/D2O mixtures are reported in ppm relative to 
DMSO residual solvent protons (δ 2.5). Chemical shifts for 13C{1H} NMR spectra run in 
DMSO-d6 or DMSO-d6/D2O mixtures are reported in ppm relative to the solvent residual carbon 
(δ 39.5). The samples for high-resolution positive ion electrospray ionization mass spectrometry 
(HRMS-ESI+) (ion trap) were prepared in 1:1 MeOH/ H2O + 0.2% formic acid. 
 Chiral HPLC analyses were performed using a Chiralpak AS-RH column (250 × 4.6 mm) 
with CH3CN/0.1% TFA in H2O as eluent. 
 Methyl esters of the protected amino acids were either purchased or prepared via reaction 
of the corresponding Boc or Cbz protected amino acids with SOCl2 in dry MeOH.
66 Weinreb 
amides were prepared by coupling the corresponding carboxylic acid with N,O-
dimethoxyhydroxylamine according to standard procedures.57 Bis(2,4-dimthoxybenzyl)amine 
was prepared according to the method of Reuillon.67 
 Unless otherwise specified all reactions were performed in flasks that were flame dried 





1.4.2 — Experimental procedures for synthesized compounds 
 
 N-Ethyl-2-oxo-2-phenylethane-1-sulfonamide (1.24). Dry diisopropylamine (0.770 mL, 
5.50 mmol, 3.3 equiv) was added to THF (6 mL) then cooled to 0 °C. n-BuLi (1.6 M in hexane, 
3.25 mL, 5.20 mmol, 3.1 equiv) was added and the mixture stirred at 0 °C for 30 min. A solution 
of sulfonamide 1.23 (0.200 g, 1.67 mmol, 1.0 equiv) in THF (6 mL) was added and the mixture 
was stirred for 1 h at 0 °C. A solution of methyl benzoate (0.231 mL, 1.84 mmol, 1.1 equiv) in 
THF (2 mL) was added and the mixture stirred for 1 h at 0 °C. The reaction was quenched with 
sat. aqueous NH4Cl and extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were 
washed with brine, dried (Na2SO4), filtered and concentrated in vacuo to give a pale yellow 
solid. Purification using flash chromatography, 75% EtOAc, 25% hexane, provided ketone 1.24 
as an amorphous white solid (0.340 g, 90% yield). 1H NMR (CDCl3, 300 MHz): δ 7.96 (d, 2H, J 
= 8.3 Hz), 7.62 (t, 1H, J = 6.8 Hz), 7.48 (dd, 2H, J = 7.3 Hz), 4.94 (bt, 1H, J = 5.4 Hz), 4.42 (s, 
2H), 3.27-3.14 (m, 2H), 1.21 (t, 3H, J = 7.8 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 190.2, 
135.6, 134.5, 129.0 (2C), 57.3, 38.8, 15.3; HRMS-ESI+ (m/z) calcd for C10H14NO3S (M + H)
+, 
228.0689; found, 228.0688. 
 
tert-Butyl (S)-2-(2-(N-methylsulfamoyl)acetyl)pyrrolidine-1-carboxylate (1.26). Sulfonamide 
1.25 (240 mg, 2.20 mmol, 2.2 equiv) was dissolved in 10 mL of THF and cooled to –78 °C. n-





for 1 h before adding Boc-Pro-OMe (229 mg, 1.00 mmol, 1 equiv) dissolved in 3 mL of THF 
dropwise. The reaction was stirred for 3 h before quenching with 10 mL of sat. NH4Cl. The 
mixture was extracted three times with 10 mL of DCM and the combined organic layers were 
dried over MgSO4, filtered, and concentrated. The residue was purified by flash chromatography 
with 60% EtOAc in hexanes to give 1.26 as a yellow oil, 202 mg (66%). 1H NMR (CDCl3, 300 
MHz)(3:7 mixture of rotamers): δ 5.69 (m, 0.7H), 5.02 (m, 0.73), 4.58 (m, 0.7H), 4.26 (d, 1H, J 
= 14.3 Hz), 4.07 (m, 1.3H), 3.44 (m, 2H), 2.77 (d, 0.9H, J = 5.1 Hz), 2.73 (d, 2.1H, J = 5.1 Hz), 
2.00 (m, 4H), 1.39 (s, 6.3H), 1.36 (s, 2.7H); 13C{1H} NMR (CDCl3, 75 MHz, 55 °C): δ 199.9, 
154.8, 80.6, 64.8, 58.1, 53.3, 47.0, 29.4, 28.3, 24.2; HRMS-ESI+ (m/z) calcd for 
C12H22N2NaO5S
+ (M + Na)+ 329.1142, found 329.1154.  
 
tert-Butyl (S)-(1-(N-ethylsulfamoyl)-2-oxo-5-phenylpentan-3-yl)carbamate (1.28). Diisopropyl 
amine (0.682 mL, 4.90 mmol, 9.8 equiv) was dissolved in 5 mL of THF. The mixture was cooled 
to -78 °C and then n-BuLi (1.6 M in hexane, 2.78 mL, 4.45 mmol, 8.9 equiv) was added. After 
being stirred for 10 min at 0 °C, this solution was cooled to -78 °C and sulfonamide 1.23 (0.198 
mL, 2.10 mmol, 4.2 equiv) in dry THF (4 ml) was added over a period of 10 min. The reaction 
mixture was allowed to warm -30 °C over a period of 45 min and was then cooled to -78 °C and 
Boc-hPhe-OMe (0.146 g, 0.500 mmol) in dry THF (4 mL) was added. The solution was allowed 
to warm to rt and followed by TLC. After 8 h the mixture was cooled to 0 °C and quenched with 
sat. aqueous NH4Cl. The mixture was extracted with ether (3 x 20 mL). The combined organic 





give a yellow oil. Purification using flash chromatography (30% EtOAc, 70% hexane) provided 
ketone 1.28 as an amorphous white solid (0.057 g, 30% yield). 1H NMR (CDCl3, 300 MHz): δ 
7.29-7.08 (m, 5H), 5.22 (bt, 1H), 5.13 (d, 1H, J = 7.1 Hz), 4.43-4.31 (m, 1H), 4.28 (d, 1H, J = 
14.4 Hz), 4.01 (d, 1H, J = 14.4 Hz), 3.11 (overlapping dq, 2H, J = 6.8 Hz), 2.65 (m, 2H), 2.25-
2.10 (m, 1H), 1.88-1.71 (m, 1H), 1.44 (s, 9H), 1.18 (t, 3H, J = 7.1 Hz); 13C{1H} NMR (CDCl3, 
75 MHz): δ 200.1, 155.9, 140.2, 128.6, 128.4, 126.4, 80.8, 59.6, 58.2, 38.7, 31.8, 31.6, 28.3, 
15.2; HRMS-ESI+ (m/z) calcd for C18H32N3O5S (M + NH4)
+, 402.2057; found, 402.2051. 
 
N-Allyl-N-ethylmethanesulfonamide (1.32). To a solution of sulfonamide 1.23 (1.00 g, 9.16 
mmol, 1 equiv) in dry acetone (10 mL) allyl bromide (0.79 mL, 9.16 mmol, 1 equiv) and 
anhydrous K2CO3 (2.53 g, 18.3 mmol, 2 equiv) were added and the mixture stirred for 24 h then 
another 0.25 equiv of ally bromide was added and the mixture stirred for an additional 6 h. 50 
mL of water was added and the solution extracted with 50 mL of DCM 3 times. The organic 
layer was dried over Na2SO4 and concentrated. Purification by flash chromatography (20% 
EtOAc, 80% hexane) gave sulfonamide 1.32 as a colorless liquid (0.89 g, 60% yield). 1H NMR 
(300 MHz, CDCl3): δ 5.76 (m, 1H), 5.23 (dd, 1H, J = 1.2, 17.1 Hz), 5.18 (dd, 1H, J = 1.2, 11.2 
Hz), 3.77 (d, 2H, J = 6.1 Hz), 3.21 (q, 2 H, J = 7.3 Hz), 2.79 (s, 3H), 1.12 (t, 3H, J = 7.3 Hz); 
13C{1H} NMR (CDCl3, 75 MHz): δ 133.0, 118.9, 49.3, 41.7, 39.3, 13.8; HRMS-ESI
+ (m/z) calcd 
for C6H14NO2S (M + H)
+, 164.0740; found, 164.0740. 
 
N-Allyl-N-methylmethanesulfonamide (1.33). To a solution of sulfonamide 1.25 (10.9 g, 100 





anhydrous K2CO3 (27.6 g, 200 mmol, 1 equiv) were added. The mixture was stirred for 18 h. 
Water was added (100 mL) and the mixture was extracted with Et2O (3 x 150 ml). The organic 
layer was washed with water (3 x 100 mL), brine (1 x 100 ml) then concentrated by rotary 
evaporation. The resulting yellow liquid was purified by vacuum distillation to give sulfonamide 
1.33 as a colorless liquid (13.3 g, 89% yield). Bp. = 67-70 °C (0.30 mm Hg). The 1H NMR 
spectrum was identical to that reported in the literature.68 1H NMR (300 MHz, CDCl3): δ 5.82 
(m, 1H), 5.27 (dd, 1H, J = 1.6, 17.0 Hz), 5.24 (dd, 1H, J = 1.6, 10.1 Hz), 3.72 (d, 2H, J = 6.3 
Hz), 2.79 (s, 3H), 2.67 (s, 3H).  
General procedure 1.1 for the preparation of methane sulfonamides  
 The amine (1 equiv) was dissolved in THF or DCM at a 1 M concentration and cooled to 
0 °C. Triethyl amine (1.1 equiv) was added followed by dropwise addition of methane sulfonyl 
chloride (1.1 equiv) (Caution. Exotherm). When the addition was complete the reaction was 
stirred at room temperature or reflux until complete by TLC and then was diluted with 3 volumes 
of water and extracted three times with 1 volume of DCM. The combined organic layers were 
derived over MgSO4, filtered and concentrated. The residue was purified by vacuum distillation, 
crystallization of flash chromatography as indicated.  
 
N,N-Diethyl methanesulfonamide (1.34). According to general procedure 1.1 using THF as the 
solvent the reaction was complete after 1 hour at reflux. After vacuum distillation 1.34 was 
obtained as a pale yellow oil (bp = 81 °C at 1 mmHg). 26.7 g (89% yield) from 20.5 mL (198 





1.20 (t, 6H, J = 7.1 Hz); 13C{1H} NMR (CDCl3, 75 MHz) σ: 14.8, 39.3, 42.4; HRMS-ESI
+ (m/z) 
calcd for C5H14NO2S (M + H)
+ 152.0740, found 152.0740.  
 
N,N-Diallyl methanesulfonamide (1.35). According to general procedure 1.1 using THF as the 
solvent the reaction was complete after 1 hour at reflux. After vacuum distillation 1.35 was 
obtained as a colourless oil (bp = 102 °C at 0.025 mmHg). 18.0 g (90% yield) from 14.1 mL 
(114 mmol) of diallylamine. 1H NMR (CDCl3, 300 MHz) σ: 5.67 (m, 2H), 5.22 (m, 4H), 3.79 (d, 
4H, J = 6.3 Hz), 2.82 (s, 3H); 13C{1H} NMR (CDCl3, 75 MHz) σ: 40.0, 49.0, 119.3, 132.4; 
HRMS-ESI+ (m/z) calcd for C7H14NO2S
+
 (M + H)
+ 176.0740, found 176.0740.  
 
N,N-Bis(2,4-dimethoxybenzyl) methanesulfonamide (1.36). According to general procedure 1.1 
using THF as the solvent the reaction was complete after 3 h at reflux. After flash 
chromatography, 20 to 60% EtOAc in hexane, 1.36 was obtained as a yellow oil which 
crystalized upon standing for several days. 11.3 g (91%) from 10 g (31.5 mmol) of Bis(2,4-
dimthoxybenzyl)amine. 1H NMR (CDCl3, 300 MHz): σ 7.22 (2H, J = 8.16 Hz), 6.45 (m, 4H), 
4.36 (s, 4H), 3.79 (s, 6H), 3.75(s, 6H), 2.72(s, 3H); 13C{1H} NMR (CDCl3, 7 MHz): σ 39.6, 44.9, 
55.0, 55.3, 98.2, 103.9, 116.8, 130.8, 158.3, 160.4 HRMS-ESI+ (m/z) calcd for C19H26NO6S
+ (M 








N,N-Bis(4-methoxybenzyl) methanesulfonamide (1.37). According to general procedure 1.1 using 
DCM as the solvent the reaction was complete after stirring overnight at 0 °C. After 
recrystallization from 350 mL of hot (5:2) hexane:ethyl acetate 1.37 was obtained as white 
crystals, 23 g (75%), from 22 g (86 mmol) of N,N-bis(4-methoxybenzyl)amine. NMR data for 
this sulfonamide was identical to literature spectra.69 1H NMR (CDCl3, 300 MHz): δ 7.22 (d, 4H, 
J = 8.7 Hz), 6.87 (d, 4H, J = 8.6 Hz), 4.24 (s, 4H), 3.80 (s, 6H), 2.71 (s, 3H); 13C{1H} NMR 
(CDCl3, 75 MHz): δ 159.3, 130.0, 127.4, 114.0, 55.2, 48.9, 40.1; 
 
N-(Diphenylmethyl)methanesulfonamide (1.38). According to general procedure 1.1 using THF 
as the solvent the reaction was complete after stirring overnight at room temperature. After 
recrystallization from 200 mL of heptane, 1.38 was obtained as a white powder, 13.1 g (92%) 
from 10 g of amino diphenylmethane (54.6 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.3 (m, 10H), 
5.75 (d, 1H, J = 7.2 Hz), 5.06 (d, 1H, J = 6.9 Hz), 2.65 (s, 3H); 13C{1H} NMR (SO(CD3)2, 75 
MHz): δ 142.6, 128.8, 127.5, 127.5, 60.7, 41.6; HRMS-ESI- (m/z) calcd for C14H14NO2S
-
 (M - 
H)- 260.0740, found 260.0736. 
 
1-(methylsulfonyl)pyrrolidine (1.39) According to general procedure 1.1 using DCM as the 
solvent the reaction was complete after stirring overnight at 0 °C. After recrystallization by slow 
evaporation of ether 1.39 was obtained as colorless crystals, 9.6 g (63%) from 8.4 mL (105 





General procedure 1.2 For the preparation of benzoyl derivatives 1.40 – 1.44 
 The sulfonamide 1.33 - 1.37 (1.0 equiv) was dissolved in one volume of THF at a 
concentration of 0.3 M and the solution was cooled to -78 °C. n-BuLi (1.1 equiv) was added 
slowly as a 2.5 M solution in hexanes and the reaction was stirred for 15 min before adding 
methyl benzoate (0.5 equiv) neat and dropwise. The reaction was stirred for another 1 hour at -78 
°C before quenching with one volume of saturated aqueous ammonium chloride. The mixture 
was extracted three times with one volume DCM and the combined organic layers were dried 
over MgSO4, filtered, and concentrated. The ß-ketone was separated from the excess methane 
sulfonamide starting material by flash chromatography.  
 
N-Methyl-N-allyl benzoylmethanesulfonamide (1.40). According to general procedure 1.2 after 
flash chromatography, 10 to 30% EtOAc in hexane, 1.40 Was obtained as a colorless oil, 1.43 g 
(77%) from methyl benzoate (1.00 g, 7.3 mmol, 0.5 equiv) and 1.33 (2.34 g, 15.7 mmol, 2.1 
equiv). 1H NMR (CDCl3, 300 MHz): δ 8.03 (d, 2H, J = 8.3 Hz), 7.63 (t, 1H, J = 7.5 Hz), 7.51 (t, 
2H, J = 7.82 Hz), 5.80 (m, 1H), 5.25 (m, 2H), 4.59 (s, 2H), 3.78 (d, 2H, J = 6.4 Hz), 2.87 (s, 
3H); 13C{1H} NMR (CDCl3, 75 MHz): δ 189.5, 135.8, 134.4, 132.6, 129.4, 128.9, 119.1, 57.8, 
53.3, 34.6; HRMS-ESI+ (m/z) calcd for C12H16NO3S
+ (M + H)+ 254.0845 found: 254.0844. 
 
N,N-Diethyl benzoylmethanesulfonamide (1.41). According to general procedure 1.2 after flash 
chromatography, 5% EtOAc in benzene, 1.41 was obtained as a white solid 6.2 g (99% yield) 





1H NMR (CDCl3, 300 MHz): δ 8.03 (d, 2H, J = 8.0 Hz), 7.61 (t, 1H, J = 7.4 Hz), 7.49 (t, 2H, J 
= 7.7 Hz), 4.54 (s, 2H), 3.28 (q, 4H, J = 7.1 Hz), 1.19 (t, 6H, J = 7.1 z); 13C{1H} NMR (CDCl3, 
75 MHz): δ, 189.2, 135.8, 134.1, 129.3, 128.8, 59.1, 42.9, 14.7; HRMS-ESI+ (m/z) calcd for 
C12H18NO3S
+
 (M + H)
+ 256.1002, found 256.1001. 
 Alternatively 1.41 was obtained if potassium tert-butoxide (2.43 g, 21.7 mmol, 4 equiv) 
was dissolved in 20 mL of THF and cooled to 0 °C, 1.34 (816 mg, 5.4 mmol, 1 equiv) was added 
followed by methyl benzoate (1.36 mL, 10.8 mmol, 2 equiv) and the resulting mixture was 
stirred overnight at room temperature. The product was isolated as above to gave 1.41 in 86% 
yield.  
 
N,N-Diallyl benzoylmethanesulfonamide (1.42). According to general procedure 1.2 after flash 
chromatography, 1% ether in benzene, 1.42 was obtained as a white solid, 2.36 g (85%) from 
methyl benzoate (1.26 mL, 10 mmol, 1 equiv) and 1.35 (3.50 g, 20 mmol, 2 equiv). 1H NMR 
(CDCl3, 300 MHz): δ 8.01 (m, 2H), 7.62 (tt, 1H, J = 7.5,1.3 Hz), 7.50 (t, 2H, J = 7.6 Hz), 5.81 
(ddt, 2H, J = 16.8, 10.4, 6.5 Hz), 5.23 (m, 4H), 4.59 (s, 2H), 3.85 (d, 4H, J = 6.3 Hz); 13C{1H} 
NMR (CDCl3, 75 MHz): δ 189.1, 135.7, 134.2, 132.7, 129.2, 128.8, 119.1, 59.8, 50.0; HRMS-
ESI+ (m/z) calcd for C14H18N1O3S
+
 (M + H)
+ 280.1002, found 280.1002. 
 
N,N-Bis(4-methoxybenzyl) benzoylmethanesulfonamide (1.44). According to general procedure 





335 mg (99%) from 95 µL (0.75 mmol) of methyl benzoate and 1.37 (502 mg, 1.5 mmol, 2 
equiv). 1H NMR (CDCl3, 300 MHz): δ 7.92 (d, 2H, J = 8.0 Hz), 7.60 (t, 1H, J = 7.4 Hz), 7.46 (d, 
2H, J = 7.7 Hz), 7.20 (d, 4H, J = 8.6 Hz), 6.81 (d, 4H, J = 8.6 Hz), 4.42 (s, 2H), 4.32 (s, 4H), 
3.76 (s, 6H); 13C{1H} NMR (CDCl3, 75 MHz): δ 189.1, 159.2, 135.8, 134.1, 130.0, 129.1, 128.7, 
127.4, 113.9, 60.0, 55.2, 50.6; HRMS-ESI+ (m/z) calcd for C24H25NO5SLi
+




N,N-Bis(2,4-dimethoxybenzyl) benzoylmethanesulfonamide (1.43). Sulfonamide 1.36 (3.95 g, 10 
mmol, 1 equiv) was dissolved in 100 mL of THF with gentle heating then cooled to -78 °C. 
Diisopropylamine (2.82 mL, 20 mmol, 2 equiv) was added followed by butyl lithium (1.6 M in 
hexane, 12.5 mL, 20 mmol, 2 equiv) and the solution was stirred for five min then N-methyl-N-
methoxybenzamide (3.30 g, 20.0 mmol, 2.00 equiv) was added. The reaction was stirred at -78 
°C for 5 h until TLC indicated that the methane sulfonamide had been completely consumed. 
The reaction was quenched with 10 mL of sat. NH4Cl and warmed to room temperature. 150 mL 
of water was added, and the mixture was extracted three times with 100 mL of DCM. The 
combined organic layers were dried over MgSO4 and concentrated. The residue was purified by 
flash chromatography, 0 to 60% EtOAc in hexane to give 3.3 g of a white solid (66%). 1H NMR 
(CDCl3, 300 MHz): δ 7.91 (d, 2H, J = 7.2 Hz), 7.58 (t, 1H, J = 7.1 Hz), 7.45 (t, 2H, J = 6.6 Hz), 
7.25 (d, 2H, J = 7.9 Hz), 6.44 (d, 2H, J = 7.7 Hz), 6.38 (s, 2H), 4.45 (s, 4H), 4.41 (s, 2H), 3.78 
(s, 6H), 3.76 (s, 6H); 13C{1H} NMR (CDCl3, 75 MHz): δ 189.0, 160.5, 158.4, 136.0, 133.8, 
131.1, 129.0, 128.6, 116.7, 104.0, 98.2, 59.7, 55.3, 55.1, 46.1; HRMS-ESI+ (m/z) calcd for 
C26H29NO7SLi
+
 (M + Li)





When the reaction was performed according to general procedure 1.2 1.43 was not observed.  
General procedure 1.3 for preparing ß-ketosulfonamides from amino acids.  
 Sulfonamide (3.5 equiv) was dissolved in THF at a concentration of 0.1-0.2 M then 
cooled to -78 °C then n-BuLi (2.5 M in hexane, 3.5 equiv) was added dropwise and the reaction 
was stirred for 30 min. A solution of N-protected amino acid methyl ester was added as a 
solution in THF (aprox. 0.2 M) dropwise and the mixture was stirred at -78 ° for 1 hour before a 
sat. aqueous solution of NH4Cl was added and the mixture extracted with CH2Cl2. The organic 
layer was dried (Na2SO4) and concentrated in vacuo. Purification by flash chromatography 
separated the ß-ketones from the excess methanesulfonamide.  
 
tert-Butyl (S)-(1-(N-allyl-N-methylsulfamoyl)-4-methyl-2-oxopentan-3-yl)carbamate (1.45). 
According to general procedure 1.3, 1.45 was obtained as an amorphous white solid (1.45 g, 97% 
yield) after flash chromatography (25% EtOAc, 75% hexane) from ester Boc-Val-OMe (1.00 g, 
4.32 mmol) and sulfonamide 1.33 (2.25 g, 15.1 mmol). 1H NMR (CDCl3, 300 MHz): δ 5.83-5.72 
(m, 1H), 5.29-5.21 (m, 2H), 5.19 (1H, d, J = 8.6 Hz), 4.29 (dd, 1H, J = 4.6, 8.8 Hz), 4.23 (d, 1H, 
J = 14.3 Hz), 4.03 (d, 1H, J = 14.3 Hz), 3.78 (d, 2H, J = 6.1 Hz), 2.83 (s, 3H), 2.35-2.26 (m, 
1H), 1.42 (s, 9H), 0.99 (d, 3H, J = 6.8 Hz), 0.81 (s, 3H, J = 6.8 Hz); 13C{1H} NMR (CDCl3, 75 
MHz): δ 199.0, 155.9, 132.5, 119.2, 80.3, 65.1, 58.1, 53.1, 34.5, 28.6, 28.2, 19.8, 16.8; HRMS-
ESI+ (m/z) calcd for C11H21N2O5S (M – C4H9 + 2H)






tert-Butyl (S)-(4-(N-allyl-N-methylsulfamoyl)-3-oxo-1-phenylbutan-2-yl)carbamate (1.46). 
According to general procedure 1.3, 1.46 was obtained as an amorphous white solid (0.370, 93% 
yield) after flash chromatography (25% EtOAc, 75% hexane) from ester Boc-Phe-OMe (0.279, 
1.00 mmol) and sulfonamide 1.33 (0.521 g, 3.2 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.46-7.21 
(m, 3H), 7.17 (d, 2H, J = 6.6 Hz), 5.82-5.69 (m, 1H), 5.26 (d, 1H, J = 18.5 Hz), 5.24 (d, 1H, J = 
9.5 Hz), 5.10 (d, 1H, J = 6.9 Hz), 4.53-4.46 (m, 1H), 4.17 (d, 1H, J = 13.8 Hz), 4.03 (d, 1H, J = 
13.8 Hz), 3.74 (d, 2H, J = 5.8 Hz), 3.20 (dd, 1H, J = 5.8, 14.4), 2.90 (d, 1H, J = 9.0, 14.3), 2.18 
(s, 3H), 1.37 (s, 9H); 13C{1H} NMR (CDCl3, 75 MHz): δ 198.8, 155.5, 136.3, 132.4, 129.3, 
128.8, 127.1, 119.3, 80.2, 61.3, 57.9, 53.1, 36.4, 34.4, 28.2; HRMS-ESI+ (m/z) calcd for 
C19H29N2O5S (M + H)
+, 397.1792; found, 397.1787. 
 
tert-Butyl (S)-(4-(N-allyl-N-methylsulfamoyl)-3-oxobutan-2-yl)carbamate (1.47). According to 
general procedure 1.3, 1.47 was obtained as an amorphous white solid (0.658, 84% yield) after 
flash chromatography (10% EtOAc, 90% benzene) from Boc-Ala-OMe (0.500, 2.46 mmol) and 
sulfonamide 1.33 (1.28 g, 8.61 mmol). 1H NMR (CDCl3, 300 MHz): 5.56-5.81 (m, 1H), 5.15-
5.32 (m, 3H), 4.19-4.35 (m, 2H), 4.06 (one half of a doublet of doublets, 1H, J = 13.9 Hz), 3.74 
(d, 2H, J = 5.6 Hz), 2.80 (s, 3H), 1.39 (s, 9H), 1.33 (d, 3H, J = 7.1 Hz); 13C{1H} NMR (CDCl3, 
75 MHz): 199.7, 155.3, 132.3, 119.1, 80.2, 57.1, 55.9, 53.0, 34.3, 28.1, 16.3; HRMS-ESI+ (m/z) 
calcd for C13H25N2O5S (M + H)






tert-Butyl (S)-(1-(N-allyl-N-methylsulfamoyl)-5-(methylthio)-2-oxopentan-3-yl)carbamate (1.48). 
According to general procedure 1.3, 1.48 was obtained as an amorphous white solid (1.12 g, 74% 
yield) after flash chromatography (33% EtOAc, 67% hexane) from Boc-Met-OMe (0.970, 3.68 
mmol) and sulfonamide 1.33 (1.90 g, 12.8 mmol). 1H NMR (CDCl3, 300 MHz): 5.8-5.65 (m, 
1H), 5.41 (d, 1H, J = 7.4 Hz), 5.24 (1H, d, J = 16.4 Hz), 5.19 (1H, d, J = 9.5 Hz), 4.32-4.44 (1H, 
m), 4.21 (1H, d, J = 13.8 Hz), 4.08 (1H, d, J = 13.8 Hz), 3.73 (d, 2H, J = 5.8 Hz), 2.79 (s, 3H), 
2.45-2.55 (m, 2H), 2.10-2.23 (1H, m), 2.03 (3H, s), 1.77-1.90 (m, 1H), 1.39 (s, 9H); 13C{1H} 
NMR (CDCl3, 75 MHz): 199.0, 155.6, 132.3, 119.3, 80.5, 59.4, 57.5, 53.0, 34.4, 30.1, 29.7, 28.2, 
15.4; HRMS-ESI+ (m/z) calcd for C15H32N3O5S2 (M + NH4)
+, 398.1778; found, 398.1773. 
 
Benzyl (S)-(1-(N-allyl-N-methylsulfamoyl)-4-methyl-2-oxopentan-3-yl)carbamate (1.49). 
According to general procedure 1.3, 1.49 was obtained as an amorphous white solid (1.12 g, 65% 
yield) after flash chromatography (30% EtOAc, 70% hexane) from ester Cbz-Val-OMe (2.00 g, 
8.02 mmol) and sulfonamide 1.33 (4.18 g, 28.0 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.31 (s, 
5H), 5.77-5.68 (m, 1H), 5.52 (d, 1H, J = 9.0 Hz), 5.27-5.19 (m, 2H), 5.09 (s, 2H), 4.40 (dd, 1H, 
J = 4.2, 9.0 H), 4.21 (d, 1H, J = 13.8 Hz), 4.02 (d, 1H, J = 13.8 Hz), 3.75 (d, 3H, J = 5.8 Hz), 
2.79 (s, 3H), 2.34-2.27 (m, 1H), 0.99 (d, 3H, J = 6.9 Hz), 0.80 (d, 3H, J = 6.4 Hz); 13C{1H} 
NMR (CDCl3, 75 MHz): δ 198.6, 156.5, 136.1, 132.4, 128.6, 128.3, 128.1, 119.2, 67.2, 65.5, 








Benzyl ((3S,4R)-1-(N-allyl-N-methylsulfamoyl)-4-methyl-2-oxohexan-3-yl)carbamate (1.50). 
According to general procedure 1.3, 1.50 was obtained as an amorphous white solid (1.00 g, 71% 
yield) after flash chromatography (33% EtOAc, 67% hexane) from Cbz-Ile-OMe (1.00 g, 3.57 
mmol) and sulfonamide 1.33 (1.87 g, 12.5 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.34 (s, 5H), 
5.85-5.69 (m, 1H), 5.37 (bd, 1H, J = 9.0 Hz), 5.27 (d, 1H, J = 17.5 Hz), 5.25 (d, 1H, J = 9.5 
Hz), 5.11 (s, 2H), 4.42 (dd, 1H, J = 4.2, 9.0 Hz), 4.22 (d, 1H, J = 14.3 Hz), 4.02 (d, 1H, J = 14.3 
Hz), 3.78 (d, 2H, J = 5.8 Hz), 2.82 (s, 3H), 1.40-1.25 (m, 1H), 1.16-1.00 (m, 1H), 1.00 (d, 3H, J 
= 6.4 Hz), 0.89 (t, 3H, J = 7.4 Hz), 13C{1H} NMR (CDCl3, 75 MHz): δ 198.6, 156.4, 136.1, 
132.4, 128.6, 128.3, 128.1, 119.3, 67.2, 65.4, 58.4, 35.6, 34.3, 24.1, 16.1, 11.5; HRMS-ESI+ (m/z) 
calcd for C19H29N2O5S (M + H)
+, 397.1792; found, 397.1785. 
 
Benzyl (S)-(1-(N-allyl-N-methylsulfamoyl)-5-methyl-2-oxohexan-3-yl)carbamate (1.51). 
According to general procedure 1.3, 1.51 was obtained as an amorphous white solid (1.00 g, 83% 
yield) after flash chromatography (25% EtOAc, 75% hexane) from Cbz-Leu-OMe (0.848 g, 3.00 
mmol) and sulfonamide 1.33 (1.56 g, 10.5 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.32 (s, 5H), 
5.79-5.65 (m, 1H), 5.25 (d, 1H, J = 17.8 Hz), 5.23 (d, 1H, J = 9.9 Hz), 5.10 (s, 2H), 4.42 (m, 
1H), 4.25 (d, 1H, J = 13.7 Hz), 4.02 (d, 1H, J = 13.7 Hz), 3.75 (d, 2H, J = 5.6 Hz), 2.79 (s, 3H), 





199.7, 156.3, 136.1, 132.4, 128.6, 128.3, 128.1, 119.3, 67.2, 59.3, 57.5, 53.0, 39.3, 34.4, 24.8, 
23.2, 21.3; HRMS-ESI+ (m/z) calcd for C19H32N3O5S (M + NH4)
+,414.2057; found, 414.2048. 
 
Benzyl (S)-(4-(N-allyl-N-methylsulfamoyl)-1-(4-(tert-butoxy)phenyl)-3-oxobutan-2-yl)carbamate 
(1.52). According to general procedure 1.3, 1.52 was obtained as an amorphous white solid 
(0.887 g, 68% yield) after flash chromatography (33% EtOAc, 67% hexane) from Cbz-Tyr(tBu)-
OMe (1.0 g, 2.59 mmol) and sulfonamide 1.33 (1.23 g, 8.29 mmol). 1H NMR (CDCl3, 300 
MHz): δ 7.38-7.24 (m, 5H), 7.02 (d, 2H, J = 8.3 Hz), 6.89 (d, 2H, J = 8.3 Hz), 5.82-5.67 (m, 
1H), 5.53 (d, 1H, J = 7.3 Hz), 5.25 (d, 1H, J = 17.1 Hz), 5.23 (d, 1H, J = 9.5 Hz), 5.15 (s, 2H), 
4.64-4.55 (m, 1H), 4.13 (d, 1H, J = 13.9 Hz), 4.00 (d, 1H, J = 13.9 Hz), 3.72 (d, 2H, J = 5.9 
Hz), 3.15 (dd, 1H, J = 5.6, 14.2), 2.91 (dd, 1H, J = 8.3, 14.2), 2.27 (s, 3H), 1.30 (s, 9H); 13C{1H} 
NMR (CDCl3, 75 MHz): δ 198.4, 156.0, 154.5, 136.0, 132.2, 130.6, 129.7, 128.6, 128.3, 128.1, 
124.4, 119.3, 78.5, 67.2, 61.7, 58.1, 53.0, 35.8, 34.3, 28.8; HRMS-ESI+ (m/z) calcd for 
C26H38N3O6S (M + NH4)
+, 520.2476; found, 520.2467. 
 
tert-Butyl (S)-2-(2-(N-allyl-N-methylsulfamoyl)acetyl)pyrrolidine-1-carboxylate (1.53). 
According to general procedure 1.3, except that only 2 equiv of the sulfonamide and n-BuLi 
were used, 1.53 was obtained as a pale-yellow oil (1.41 g, 95% yield) after flash chromatography 
(0 to 50% EtOAc in DCM) from Boc-Pro-OMe (1.0 g, 4.3 mmol, 0.5 equiv) and sulfonamide 





1H), 4.15 (m, 2H), 3.81 (m, 2H), 3.47 (m, 2H), 2.85 (s, 3H), 2.14 (m, 2H), 1.90 (m, 2H), 1.43 (2, 
9H); 13C{1H} NMR (CDCl3, 75 MHz): δ (major rotamer)199.8, 154.8, 132.6, 119.0, 80.3, 65.5, 
57.8, 53.1, 47.0, 28.5, 28.3, 24.6; (minor rotamer) 199.3, 153.6, 132.4, 119.2, 80.7, 66.0, 56.9, 
53.4, 46.8, 34.3, 29.4, 23.6; HRMS-ESI+ (m/z) calcd for C15H26N2NaO5S
+
 (M + Na)
+ 369.1455, 
found 369.1472.  
 
tert-Butyl (S)-(1-(N-allyl-N-ethylsulfamoyl)-2-oxo-5-phenylpentan-3-yl)carbamate (1.54). 
According to general procedure 1.3, 1.54 was obtained as an amorphous white solid (0.189 g, 
92% yield) after flash chromatography 20% EtOAc in hexane, from Boc-hPhe-OMe (0.146 g, 
0.500 mmol) and sulfonamide 1.32 (0.261 g, 1.60 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.32-
7.14 (m, 5H), 5.38-5.25 (m, 1H), 5.30-5.20 (m, 3H), 4.35-4.27 (m, 1H), 4.25 (d, 1H, J =13.7 Hz), 
3.95 (d, 1H, J = 13.7 Hz), 3.83 (d, 1H, J = 6.1 Hz), 3.27 (q, 2H, J = 7.1 Hz), 2.71-2.64 (m, 1H), 
2.33-2.20 (m, 1H), 1.94-1.80 (m, 1H), 1.45 (s, 9H), 1.16 (t, 3H, J = 7.1 Hz); 13C{1H} NMR 
(CDCl3, 75 MHz): δ 199.2, 155.6, 140.6, 133.1, 128.6, 128.5, 126.3, 119.0, 80.4, 60.0, 59.2, 
50.1, 42.6, 32.2, 31.7, 28.3, 14.0; HRMS-ESI+ (m/z) calcd for C21H36N3O5S (M + NH4)
+, 








tert-Butyl (4-(N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)-3-oxobutan-2-yl)carbamate (1.56). 
Sulfonamide 1.36 (1.35 g, 3.38 mmol, 3.1 equiv) was dissolved in 38 mL of THF and cooled to -
78 °C. n-BuLi (2.5 M in hexanes, 1.35 mL, 3.38 mmol, 3.1 equiv) was added dropwise and the 
resulting solution was stirred for 30 min before adding Weinreb amide 1.55 (253 mg, 1.09 mmol, 
1 equiv) as a solution in 7 mL of THF. After stirring for 4 h at –78 °C the reaction was complete 
by TLC and quenched with 5 mL of saturated ammonium chloride. The mixture was diluted with 
200 mL of water and extracted three times with 200 mL of DCM. The combined organic layers 
were dried over MgSO4, filtered, and concentrated. The residue was subjected to flash 
chromatography with 10% EtOAc in benzene which yielded 536 mg of 1.56 (87%) as a white 
solid. Additionally, 817 mg of 1.36 was recovered. 1H NMR (CDCl3, 300 MHz): δ 7.35 (s, 2H), 
7.19 (d, 2H, J = 8.0 Hz), 6.2 (m, 4H), 5.28 (d, 1H, J = 5.3 Hz), 4.4 (s, 4H), 4.30 (t, 1H, J = 6.7 
Hz), 4.08 (d, 1H, J = 13.2 Hz), 3.85 (d, 1H, J = 13.4 Hz), 3.78 (s, 6H), 3.77 (s, 6H), 1.42 (s, 9H), 
1.3 (d, 3H, J = 7.0 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 199.5, 160.6, 158.4, 155.2, 131.0, 
116.5, 104.1, 98.3, 80.1, 59.8, 55.9, 55.4, 55.2, 45.9, 28.3, 16.9; HRMS-ESI+ (m/z) calcd for 
C27H38N2O9SLi
+
 (M + Li)







tert-Butyl (S)-2-(2-(N,N-bis(4-methoxybenzyl)sulfamoyl)acetyl)pyrrolidine-1-carboxylate (1.57) 
Sulfonamide 1.37 (3.66 g, 10.9 mmol, 2.5 equiv) was dissolved in 60 mL of THF and cooled to -
78 °C before adding n-BuLi (2.5 M in hexanes, 4.36 mL, 10.9 mmol, 2.5 equiv). The solution 
was stirred for 30 min before adding Boc-Pro-OMe (1.00 g, 4.36 mmol, 1.00 equiv) dropwise as 
a solution in 5 mL of THF. The reaction was stirred for 2 h then quenched with 5 mL of 
saturated NH4Cl. The mixture was diluted with 100 mL of water and extracted three times with 
100 mL of DCM. The combined organic layers were dried over MgSO4, filtered, and 
concentrated. The residue was subjected to column chromatography, 10% EtOAc in benzene, to 
give 1.60 g (69% yield) of 1.57 as a white amorphous solid. 1H NMR (CDCl3, 300 MHz): δ 
(10:9 mixture of rotamers) 7.26 (d, 2H, J = 7.9 Hz), 7.20 (d, 2H, J = 8.0 Hz), 6.88 (d, 2H, J = 
8.2 Hz), 6.84 (d, 2H, J = 8.1 Hz), 4.35 (m, 5H), 4.14 (d, 0.5H, J = 14.3 Hz), 4.11 (d, 0.5H, J = 
14.3 Hz), 3.93 (d, 0.5H, J = 14.7 Hz), 3.81 (s, 6H), 3.76 (d, 0.5H, J = 14.3 Hz), 3.56-3.45 (m, 
2H), 2.2-1.8 (m, 4H), 1.46 (s, 4.7H), 1.38 (s, 4.3H); 13C{1H} NMR (CDCl3, 75 MHz): δ (major 
rotamer) 199.7, 159.3, 154.8, 130.0, 127.4, 114.0, 80.3, 65.4, 60.9, 55.3, 50.2, 47.1, 28.7, 28.4, 
24.7; (minor rotamer) 199.1, 159.4, 153.6, 130.1, 127.4, 114.1, 80.7, 66.1, 59.6, 55.3, 50.3, 46.8, 
29.5, 28.2, 23.7; HRMS-ESI+ (m/z) calcd for C27H37N2O7S
+
 (M + H)







Benzyl (S)-2-(2-(N,N-bis(4-methoxybenzyl)sulfamoyl)acetyl)pyrrolidine-1-carboxylate (1.58) 
Sulfonamide 1.37 (2.70 g, 8.0 mmol, 2.1 equiv) was dissolved in 60 mL of THF and cooled to -
78 °C and n-BuLi (2.5 M in hexane, 3.2 mL, 8.0 mmol, 2.1 equiv) was added dropwise. The red 
solution was stirred for 30 min before adding Cbz-Pro-OMe (1.00 g, 3.80 mmol, 1.00 equiv) as a 
neat oil. The orange solution was stirred for 2 h before quenching with 5 mL of saturated NH4Cl. 
The mixture was diluted with 100 mL of water then extracted three times with 100 mL of DCM. 
The combined organic layers were dried over MgSO4, filtered, concentrated, and then subjected 
to flash chromatography, 20 to 50% EtOAc in hexanes, to give 1.58 as 1.60 g (75%) of a white 
amorphous solid. In CDCl3 at room temperature this sulfonamide existed as a mixture of 
conformational isomers, but in (CD3)2SO the rotamers resolved at 120 °C. 
1H NMR (CDCl3, 300 
MHz) (7:3 ratio of rotamers) δ: 7.35 (m, 5H), 7.20 (m, 4H), 6.88 (d, 4H, J = 8.5 Hz), 5.18 (d, 
0.7H, J = 12.4 Hz), 5.12 (d, 0.7H, J = 12.4 Hz), 5.08 (m, 0.6H), 4.57 (dd, 0.7H, J = 7.9, 5.6 Hz), 
4.3-4.0 (m, 5H), 3.82 (m, 7H), 3.60 (m, 2H), 2.7-1.8 (m, 4H); 13C{1H} NMR ((CD3)2SO, 125 
MHz, 120 °C): δ 198.6, 159.7, 154.7, 137.4, 130.2, 128.8, 128.7, 128.2, 127.9, 114.7, 66.9, 66.1, 
60.3, 55.9, 51.2, 47.3, 28.8, 23.9; HRMS-ESI+ (m/z) calcd for C30H38N3O7S (M + NH4)
+ 








tert-Butyl (S)-2-(2-(N-benzhydrylsulfamoyl)acetyl)pyrrolidine-1-carboxylate (1.59) n-BuLi (2.5 
M in hexane, 12.9 mL, 33 mmol, 3 equiv) was dissolved in 20 mL of THF at -40 °C, hydrogen 
chloride (4 M in dioxane, 2.7 mL, 10.9 mmol, 1 equiv) was added. Sulfonamide 1.38 (2.81 g, 
10.9 mmol, 1 equiv) was added as solution in 20 mL of THF to gave a red solution which was 
stirred at -40 °C for 30 min before adding Boc-Pro-OMe (1.0 g, 4.3 mmol, 0.40 equiv) as a 
solution in 10 mL of THF. The reaction was stirred for an additional 1 hour before quenching 
with 10 mL of saturated NH4Cl solution. The mixture was diluted with 150 mL of water and 
extracted 3 times with 100 mL DCM. The combined organic layers were dried over MgSO4, 
filtered, and concentrated. The residue was purified by flash chromatography, 0 to 50% EtOAc 
in DCM, to give 1.66 g (80%) of 1.59 as a white amorphous solid. 1H NMR (CDCl3, 300 
MHz)(4:5 mixture of rotamers): δ 7.30 (m, 10H), 6.65 (d, 0.5H, J = 8.2 Hz), 6.16 (d, 0.4H, J = 
8.9 Hz), 5.77 (d, 1H, J = 8.9 Hz), 4.44 (m, 0.5H), 4.06 (m, 1H), 3.77 (m, 1.5H), 3.35 (m, 2), 1.96 
(m, 1H), 1.71 (m, 3H), 1.38 (s, 5H), 1.30 (s, 4H); 13C{1H} NMR (CDCl3, 75 MHz): δ 200.3, 
199.9, 154.6, 153.5, 140.9, 140.5, 140.5, 128.8, 128.8, 128.8, 128.8, 128.7, 128.7, 128, 128, 
127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 80.9, 80.5, 65.9, 64.2, 61.7, 61.5, 60.9, 58.5, 47, 46.7, 
29.4, 28.4, 28.3, 28.2, 24.4, 23.6; HRMSESI- (m/z) calcd for C24H29N2O5S
-










Allyl (S)-2-(2-(N-benzhydrylsulfamoyl)acetyl)pyrrolidine-1-carboxylate (1.60) n-BuLi (2.5 M, in 
hexane, 14 mL, 35.2 mmol, 7.5 equiv) was dissolved in 20 mL of THF at -78 °C, then hydrogen 
chloride (4 M in dioxane, 2.93 mL, 11.7 mmol, 2.5 equiv) was added. A white precipitate formed 
which dissolved when the temperature was raised to -40 °C. Sulfonamide 1.38 (3.06 g, 11.7 
mmol, 2.5 equiv) was added as solution in 20 mL of THF to give a red solution which was 
stirred at -40 °C for 30 min before adding Alloc-Pro-OMe (1.0 g, 4.6 mmol, 1 equiv) as a 
solution in 10 mL of THF. The reaction was stirred for an additional 1 hour before quenching 
with to 10 mL of saturated NH4Cl solution. The mixture was diluted with 150 mL of water and 
extracted 3 times with 100 mL DCM. The combined organic layers were dried over MgSO4, 
filtered and concentrated. The residue was purified by flash chromatography, 20 to 50% EtOAc 
in hexane, to give 1.34 g (66% yield) of 1.60 as a white amorphous solid. 1H NMR (CDCl3, 500 
MHz)(7:3 ratio of rotamers): δ 7.33 (m, 10H), 6.53 (br, 0.7H), 6.13 (d, 0.3H, J = 7.1 Hz), 5.90 
(m, 0.6H), 5.81 (m, 1.4H), 5.30 (d, 0.6H, J = 17.2 Hz), 5.19 (m, 1.4H), 4.49 (m, 2.7H), 4.29 (m, 
0.3H), 4.07 (d, 0.7H, J = 14.8 Hz), 3.94 (d, 0.7H, J = 14.8 Hz), 3.86 (d, 0.3H, J = 15.5 Hz), 3.80 
(d, 0.3 Hz, J = 15.5 Hz), 3.46 (m, 2H), 2.04 (m, 1H), 1.80 (m, 3H); 13C{1H} NMR (CDCl3, 125 
MHz): δ (major rotamer)199.4, 154.9, 140.8, 140.5, 132.6, 128.8, 128.7, 127.9, 127.8, 127.7, 
127.6, 127.6, 127.5, 118.2, 117.6, 66.3, 64.7, 61.7, 60.9, 46.7, 28.2, 24.3 (minor rotamer) 199.6, 
153.9, 140.4, 140.3, 132.5, 128.8, 128.7, 127.9, 127.8, 127.7, 127.6, 127.6, 127.5, 118.2, 66.3, 
65.5, 61.6, 59.0, 47.2, 29.2, 23.4; HRMS-ESI+ (m/z) calcd for C23H30N3O5S
+ (M + NH4)
+ 







(1.61). NaH (60% dispersion in mineral oil, 0.030 g, 0.746 mmols, 2.6 equiv), was rinsed three 
times with 5 mL of THF then suspended in 5 mL of THF. This mixture was cooled to 0 °C and 
ß-ketosulfonamide 1.45 (0.100 g, 0.287 mmol, 1 equiv) was added and stirred for 20 min. After 
20 min the mixture was cannulated into a flask containing Selectfluor (0.305 g, 0.862 mmols, 3.0 
equiv) in acetonitrile (5 mL) under argon atmosphere at -10 °C with stirring. This mixture was 
warmed to room temperature and stirred 20 h then quenched with water (50 mL) and extracted 
three times with diethyl ether (50 mL). The combined organic layers were dried with sodium 
sulfate, filtered, and concentrated. Purification using flash chromatography 15 to 35% EtOAc in 
hexanes provided monofluoro ketone 29 as a colorless oil (1:1 mixture of diastereomers, 0.074 g, 
70% yield). 1H NMR (CDCl3, 500 MHz): δ 5.80 (d, 2H, J = 48 Hz), 5.79 (m, 2H), 5.31 (m, 4H), 
5.20 (d, 1H, J = 8.5 Hz), 5.05 (d, 1H, 8.7Hz), 4.71 (d, 1H, J = 8.9 Hz), 4.63 (dd, 1H, J = 6.2 Hz, 
6.5 Hz), 3.95 (dd, 2H, J = 5.7 Hz, 15 Hz), 3.83 (m, 2H), 2.94 (s, 3H), 2.93 (s, 3H), 2.43 (bs, 1H), 
2.23 (m, 1H), 1.45 (s, 18H), 1.05 (d, 3H, J = 6.7 Hz), 1.02 (d, 3H, J = 6.7 Hz), 0.89 (d, 3H, J = 
6.7Hz), 0.83 (d, 3H, J = 6.7 Hz); 13C{1H} NMR (CDCl3, 125 MHz): δ 198.3 (d, J = 19.0 Hz), 
197.4 (d, J = 19.9 Hz), 155.7, 155.6, 132.0, 131.9, 119.8, 119.7, 99.5 (d, J = 225.7 Hz), 98.9 (d, 
J = 224.9 Hz), 80.4, 80.4, 62.6, 61.1, 53.4, 53.3, 34.8, 34.8, 28.9, 28.7, 28.2, 19.9, 19.8, 16.8, 
16.3; 19F NMR (CDCl3, 282 Hz): δ -184.4 (d, 1F, J = 47.9 Hz), -185.5 (d, 1F, J = 50.8 Hz); 
HRMS-ESI+ (m⁄z) calculated for C15H28FN2O5S





General procedure 1.4 for fluorination of ß-keto sulfonamides derived from amino acids.  
 To a solution of the ß-ketosulfonamide in dry DMF (0.025 M) CsF or TBAF 1 M in THF 
(4 equiv) was added followed by Selectfluor (4 equiv). The Reaction was stirred until complete 
by TLC (1 hour or less). Then the mixture was diluted with water then extracted with Et2O (3x). 
The combined organic layers were washed with brine then dried over sodium or MgSO4, filtered, 




(1.62). According to general procedure 1.4 using CsF, 1.62 was obtained as a colorless liquid 
(0.926 g, 84% yield) after flash chromatography (20% EtOAc, 80% hexane) from ketone 1.45 
(1.00 g, 2.87 mmol). 1H NMR (CDCl3, 300 MHz): δ 5.83-5.71 (m, 1H), 5.32 (d, 2H, J = 14.7 
Hz), 5.06 (d, 1H, J = 9.3 Hz), 4.83 (d, 1H, J = 9.3 Hz), 3.95 (bs, 1H), 2.42-2.34 (m, 1H), 1.45 (s, 
9H), 1.06 (d, 3H, J = 6.8 Hz), 0.84 (d, 3H, J = 6.8 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 
195.4 (t, J = 26.3 Hz), 155.3, 131.8, 120.2, 115.6 (t, J = 297.6), 80.3, 61.0, 53.7, 35.0, 28.9, 
28.1, 19.9, 16.0; 19F NMR (CDCl3, 282 MHz): δ -106.5 (d, J = 246.6 Hz), -106.9 (d, J = 246.6 
Hz), -108.0 (d, J = 246.6 Hz), -108.8 (d, J = 246.6 Hz); HRMS-ESI+ (m/z) calcd for 
C15H27F2N2O5S (M + H)
+, 385.1603; found, 385.1603. 








(1.63). According to general procedure 1.4 using CsF, 1.63 was obtained as a pale yellow 
amorphous solid (0.724 g, 84% yield) after flash chromatography (15% EtOAc, 85% hexane) 
from ketone 1.46 (0.800 g, 2.00 mmol).1H NMR (CDCl3, 300 MHz): δ 7.36-7.24 (m, 3H), 7.16 
(d, 2H, J = 6.8 Hz), 5.83-5.73 (m, 1H), 5.29 (d, 2H, J = 13.2 Hz), 5.12-4.85 (m, 2H), 3.92 (bs, 
2H), 3.30 (bd, 1H, J = 13.9 Hz), 2.97 (s, 3H), 3.00-2.79 (m, 1H), 1.53 (s, 9H); 13C{1H} NMR 
(CDCl3, 75 MHz): δ 194.5 (t, J= 24.3 Hz), 154.7, 135.1, 131.7, 129.4, 128.7, 127.2, 120.2, 115.8 
(t, J = 297.6 Hz), 80.5, 57.0, 53.7, 36.5, 35.0, 28.1; 19F NMR (CDCl3, 282 MHz): δ -107.1 (d, J 
= 244.8 Hz), -107.2 (d, J = 244.8 Hz), -108.1 (d, J = 244.8 Hz), -108.3 (d, J = 244.8 Hz); 
HRMS-ESI+ (m/z) calcd for C15H19F2N2O5S (M – (CH3)3 + 2H)
+, 377.0977; found, 377.0976. 
 
tert-Butyl (S)-(4-(N-allyl-N-methylsulfamoyl)-4,4-difluoro-3-oxobutan-2-yl)carbamate (1.64). 
According to general procedure 1.4 using CsF, 1.64 was obtained as a white solid (0.131 g, 76% 
yield) after flash chromatography (20% EtOAc, 80% benzene) from ketone 1.47 (0.155 g, 0.484 
mmol). 1H NMR (CDCl3, 300 MHz): δ 5.80-5.68 (m, 1H), 5.29 (d, 1H, J = 15.7 Hz), 5.28 (d, 
1H, J = 11.2 Hz), 5.09 (s, 1H), 4.81 (dq, 1H, J = 7.0, 7.0 Hz), 3.90 (bs, 2H), 2.95 (s, 3H), 1.41 
(s, 1.5H, one half of the doublet corresponding to CH-CH3), 1.39 (s, 12H, 9H from (CH3)3-C 
overlapping with one half of the doublet corresponding to CH-CH3); 
13C{1H} NMR (CDCl3, 75 





35.0, 28.2, 17.1; 19F NMR (CDCl3, 282 MHz): δ -106.3, (d, J = 251.7 Hz), -106.7 (d, J = 246.6 
Hz), -108.2 (d, J = 246.6 Hz), -108.8 (d, J = 253.5 Hz); HRMS-ESI+ (m/z) calcd for 
C9H15F2N2O5S (M - (CH3)3 + 2H)
+, 301.0662; found, 301.0663. 
 
Benzyl (S)-(1-(N-allyl-N-methylsulfamoyl)-1,1-difluoro-4-methyl-2-oxopentan-3-yl)carbamate 
(1.66). According to general procedure 1.4 using CsF, 1.66 was obtained as a colorless liquid 
(0.511 g, 93% yield) after flash chromatography (30% EtOAc, 70% hexane) from ketone 1.49 
(0.500 g, 1.31 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.35 (s, 5H), 5.84-5.70 (m, 1H), 5.32-5.27 
(m, 3H), 5.11 (s, 2H), 4.92 (dd, 1H, J = 3.7, 9.3 Hz), 3.92 (bs, 2H), 2.96 (s, 3H), 2.43-2.33 (m, 
1H), 1.05 (d, 3H, J = 6.6 Hz), 0.82 (d, 3H, J = 6.8 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 
195.0 (t, J = 24.7 Hz), 156.0, 136.0, 131.7, 128.6, 128.3, 128.2, 120.3, 119.6, (t, J = 297 Hz), 
67.4, 61.5, 53.7, 35.0, 29.1, 19.9, 16.0; 19F NMR (CDCl3, 282 MHz): δ -106.6 (d, J = 246.6 Hz), 
-107.3 (d, J = 244.8 Hz), -108.1 (d, J = 246.6 Hz), -108.5 (d, J = 244.8 Hz); HRMS-ESI+ (m/z) 
calcd for C18H25F2N2O5S (M + H)
+, 419.1447; found, 419.1446. 
 
Benzyl ((3S,4S)-1-(N-allyl-N-methylsulfamoyl)-1,1-difluoro-4-methyl-2-oxohexan-3-
yl)carbamate (1.67). According to general procedure 1.4 using CsF 1.67 was obtained as a 
colorless oil (0.196 g, 90% yield) after flash chromatography (15% EtOAc, 85% hexane) from 
ketone 1.50 (0.200 g, 0.504 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.33 (s, 5H), 5.80-5.71 (m, 





2.10 (bs, 1H), 1.38-1.21 (m, 1H), 1.06-0.95 (m, 4H, J = 6.6 Hz), 0.86 (t, 3H, J = 7.1 Hz); 
13C{1H} NMR (CDCl3, 75 MHz): δ 195.1 (t, J = 24.3 Hz), 156.0, 136.1, 131.8, 128.6, 128.3, 
128.2, 120.2, 115.7 (t, J = 297.1 Hz), 67.3, 61.7, 53.7, 35.7, 35.0, 23.3, 16.2, 11.3; 19F NMR 
(CDCl3, 282 MHz): -106.2 (d, J = 246.6 Hz), -106.9 (d, J = 246.6 Hz), -108.1 (d, J = 246.6 Hz), 





(1.68). According to general procedure 1.4 using CsF 1.68 was obtained as a colorless oil (0.180 
g, 82% yield) after flash chromatography (15% EtOAc, 85% hexane) from ketone 1.51 (0.200 g, 
0.504 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.32 (s, 5H), 5.87-5.69 (m, 1H), 5.38-5.25 (m, 3H), 
5.10 (s, 2H), 5.03-4.18 (m, 1H), 3.91 (bs, 2H), 2.95 (s, 3H), 1.84-1.60 (m, 2H), 1.49-1.30 (m, 
1H), 0.98 (d, 3H, J = 5.4 Hz), 0.93 (d, 3H, J = 5.6 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 
195.6, (t, J = 23.7 Hz), 155.6, 135.9, 131.7, 128.4, 128.1, 128.0, 120.1, 115.7, (t, J = 297.1, Hz), 
67.1, 55.3, 53.6, 39.6, 34.9, 24.8, 23.1, 20.9; 19F NMR (CDCl3, 282 MHz): -106.8 (d, J = 246.6 
Hz), -107.58, -107.6, (d, J = 246.6 Hz), HRMS-ESI+ (m/z) calcd for C19H27F2N2O5S (M + H)
+, 









yl)carbamate (1.69). According to general procedure 1.4 using CsF 1.69 was obtained as a 
colorless oil (0.180 g, 82% yield) after flash chromatography (15% EtOAc, 85% hexane) from 
ketone 1.52 (0.200 g, 0.504 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.32 (s, 5H), 5.87-5.69 (m, 
1H), 5.38-5.25 (m, 3H), 5.10 (s, 2H), 5.03-4.18 (m, 1H), 3.91 (bs, 2H), 2.95 (s, 3H), 1.84-1.60 
(m, 2H), 1.49-1.30 (m, 1H), 0.98 (d, 3H, J = 5.4 Hz), 0.93 (d, 3H, J = 5.6 Hz); 13C{1H} NMR 
(CDCl3, 75 MHz): δ 195.6, (t, J = 23.7 Hz), 155.6, 135.9, 131.7, 128.4, 128.1, 128.0, 120.1, 
115.7, (t, J = 297.1, Hz), 67.1, 55.3, 53.6, 39.6, 34.9, 24.8, 23.1, 20.9; 19F NMR (CDCl3, 282 
MHz): -106.8 (d, J = 246.6 Hz), -107.58, -107.6, (d, J = 246.6 Hz), HRMS-ESI+ (m/z) calcd for 
C19H27F2N2O5S (M + H)
+, 433.1603; found, 433.1603. 
 
tert-Butyl (R)-2-(2-(N-allyl-N-methylsulfamoyl)-2,2-difluoroacetyl)pyrrolidine-1-carboxylate 
(1.70). According to general procedure 1.4 using CsF 1.70 was obtained as a colorless oil (756 
mg, 69%) from 1.00 g (2.9 mmol) of 1.53. 1H NMR (CDCl3, 300 MHz)(6:4 ratio of rotamers): 
5.79 (m, 1H), 5.31 (m, 2H), 4.88 (m, 1H), 3.95 (br, 2H), 3.50 (m, 2H), 3.00 (s, 1.8H), 2.97 
(1.2H), 2.31 (m, 1H), 2.12 (m, 1H), 1.90 (m, 2H), 1.43 (s, 5.4H), 1.39 (s, 3.6H); 13C{1H} NMR 
(CDCl3, 75 MHz): δ, (major rotamer)195.0 (m), 153.1, 131.7, 120.2, 115.8(ap t, J = 296.9 Hz), 





(ap t, J = 297.4 Hz), 80.2, 60.9, 53.7, 46.7, 35.0, 29.3, 28.3, 24.5; 19F NMR (CDCl3, 282 MHz): 
δ (major rotamer) -106.8 (d, J = 247.8 Hz), -108.8 (d, J = 247.7 Hz); (minor rotamer) -107.6 (d, 
J = 248.3 Hz), -108.6 (d, J = 247.2 Hz) HRMS-ESI+ (m/z) calcd for C15H24NO5SF2Na
+
 (M + 
Na)+ 405.1266, found 405.1261. 
 
tert-Butyl (S)-(1-(N-allyl-N-ethylsulfamoyl)-1,1-difluoro-2-oxo-5-phenylpentan-3-yl)carbamate 
(1.71). According to general procedure 1.4 using CsF, 1.71 was obtained as a colorless oil (0.185 
g, 85% yield) after flash chromatography (20% EtOAc, 80% hexane) from ketone 1.54 (0.200 g, 
0.471 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.28-7.16 (m, 5H), 5.87-5.70 (m, 1H), 5.29 (d, 1H, 
J = 17.8 Hz), 5.27 (d, 1H, J = 8.3 Hz), 5.16 (d, 1H, J = 6.6 Hz), 4.88 (m, 1H), 3.96 (bd, 2H, J = 
5.4 Hz), 3.42 (dd, 1H, J = 6.6, 7.1 Hz), 2.80-2.60 (m, 2H), 2.36-2.20 (m, 1H), 1.94-1.79 (m, 1H), 
1.44 (s, 9H), 1.19 (t, 3H, J = 7.1 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 195.2 (t, J = 24.8 Hz), 
155.0, 140.3, 132.5, 128.6, 128.5, 126.3, 120.0, 115.3 (t, J = 297.1 Hz), 80.5, 56.2, 50.4, 42.9, 
32.6, 31.5, 28.2, 13.8; 19F NMR (CDCl3, 282 MHz): -107.3 (d, J = 244.8 Hz), -107.4, (d, J = 
243.1 Hz), -108.6 (d, J = 243.1 Hz), -108.9 (d, J = 244.8 Hz); HRMS-ESI+ (m/z) calcd for 
C21H31F2N2O5S (M + H)









yl)carbamate (1.72). According to general procedure 1.4 using TBAF, 1.72 was obtained as a 
white solid (743 mg, 64%) after flash chromatography (25% EtOAc in hexane) from ketone 1.56 
(1.1 g, 1.94 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.11 (d, 2H, J = 8.4 Hz), 6.36 (dd, 2H, J = 
8.4, 2.3 Hz), 6.27 (d, 2H, 6.3 Hz), 5.08 (br, 1H), 4.87 (br, 1H), 4.50 (s, 4H), 3.76 (s, 6H), 3.65 (s, 
6H), 1.43 (m, 12H); 13C{1H} NMR (CDCl3, 75 MHz): δ 196.0 (t, J = 23.2 Hz), 160.6, 158.2, 
154.7, 130.5, 116.0, 115.8 (t, J = 297.9 Hz), 103.9, 97.8, 80.3, 55.4, 55.0, 52.3, 47.0, 28.2, 17.5; 
19F NMR (CDCl3, 282 MHz): δ -106.3 (d, J = 240.9 Hz), -108.0 (d, J = 240.8 Hz); HRMS-ESI
+ 
(m/z) calcd for C27H36F2N2NaO9S+
+
 (M + Na)
+ 625.2002, found 625.1995.  
 
tert-Butyl (S)-2-(2-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,2-difluoroacetyl)pyrrolidine-1-
carboxylate (1.73). According to general procedure 1.4 using CsF, 1.73 was obtained as an 
amorphous white solid (1.15 g, 87%) after flash chromatography (30% EtOAc in hexane) from 
ketone 1.57 (1.2 g, 2.25 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.11 (d, 4H, J = 8.7 Hz), 6.83 (d, 
4H, J = 8.6 Hz), 4.93 (m, 1H), 4.36 (s, 4H), 3.80 (s, 6H), 3.52 (m, 1H), 2.35 (m, 1H), 2.18 
(m,1H), 1.91 (m,2H), 1.42 (s, 9H); 13C{1H} NMR (CDCl3, 75 MHz): δ (major rotamer) 194.8 (t, 





46.6, 30.3, 28.1, 23.2; (minor rotamer) 195.2 (t, J = 22.7), 159.4, 153.9, 130.1, 126.2, 115.4 (t, J 
= 297.8), 113.9, 80.0, 60.7, 55.0, 50.5, 46.8, 29.7, 28.2, 24.5 19F NMR (CDCl3, 282 MHz)(5:4 
mixture of rotamers): δ (major rotamer) -106.5 (d, J = 244.3 Hz), -108.3 (d, J = 244.4 Hz); 
(minor rotamer) -107.7 (d, J = 240.7 Hz), -108.8 (d, J = 240.5 Hz); HRMS-ESI+ (m/z) calcd for 
C27H38N2O7SF2
+
 (M + NH4)
+ 586.2393, found 586.2393.  
 
Benzyl (S)-2-(2-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,2-difluoroacetyl)pyrrolidine-1-
carboxylate (1.74). According to general procedure 1.4 using CsF, 1.74 was obtained as an 
amorphous white solid (1.41 g, 89%) after flash chromatography (30% EtOAc in hexane) from 
ketone 1.58 (1.5 g, 2.65 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.33 (m, 5H), 7.10 (m, 4H), 6.84 
(d, 4H, J = 7.6 Hz), 5.08 (m, 3H), 4.34 (d, 4H, J = 11 Hz), 3.80 (s, 6H), 3.59 (m, 2H), 2.36 (m, 
1H), 2.18 (m, 1H), 1.96 (m, 2H); 13C{1H} NMR ((CD3)2SO, 125 MHz): δ (Major Rotamer) 
194.8 (t, J = 22.9 Hz), 159.1, 153.9, 136.7, 129.9, 128.5, 128.0, 127.6, 126.5, 115.2 (t, J = 296.6 
Hz), 114.0, 66.6, 61.3, 55.2, 50.8, 46.5, 29.3, 24.4; (minor rotamer) 194.8 (t, J = 22.9 Hz), 153.0 
136.5 129.9 128.3 127.9 127.7 126.4, 115.3 (t, J = 296.6 Hz), 114.0 66.5 61.4 55.2 50.8 47.0 
29.9 23.1; 19F NMR (CDCl3, 282 MHz)(10:9 mixture of rotamers): δ (minor rotamer) -107.8 (d, 
J = 241.4 Hz), -108.7 (d, J = 242.0 HZ); (major rotamer) -107.8 (d, J = 239.7 Hz), -109.0 (d, J 
= 239.6 Hz); HRMS-ESI+ (m/z) calcd for C30H36N3O7SF2
+
 (M + NH4)







tert-Butyl (S)-(1-(N-ethylsulfamoyl)-1,1-difluoro-2-oxo-5-phenylpentan-3-yl)carbamate (1.75). 
According to general procedure 1.4 using TBAF, 1.75 was obtained as a white solid (0.078 g, 
74% yield) after flash chromatography (15% EtOAc, 85% hexane) from ketone 1.28 (0.096 g, 
0.250 mmol). 1H NMR (CDCl3, 300 MHz): δ 7.38-7.10 (m, 5H), 6.19 (s, 1H), 5.05 (d, 1H, J = 
7.6 Hz), 4.78-4.73 (bt, 1H, J = 7.1 Hz), 3.35-3.10 (m, 2H), 2.84-2.61 (m, 2H), 2.32-2.18 (m, 
1H), 1.89-1.71 (m, 1H), 1.43 (s, 9H), 1.43 (t, 3H, J = 7.1 Hz), 1.44 (s, 9H), 1.19 (t, 3H, J = 7.1 
Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 195.8 (t, J = 23.7 Hz), 155.9, 139.5, 128.7, 128.4, 
126.6, 115.3 (t, J = 299.1 Hz), 81.5, 56.5, 39.3, 31.8, 28.1, 15.5; 19F NMR (CDCl3, 282 MHz): -
108.3 (d, J = 244.8 Hz), -109.4, (d, J = 244.8 Hz); HRMS-ESI+ (m/z) calcd for C18H31F2N3O5S 
(M + NH4)
+, 438.1869; found, 438.1862. If CsF was used instead of TBAF then 1.75 was 
obtained in a 68% yield. 
 
tert-Butyl (S)-2-(2-(N-benzhydrylsulfamoyl)-2,2-difluoroacetyl)pyrrolidine-1-carboxylate (1.76). 
According to general procedure 1.4 using TBAF, 1.76 was obtained as a white amorphous solid 
(570 mg, 44%) after flash chromatography (15 to 20% EtOAc in hexane) from ketone 1.59 (1.2 
g, 2.5 mmol). 
1H NMR (CDCl3, 300 MHz)(1:3 ratio of rotamers): δ 7.95 (s, 1H), 7.35 (m, 10H), 





13C{1H} NMR (CDCl3, 75 MHz): δ (major rotamer)194.4 (t, J = 22.5 Hz), 154.4, 141.0, 140.3, 
128.7, 127.9, 127.4, 115.1 (t, J = 296.5 Hz), 81.1, 62.4, 61.2, 47.0, 29.4, 28.3, 24.3; (minor 
rotamer) 194.6 (t, J = 23.5 Hz), 153.4, 140.6, 140.5, 128.6, 127.8, 127.6, 114.2 (t, J = 294.3 Hz), 
81.1, 62.5, 61.5, 46.6, 30.1, 28.2, 23.2 
19F NMR (CDCl3, 282 MHz)(1:3 ratio of rotamers): δ 
(minor rotamer) -106.7 (d, J = 252.7), -109.6 (d, J = 252.7 Hz); (major rotamer) -110.8 (d, J = 
239.9 Hz) -111.7 (d, J = 238.6 Hz); HRMSESI- (m/z) calcd for C24H27N2O5SF2
-
 (M - H)
- 
493.1603, found 493.1610.  
 
 Allyl (S)-2-(2-(N-benzhydrylsulfamoyl)-2,2-difluoroacetyl)pyrrolidine-1-carboxylate (1.77). 
According to general procedure 1.4 using CsF, 1.77 was obtained as an amorphous white solid 
(665 mg, 41%) after flash chromatography (10 to 30% EtOAc in hexane) from ketone 1.60 (1.34 
g, 3.00 mmol).1H NMR (CDCl3, 300 MHz)(1:5 ratio of rotamers): δ 7.56 (s, 1H), 7.31 (m, 10H), 
5.79 (m, 2H), 5.19 (m, 2H), 4.88 (dd, 0.17H, J = 8.8, 4.4 Hz), 4.71 (m, 0.83H), 4.43 (m, 2H), 
3.46 (m, 2H), 1.97 (m, 4H); 13C{1H} NMR (CDCl3, 75 MHz): δ (major rotamer) 194.3 (t, J = 
22.9 Hz), 154.7, 140.9, 140.1, 132.4, 128.7, 128.6, 127.9, 127.5, 117.9, 115.1 (t, J = 297.6 Hz), 
66.6, 62.5, 61.7, 46.8, 29.4, 24.4; (minor rotamer) 194.3 (t, J = 297.6 Hz), 153.6, 140.9, 140.3, 
132.6, 128.8, 128.7, 128.6, 128.1, 127.9, 127.5, 118.3, 114.5 (t, J = 297.2 Hz), 66.5, 62.5, 61.5, 
47.0, 30.1, 23.3; 19F NMR (CDCl3, 282 MHz)(1:6 ratio of rotamers): δ (minor rotamer) -108.4 
(d, J = 250.4 Hz), -109.2 (d, J = 250.0 Hz); (major rotamer) -110.6 (d, J = 239.5 Hz), -111.2 (d, 
J = 239.0 Hz); HRMS-ESI+ (m/z) calcd for C23H28N3O5SF2
+
 (M + NH4)






General procedure 1.5 for the preparation of iminoketones 1.78 – 1.80.  
To a solution of the ß-ketosulfonamide in dry DMF (0.025 M) Cs2CO3 (4 equiv) was added 
followed by Selectfluor (4 equiv). The reaction was stirred at room temperature for 1 hour. Then 
the mixture was diluted with water then extracted with Et2O (3x). The combined organic layers 
were washed with saturated brine then dried (Na2SO4) and concentrated by rotary evaporation. 
flash chromatography of the residue provided imines 1.78 – 1.80. 
 
tert-Butyl (E)-(4-(N-allyl-N-methylsulfamoyl)-4,4-difluoro-3,3-dihydroxybutan-2-ylidene)-
carbamate (1.78). According to general procedure 1.5, 1.78 was obtained as an amorphous white 
solid (0.041 g, 35% yield) after flash chromatography (30% EtOAc, 70% hexane) from ketone 
1.47 (0.100 g, 0.312 mmol). 1H NMR (CDCl3, 300 MHz): δ 8.70 (bs, 1H), 5.82-5.69 (m, 1H), 
5.28 (bd, 2H, J = 13.4 Hz), 4.37 (s, 1H), 3.92 (bs, 1H), 2.95 (s, 3H), 1.73 (s, 3H), 1.48 (s, 9H), 
1.43 (t, 3H, J = 7.1 Hz), 1.44 (s, 9H), 1.19 (t, 3H, J = 7.1 Hz); 13C{1H} NMR (CDCl3, 75 MHz): 
δ 160.5, 148.7, 131.7, 121.7 (t, J = 295.1 Hz), 120.1, 83.1, 76.8 (t, J = 21.7 Hz), 53.6, 34.9, 27.9, 
21.0; 19F NMR (CDCl3, 282 MHz): δ -106.3 (bd, J = 243.3 Hz), -107.4 (d, J = 243.1 Hz); 
HRMS-ESI+ (m/z) calcd for C13H22F2N2O6LiS (M + Li)
+, 379.1321; found, 379.1320. 
 
tert-Butyl (E)-(4-(N-allyl-N-methylsulfamoyl)-4,4-difluoro-3,3-dihydroxy-1-phenylbutan-
2-ylidene) carbamate (1.79). According to general procedure 1.5 1.79 was obtained as an 





hexane) from ketone 1.46 (0.050 g, 0.126 mmol). 1H NMR (CDCl3, 300 MHz): δ 8.35 (s, 1H), 
7.40-7.21 (m, 5H), 5.89-5.73 (m, 1H), 5.34 (two overlapping doublets with J ~ 11.5 Hz, 2H), 
4.2-3.7 (bs, 1H), 3.98 (s, 2H), 3.62 (d, 1H, J = 14.1 Hz), 3.36 (d, 1H, J = 14.1 Hz), 3.02 (s, 3H), 
1.44 (s, 9H); 13C{1H} NMR (CDCl3, 75 MHz): δ 165.3, 148.2, 132.1, 131.7, 130.7, 128.7, 127.7, 
121.7 (t, J = 297.1 Hz), 120.2, 82.80, 79.5 (t, J = 26.2 Hz), 53.6, 38.6, 35.0, 27.8; 19F NMR 
(CDCl3, 282 MHz): δ -105.7; HRMS-ESI
+ (m/z) calcd for C15H19F2N2O6S(M – C4H9 + 2H)
+, 
393.0926; found, 393.0933. 
 
tert-Butyl (E)-(1-(N-allyl-N-ethylsulfamoyl)-1,1-difluoro-2,2-dihydroxy-5-phenylpentan-3-
ylidene)carbamate (1.80). According to general procedure 1.5 1.80 was obtained as an 
amorphous white solid (0.036 g, 64% yield) after flash chromatography (20% EtOAc, 80% 
hexane) from ketone 1.54 (0.050 g, 0.118 mmol). 1H NMR (CDCl3, 300 MHz): δ 8.76 (s, 1H), 
7.32-7.16 (m, 5H), 5.88-5.71 (m, 1H), 5.31 (d, 1H, J = 17.3 Hz), 5.30 (d, 1H, J = 7.7 Hz), 4.28 
(s, 1H), 4.10-3.90 (m, 1H), 3.53-3.36 (m, 1H), 3.90-3.75 (m, 1H), 2.66-2.52 (m, 2H), 2.41-2.38 
(m, 1H), 1.55 (s, 9H), 1.20 (t, 3H, J = 7.0 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 165.3, 148.5, 
140.1, 132.2, 128.5, 128.4, 126.2, 120.7 (t, J = 296.5 Hz), 119.9, 83.1, 79.5 (t, J = 21.6Hz), 50.2, 
42.8, 34.8, 28.8, 27.9, 13.6; 19F NMR (CDCl3, 282 MHz): δ -107.2 (d, J = 243.1 Hz), -108.1 (d, 
J = 243.1 Hz); HRMS-ESI+ (m/z) calcd for C21H30F2N2O6NaS (M + Na)






General procedure 1.6 Fluorination of benzoyl methane sulfonamides 1.41 - 1.44. 
The benzoyl methane sulfonamide was dissolved in dry DMF (0.25 M) and cooled to -15 °C 
before TBAF (1 M in THF, 4 equiv) followed by Selectfluor (4 equiv) were added. The reaction 
was stirred for 2-4 h until completed by TLC, then was diluted with four volumes of water. The 
mixture was extracted three times with four volumes of diethyl ether the then combined organic 
layers were washed three times with four volumes of water then dried over MgSO4, filtered, and 
concentrated. The residue was purified by flash chromatography, eluting with ethyl acetate and 
hexanes.  
 
N,N-Diallyl-1,1-difluoro-2-oxo-2-phenylethane-1-sulfonamide (1.81) According to general 
procedure 1.6, 1.81 was obtained as white solid (1.31 g, 88%) after flash chromatography (10% 
ethyl acetate in hexanes) from 1.42 (1.32 g mg, 4.7 mmol). 1H NMR (CDCl3, 300 MHz): δ 8.17 
(d, 2H, J = 8.1 Hz), 7.67 (t, 1H, J = 7.5 Hz), 7.52 (t, 2H, J = 7.7 Hz), 5.82 (ddt, 2H, J = 16.9, 
10.3, 6.6 Hz), 5.29 (m, 4H), 4.00 (d, 4H, J = 6.5 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ ν(F1) 
[ppm] 184.5 (t, J = 23.8 Hz), 135.1, 131.9, 131.7, 130.7, 130.6, 130.6, 128.7, 120.3, 116.8 (t, J = 
295.5 Hz), 50.1; 19F NMR (CDCl3, 282 MHz): δ -102.0; HRMS-ESI
+ (m/z) calcd for 
C14H15NO3SF2
+
 (M + K)
+ 354.0378, found 354.0372.  
 
N,N-Diethyl-1,1-difluoro-2-oxo-2-phenylethane-1-sulfonamide (1.82) According to general 





ethyl acetate in hexanes) from 1.41 (714 mg, 2.8 mmol). 1H NMR (CDCl3, 300 MHz): δ 8.17 (d, 
2H, J = 7.6 Hz), 7.67 (t, 1H, J = 7.4 Hz), 7.51 (t, 2H, J = 7.7 Hz), 3.49 (br, 4H), 1.26 (t, 6H, J = 
7.2 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 184.8 (t, J = 23.8 Hz), 135.2, 131.9, 130.7, 130.7, 
130.7, 128.8, 117.1 (t, J = 295.3 Hz), 43.0, 14.3; 19F NMR (CDCl3, 282 MHz): δ -102.0; HRMS-
ESI+ (m/z) calcd for C12H16NO3SF2
+
 (M + H)
+ 292.0814, found 292.0813. 
 
N,N-Bis(2,4-dimethoxybenzyl)-1,1-difluoro-2-oxo-2-phenylethane-1-sulfonamide (1.83) 
According to general procedure 1.6, 1.83 was obtained as white solid (66 mg, 62%) after flash 
chromatography (10% ethyl acetate in hexanes) from 1.43 (100 mg, 0.2 mmol). 1H NMR 
(CDCl3, 300 MHz): δ 8.17 (d, 2H, J = 7.9 Hz), 7.64 (t, 1H, J = 7.4 Hz), 7.49 (t, 2H, J = 7.8 Hz), 
7.15 (d, 2H, J = 8.4 Hz), 6.36 (dd, 2H, J = 8.4, 1.8 Hz), 6.28 (d, 2H, J = 1.8 Hz), 4.55 (s, 4H), 
3.75 (s, 6H), 3.66 (s, 6H); 13C{1H} NMR (CDCl3, 75 MHz): δ 184.9 (t, J = 23.8 Hz), 160.6, 
158.3, 134.9, 132.0, 130.8, 130.6, 128.7, 117.4 (t, J = 296.5 Hz), 116.1, 103.9, 97.8, 55.3, 54.9, 
47.1; 19F NMR (CDCl3, 282 MHz): δ -101.0; HRMS-ESI
+ (m/z) calcd for C26H28NO7SF2
+
 (M + 
H)+ 536.1560, found 536.1551. 
 
1,1-Difluoro-N,N-bis(4-methoxybenzyl)-2-oxo-2-phenylethane-1-sulfonamide (1.84) According 
to general procedure 1.6, 1.84 was obtained as white solid (67 mg, 72%) after flash 





(CDCl3, 300 MHz) δ: 8.24 (d, 2H, J = 7.8 Hz), 7.68 (t, 1H, J = 7.33 Hz), 7.53 (t, 2H, J = 7.7 
Hz), 7.14 (d, 4H, J = 8.4 Hz), 6.83 (d, 4H, J = 8.4 Hz), 4.39 (s, 4H), 3.80 (s, 6H);13C{1H} NMR 
(CDCl3, 75 MHz) δ: 184.6 (t, J = 23.8 Hz), 159.4, 135.1, 131.8, 130.7, 130.2, 128.7, 126.2, 
117.1 (t, J = 296.1 Hz), 113.9, 77.4, 76.9, 76.5, 55.2, 50.6;19F NMR (CDCl3, 282 MHz) δ: -
101.0; HRMS-ESI+ (m/z) calcd for C24H23NO5SF2
+
 (M + Li)
+ 482.1420, found 482.1420. 
 
tert-Butyl (S)-(1,1-difluoro-4-methyl-1-(N-methylsulfamoyl)-2-oxopentan-3-yl)carbamate (1.85) 
To a solution of 1.62 (50 mg, 0.130 mmol, 1 equiv) and DMBA (110 mg, 0.71 mmol, 5 equiv) in 
2.5 mL dry acetonitrile in a pressure tube Pd(PPh3)4 (15 mg, 0.0130, 0.1 equiv) was added. The 
mixture was heated to 100 °C for 24 h. After cooling, the mixture was diluted with EtOAc and 
washed with sat. NaHCO3 (3x), water (1x) and brine (1x), dried (Na2SO4) and concentrated by 
rotary evaporation. The residue was purified by flash chromatography (20% EtOAc, 80% 
hexane) to give 1.85 as a white amorphous solid (36 mg, 81%). 1H NMR (DMSO-d6, 300 MHz): 
δ 6.02 (bs, 1H), 4.98 (d, 1H, J = 8.6 Hz), 4.73 (dd, 1H, J = 2.9, 7.6 Hz), 2.92 (d, 3H, J = 3.9 
Hz), 2.43-2.31 (m, 1H), 1.42 (s, 9H), 1.08 (d, 3H, J = 6.6 Hz), 0.85 (d, 3H, J = 6.8 Hz), 13C{1H} 
NMR (DMSO-d6, 75 MHz): δ 195.5 (t, J = 22.7 Hz), 156.1, 115.2 (t, J = 297.0 Hz), 81.2, 61.4, 
30.1, 28.6, 28.1, 19.9, 16.1; 19F NMR (DMSO-d6, 282 MHz): δ -105.8 (d, J = 249.6 Hz), -106.0 
(d, J = 245.0 Hz), -110.2 (d, J = 246.1 Hz), -110.8 (d, J = 245.3 Hz); HRMS-ESI+ (m/z) calcd 
for C12H23F2N2O5S (M + H)






tert-Butyl (S)-(4,4-difluoro-4-(N-methylsulfamoyl)-3-oxo-1-phenylbutan-2-yl)carbamate (1.86) 
To a solution of 1.63 (50 mg, 0.140 mmol, 1 equiv) and DMBA (110 mg, 0.71 mmol, 5 equiv) in 
2.5 mL dry acetonitrile in a pressure tube Pd(PPh3)4 (15 mg, 0.0140, 0.1 equiv) was added. The 
mixture was heated to 100 °C for 24 h. After cooling, the mixture was diluted with EtOAc and 
washed with sat. NaHCO3 (3x), water (1x) and brine (1x), dried (Na2SO4) and concentrated by 
rotary evaporation. The residue was purified by flash chromatography (30% EtOAc, 70% 
hexane) to give 1.86 as a white amorphous solid (41 mg, 76%). 1H NMR (CDCl3, 300 MHz): δ 
7.36-7.24 (m, 3H), 7.16 (d, 2H, J = 6.8 Hz), 6.10 (bs, 1H), 5.10-5.01 (m, 1H), 4.92 (d, 1H, J = 
6.3 Hz), 3.30 (dd, 1H, J = 3.4, 17.1 Hz), 2.94-2.77 (m, 4H), 1.36 (s, 9H), 13C{1H} NMR (CDCl3, 
75 MHz): δ 195.1 (t, J = 23.2 Hz), 155.6, 134.4, 129.2, 129.0, 127.6, 115.5 (t, J = 298.1 Hz), 
83.4, 57.6, 36.0, 30.0, 28.1; 19F NMR (CDCl3, 282 MHz): δ -106.8 (d, J = 246.6 Hz), -108.2 (d, 
J = 246.6 Hz); HRMS-ESI+ (m/z) calcd for C16H23F2N2O5S (M + H)
+, 393.1290; found, 
393.1290.  
 
tert-Butyl (S)-2-(2,2-difluoro-2-sulfamoylacetyl)pyrrolidine-1-carboxylate (1.87). Sulfonamide 
1.76 (200 mg, 0.4 mmol, 1 equiv) was dissolved in 5 mL of THF and 15 mL of EtOH. DIPEA 
(70 µL, 0.40 mmol, 1 equiv) followed by Pd(OH)2 20 wt% on carbon (56 mg, 0.08 mmol, 0.2 





through celite and rinsed with 100 mL of EtOAc. The eluent was washed once with 50 mL of 5% 
NaHCO3 and once with 50 mL of 0.1 M HCl. The organic layer was dried over MgSO4, filtered, 
and concentrated to dryness then the residue was purified by flash chromatography using 20% 
EtOAc in hexanes to give 1.87 as (100 mg, 76%) of a white solid. 1H NMR (CDCl3, 500 
MHz)(4:1 mixture of rotamers): δ 6.28 (br, 1.6H), 5.64 (br, 0.4H), 5.07 (dd, 0.8H, J = 8.7, 4.1 
Hz), 4.90 (dd, 0.2H, J = 8.5, 4.1 Hz), 3.57 (m, 1H), 3.46 (m, 1H), 2.37 (m, 1H), 1.98 (m, 3H), 
1.45 (s, 7.2H), 1.41 (s, 1.8H); 13C{1H} NMR (CDCl3, 75 MHz): δ (major rotamer) 194.9 (ap t, J 
= 23.0 Hz), 154.6, 114.7 (ap t, J = 295.9 Hz), 81.5, 61.6, 47.0, 29.3, 28.3, 24.4; (minor rotamer) 
194.9 (ap t, J = 23.0 Hz), 154.6, 114.7 (ap t, J = 295.9 Hz), 81.2, 61.6, 46.5, 29.8, 28.2, 23.3; 19F 
NMR (CDCl3, 472 MHz): (minor rotamer) δ -106.7 (d, J = 257.6 HZ), -111.9 (d, J = 257.6 Hz); 
(major rotamer) -112.8 (apparent singlet); HRMS-ESI+ (m/z) calcd for C11H17N2O5SF2
+
 (M + H)
+ 
327.0821, found 327.0828.  
 
tert-Butyl (S)-2-(2-sulfamoylacetyl)pyrrolidine-1-carboxylate (1.27). Prepared by deprotection of 
1.59. Sulfonamide 1.59 (830 mg, 1.81 mmol, 1 equiv) was dissolved in 60 mL of EtOH and 20 
mL of THF. DIPEA (320 µL, 1.81 mmol, 1 equiv) was added followed by Pd(OH)2 20wt% on 
carbon (254 mg, 0.36 mmol, 0.2 equiv) was added and the reaction was stirred under hydrogen 
atmosphere for 36 h. The mixture was filtered through celite concentrated. The residue was 
purified by flash chromatography, 20 to 50% EtOAc in hexanes to give 1.27 as 320 mg (60% 
yield) of a white solid. 113 mg (14%) of unreacted starting material was recovered. 1H NMR 





Hz), 4.26 (m, 0.9H), 4.11 (d, 0.7H, J = 14.7 Hz), 3.45 (m, 2H), 2.17 (m, 1H), 1.89 (m, 3H), 1.40 
(s, 6.3H), 1.38 (s, 2.7H); 13C{1H} NMR (CDCl3, 75 MHz): δ (major rotamer) 200.2, 154.7, 80.8, 
64.6, 61.8, 47.0, 28.2, 28.1, 24.2; (minor rotamer) 200.8, 153.5, 81.1, 66.1, 59.4, 46.7, 29.3, 28.2, 
23.6; HRMS-ESI+ (m/z) calcd for C11H20N2O5SNa
+
 (M + Na)
+ 315.0996, found 315.0984.  
 
Benzyl (S)-2-(2,2-difluoro-2-sulfamoylacetyl)pyrrolidine-1-carboxylate (1.88). Protected 
sulfonamide 1.74 (250 mg, 0.415 mmol, 1 equiv) was dissolved in 20 mL of CH3CN and cooled 
to 0 °C. CAN (1.82 g, 3.32 mmol, 8 equiv) was added dissolved in 8 mL of water. The mixture 
was stirred in an ice bath for 4 h until complete by TLC. 50 mL of water was added and the 
reaction was extracted 3 times with 30 mL of EtOAc, the combined organic layers were washed 
with 50 mL of water and 50 mL of brine then dried over MgSO4, filtered, and concentrated. 
Residue was purified by flash chromatography, 5 to 50% EtOAc in hexanes. Fractions 
containing product were pooled and further purified by reverse phase chromatography using a 
Biotage Isolera One Flash purification system including a C-18 reversed-phase preparative 
Biotage column (30 g) using a gradient of 5 to 100% methanol over 20 min at 25 mL per minute 
(RT = 14 min) giving 1.88 as 21 mg of a colorless oil (14% yield). This existed as a 1:8 ratio of 
rotamers as determined by 19F NMR. 1H NMR (CDCl3, 300 MHz): δ ; 6.74 (m, 5H), 5.59 (bs, 
2H), 5.1 (m, 3H), 3.98 (m, 2H), 3.09 (m, 1H), 2.81 (m, 3H); 13C{1H} NMR (CDCl3, 125 MHz): 
δ ; 194.6 (ap t, J = 23.0 Hz), 155.1, 135.8, 128.6, 128.3, 127.9, 114.8 (ap t, J = 297.6 Hz), 67.9, 
62.1, 47.0, 29.4, 24.5; 19F NMR (CDCl3, 282 MHz): δ (minor rotamer) -109.4 (d, 1F, J = 254.6 





= 240.0 Hz); HRMS-ESI+ (m/z) calcd for C14H16O5N2F2NaS
+
 (M + Na)
+ 385.0640, found 
385.0632. 
 
1,1-Difluoro-2-oxo-2-phenylethane-1-sulfonamide (1.89). Protected sulfonamide 1.84 (86 mg, 
0.16 mmol) was dissolved in 2 mL of TFA and cooled to 0 °C, 3 mL of TFA was then added 
dropwise and the mixture was stirred at room temperature for 2 h until complete. The reaction 
gradually developed an insense purple color. The reaction was diluted with 50 mL of toluene and 
50 mL of iPrOH and concentrated in the presence of silica then purified by flash 
chromatography, 10 to 30% EtOAc in hexanes to give 1.89 as a white solid. 30 mg (79% yield). 
1H NMR (CDCl3, 300 MHz): δ ; 8.15 (dd, 2H, J = 8.5, 1.2 Hz), 7.73 (tt, 1H, J = 7.5, 1.4 Hz), 
7.57 (t, 2H, J = 7.8 Hz), 5.09 (br, 2H); 13C{1H} NMR (CDCl3, 125 MHz): δ ; 185.2 (t, J = 24.7 
Hz), 135.7, 131.4, 130.6 (t, J = 3.1 Hz), 129.0, 115.0 (t, J = 297.0 Hz); 19F NMR (CDCl3, 282 
MHz): δ -102.8 (s, 2F); HRMS-ESI+ (m/z) calcd for C8H7F2NNaO3S
+
 (M + Na)












Chapter 2 — Synthesis of ß-hydroxy-α,α-difluorosulfonamides 
2.1 — Introduction 
 Much like the analogous ketones discussed in Chapter 1, ß-hydroxy-α,α-
difluorosulfonamides are a relatively unexplored class of molecules that have been reported only 
once. If these molecules could be easily accessed then we would expect them to be of interest 
because ß-hydroxysulfonamides and ß-hydroxy-α,α-difluoroamides are known to be biologically 
active. The synthesis of ß-hydroxy-α,α-difluorosulfonamides, with emphasis on those derived 
from amino acids in diastereomerically pure fashion, will be the subject of this chapter.  
2.1.1 — ß-hydroxy-α,α-difluorosulfonamides 
 To the best of our knowledge, there is only a single report describing the synthesis of ß-
hydroxy-α,α-difluorosulfonamides, and this report was not concerned with their biological 
activity.71 On the other hand, closely related groups of molecules have been prepared and these 
are known to be enzyme inhibitors. The two most closely related groups are nonfluorinated ß-
hydroxysulfonamides and ß-hydroxy-α,α-difluoroamides. Numerous ß-hydroxy-α,α-
difluoroamides have been investigated as renin inhibitors, and examples are known with IC50 
values in the low or sub-nanomolar region, such as peptidomimetic 2.1 (Figure 2.1).28,72-75 
Similarly, ß-hydroxysulfonamide-based renin inhibitors, such as sulfonamide 2.2, have been 





hydroxy-α,α-difluorosulfonamides of appropriate structure might be potent inhibitors of renin, 
and perhaps other enzymes as well.  
 
Figure 2.1. Structure ß-hydroxy-α,α-difluoroamide and ß-hydroxysulfonamide renin inhibitors. 
 There are two approaches to the synthesis of ß-hydroxy-α,α-difluorosulfonamides that are 
obvious to us. The first is by reduction of the analogous ketones. This method has been used 
previously for the synthesis of non-fluorinated ß-hydroxysulfonamide 2.3 (Scheme 2.1).31 The 
synthesis of the ß-keto-α,α-difluorosulfonamides was discussed in the previous chapter and we 
expect that their reduction should be feasible and that, with sufficient experimentation, it might 
even be accomplished with a high dr. However, as part of our larger interest in peptidomimetics, 
a route that would be compatible with as many amino acid side chains as possible was desirable. 
The ß-keto-α,α-difluorosulfonamide derivatives of amino acids that can be accessed by the 
electrophilic fluorination route are limited to those which have side chains that can tolerate 
electrophilic fluorination and reaction with excess alkyl lithium, which does not include, for 
example, methionine and aspartate derivatives. Additionally, it is equally feasible that ß-
hydroxy-α,α-difluorosulfonamides could be oxidized to ketones providing a synthesis that is 






Scheme 2.1. Synthesis of ß-hydroxysulfonamides via carbonyl reduction. 
 The second approach involves reacting carbanions of difluoromethane sulfonamides with 
aldehydes (Scheme 2.2). This approach would have the advantage of using the same fluorinated 
precursor for every derivative and would avoid late stage electrophilic fluorination which is 
problematic for certain substrates.  
 
Scheme 2.2. General synthesis of ß-hydroxy-α,α-difluorosulfonamides. 
 An approach that is similar to that outlined in Scheme 2.2 was reported by Li and Liu in 
2007, and this is the only report describing the synthesis of this class of compounds.71 In their 
approach, the precursor 2.6 was prepared in a double nucleophilic displacement of fluorides from 
2.4 in two steps (Scheme 2.3a). Amide 2.6 was reacted with an excess of potassium tert-butoxide 
in DMF in the presence of aryl aldehydes at low temperatures to give tert-butyl morpholine 
carbamate and difluoromethane sulfonamide carbanion 2.7, which reacts with the aromatic 
aldehydes to give 2.8 in good yield (Scheme 2.3b). If the temperature was allowed to rise to rt 
then the sulfur atom was also attacked by tert-butoxide to give tert-butyl morpholine sulfonate 
with a second difluoromethane carbanion as a leaving group that can react with a second 
aldehyde to give anti-1,3-diols 2.9. This method suffers from significant limitations. While 2.4 is 
commercially available, it is expensive, toxic, and volatile. The reaction requires anhydrous 





expensive or must be prepared. Furthermore, this approach failed entirely using enolizable 
aldehydes which would be required for our purposes. We reasoned that it should be possible to 
generate carbanion 2.7 from a difluoromethane sulfonamide and a suitable base because this 
approach was successful with the methane sulfonamides described in Section 1.2.3 and the 
difluoromethane sulfonamides should be more acidic due to the presence of electron 
withdrawing groups.  
 
Scheme 2.3. Literature synthesis of ß-hydroxy-α,α-difluorosulfonamides. 
2.1.2 — Fluorinated carbanions as nucleophiles 
 Fluoroalkylation chemistry is markedly different from standard alkylation chemistry. A 
complete discussion of this topic is far beyond the scope of this work and has been reviewed.77 
There are, however, important features that must be summarized here regarding fluoroalkyl 
nucleophiles. Relative to alkyl carbanions, fluoroalkyl carbanions are harder nucleophiles and 
are kinetically unstable, and both of these factors make nucleophilic fluoroalkylations difficult.78 
One of the reasons for this instability is that fluorocarbanions can undergo α-elimination to expel 
fluoride and yield a carbene. However, fluoride is a very poor leaving group, especially if it is 





temperatures.79 The α-elimination can only take place if a Lewis acid, such as a metal ion, is 
present to accept the fluoride. Lithium is a stronger Lewis acid than sodium or potassium, 
meaning that the lithium fluorocarbanions salts are less stable than sodium or potassium salts. 
The opposite is true for unfluorinated carbanions where the potassium salts are less stable due to 
the relative strength of the carbon-lithium and carbon-potassium bond.80 Unfluorinated alkyl 
metal salts can generally be prepared and stored, many being commercially available. On the 
other hand, fluoroalkyl carbanions are generally prepared in situ and usually in the presence of 
the electrophile because they break down rapidly even at low temperatures.81,82 
 Alkyl lithium salts are generally less reactive than their sodium or potassium 
counterparts, due to relatively strong bonding between carbon and lithium and the greater 
tendency of lithium salts to form stable oligomers.80 However, with fluorinated carbanions, 
reactivity can be difficult to predict. In some cases, the greater stability and reactivity of the 
potassium salts leads to a superior outcome, for example, when sulfone 2.11 reacts with sulfinyl 
imine 2.10 to give 2.12, the yield is much higher using potassium than with sodium or lithium 
(Table 2.1).83 In other cases the exact opposite trend is observed, for example, the lithium salt of 
2.13 reacts with benzaldehyde to give much higher yields of 2.14 due to strong chelation 





Table 2.1. The effect of counterions on nucleophilic fluoroalkylation of sulfinyl imine 2.10 with 
difluoromethyl sulfone 2.11. 
 





Table 2.2. The effect of counterions on nucleophilic fluoroalkylation of benzaldehyde with 
sulfone 2.13. 
 





 ß-hydroxy-α,α-difluoro phosphonates85 and sulfones86 have been prepared by reaction of 
carbonyl compounds with the lithium salts of difluoromethane phosphonates and sulfones 
(Scheme 2.4). Therefore, we were confident that a similar transformation would be possible 
using the lithium salts of difluoromethanesulfonamides, provided that we could easily access the 
difluoromethane sulfonamide starting materials.  
 







2.1.3 — Difluoromethane sulfonamides 
 The most direct synthesis of sulfonamides is via sulfonylation of amines with the 
appropriate sulfonyl chloride (Scheme 2.5a). In most cases the transformation is straightforward 
and high yielding; however, difluoromethane sulfonyl chloride is an exception and sulfonylations 
with this reagent typically give low yields of difluoromethane sulfonamides.14,87-90 This is 
because sulfonylations in the presence of an amine base proceed through a sulfene 
intermediate.91 When difluoromethane sulfonyl chloride is used, it is possible that that reagent 
undergoes α-elimination rather than ß-elimination leading to difluorocarbene and sulfur dioxide 
(Scheme 2.5b). Furthermore, difluoromethane sulfonyl chloride is expensive, and is prepared 
from ozone depleting chemicals. Yields are slightly higher using difluoromethane sulfonyl 
fluoride 2.17 which reacts with morpholine to give 2.18 in 36 % yield (Scheme 2.5c).92 
Unfortunately 2.17 is prohibitively expensive although it can be prepared in a multistep low 
yielding procedure from 2.15.  
 
Scheme 2.5. Sulfonylation of nucleophiles with sulfonyl halides. 
 Another method would be alkylation of a precursor with a difluorohalomethane. Fluorine 
stabilizes carbocations, carbenes, and radicals more effectively than other halogens due to more 





analogs due to fluorine’s high electronegativity.77 These properties allow mixed 
fluorohalomethanes to react with nucleophiles in ways that other mixed halomethanes cannot. 
This general approach has been used for the synthesis of a variety of α,α-difluoro compounds 
including sulfides (Scheme 2.6a),93 phosphonates (Scheme 2.6b),85 phosphine oxides (Scheme 
2.6c)94 sulfones (Scheme 2.6d),95 and sulfonates (Scheme 2.6e).11 This approach would be 
difficult for the direct synthesis of difluoromethane sulfonamides because it would require S-
alkylation’s of sulfuramidous acids which have occasionally been used as nucleophiles but not 
using halomethanes.96,97  
 
Scheme 2.6. Synthesis α,α-difluoro compounds via alkylation with halomethanes. 
 Difluoromethyl phenylsulfone has also been made by difluoromethylation of thiophenol 
followed by oxidation (Scheme 2.7a).98 Oxidation of sulfenamides to sulfonamides is well 
known, including examples with α-halogens.99,100 Therefore, a route to difluoromethane 
sulfenamides should provide access to the desired sulfonamides. Sulfenamide 2.21 has been 





(Scheme 2.7b).101 The same reaction using chlorodifluoromethane should yield 2.22. 
Alternatively, difluoromethylthiolation of amines has been accomplished in high yields using 
reagent 2.23 which yields sulfenamide 2.24 that could, theoretically, be oxidized to 
difluoromethane sulfonamide 2.25 (Scheme 2.7c).102 A related reagent, 2.26, for the transfer of a 
thiodifluoromethyl phosphonate group has recently been developed which reacts with a variety 
of nucleophiles including amines to give 2.27. After oxidation of the sulfur atom, the 
phosphonate was hydrolyzed to yield the difluoromethane sulfonamide 2.28 (Scheme 2.7d).103 
 
Scheme 2.7. Literature preparations and proposed routes to difluoromethane sulfones and 






2.1.4 — Research objectives  
 The principal objective of this chapter is to develop an effective synthesis for ß-hydroxy-
α,α-difluorosulfonamides derived from amino acids via the route outlined in Scheme 2.2. This 
requires an efficient synthesis of difluoromethane sulfonamide precursors, an exploration of the 
chemistry of the alkali metal salts of these compounds and their reaction with aldehydes, and the 
preparation of the target ß-hydroxy-α,α-difluorosulfonamides. Ideally, the approach should 
provide the desired alcohols diastereoselectively and without epimerization at the amino acid α-
carbon. Finally, these sulfonamides should be deprotected under mild conditions to allow for 
their elaboration into peptidomimetics, which may act as inhibitors of renin and other aspartic 
proteases.  
2.2 — Results and discussion. 
 
2.2.1 — Synthesis of difluoromethane sulfonamides.  
In addition to the routes described in Section 2.1.3 for the preparation of 
difluoromethanesulfonamides, another possible approach is via decomposition of ß-
ketosulfonamides as outlined in Scheme 2.8. We anticipated that this should be possible because 
we observed difluoromethane sulfonamide 2.30 as a side product during electrophilic 
fluorination of ß-ketosulfonamides, such as 2.29 in Chapter 1 (Scheme 2.8). If this approach 
could be achieved in high yield, then it would be superior to the above methods which are either 







Scheme 2.8. Electrophilic fluorination of a ß-ketosulfonamide gives rise to a difluoromethane 
sulfonamide as a minor side product.  
 
To investigate this approach, we subjected sulfonamides 2.31-2.34 (described in Chapter 
1, section 1.2.3) to the fluorination conditions outlined in Section 1.2.5 to give ketones 2.35-2.38 
(Scheme 2.9) which were not isolated. NaOH was added to the reaction mixture which gave 
2.39-2.42 in good to outstanding overall yield.  
 
Scheme 2.9. Fluorination of ß-ketosulfonamides derived from methyl benzoate. 
 While this method does provide access to the desired difluoromethanesulfonamides in 
good yields, it suffers from two drawbacks. First, the reaction requires four equiv of Selectfluor 
which is inefficient. Secondly, the starting materials 2.31-2.34 are prepared using an excess of a 
methane sulfonamide which was difficult to remove from the sulfonamide product. Furthermore, 
this is wasteful in cases where the methane sulfonamide is derived from amines that are not 
commercially available and must be synthesized. 
 We reasoned that if we replaced methyl benzoate with a Weinreb amide then the 
synthesis could be performed without an excess of the methane sulfonamide which would 
simplify the isolation of the ß-ketone. When we performed this reaction using N-methyl-N-





must be removed by tedious chromatography so this provides no benefit over a methyl ester. 
Next, we employed N-methyl-N-methoxy trifluoroacetamide, reasoning that this would be more 
electrophilic, leading to a higher yield. Also, the trifluoromethyl ketone product should increase 
the acidity of the methylene protons of the ß-ketone, facilitating fluorination. This approach gave 
ß-ketones 2.47-2.50 in good to excellent yields (Scheme 2.10). The purification of these 
molecules is facilitated by the absence of substantial quantities of methane sulfonamides 2.43-
2.46 in the crude mixture.  
 
Scheme 2.10. Trifluoroacylation of methane sulfonamides. 
 We selected ketone 2.50 as a model substrate for the fluorination reaction. We hoped to 
reduce the number of equiv of Selectfluor employed from 4 to at most 2.5. We attempted the 
reaction using a variety of solvents, bases, and temperatures (Table 2.3). The yields of 2.52 as 
well as its hydrolysis product 2.53 and the monofluorinated intermediate, 2.51 were estimated by 
19F NMR. The best result was obtained with lithium carbonate in DMF at room temperature 
(entry 21), although sodium and potassium bicarbonates also give quite high yields (entries 24 
and 19). Good results could also be obtained with no base when the reaction was heated to 100 






Table 2.3. Optimization of fluorination conditions for 2.50. 
 
Entrya Solvent Temp Base (2.5 equiv) Time 2.50 (%) 2.51 (%) 2.52 (%) 2.53 (%) 
1 Acetone 80 None 8 h 75 25 trace 0 
2 AcOH 80 None 8 h Complex Mixture 
3 CH3CN 80 None 8 h Complex Mixture 
4 Dioxane 80 None 8 h 22 15 0 0 
5 Pyridine 80 None 8 h 25 0 50 0 
6 Pyridine RT None 16 h 2 36 43 0 
7 TEA 80 None 8 h Complex Mixture 
8 Water 80 None 8 h Complex Mixture 
9 DMF 45 None 16 h trace 30 34 0 
10 DMF 60 None 16 h 2 2.5 82 0 
11 DMF 80 None 4 h 20 0 63 0 
12 DMF 100 None 1 h 0 trace 78 0 
13 DMF 120 None 30 m 0 0 72 0 
14 DMF RT Cs2CO3 16 h 6 60 21 7 
15 DMF RT CsF 16 h 0 38 44 3 
16 DMF RT K2CO3 16 h 0 0 30 40 
17 DMF RT K3PO4 16 h 0 8 47 8 
18 DMF RT KF 16 h 0 20 65 trace 
19 DMF RT KHCO3 4 h 0 1 88 0 
20 DMF RT KOAc 16 h 2 11 46 0 
21 DMF RT Li2CO3 4 h 0 0 93 0 
22 DMF RT Na2CO3 16 h 0 0 69 20 
23 DMF RT NaF 16 h 1 36 60 0 
24 DMF RT NaHCO3 16 h 3 0 87 0 
25 DMF RT NaOAc 16 h 0 12 79 0 
a2.50 (28 mg, 0.110 mmol, 1 equiv) and Selectfluor (100 mg, 0.282 mmol, 2.50 equiv) were dissolved in 1 mL of 
solvent then the base was added. After the indicated time, 3-fluorotoluene (0.11 mmol, 1 equiv) was added and the 
yield was estimated by 19F NMR.  
 
 Pentafluoroketone 2.52 was prone to hydrolysis on silica and difficult to isolate; however, 
the monohydrate could be isolated by crystallization from hexanes in 20% yield. Fortunately, 





hydroxide to the reaction mixture once fluorination was complete to give 
difluoromethanesulfonamide 2.53 in good yield (Scheme 2.11). This methodology was applied to 
sulfonamides 2.47-2.49 to give difluoromethane sulfonamides 2.39, 2.41, and 2.42 in good to 
excellent yields.  
 
Scheme 2.11. Fluorination of trifluoroacetyl methane sulfonamides.  
aDetermined by 19F NMR.  
bCs2CO3 was used instead of Li2CO3. 
 
 In addition to their use as precursors for making ß-hydroxy-α,α-difluorosulfonamides, 
difluoromethane sulfonamides are of interest in their own right, such as the herbicide 
pyrimsulfan; however, these are rare due to the difficulty of efficiently installing a 
difluoromethanesulfonamide moiety. Our approach provides straightforward access to this 
functional group without the need for ozone-depleting reagents which should pave the way for 
further exploration in new areas. For example, we have found that we could treat proline-derived 
sulfonamide 2.54 with 2.1 equiv n-BuLi and react the resulting dianion with N-methyl-N-
methoxy trifluoroacetamide to give ketone 2.55 in 45% yield (Scheme 2.12). Treating 2.55 with 
Selectfluor in the presence of Li2CO3 for 1 h, followed by the addition of aq. NaOH, gave 
difluoromethane sulfonamide 2.56 in a 68% yield. Notably, both reactions proceed in the 
presence of an unprotected carboxylic acid. To the best of our knowledge, N-
difluomethanesulfonyl amino acids are unknown in the literature (Scheme 2.12). The ee of 2.55 






Scheme 2.12. Synthesis of an N-difluoromethanesulfonyl amino acid. 
2.2.2 — Difluoromethane sulfonamide anions.  
With the difluoromethane sulfonamides in hand we turned our attention to the reaction of 
their metalated derivatives with electrophiles using 2.41 as a model sulfonamide substrate. We 
had anticipated that the lithium salt of 2.41 would readily be prepared using n-BuLi and would 
react with electrophiles such as benzaldehyde and methyl benzoate to yield ß-hydroxy and ß-keto 
α,α-difluoro sulfonamides respectively. However, when sulfonamide 2.41 was treated with 1.1 
equiv of n-BuLi for 15 min in THF at -78 °C followed by addition of benzaldehyde, none of the 
desired product 2.57 was obtained (Scheme 2.13). Indeed, only starting material was observed by 
19F NMR after quenching the reaction with NH4Cl and extraction into ether. Similar results were 
obtained using methyl benzoate, benzoyl chloride and the Weinreb amide of benzoic acid.  
 
Scheme 2.13. Attempted reaction of the lithium salt of 2.41 with benzaldehyde. 
These results raised the question of whether or not the 2.41 was deprotonated by n-BuLi. 
To determine this, we performed a deuterium exchange experiment which involved treating, 2.41 
with n-BuLi as above, followed by quenching the reaction with aq. deuterium chloride after 30 





19F NMR spectrum and much of 2.41 remained unreacted; however, a small peak at -191 was 
observed corresponding to deuterium fluoride (Figure 2.2). Bis(4-methoxybenzyl)amine was the 
only new compound observed in the crude reaction by TLC. 
 
Figure 2.2. 19F NMR spectrum of the reaction mixture of 2.41 after treatment with 1.1 equiv n-
BuLi and quenching with DCl after 15 min. The doublet at -122 corresponds to 2.41 the broad 
peak at -190 corresponds to deuterium fluoride and the multiplet at -115 corresponds to the 
internal standard 3-fluorotoluene. 
 
Under the same reaction conditions the analogous methane sulfonamide underwent 






Figure 2.3. 1H NMR spectrum of 2.44 after treatment with n-BuLi in THF at -78 °C then quenching 
with DCl (aq) and extraction into EtOAc.   
(a) Starting material  
(b) Crude product. The peak at 2.7 corresponds to the methyl group which undergoes partial 
deuterium exchange.  
 
 We thought it unlikely that the fluorinated derivative should be less acidic than methane 
sulfonamide; therefore, it seemed more likely that some side reaction was taking place involving 
more than 1 equiv of n-BuLi. To further investigate this possibility, we reacted 2.41 with 
different amounts of n-BuLi and determined the amount of 2.41 remaining by 19F NMR using 3-






Figure 2.4. 19F NMR spectra of the organic layer of the reaction mixtures of sulfonamide 2.41 
after treatment with varying amounts of n-BuLi in THF at – 78 °C and quenching after 15 min 
with NH4Cl and extracting into Et2O.  The doublet at 122.5 ppm corresponds to 2.41 and the 
multiplet at -115 ppm corresponds to the internal standard, 3-fluorotoluene (3-FT). 
 
Table 2.4 Amount of 2.41 remaining in Figure 2.4. 
Entry equiv n-BuLi % 2.41 remaining 
1 0 100 
2 0.5 89 
3 1.0 63 
4 1.5 40 
5 2 2.5 






 The reaction required 2 equiv of n-BuLi before almost all of 2.41 was consumed after 15 
min at –78 °C. When 1.5 or more equiv of n-BuLi was used, a small doublet of triplets at 
approximately -116 ppm was observed which corresponds to 1,1-difluoropentane.104 The 
remainder of the fluorine is expected to be converted to lithium fluoride which remained in the 
aqueous layer. These results are in contrast to the related difluoromethyl phenylsulfone, which is 
recovered unchanged after deprotonation with LiHMDS and normal workup.105  
 Considering the mechanism of decomposition, α-elimination could take place cleaving 
either a carbon-fluorine bond or the carbon-sulfur bond. α-Elimination to give lithium fluoride is 
known to be very favorable in the case of lithium trifluoromethide.79,106 Fluoride α-elimination to 
produce fluorinated carbenes is also observed in the Grignard and organolithium derivatives of 
difluoromethane107 as well by deprotonation of certain difluoromethyl alkanes.108,109 Conversely 
difluoromethyl phenylsulfone decomposes to give difluorocarbene by α-elimination of a 
phenylsulfinic acid in the presence of sodium methoxide.98  
 A plausible mechanism for the major decomposition pathway is shown in Scheme 2.14. 
The lithium salt of 2.41 undergoes α-elimination to form sulfur dioxide, difluorocarbene and bis-
PMB amide. The carbene reacts with the amide to give carbanion 2.58. This would undergo a 
second α-elimination to lose lithium fluoride and yield carbene 2.59 which would be stabilized 
by resonance. Nucleophilic addition of a second molecule of n-BuLi would give carbanion 2.60 
which can decompose yielding a second equivalent of lithium fluoride and producing stabilized 
carbene 2.61. This molecule would persist until the reaction is quenched at which point it would 
be hydrolyzed to give bis-PMB amine and pentanal. Although it must be said that this 





intermediates. 1,1-Difluoropentane most likely arises from the reaction of n-BuLi and 
difluorocarbene, although it could also form by a direct SN2 attack of n-BuLi on 2.41.  
 
Scheme 2.14. Proposed mechanism for the decomposition of 2.41. 
 We hoped that we would be able to intercept the lithium salt of 2.41 if it were generated 
in the presence of the electrophile. We selected benzaldehyde as a model substrate, anticipating 
that a nonenolizable aldehyde would be the best substrate (Table 2.5). When 1.2 equiv of n-BuLi 
was added to a mixture of benzaldehyde and 2.41, no product 2.57 was formed. However, the 
amount of sulfonamide remaining was much greater than would be expected from the trend in 
Figure 2.4; therefore, we suspected n-BuLi reacted with benzaldehyde faster than it deprotonated 
2.41 (entry 2). Not surprisingly, no product or decomposition was observed when the 
sulfonamide was added to a mixture of the n-BuLi and benzaldehyde (entry 3). Adding 
benzaldehyde to a mixture of n-BuLi and 2.41 gave none of the desired product but did give the 
lowest level of unreacted 2.41 suggesting that much of 2.41 had decomposed (entry 4). Next, we 
turned to more sterically hindered bases, namely, LDA, LiHMDS, and LiOtBu; however, these 
bases also yielded little to no product (entries 5-7). Warming the reaction to -20 °C (entry 8), 
adding TMSCl (entry 9) or LiCl (entry 10) had no effect on the outcome; however, adding 





Table 2.5. Reaction of sulfonamide 2.41 in the presence of benzaldehyde and lithium bases. 
 
Entry Base Time (min) Unreacted 2.41a (%) Yield (2.57) 
1 - 15 100 0 
2 n-BuLi 15 88 0 
3b n-BuLi 15 99 0 
4c n-BuLi 15 32 0 
5 LiOtBu 15 65 Trace 
6 LDA 15 87 0 
7 LiHMDS 15 69 Trace 
8d LiHMDS 60 85 0 
9e LiHMDS 15 85 0 
10f LiHMDS 60 86 0 
11g LiHMDS 60 88 8 
a19F NMR yield determined after the reaction was quenched with NH4Cl. 3-fluorotoluene as an internal standard. 
bBase added to a solution of PhCHO at – 78 °C, stir 15 min, then add 2.41. Stir 15 min at – 78 °C. 
cBase added to a solution of 2.41 at – 78 °C, stir 15 min, then add PhCHO. Stir 15 min at – 78 °C. 
dReaction warmed to -20 °C after 5 min 
eReaction performed in the presence of 1.2 equiv TMSCl. 
fReaction performed in the presence of 4 equiv LiCl. 
gReaction performed in 5% HMPA/THF. 
 
 In all cases using LiHMDS, most of 2.41 remained unreacted, suggesting that this base is 
not strong enough to deprotonate 2.41 to an appreciable degree. KHMDS is a stronger base than 
LiHMDS,110 therefore, we examined NaHMDS and KHMDS. These bases (1.2 equiv) were 
added to a solution of 2.41 in THF at -78 °C in the absence of an electrophile then quenched after 
4 min with deuterium chloride in MeOD and analyzed by 19F NMR (Figure 2.5). Most of 2.41 
remained unreacted in the case of LiHMDS but was completely decomposed by NaHMDS or 
KHMDS, which are stronger bases. In all cases no deuterium incorporation was observed which 






Figure 2.5. 19F NMR spectra of the reaction mixtures of sulfonamide 2.41 after treatment with 
LiHMDS, NaHMDS or KHMDS in THF at – 78 °C and quenching after 4 min with DCl.  
 
 It is interesting to note that complete decomposition was observed with just 1.2 equiv of 
KHMDS or NaHMDS, while approximately 2 equiv of n-BuLi was required (Table 2.4). A 
plausible mechanism that would explain the difference is described in Scheme 2.15. Following 
deprotonation, the sulfonamide carbanion rapidly decomposes yielding difluorocarbene. The 
difluorocarbene then reacts with hexamethyldisilazane followed by a series of proton transfers 
and retro 2+2 reactions to give hydrogen cyanide and two equiv of fluorotrimethylsilane. This 








Scheme 2.15. Proposed mechanism of decomposition of 2.41 with KHMDS. 
 Another ion which decomposes rapidly to yield difluorocarbene is trifluoromethide. 
Computational studies on the CF3 carbanion have shown that the counterion has a dramatic effect 
on the lifetime of this species, specifically decomposition to a metal fluoride becomes more 
favorable with smaller cations because of stronger bonds to fluoride.106  DFT calculations 
predicted that trimethylsilylation of -CF3 should occur when the counterion is Na
+, K+, Rb+ or 
Cs+, but α-elimination to difluorocarbene when the counterion is lithium (Scheme 2.16). This 
result is in agreement with experiments where KHMDS promotes the trimethylsilation of 
fluoroform but LiHMDS does not.112 
 
Scheme 2.16. Decomposition of the LiCF3 anion is favored over trifluoromethylation. 
 These results are also in good agreement with the synthesis of trifluoromethide anions by 
Prakash et al. In this study researchers prepared (18-crown-6)K+ CF3
- (Scheme 2.17).79 Due to 
the chelating action of the crown ether, the potassium ion is not strongly associated with the CF3 
anion and a metal fluoride bond is unable to form. This means that a ‘naked’ fluoride would need 
to be eliminated in order for the molecule to decompose; this elimination is unfavorable enough 
that (18-crown-6)K+ CF3





trifluoromethane is used as the starting material because this leads to a bulky by-product 2.62, 
which prevented the formation of a pentacoordinate silicon side products such as 2.63. 
 
Scheme 2.17. Literature synthesis of a long lived CF3 anion. 
 
 In the case of 2.41, we suspect that decomposition initially proceeds by breaking the 
carbon-sulfur bond liberating difluorocarbene, sulfur dioxide and a lithium dialkylamide. We 
hoped that we might observe an increase in stability of the carbanion derived from 2.41 by 
switching to a potassium base. This is because we suspect 2.41 decomposes to give an amide 
(Scheme 2.14) and the lithium-nitrogen bond is stronger than the potassium-nitrogen bond, 
therefore, α-elimination from a salt of 2.41 should be slower when a potassium base is used.  
 We reasoned that if a potassium salt of 2.41 formed, then we should be able to trap it with 
deuterium cations and observe the deuterated sulfonamide by 19F NMR. We knew that the anion 
completely decomposed after 4 min at -78 °C (Figure 2.5). To determine if deuterium exchange 
into 2.41 could be detected at lower temperature and shorter reaction times, 1.2 equiv of 
KHMDS was added to a solution of 2.41 in a 3:2 mixture of THF:Et2O at -128 °C. The mixture 
was quenched with trifluoroacetic acid-d1 after 10, 20 or 30 sec and the 
19F NMR spectra was 
recorded (Figures 2.6 and 2.7). Deuterium incorporation was observed by the appearance of a 
1:1:1 triplet at -123 ppm, slightly upfield from 2.41. A number of decomposition products are 
observed, two of these are unknown; a doublet of triplets at -136 and a set of AB doublets at -119 





assigned to the trimethylsilyl difluoromethanesulfonamide, the same signal being observed on 
reaction of 2.41 with excess KHMDS and TMSCl.  
 
 Figure 2.6. 19F NMR spectra of the reaction of 2.41 with KHMDS at –128 °C in a 3:2 mixture of 









Figure 2.7. Expansion of Figure 2.6c. 
 
 Knowing that the carbanion could be generated briefly using KHMDS, we attempted the 
reaction in the presence of benzaldehyde at -95 °C in THF, and quenched the reaction after 5, 10 
or 15 sec using TFA-d1 (Figure 2.8). During this time period it is clear that the reaction is still 
actively occurring due to the gradual increase of product 2.57 observed at -105 and -118 ppm. 
The fluorines in 2.57 are diastereotopic, and give rise to different chemical shifts, the difference 
in chemical shift is large because one fluorine can hydrogen bond to the alcoholic proton. 
However, there is no sign of any deuterated sulfonamide at -123 ppm. This demonstrates that 





were observed in Figure 2.7 were present, even though this reaction was run approximately 30 
°C warmer. This indicates that 1,2 addition to the aldehyde is very much faster than α-
elimination to the carbene, or that the aldehyde stabilizes the carbanion through coordination to 
potassium. 
 
Figure 2.8. 19F NMR spectra of the reaction of 2.41, benzaldehyde, and KHMDS in THF at – 95 °C 
after quenching with TFA-d1 after (a) 5, (b) 10, and (c) 15 sec.  
 
 The reaction of 2.41 with benzaldehyde using KHMDS provided 2.57 in almost 
quantitative yield in just 5 min at -78 °C (Table 2.6, entry 1). It occurred to us that the reverse 
reaction might lead to decomposition to difluorocarbene if the reaction time was too long; 
therefore, we repeated the reaction, this time stirring for one hour, but the yield remained 





considerably lower yield (entries 3 and 4). NaOtBu did not result in any reaction after 1 hour 
(entry 5). Using KHMDS, difluoromethane sulfonamides 2.39, 2.42 and 2.53 reacted with 
benzaldehyde to give alcohols 2.64 - 2.66 in good yield within 5 min at –78 °C (entries 6-8).  
Table 2.6. Reaction of benzaldehyde with difluoromethane sulfonamides using Na+ and K+ bases. 
 
entry R base time (min) yield (%)a 
1 PMB (2.41) KHMDS 5 99 (2.57) 
2 PMB KHMDS 60 93 
3 PMB KOtBu 60 67 
4 PMB NaHMDS 15 42 
5 PMB  NaOtBu 60 0  
6 pyrrolidine (2.53) KHMDS 5 71 (2.64) 
7 allyl (2.39) KHMDS 5 84 (2.65) 
8 DMB (2.42) KHMDS 5 88 (2.66) 
  
We applied these conditions to a number of other carbonyl compounds (Table 2.7). The 
yields were high with non-enolizable aldehydes (entries 1-7) and ketones (entries 8-9). Reaction 
with cinnamaldehyde (entry 4) yielded only the 1,2-addition product which is consistent with the 
expected hardness of the fluorinated carbanion.113 Meanwhile with methyl 4-
carboxybenzaldehyde, addition was observed exclusively at the aldehyde position and not at the 
ester (entry 5). With enolizable aldehydes and ketones (entries 10 to 15) yields were generally 
lower. The worst-case example was phenyl acetaldehyde which yielded only 11% of 2.81 (entry 
15). The yield could be dramatically improved by reducing the temperature to -128 °C and by 





Table 2.7. Reaction of 2.41 with Aldehydes and Ketones.
 
Entry Electrophile Yield (%) Entry Electrophile Yield (%) 
1 
 




















76 (2.71) 14  43 (2.80) 
6 
 
77 (2.72) 15 
 
11 (2.81) 










85 (2.75)    
aReaction performed at -128 °C in 2:3 Et2O:THF.  
b4 equiv of aldehyde and 2 equiv of KHMDS 
 
2.2.3 — Synthesis of ß-hydroxy-α,α-difluorosulfonamides derived from amino acids  
We were particularly interested in ß-hydroxy-α,α-difluoromethanesulfonamides derived 
from amino acids. This required α-amino aldehydes in enantiomerically pure form. To prepare 
enantiomerically pure amino aldehydes such as 2.82 (Scheme 2.18), we used the procedure of 
Ivkovic which involves reacting an Nα-protected amino acid with CDI followed by reduction of 
the resulting activated amino acid with DIBAL-H.114 When we subjected 2.41 to KHMDS in the 
presence of 2.82 at -78 °C, ß-hydroxy-α,α-difluoromethanesulfonamide, 2.83/2.84, was obtained 
in only a 7% yield (Scheme 2.18). This was consistent with the low yield obtained with 
enolizable aldehydes (Table 2.7). The yield could be improved to 26% by reducing the 





diastereomers, which were difficult to separate. A portion of one of the diastereomers was 
separated to give 2.84 in 10% yield from 2.82. Given the tendency of 2.82 to epimerize under 
basic conditions, it seemed likely that epimerization would occur during the reaction with 2.41 
and KHMDS, if this occurred then a mixture of 4 stereoisomers would be obtained and 2.84 
would exist as a mixture of enantiomers. To examine this possibility the Boc group was removed 
by treatment with acid and the free amine was divided into two portions. The crude amine was 
coupled to either D or L N-benzenesulfonyl proline to give 2.86 or 2.87. The diastereomers could 
be separated by HPLC which showed that epimerization was not significant (Figure 2.9). This 
can be rationalized if deprotonation of the sulfonamide, which is the rate limiting step, is faster 
than deprotonation of the aldehyde α-carbon. The absolute stereochemistry in 2.83 and 2.84 was 
not determined.  
 






Figure 2.9. Analytical HPLC trace of Boc alanine derivatives 2.86 and 2.87.  (a) HPLC trace of 
compound 2.87 0.1% TFA 47% CH3CN:H2O (b)HPLC trace of a mixture of compounds 2.86 and 
2.87 0.1% TFA 47% CH3CN:H2O. 
 
It should be possible to further improve the yield of alcohol 2.83 by using a large excess 
of the aldehyde; however, the lack of diastereoselectivity in this reaction and the difficulty in 
separation remained problematic. The cause of the low yield is likely because 2.82 is 
deprotonated by KHMDS. The nitrogen may be deprotonated, resulting in a charged species 
which does not react due to electrostatic repulsion, or deprotonation may occur at the α-carbon 
resulting in an enolate which would not reaction with 2.41 (Scheme 2.19). We reasoned that 
deprotonation in both locations would be prevented by using the 9-phenyl-9-fluorenyl (PhF) 
protecting group. The PhF group is known to prevent enolization of α-amino aldehydes.115 
Additionally, the nitrogen is much less acidic since it is an amine rather than a carbamate. See 
section 3.1.1 for a detailed discussion of the PhF protecting group. The preparation of PhF 






Scheme 2.19. Deprotonation of Boc-alanal leads to two possible unreactive side products. 
When using PhF-alanal at -78 °C, a 60% yield of amino alcohol 2.89 was obtained and 
the dr was 5.1 to 1 (Scheme 2.20). By reducing the temperature to -114 °C, the yield was 
improved to 87% with a dr of 5.7:1. The diastereomers were separated and the major 
diastereomer was further derivatized to test for epimerization. The PhF group was removed by 
hydrogenolysis and the free amine 2.91 was divided and coupled to either D or L N-
benzenesulfonylproline to give either 2.92 or 2.93. HPLC of the crude material showed that no 
epimerization occurred (Figure 2.10a and b). The absolute stereochemistry of 2.89 and 2.90 is 
discussed below. 
 






Figure 2.10. Analytical HPLC trace of Boc-alanine derivatives 2.92 and 2.93.  (a) HPLC trace of a 
mixture of compounds 2.92 and 2.93 (b) HPLC trace of compound 2.92 10 to 90% CH3CN 0.1% 
TFA:H2O over 45 min. 
 
Using 2.41 and the PhF-protected amino aldehydes derived from methionine, t-butyl 
aspartate, and proline, we prepared several other ß-hydroxy-α,α-difluorosulfonamides (2.97-
2.102, Table 2.8). Excellent yields were achieved with all PhF protected α-amino aldehydes. 
Methionine and aspartate were selected because the corresponding ß-hydroxy-α,α-
difluorosulfonamides would be difficult to prepare using the electrophilic fluorination approach 
(after reduction of the ketone) described in Chapter 1: methionine is very sensitive to oxidation 
and incompatible with Selectfluor while aspartate is incompatible with the required 3-fold excess 
of alkyl lithium (see Chapter 1 for details). Proline was selected as we wished to incorporate the 
ß-hydroxy-α,α-difluorosulfonamide derived from proline into a peptidomimetic (discussed in 
Chaper 4). Unfortunately, the dr of these alcohols was modest, ranging from 2.3 to 5.7, and the 





Table 2.8. Reaction of 2.41 with PhF-protected α-amino aldehydes and KHMDS
 
Entry Aldehyde Products Yield % dr (RS:SS) 
1 PhF-Ala (2.88) 2.89 and 2.90 87 5.7:1 
2 PhF-Met (2.94) 2.97 and 2.100 93 5.5:1 
3 PhF-Asp(tBu) (2.95) 2.98 and 2.101 94 2.3:1 
4 PhF-Pro (2.96) 2.99 and 2.102 96 5.0:1 
 
The absolute configuration in alcohol 2.99, the major proline diastereomer, was 
determined to be 2R,3S (syn configuration) by X-ray crystallography (Figure 2.11). 2.89, 2.97 
and 2.98 was assigned as 2R,3S. For all of the compounds in Table 2.8 the 19F NMR spectra 
showed the major isomer upfield of the minor isomer; therefore, the relative stereochemistry in 
each case is likely to be the same and 2.89, 2.97 and 2.98 were also assigned as 2R,3S. 
 






This configuration can be explained by a mechanism involving chelation-controlled 
addition (Figure 2.12a). A Felkin-Anh model would predict the 2S,3S configuration (Figure. 
2.12b). However, the standard Felkin-Anh model may not be an appropriate for nucleophilic 
addition to PhF-protected α-amino aldehydes. The PhF group forces the aldehyde into a 
conformation such that the α-proton is coplanar with the carbonyl which prevents enolization. 
Computational studies by Paz and Sardina have shown that the angle between the α-proton and 
the carbonyl may be either 0° or 180°.116 A 0° angle would also explain the 2R,3S configuration 
(Figure 2.12c).  
 
Figure 2.12. (a) Chelation mechanism predicts the syn isomer; (b) Felkin-Ahn model predicts anti 
isomer; (c) Paz/Sardina model predicts the syn isomer if the dihedral angle between the α-






 In order to gain a better understanding of the factors that control diasteroselectivity, we 
repeated the between sulfonamide 2.41 and proline derivative 2.96 using NaHMDS because Na+ 
chelates oxygen better than K+. At -78 °C, the dr was significantly higher at 11:1 (Table 2.9 entry 
1) and was further improved to 24:1 by lowering the temperature to -128 °C (entry 2). Curiously, 
the reaction required 2.2 equiv of NaHMDS and was incomplete when only 1.2 equiv was used 
(entry 3). This is seemingly at odds with the fact that 1.2 equiv of NaHMDS was sufficient to 
completely decompose sulfonamide 2.41 (Figure 2.5), although the lower temperature in this 
reaction may have an effect. These conditions were applied to 2.88, 2.94 and 2.95; however, 
these did not show any significant increase in dr and the yields were variable (entries 4-6). These 
results suggest that only aldehyde 2.96 reacts through a chelation-controlled mechanism while 
aldehydes 2.88, 2.94, and 2.95 react through the non-chelation controlled addition with the 
stereochemistry predicted by the Paz/Sardina model.  
Table 2.9. Reaction of 2.41 with PhF protected α-aminoaldehydes and NaHMDS. 
 
Entry Aldehyde Products Yield (%)a dr (RS:SS)a 
1b PhF-Pro (2.96) 2.99 and 2.102 99 11:1 
2 PhF-Pro (2.96) 2.99 and 2.102 96d 24:1 
3c PhF-Pro (2.96) 2.99 and 2.102 65 19:1 
4 PhF-Ala (2.88) 2.89 and 2.90 31 7.2:1 
5 PhF-Met (2.94) 2.97 and 2.100 59 10.5:1 
6 PhF-Asp(tBu) (2.95) 2.98 and 2.101 93 3.0:1 
aEstimated from the 19F NMR of the crude reaction mixture. 
bReaction run at -78 °C.  







 The results in Table 2.9 led us to suspect that a tertiary amine would be necessary for 
high dr. Therefore, we prepared PhF protected aldehydes 2.103-2.106, in which the nitrogen is 
protected by both benzyl and PhF groups (see experimental section for details). Using 2.41 and 
NaHMDS, all of these alcohols showed excellent dr (Table 2.10). For alcohols 2.107, 2.108 and 
2.110 only one isomer was observed in the 19FNMR spectrum. In the case of aspartate derived 
alcohol 2.109, a set of peaks was observed in the 19F NMR spectrum which suggested 3% of a 
second diastereomer, but this was not separated and the identity of the second diastereomer is 
unconfirmed. Unlike the proline derivative, the diastereoselectivity of these molecules did not 
appear to be strongly dependent on the cation. Indeed, the aspartate and valine derivatives 
showed similar dr when 1.2 equiv of KHMDS was used instead of NaHMDS. In the case of 
valine, the yield was also much higher using KHMDS, this is probably because the valine 
aldehyde is quite hindered and reacts better with the longer-lived potassium carbanion.  
Table 2.10 Reaction of 2.41 with N-benzyl-N-PhF protected α-aminoaldehydes 
 
Entry Aldehyde Products Yield dr (RS:SS)a 
1 PhF-BnAla (2.103) 2.107 81  >99:1 
2 PhF-BnMet (2.104) 2.108 89  >99:1 
3 PhF-BnAsp(OtBu) (2.105) 2.109 69  34:1 
4 PhF-BnVal (2.106) 2.110 51 >99:1 
5c PhF-BnAsp(OtBu) (2.105) 2.109 70a 25:1 
6b,c PhF-BnVal (2.106) 2.110 96  >99:1 
aDetermined by 19F NMR  
b1.0 equiv of 2.41 was used.  
c1.2 equiv of KHMDS was used instead of NaHMDS. 
 
 It would appear that proline is a special case and that the other derivatives are not 





stereochemistry by analogy to the proline derivative. We selected ß-hydroxy sulfonamides 2.110 
and 2.89 and deprotected these molecules to give ß-hydroxy amines 2.111 and 2.91 which were 
cyclized in the presence of triphosgene to give 2.112 and 2.113 (Scheme 2.21). In both cases, 
NOE contacts confirmed a trans relationship in the ring which confirmed that the absolute 
configuration was indeed 2R,3S which is the same configuration as the proline derivative. It 
would appear that the proline derivative progresses through chelation-controlled addition, while 
the other N-PhF and N-PhF-N-benzyl-protected α-amino aldehydes adopt a 0 °C conformation as 
predicted by the Paz-Sardina model. Both cases lead to a 2R,3S or syn configuration in the major 
product. The configuration in the remaining N-PhF and N-PhF-N-benzyl compounds can be 
assigned as 2R,3S for the major isomer by analogy to 2.89 or 2.110.  
 
Scheme 2.21. Determination of stereochemistry in compounds 2.112 and 2.113. 
 
 We had originally planned to perform the synthesis of all ß-hydroxy-α,α-
difluoromethanesulfonamides in 100% THF at -78 °C. However, during the course of these 
studies we found that it was useful to perform these reactions at lower temperatures. THF freezes 
at -108 °C; therefore, we employed a 1:1 mixture of THF and Et2O for reactions at -114 °C and 
later discovered that a 3:2 mixture of THF:Et2O remained liquid at -128 °C. To rule out the 





in various mixtures of THF and Et2O (Table 2.11). There was no significant change in dr up to 
75% Et2O, however at 96% Et2O the dr fell almost to 1:1. Since all of our studies were 
performed between 0 and 50% Et2O we can safely ignore any solvent effect on dr. A temperature 
of -128 °C is obtained by partially freezing a mixture of 86% methanol and 14% water.  
Table 2.11. Solvent effects on the diastereoselectivity of the reaction of 2.41 and PhF-prolinal. 
 
Entry Solvent dr (RS:RR)a 
1 THF 2.5 
2 THF:Et
2
O 3:1 2.76 
3 THF:Et
2
O 1:1 2.82 
4 THF:Et
2
O 1:3 2.6 
5 THF:Et
2
O 1:25 1.14 
aDetermined by 19F NMR 
 
2.2.4 — Synthesis of a peptidomimetic.  
 To demonstrate the applicability of our approach to peptidomimetics we sought to 
prepare 2.120 (Scheme 2.22). ß-hydroxy-α,α-difluorosulfonamide 2.120 is structurally similar to 
a reported ß-hydroxy-α,α-difluoroamide renin inhibitor 2.1 (Figure 2.1).75 Beginning with 
commercially available amino acid ester 2.114, the nitrogen was benzoylated, followed by 
reduction of both the amide and ester groups to give 2.115. PhF protection of the amine with 
temporary protection of the alcohol group yields 2.116. Attempts to oxidize this alcohol using 
Swern protocols gave inconsistent yields and side products. Fortunately, Dess Martin oxidation 
gave an excellent yield of 2.106 on a multigram scale. Reaction with sulfonamide 2.41 yielded ß-





hydrogenolysis with a small amount of acid present, but removal of the benzyl group was 
sluggish; therefore, we employed a combination of palladium and palladium hydroxide catalysts 
which is reported to give better results than either catalyst alone.117 Under these conditions, the 
PhF group is completely removed in less than 1 hour, while the benzyl group requires overnight 
treatment to reveal 2.111. Tripeptide 2.118 was constructed using standard peptide coupling 
methodology. PMB groups in sulfonamides are usually removed using TFA.10 However, due to 
the α-fluorines, the sulfonamide nitrogen in 2.118 has reduced basicity, and an overnight reflux 
with TFA was required to remove PMB groups as demonstrated using sulfonamide 2.99 as a 
model system. PMB groups in sulfonamides have also been removed using CAN.10 This reaction 
generates nitric acid which could result in removal of the Boc group; however, we found that this 
reaction on 2.118 proceeds at 0 °C using excess CAN, and provided primary sulfonamide 2.119 
without significant loss of the terminal Boc group.  
 Finally, a Mitsunobu reaction furnished N-alkyl sulfonamide 2.120. Using typical 
DIAD/PPh3 conditions, only trace product could be observed by HPLC. This is probably due to 
the formation of a triphenylphosphine sulfonyl imine which is a known side reaction with 
primary sulfonamides.118 To overcome this side reaction, we employed 
cyanomethyltributylphosphorane (CMBP) which cannot form similar side products and provided 
the desired monoalkylation in 64% yield.119 Under these conditions no overalkylation was 







Scheme 2.22. Synthesis peptidomimetic 2.120. 
2.2.6 — Reactions of α,α-difluoromethanesulfonamides with imines: preliminary results  
 Encouraged by our success with ß-hydroxy-α,α-difluoromethanesulfonamides we decided 
to further explore the chemistry of α,α-difluoromethanesulfonamide carbanions with non-
carbonyl electrophiles, beginning with imines 2.121-2.124 (Scheme 2.23). None of the desired 
product was formed in the reaction with benzyl imine 2.121 and 2.41 was completely 
decomposed. Using the more electrophilic iminium salt, 2.122, the ß-amino-α,α-
difluorosulfonamide 2.125 was obtained in 70% yield. This reaction was complicated by the 
poor solubility of 2.122 in THF or THF:Et2O mixtures, especially at low temperatures; however, 
2.122 was soluble in 10% DMF in THF at -98 °C. Next, we attempted the reaction with 





than 2.122. To our delight, the desired 2.126 was obtained with high dr and this was improved 
even further by changing the base to NaHMDS leading to a quantitative yield of 2.126 with 97:3 
dr. The reaction was also successful with 2.124 leading to valine analog 2.127 with excellent dr, 
this reaction is particularly notable because 2.124 is enaminizable. The synthesis of ß-amino-α,α-
difluorosulfones from sulfinimines is well known.122-126 Therefore, the stereochemistry of 2.126 
and 2.127 can tentatively be assigned by analogy to the sulfones which proceed through a boat 
like chelation controlled transition state.126  
 
Scheme 2.23. Synthesis of ß-amino-α,α-difluorosulfonamides. Relative stereochemistry is shown, 
sulfinimines 2.123 and 2.124 were racemic. 
 
2.2.5 — Reactions of α,α-difluoromethanesulfonamides with carboxylic acid derivatives: 
preliminary results 
While nonfluorinated Grignard reagents and organolithiums generally add to simple esters 
twice to generate tertiary alcohols, fluorinated nucleophiles may add one or two times. The 





just once to ethyl phenylacetate but twice to ethyl hexanoate (Scheme 2.24 a and b). The 
difference was shown to be due to the stability of the tetrahedral intermediate rather than to the 
formation of an enolate.120 In some cases the tetrahedral intermediate is stable enough to be 
isolated (Scheme 2.23 c).121 
 
Scheme 2.24. Literature reactions for the addition of fluoroalkyl nucleophiles to esters. 
 We considered that the reaction of α,α-difluoromethanesulfonamides with esters would 
be a more efficient route to ß-keto-α,α-difluorosulfonamides than was described in Chapter 1. 
Unfortunately, reaction with methyl benzoate yielded none of the desired product (Table 2.12) 
probably because the methoxide leaving group is too poor and the reverse reaction dominates. 
When phenyl benzoate was used instead, double addition to the carbonyl was observed yielding 
a mixture of tertiary alcohol 2.128 and a number of unidentified side products. Using benzoic 
anhydride, a mixture of double and single addition was observed. By reducing the temperature to 
-128 °C and, using 2 equiv of KHMDS and 4 equiv of benzoic anhydride, single addition could 
be obtained as the main product giving 2.37. We had hoped that this reaction would also be 
applicable to amino acid derivatives. Unfortunately, none of the desired ketone was obtained 





and isobutyl chloroformate. No product was obtained from the reaction of 2.41 with the 
Weinreb’s amide of benzoic acid. 
Table 2.12. Reaction of 2.41 with benzoic acid derivatives. 
 
Entry Electrophile KHMDS Temperature Yield 2.128 (%) Yield 2.37 (%) 
1 methyl benzoate (1.2 equiv) 1.2 equiv -78 °C 0 0 
2 phenyl benzoate (1.2 equiv) 1.2 equiv -78 °C 35 0 
3 benzoic anhydride (1.2 equiv) 1.2 equiv -78 °C 36 24 
4 benzoic anhydride (4 equiv) 2 equiv -128 °C trace 65 
 
2.3 — Conclusions and future studies.  
 In section 2.2.1 of this chapter, we have developed an efficient method for the synthesis 
of difluoromethane sulfonamides. This method is more efficient than previously reported 
methods and does not rely on ozone depleting chemicals. However, our route does involve 
several steps, namely mesylation of an amine, deprotonation using n-BuLi, acylation of the 
resulting carbanion, electrophilic fluorination, and basic hydrolysis. These steps limit the 
substrate scope. Boyle et al. have published the synthesis of ß-amido-α,α-difluorosulfonyl 
chloride 2.128 which is prepared in 4 steps from difluorochloroacetic acid. 2.128 reacts with 
ammonia to give the sulfonamide 2.129 which is hydrolyzed to give the carboxylic acid 2.130 
(Scheme 2.25a).11 We envision that sulfonyl chloride 2.128 could also react with other amines to 
give sulfonamides of type 2.131 (Scheme 2.25b). ß-Amido-α,α-difluorosulfonamides have 





sulfonamide carbanion which we hypothesize could be trapped with water to give the 
difluoromethane sulfonamides 2.132.71 This route would be superior in cases where the amine 
contains sensitive groups that would not tolerate n-BuLi or Selectfluor. This approach also 
delivers 2.132 in fewer linear steps from the amine; therefore, this would be attractive for the late 
stage difluoromethane sulfonylation of complex amines.  
 
Scheme 2.25. (a) Literature synthesis of 2,2-difluoro-2-sulfamoylacetic acid; (b) Proposed 
synthesis of difluoromethane sulfonamides via a ß-amido-α,α-sulfonyl chloride. 
 
 We have shown that the lifetime of difluoromethanesulfonamide carbanions is strongly 
dependent on the counter ion, with potassium salts being longer lived than lithium salts; 
however, we have not yet thoroughly investigated the larger rubidium and cesium ions. 
Deuterium exchange in 2.41 could be affected by Cs2CO3 in a mixture of DMF and D2O in 1 
hour at room temperature without detectable decomposition. However, under these conditions 
2.41 did not show any reaction with benzaldehyde, probably because carbonate is not a strong 
enough base to deprotonate a significant portion of the sulfonamide. However, if the cesium salt 





to be longer lived for the reasons discussed in Section 2.2.2 and a this might allow for reactions 
with a larger range of electrophiles such as alkyl halides or epoxides.  
 The chemistry of difluoromethanesulfonamide anions was explored, and in particular 
their reactions with aldehydes to give ß-hydroxy-α,α-difluoromethanesulfonamides. This 
reaction works well using non-enolizable aldehydes and ketones and modestly using enolizable 
substrates. Nevertheless, by employing PhF-protected α-amino aldehydes we were able to 
achieve excellent yields of ß-hydroxy-α,α-difluoromethanesulfonamides derived from amino 
acids, and by fully protecting the nitrogen with a PhF and a benzyl group, we were able to 
achieve good to excellent yields and excellent dr values. Furthermore, we have demonstrated that 
these can be deprotected and elaborated into peptidomimetics and we expect these to have 
applications as inhibitors of aspartyl proteases.  
 The sulfonamide carbanions also reacted effectively with sulfonyl imines to give ß-
amino-α,α-difluorosulfonamides 2.133 in good yields with high diastereoselectivity. Future 
studies in the Taylor group will involve the incorporation of these molecules into 
peptidomimetics. This will involve deprotection of the amine followed by elaboration of the 
molecule with standard peptide couplings to give ß-amino-α,α-difluorosulfonamides 2.134. 
Following deprotection, sulfonamides of type 2.135 will be obtained by Mitsunobu reaction with 
alcohols (Scheme 2.26). There is one other example of ß-amino-α,α-difluorosulfonamides which 
involves synthesis of the analogous sulfone followed by a laborious and low yielding conversion 
to the sulfonyl chloride which reacts with amines to give the sulfonamides of type 2.135.122 The 






Scheme 2.26. Proposed synthesis of peptidomimetics incorporating ß-amino-α,α-
difluorosulfonamides.  
 
We have shown that proline derivative 2.56 can be prepared by the procedure outlined in 
Scheme 2.12 (shown again below). It would be of interest to determine if this procedure could be 
optimized and expanded to other amino acids to give compounds of type 2.136 as outlined in 
Scheme 2.27.  
 
Scheme 2.12. Synthesis of a N-difluoromethanesulfonyl amino acid. 
 
 
Scheme 2.27. Synthesis of a N-difluoromethanesulfonyl amino acids. 
 
It would also be of interest if amino acid derivitives of type 2.136 could be used to 
prepare ß-hydroxyl and ß-amino sulfonamides of type 2.137 and 2.138 as outlined in Scheme 
2.28 and 2.29. Although, the carboxylic acid of 2.136 may require protection in this 
transformation. Sulfonamides 2.137 and 2.138 could be added to a peptide chain followed by 






Scheme 2.28. Proposed synthesis of peptidomimetics incorporating α,α-difluorosulfonamides 
using compounds of type 2.136. 
 
 
Scheme 2.29. Proposed synthesis of peptidomimetics incorporating ß-hydroxy-α,α-
difluorosulfonamides using compounds of type 2.136. 
 
2.4 — Experimental.  
2.4.1 — General information.  
  All reagents and starting materials were obtained from commercial sources and used as 





calcium hydride. Diethyl ether, THF, toluene and hexane were distilled from sodium metal. All 
reactions were performed under an argon atmosphere using flame dried glassware unless stated 
otherwise. Reactions were monitored by TLC until deemed complete using aluminium backed 
silica plates. Plates were visualized under ultraviolet light (254 nm) and/or staining with KMnO4 
or cerium ammonium molybdate. Cooling of reaction mixtures to -78 °C was achieved using a 
dry ice-acetone bath, -98 °C with liquid N2 /MeOH, -114 °C with liquid N2 /EtOH, and -128 with 
liquid N2 and 86:14 MeOH:H2O.  
 All 13C NMR spectra were proton decoupled. All 19F NMR were not proton decoupled, in 
cases where yield is estimated by 19F NMR the relaxation delay between scans is increased to 16 
sec. Chemical shifts (δ) for 1H NMR spectra run in CDCl3 are reported in ppm relative to the 
standard TMS. Chemical shifts for 13C NMR spectra run in CDCl3 are reported in ppm relative to 
the solvent residual carbon (δ 77.16 for central peak). Chemical shifts for 19F NMR spectra run 
in CDCl3 are reported in ppm relative to the standard CFCl3. High-resolution positive ion 
electrospray (ESI+) mass spectra were obtained using a quadrupole-orbitrap Mass spectrometer, 
dissolving samples in 1:1 MeOH/H2O +
 0.1% formic acid. 
2.4.2 — Experimental procedures for synthesized compounds.  
General procedure 2.1 Fluorination and cleavage of benzoyl methanesulfonamides.  
 See Chapter, 1 Section 1.2.3 for the synthesis of benzoyl methanesulfonamides 2.31-2.34.  
The sulfonamide (1 equiv) was dissolved in DMF (10 mL per g of Selectfluor) and 
cooled to -20 °C then TBAF (1 M in THF, 4 equiv) and Selectfluor (4 equiv) were added. The 
mixture was stirred until complete by TLC (2-4 h) then 10 equiv of 6 M NaOH was added. The 
reaction was stirred for 1 hour, generally it is not possible to separate the difluoromethane 





volumes of water and extracted three times with 2 volumes of diethyl ether. The combined 
organic layers are washed three times with an equal volume of water then dried over magnesium 
sulfate, filtered, and concentrated to dryness. The residue was purified by flash chromatography 
if necessary. 
 
N,N-diallyl difluoromethanesulfonamide (2.39). Prepared according to general procedure 2.1 and 
obtained as a colorless oil without further purification. 1.50 g (99% yield) from 2.00 g (7.17 
mmol) of 2.31. 1H NMR (CDCl3, 300 MHz): δ 6.16 (t, 1H, J = 53.9 Hz), 5.78 (m, 2H), 5.28 (m, 
4H), 3.93 (d, 4H, J = 6.1 Hz); 13C{1H} NMR (CDCl3, 125 MHz): δ 132.0, 120.0, 114.0 (t, J = 
282.7 Hz), 49.5; 19F NMR (CDCl3, 282 MHz): δ -122.1 (d, J = 53.7 Hz); HRMS (ESI
+) m⁄z: [M 
+ Na]+ calcd for C7H11F2NNaO2S, 234.0371; found, 234.0361.  
 
N,N-diethyl difluoromethanesulfonamide (2.40). Prepared according to general procedure 2.1 and 
obtained as a colorless oil after flash chromatography with 10% EtOAc in hexanes. 900 mg 68% 
yield) from 1.8 g of 2.32. 1H NMR (CDCl3, 300 MHz):δ 6.12 (t, 1H, J = 54.0 Hz), 3.41 (q, 4H, J 
= 7.2 Hz), 1.21 (t, 6H, J = 7.1 Hz); 13C{1H} NMR (CDCl3, 125 MHz): δ 114.2 (t, J = 280.3 Hz), 
42.3, 14.3; 19F NMR (CDCl3, 282 MHz): δ -122.3 (d, J = 53.6 Hz); HRMS (ESI
+) m⁄z: [M + H]+ 








N,N-bis(2-methoxybenzyl) difluoromethanesulfonamide (2.41). Prepared according to general 
procedure 2.1 and was obtained as a white solid after flash chromatography with 15% EtOAc in 
hexane. 630 mg (99 % yield) from 755 mg of 2.33. 1H NMR (CDCl3, 300 MHz): δ 7.16 (d, 4H, J 
= 8.2 Hz), 6.87 (d, 4H, J = 8.2 Hz), 6.04 (t, 1H, J = 53.8 Hz), 4.32 (s, 4H), 3.80 (s, 6H); 13C{1H} 
NMR (CDCl3, 125 MHz): δ 159.6, 130.1, 126.7, 114.4 (t, J = 280.9 Hz), 114.2, 55.1, 50.0; 
19F NMR (CDCl3, 282 MHz): δ -121.08 (d, J = 53.8 Hz); HRMS (ESI
+) m⁄z: [M + Na]+ calcd for 
C17H19F2NNaO4S, 394.0895; found, 394.0879. 
 
N,N-bis(2,4-dimethoxybenzyl) difluoromethanesulfonamide (2.42). Prepared according to general 
procedure 2.1 and was obtained as a white solid after flash chromatography 20 to 30% EtOAc 
hexane, 60 mg (62% yield) from 112 mg of 2.34. 1H NMR (CDCl3, 300 MHz): δ 7.15 (d, 2H, J = 
8.2 Hz), 6.43 (m, 4H), 5.84 (t, 1H J = 54.2 Hz), 4.43 (s, 4H), 3.75 (s, 6H), 3.72 (s, 6H); 13C{1H} 
NMR (CDCl3, 75 MHz): δ 160.9, 158.5, 130.9, 115.9, 113.9 (t, J = 230.4 Hz), 104.3, 98.2, 55.2, 
55.0, 46.1; 19F NMR (CDCl3, 283 MHz) : δ -121.94 (d, J = 54.5 Hz); HRMS (ESI
+) m⁄z: [M + 
H]+ calcd for C19H24F2N2O6S, 432.1287; found, 432.1286.  
General procedure 2.2 for the preparation of trifluoracetyl methanesulfonamides 2.47 – 
2.50 





 A solution of methane sulfonamide (1.00 equiv) in THF (0.1-0.33 M) was cooled to –78 
°C and n-BuLi (2.5 M in hexane, 1.05 equiv) was added dropwise. The resulting solution was 
stirred for 15 min then N-methyl-N-methoxytrifluoroacetamide (1.10 equiv) was added as a neat 
liquid. Stirring was continued for 1 hour before the reaction was quenched with saturated NH4Cl 
and extracted three times into DCM. The combined organic layers were dried over magnesium 
sulfate, filtered, and concentrated to give crude products. Yields are calculated based on the 
molecular weight of the ketone form, however a ketone-hydrate mixture was typically observed 
by NMR.  
 
1-trifluoroacetyl-N,N-diallyl methanesulfonamide (2.47). Prepared according to general 
procedure 2.The crude product was dissolved in 200 mL 1:1 Et2O:hexane and extracted three 
times with 100 mL 5% Na2CO3, the combined aqueous layers were acidified to pH 1 and back 
extracted three times with 200 mL DCM. The combined DCM layers were dried over 
magnesium sulfate, filtered and concentrated to give 2.47 as a white solid (6.5 g, 94% yield) 
from 4.45 g (25.5 mmol) of 2.43. 1H NMR (acetone-d6 : D2O 1:1, 300 MHz): δ 6.19 (m, 2H), 
5.63 (m, 4H), 4.25 (d, 4H, J = 6.3 Hz); 13C{1H} NMR (acetone-d6 : D2O 1:1, 75 MHz): δ 135.8, 
125.3 (q, J = 288.0 Hz), 121.1, 94.1 (q, J = 32.6 Hz), 56.7 (quintet, J = 20.9 Hz), 52.3 (note that 
the methylene group of the hydrated ketone undergoes rapid deuterium exchange); 19F NMR 
(acetone-d6 : D2O, 300 MHz): δ -83.6; HRMS(ESI
+) m/z: [M + H2O +
 Na]+ calcd for 
C9H14F3NNaO4S,






1-trifluoroacetyl-N,N-bis(4-methoxybenzyl)methanesulfonamide (2.48).  Prepared according to 
general procedure 2.2. The crude material was dissolved in approximately 50 mL EtOAc and 250 
mL hexane at reflux temperature, then slowly cooled to -78 °C overnight to yield 20.8 g white 
crystals. The mother liquor was evaporated and subjected to flash chromatography 0 to 10% 
EtOAc in DCM to yield a further 4.1 g. A total of 24.9 g (96% yield) of 2.48 was obtained from 
20.1 g (60 mmol) of 2.44. 1H NMR (CDCl3, 300 MHz): δ 7.19 (d, 4H, J = 8.0 Hz), 6.86 (d, 4H, J 
= 8.0 Hz), 4.68 (s, 2H), 4.31 (s, 4H), 3.80 (s, 6H), 3.22 (s, 2H); 13C{1H} NMR (9:1 acetone-
d6:D2O, 125 MHz): δ 159.2, 130.0, 128.1, 122.7 (q, J = 288.1 Hz), 113.8, 91.7 (q, J = 32.1 Hz), 
54.8, 50.6, 49.4 (Note that the methylene carbon undergoes exchange with D2O); 
19F NMR 
(CDCl3, 282 MHz): δ -78.6 (ketone), -87.0 (hydrate); HRMS (ESI
+) m⁄z: [M + H2O+Li]
+ calcd 
for C19H22F3LiNO6S, 456.1275; found, 456.1268. 
 
1-trifluoroacetyl-N,N-bis(2,4-dimethoxybenzyl)methanesulfonamide (2.49). The crude product 
was purified by flash chromatography, eluting with 0 to 10% EtOAc in DCM, to yield 2.49 as a 
white solid (368 mg, 75% yield) from 395 mg (1.00 mmol) of 2.45. 1H NMR (9:1 acetone-
d6:D2O, 500 MHz): δ 7.11 (d, 2H, J = 8.7 Hz), 6.47 (s, 2H), 6.44 (d, 2H, J = 8.7 Hz), 4.35 (s, 
4H), 4.05(s, 2H), 3.74 (s, 12H); 13C{1H} NMR (9:1 acetone-d6:D2O, 125 MHz): δ 160.7, 158.4, 
130.7, 122.7 (q, J = 286.0 Hz), 116.2, 104.4, 98.0, 91.7 (q, J = 32.6 Hz), 54.9, 54.8, 54.2, 45.1 





acetone-d6:D2O, 282 MHz): δ -86.5; HRMS (ESI
+) m⁄z: [M + H2O + Na]
+ cald for 
C21H26F3NO8SNa, 532.1223; found, 532.1215. 
 
1,1,1-trifluoro-3-(pyrrolidin-1-ylsulfonyl)propan-2-one (2.50). Prepared according to general 
procedure 2.2. The crude product was purified by recrystallization from hot Et2O and hexane to 
give 2.50 (4.95 g, 80% yield) from 3.73 g (25.0 mmol) of 2.46 as a monohydrate. 1H NMR 
(acetone-d6, 300 MHz): δ 6.42 (s, 2H), 3.53 (s, 2H) 3.43 (m, 4H), 1.94 (m, 4H); 
13C{1H} NMR 
(acetone-d6, 75 MHz): δ 127.9 (q, J = 287.0 Hz), 97.0 (q, J = 32.0 Hz), 55.3, 52.7, 30.6; 
19F NMR (acetone-d6, 282 MHz): δ -81.6; HRMS (ESI
+) m/z: [M + H+] calcd for C7H11O3NF3S, 
246.0406; found, 246.0407. 
 
1,1,1,3,3-pentafluoro-3-(pyrrolidin-1-ylsulfonyl) propane-2,2-diol (2.52). Ketone 2.50 (280 mg, 
1.14 mmol, 1.00 equiv) was dissolved in 10 mL of DMF and Selectfluor (1.00 g, 2.82 mmol, 
2.50 equiv) was added. The reaction was placed in a preheated oil bath at 100 °C and stirred for 
1 hour. The reaction was cooled, and an aliquot was removed and examined by 19F NMR 
spectroscopy which indicated complete conversion. The mixture was diluted with 40 mL of 
water and extracted three times with 30 mL ether. The combined organic layers were washed 
three times 50 mL water and the aqueous washes were back extracted once with 100 mL ether. 
The combined ether layers were dried over magnesium sulfate, filtered, and concentrated to give 
245 mg of a yellow solid. This was recrystallized from hot ether and hexane to yield 2.52 (68 





4.58 (br, 2H), 3.58 (m, 4H), 2.00 (m, 4H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 118.5 (tq, J = 
298.0, 1.3 Hz), 116.9 (qt, J = 289.6, 2.3 Hz), 91.6 (qt, J = 55.6, 25.4 Hz), 49.3, 25.8; 
19F NMR(CDCl3, 282 MHz) δ: 81.4 (t, 3F, J = 11.2 Hz), -110.76 (d, 2F, J = 11.2 Hz); HRMS 
(ESI+) m/z: calcd for C7H10NO4SF5Na
+ (M + Na)+: 322.0143, found 322.0143.  
General procedure 2.3 for the preparation of difluoromethanesulfonamides from 
trifluoracetyl methanesulfonamides  
 
 The sulfonamide (1.00 equiv) were dissolved in DMF (0.1 M). Selectfluor (2.50 equiv) 
was added followed by lithium carbonate (2.50 equiv) and the mixture was stirred for 3 h at 
room temperature until the reaction was complete as determined by 19F NMR (The fluorinated 
and unfluorinated ketones were usually difficult to distinguish by TLC due to partial hydrolysis 
of the fluorinated ketone). The mixture was then cooled to 0 °C and 6 M aq. sodium hydroxide 
(10 equiv) was added. The mixture is stirred a further 15 min. The reaction was diluted with 4 
volumes of water and extracted three times with 2 volumes of diethyl ether. The combined 
organic layers are washed three times with an equal volume of water then dried over magnesium 
sulfate, filtered, and concentrated to dryness. The residue was purified by flash chromatography 
if necessary.  
 
N,N-diallyl difluoromethanesulfonamide (2.39). Prepared according to general procedure 2.3. 
The crude material was purified by flash chromatography, eluting with 0 to 50% Et2O in hexane, 
to give 2.39 (4.20 g, 95% yield) from 5.69 g (21.0 mmol) of 2.47. This material was identical to 






N,N-bis(4-methoxybenzyl) difluoromethanesulfonamide (2.41). Prepared according to general 
procedure 2.3 and was obtained as a white solid after flash chromatography, 50 to 70% DCM in 
hexane, to give 2.55 g of 2.41 (74% yield) from 4.00 g (9.28 mmol) of 2.48. This material was 
identical to that prepared according to general procedure 2.1. 
 
1-((difluoromethyl)sulfonyl)pyrrolidine (2.53). Prepared according to general procedure 2.3 and 
was obtained as a pure solid without further purification (250 mg, 67% yield) from 500 mg (2.04 
mmol) of 2.50. 1H NMR (CDCl3, 300 MHz): δ 6.18 (t, 1H, J = 53.9 Hz), 3.48 (m, 4H), 1.94 (m, 
4H); 13C{1H} NMR (CDCl3, 125 MHz): δ 114.9 (t, J = 280.1 Hz), 48.6, 25.9; 
19F NMR (CDCl3, 
282 MHz): δ -121.8 (d, J = 53.6 Hz); HRMS (ESI+) m⁄z: [M + Na]+ calcd for C5H9F2NNaO2S
+, 
208.0214; found, 208.0215.  
 
N,N-bis(2,4-dimethoxybenzyl) difluoromethanesulfonamide (2.42). Ketone 2.49 (970 mg, 1.98 
mmol, 1.00 equiv) and Cs2CO3 (1.60 g, 5.00 mmol, 2.50 equiv) were dissolved in 20 mL DMF 
and cooled to -20 °C. Selectfluor (1.75 g, 4.93 mmol, 2.50 equiv) was added dropwise as a 
solution in 60 mL DMF over 3 h. Stirring was continued for two more h while the reaction was 
warmed slowly to 0 °C. 15 mL of 6 M NaOH was added and the mixture was stirred for 15 min. 





The combined organic layers were washed three times with 200 mL of water, dried over 
magnesium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography, eluting with 10 to 100% DCM in hexane, to yield 2.42 as a white solid (707 
mg, 83% yield). This material was identical to that prepared according to general procedure 2.1. 
 
((3,3,3-trifluoro-2-oxopropyl)sulfonyl)-L-proline (2.55). Methane sulfonyl proline was prepared 
according to a literature procedure.127 Methanesulfonyl proline (712 mg, 3.69 mmoles, 1 equiv) 
was dissolved in 20 mL THF and cooled to -78 °C under an argon atmosphere. n-Butyllithium 
(7.75 mmols, 3.87 mL in hexanes, 2.1 equiv) was added dropwise and allowed to stir for 15 min 
before N-methyl-N-methoxytrifluoroacetamide (636 mg, 4.05 mmols, 1.1 equiv) was added neat, 
dropwise. The reaction was quenched after 1 hour with 20 mL 10% citric acid and extracted 
three times with 20 mL methylene chloride. The combined organic layers were dried over 
magnesium sulfate, filtered, and concentrated. The residue was purified by flash chromatography 
gradient elution 4:6 EtOAc:hexane to 98% EtOAc 2% AcOH to yield 475 mg colorless oil 
(45%). 1H NMR (D2O, 500 MHz): δ 4.53 (d of d, 1H, J = 9.0, 4.1 Hz), 3.55 (m, 2H), 2.36 (m, 
1H), 2.11 (m, 1H), 2.01 (m, 2H); 13C{1H} NMR (D2O, 125 MHz): 176.9, 122.2 (q, J = 288.1 
Hz), 91.4 (q, J = 34.9 Hz), 60.8, 51.3 (broad signal due to deuterium exchange), 48.7, 30.9, 24.5; 
19F NMR (D2O, 471 MHz): δ -86.29 (s, 3F); HRMS-ESI+ (m/z) [M + H]
+ calcd for 
C8H11O5NF3S






((difluoromethyl)sulfonyl)-L-proline (2.56). Ketone 2.55(420 mg, 1.45 mmol 1 equiv) was 
dissolved in 30 mL of DMF and Li2CO3 (270 mg, 3.6 mmol, 2.50 equiv) followed by Selectfluor 
(1.28 g, 3.60 mmol, 2.5 equiv) were added as solids. The mixture was stirred at room 
temperature until complete by TLC then cooled to 0 °C. 10 mL of 6 M NaOH was added and the 
reaction was stirred for an additional 30 min and then quench with 100 mL of 1 M HCl and 100 
mL of brine. The mixture was extracted 3 times with 100 mL EtOAc, the combined organic 
layers were washed with 100 mL 0.1 M HCl and brine. Then dried over magnesium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography 0 to 10% MeOH in 
DCM to give 225 mg (68% yield) as a white gum. 1H NMR (CDCl3, 300 MHz): δ 10.93 (s, 1H), 
6.35 (t, 1H, J = 53.8 Hz), 4.6 (dd, 1H, J = 8.5, 3.5 Hz), 3.66 (m, 2H), 2.41 (m, 1H), 2.2 (m, 1H), 
2.07 (m, 2H); 13C{1H} NMR (D2O, 75 MHz): δ 181.9, 116.9 (3, J = 279.7 Hz), 66.7, 52.3, 34.1, 
27.5; 19F NMR (D2O, 282 MHz): δ-121.6 (dd, 1F, J = 277.2, 53.0 Hz), -122.8 (dd, F, J = Hz); 
HRMS-ESI+ (m/z) [M + NH4]
+ calcd for C6H13F2N2O4S
+: 247.0559 found:.247.0561 
General procedure 2.4 preparation of ß-hydroxy sulfonamides 2.57, 2.64-2.66. 
 The sulfonamide was dissolved in THF (0.1 M) and benzaldehyde (1.20 equiv) was 
added. The mixture was cooled to -78 °C and then KHMDS (0.5 M in toluene, 1.2 equiv) was 
added dropwise. The reaction was stirred for 5 min then quenched with NH4Cl. The mixture was 
diluted with water and extracted three times with DCM. The combined organic layers were dried 
over magnesium sulfate, filtered, and concentrated. The residue was purified by flash 








Prepared according to general procedure 2.4, colorless oil (128 mg, 99% yield) from 100 mg 
(0.269 mmol) of 2.41. 1H NMR (CDCl3, 300 MHz): δ 7.53 (m, 2H), 7.42 (m, 3H), 7.10 (d, 4H, J 
= 8.5 Hz), 6.83 (d, 4H, J = 8.5 Hz), 5.43 (d, 1H, J = 21.6 Hz), 4.34 (s, 4H), 3.79 (s, 6H), 3.35 (s, 
1H); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 134.0, 130.2, 129.4, 128.4, 128.2, 126.4, 121.3 
(dd, J = 293.4, 284.6 Hz), 114.0, 72.3 (dd, J = 26.9, 20.4 Hz), 55.3, 50.1; 19F NMR (CDCl3, 282 
MHz): δ -105.2 (d, 1F, J = 237.7 Hz), -119.4 (dd, 1F, J = 273.7, 21.2 Hz); HRMS (ESI+) m/z: [M 
+ Na]+ calcd for C24H25O5NF2NaS, 500.1314; found, 500.1307. 
 
2,2-difluoro-1-phenyl-2-(pyrrolidin-1-ylsulfonyl)ethan-1-ol (2.64). Prepared according to general 
procedure 2.4, colorless oil (47 mg, 71% yield) from 42 mg (0.227 mmol) of 2.53. 1H NMR 
(CDCl3, 300 MHz): δ 7.51 (m, 2H), 7.42 (m, 3H), 5.35 (dd, 1H, J = 21.6, 8.0 Hz), 3.59 (m, 4H), 
3.36 (bs, 1H), 1.98 (m, 4H); 13C{1H} NMR (CDCl3, 75 MHz): δ 133.8, 129.3, 128.3, 128.1, 
122.3 (dd, J = 292.3, 284.7 Hz), 72.2 (dd, J = 26.2, 20.7 Hz), 48.9, 25.9; 19F NMR (CDCl3, 282 
MHz): δ -104.4 (dd, 1F, J = 240.5, 1.5 Hz), -118.6 (dd, 1F, J = 240.7, 21.6 Hz); HRMS (ESI+) 






1,1-difluoro-2-hydroxy-N,N-diallyl-2-phenylethane-1-sulfonamide (2.65). Prepared according to 
general procedure 2.4, colorless oil (144 mg, 84% yield) from 114 mg (0.54 mmol) of 2.39. 
1H NMR (CDCl3, 300 MHz): δ 7.47 (m, 2H), 7.39 (m, 3H), 5.74 (m, 2H), 5.37-5.20 (m, 5H), 
3.95 (d, 4H, J = 6.4 Hz), 3.20 (d, 1H, J = 3.4 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 133.9, 
132.1,129.4, 128.4, 128.1, 121.0 (dd, J = 292.8, 284.1 Hz), 120.1, 72.1 (dd, J = 26.9, 20.5 Hz), 
49.8; 19F NMR (CDCl3, 282 MHz): δ -106.0 (d, 1F, J = 238.8 Hz), -120.3 (dd, 1F, J = 239.2, 
21.7 Hz); HRMS (ESI+) m/z: [M + Na]+ calcd for C14H17O3NF2NaS, 340.0789; found, 340.0793. 
 
1,1-difluoro-2-hydroxy-N,N-bis(2,4-dimethoxybenzyl)-2-phenylethane-1-sulfonamide (2.66). 
Prepared according to general procedure 2.4, white solid (127 mg, 88% yield) from 116 mg 
(0.269 mmol) of 2.42. 1H NMR (CDCl3, 300 MHz): δ 7.48 (m, 2H), 7.38 (m, 3H), 7.15 (d, 2H, J 
= 8.4 Hz), 6.36 (dd, 2H, J = 8.4, 2.4 Hz), 6.27 (d, 2H, J = 2.4 Hz), 5.30 (m, 1H), 4.50 (s, 4H), 
3.75 (s, 6H), 3.62 (s, 6H), 3.40 (d, 1H, J = 3.2 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 160.5, 
158.2, 134.0, 130.3, 129.2, 128.3, 128.2, 121.4 (dd, J = 294.3, 286.0 Hz), 116.2, 104.0, 97.9, 
72.3 (dd, J = 26.4, 20.4 Hz, 55.3, 54.9, 46.5; 19F NMR (CDCl3, 282 MHz): δ -105.1 (d, 1F, J = 
238.2 Hz), -119.3 (dd, 1F, J = 238.2, 21.4 Hz); HRMS (ESI+) m/z: [M + Na]+ calcd for 
C26H29O7NF2NaS, 560.1525; found, 560.1526. 
General procedure 2.5 for the synthesis of ß-hydroxy sulfonamides 2.67 - 2.81 
 Difluoromethane sulfonamide 2.41 (100 mg, 0.27 mmol, 1.00 equiv) and the carbonyl 
electrophile (0.32 mmol, 1.2 equiv) were dissolved in 5 mL THF and cooled to -78 °C. KHMDS 
(0.5 M in toluene, 640 µL, 0.32 mmol, 1.2 equiv) was added dropwise over approximately 1 





mL of sat. NH4Cl and extracted with 10 mL of DCM three times. The combined organic layers 
were dried over magnesium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography to yield pure ß-hydroxy-α,α-difluorosulfonamides. 
 
1,1-difluoro-2-hydroxy-N,N-bis(4-methoxybenzyl)-2-(4-methoxyphenyl)ethane-1-sulfonamide 
(2.67). Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 43 mg 
4-methoxybenzaldehyde (0.32 mmol) and was obtained as a white solid after chromatography 
eluting with 10 to 40% EtOAc in hexane (122 mg, 90% yield). 1H NMR (CDCl3, 300 MHz): δ 
7.48 (d, 2H, J = 8.6 Hz), 7.14 (d, 4H, J = 8.7 Hz), 6.98 (d, 2H, J = 8.8 Hz), 6.86 (d, 4H, J = 8.7 
Hz), 5.40 (dt, 1H, J = 21.2, 2.8 Hz), 4.37 (s, 4H), 3.86 (s, 3H), 3.83 (s, 6H), 3.33 (d, 1H, J = 3.2 
Hz); 13C{1H} NMR (CDCl3, 75 MHz): d 160.4, 159.4, 130.2, 129.4, 126.4, 121.4 (dd, J = 293.1, 
284.1 Hz), 114.0, 113.9, 71.8 (dd, J = 26.9, 20.4 Hz), 55.3, 50.1; 19F NMR (CDCl3, 282 MHz): δ 
-105.0 (dd, 1F, J = 237.1, 1.9 Hz), -119.12 (dd, 1F, J = 237.1, 21.2 Hz); HRMS (ESI+) m/z: [M + 
Li]+ calcd for C25H27O6NF2SLi, 514.1682; found, 514.1687. 
 
1,1-difluoro-2-hydroxy-N,N-bis(4-methoxybenzyl)-2(2,4-dimethoxyphenyl)ethane-1-sulfonamide 
(2.68). Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 53 mg 
(0.32 mmol) 2,4-dimethoxybenzaldehyde and was obtained as a white solid after 
chromatography eluting with 10 to 40% EtOAc in hexane (144 mg, 99% yield). 1H NMR 





6.6 (dd, 1H, J = 8.5, 2.4 Hz), 6.53 (d, 1H, J = 2.3 Hz), 5.76 (ddd, 1H, J = 21.6, 6.0, 3.4 Hz), 4.37 
(s, 4H), 3.88 (s, 3H), 3.86 (s, 3H), 3.82 (s, 6H), 3.71 (d, 1H, J = 6.1 Hz); 13C{1H} NMR (CDCl3, 
75 MHz): d 161.6, 159.4, 158.8, 130.5, 130.2, 126.7, 122.0 (dd, J = 292.7, 285.7 Hz), 114.7, 
113.9, 104.8, 98.7, 69.9 (dd, J = 27.3, 20.6 Hz), 55.8, 55.4, 55.3, 50.1; 19F NMR (CDCl3, 282 
MHz): δ -105 (dd, 1F, J = 236.1, 3.0 Hz), -117.3 (dd, 1F, J = 236.0, 21.7 Hz); HRMS (ESI+) m/z: 
[M + NH4]
+ calcd for C26H33F2N2O7S, 555.1971; found, 555.1960. 
 
N,N-bis(4-methoxybenzyl)-2-(4-trifluoromethylphenyl)-2-hydroxyl-1,1-difluoroethane-
sulfonamide (2.69). Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 
and 56 mg (0.32 mmol) 4-trifluoromethylbenzaldehyde and was obtained as a yellow oil after 
chromatography, eluting with 5 to 25% EtOAc in hexane (105 mg, 81% yield). 1H NMR (CDCl3, 
300 MHz): δ 7.71 (m, 4H), 7.13 (d, 4H, J = 8.6 Hz), 6.87 (d, 4H, J = 8.7 Hz), 5.52 (dt, 1H, J = 
21.0, 2.3 Hz), 4.38 (m, 4H), 3.83 (s, 6H), 3.55 (s, 1H); 13C{1H} NMR (CDCl3, 75 MHz): δ 
159.5, 137.7, 131.5 (q, J = 32.5 Hz), 130.1, 128.6, 126.2, 125.3 (q, J = 3.7 Hz), 123.9 (q, J = 
272.3 Hz), 120.9 (dd, J = 293.7, 285.5 Hz), 114.1, 77.2 (dd, J = 26.4, 20.7 Hz), 55.3, 50.1; 
19F NMR (CDCl3, 282 MHz): δ -62.7 (s, 3F), -105.2 (d, 1F, J = 238.0 Hz), -119.1 (dd, 1F, J = 
238.2, 21.0 Hz); HRMS (ESI+) m/z: [M + NH4]










Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 42 mg (0.32 
mmol) cinnamaldehyde and was obtained as a yellow oil after chromatography eluting with 10 to 
40% EtOAc in hexane (116 mg, 86% yield). 1H NMR (CDCl3, 300 MHz): δ 7.47 (m, 2H), 7.35 
(m, 3H), 7.16 (d, 4H, J = 8.6 Hz), 6.93 (d, 1H, J = 16.5 Hz), 6.88 (d, 4H, J = 8.7 Hz), 6.35 (dd, 
1H, J = 15.9, 6.4 Hz), 5.04 (m, 1H), 4.39 (s, 4H), 3.83 (s, 6H), 3.06 (s, 1H); 13C{1H} NMR 
(CDCl3, 75 MHz): δ 159.4, 136.0, 135.8, 130.2, 128.7, 128.5, 127.0, 126.5, 121.7 (dd, J = 290.9, 
286.2 Hz), 121.0 (dd, J = 2.82, 2.31 Hz), 114.1, 114.0, 71.8 (dd, J = 25.7, 22.3 Hz), 55.3, 50.2; 
19F NMR (CDCl3, 282 MHz): δ -107.1 (dd, 1F, J = 237.0, 5.2 Hz), -115.4 (dd, 1F, J = 236.8, 
16.9 Hz); HRMS (ESI+) m/z: [M + Na]+ calcd for C26H27O5NF2SNa, 526.1470; found, 526.1449. 
 
N,N-bis(4-methoxybenzyl)-2-(4-(methylcarboxy)phenyl)-2-hydroxyl-1,1-difluoroethane-
sulfonamide (2.71). Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 
and 52 mg (0.32 mmol) methyl 4-formylbenzoate and was obtained as a white solid after 
chromatography eluting with 5 to 25% EtOAc in hexane (110 mg, 76% yield). 1H NMR (CDCl3, 
300 MHz): δ 8.1 (d, 2H, J = 8.3 Hz), 7.64 (d, 2H, J = 8.1 Hz), 7.12 (d, 4H, J = 8.6 Hz), 6.85 (d, 
4H, J = 8.6 Hz), 5.52 (d, 1H, J = 20.8 Hz), 4.36 (s, 4H), 3.94 (s, 3H), 3.8 (s, 1H), 3.88 (s, 6H); 
13C{1H} NMR (CDCl3, 75 MHz): δ 166.7, 159.4, 138.9, 131.0, 130.1, 129.6, 128.2, 126.3, 121.1 





282 MHz): δ -105.0 (d, 1F, J = 238.4 Hz), -118.2 (dd,1F J = 238.3, 20.7 Hz), HRMS (ESI+) m/z: 
[M + NH4]
+ calcd for C26H31F2N2O7S, 553.1815; found, 553.1808. 
 
1,1-difluoro-2-hydroxyl-2-(o-chlorophenyl)-N,N-bis(4-methoxybenzyl)ethanesulfonamide (2.72). 
Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 45 mg (0.32 
mmol) 2-chlorobenzaldehyde and was obtained as a colorless oil after chromatography, eluting 
with 10 to 40% EtOAc in hexane (106 mg, 77% yield). 1H NMR (CDCl3, 300 MHz): δ 7.81 (m, 
1H), 7.41 (m, 3H), 7.15 (d, 4H, J = 8.7 Hz), 6.86 (d, 4H, J = 8.7 Hz), 6.09 (dd, 1H, J = 22.0, 3.3 
Hz), 4.39 (s, 4H), 3.83 (s, 6H), 3.45 (d, 1H, J = 3.4 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 
159.4, 134.1, 132.0, 130.4, 130.2, 129.8, 129.8, 129.5, 127.1, 126.3, 121.3 (dd, J = 294.1, 286.8 
Hz), 114.0, 68.1 (dd, J = 27.4, 19.9 Hz), 55.3, 50.2; 19F NMR (CDCl3, 282 MHz): δ -105.1 (d, 
1F, J = 238.5 Hz), -119.0 (dd, 1F, J = 238.5, 22.0 Hz); HRMS (ESI+) m/z: [M + Na]+ calcd for 
C24H24O5NF2SClNa, 534.0924; found, 534.0949. 
 
N,N-bis(4-methoxybenzyl)-1,1-difluoro-2-hydroxy-3,3-dimethylbutanesulfonamide (2.73). 
Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 28 mg (0.32 
mmol) trimethyl acetaldehyde and was obtained as a colorless oil after chromatography, eluting 
with 10 to 40% EtOAc in hexane (91 mg, 74% yield). 1H NMR (CDCl3, 300 MHz): δ 7.14 (d, 
4H, J = 8.6 Hz), 6.87 (d, 4H, J = 8.7 Hz), 4.10 (d, 2H, J = 15.2 Hz), 4.33 (d, 2H, J = 15.1 Hz), 
4.08 (ddd, 1H, J = 25.7, 4.9, 1.0 Hz), 3.83 (s, 6H), 2.91 (d, 1H, J = 4.9 Hz), 1.16 (s, 9H); 





75.4 (dd, J = 24.0, 19.8 Hz), 55.3, 50.3, 35.8 (ap t, J = 2.0 Hz), 26.7 (dd, J = 3.2, 2.0 Hz); 
19F NMR (CDCl3, 282 MHz): δ -102.1 (d, 1F, J = 233.0 Hz), -114.8 (dd, 1F, J = 233.0, 25.7 Hz); 
HRMS (ESI+) m/z: [M + NH4]
+ calcd for C22H33F2N2O5S, 475.2073; found, 475.2065. 
 
N,N-bis(4-methoxybenzyl)-1,1-difluoro-2-hydroxy-2,2-diphenylethanesulfonamide (2.74). 
Prepared according to general procedure 2.5 from 100 mg 100 mg (0.27 mmol) 2.41 and 58 mg 
(0.32 mmol) benzophenone and was obtained as a colorless oil after chromatography eluting 
with 5 to 25% EtOAc in hexane (128 mg, 86% yield). 1H NMR (CDCl3, 300 MHz): δ 7.73 (d, 
4H, J = 6.7 Hz), 7.39 (m, 6H), 7.11 (d, 4H, J = 8.7 Hz), 6.82 (d, 4H, J = 8.8 Hz), 4.49 (s, 1H), 
4.36 (s, 4H), 3.81 (s, 6H); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.5, 138.9, 130.2, 128.5, 128.1, 
127.7, 126.5, 123.0 (t, J = 297.4 Hz), 114.0, 80.1 (t, J = 20.7 Hz), 55.3, 50.5; 19F NMR (CDCl3, 
282 MHz): δ -98.6 (s); HRMS (ESI+) m/z: [M + NH4]




Prepared according to general procedure 2.5 from 2.41 (100 mg, 0.27 mmol) and 
2,2,2-trifluoroacetophenone (56 mg, 0.32 mmol) and was obtained as a white solid after 





300 MHz): δ 7.83 (m, 2H), 7.52 (m, 3H), 7.09 (d, 4H, J = 8.7 Hz), 6.85 (d, 4H, J = 8.7 Hz), 4.78 
(s, 1H), 4.35 (bs, 4H), 3.82 (s, 6H); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.6, 130.2, 128.4, 
127.4, 126.0, 123.0 (q, J = 287.8 Hz), 120.0 (ap t, J = 297.4 Hz), 114.1, 78.4 (qt, J = 30.1, 21.8 
Hz), 55.3, 50.6; 19F NMR (CDCl3, 282 MHz): δ -72.8 (dd, 3F, J = 11.1, 8.6 Hz), -104.5 (dq, 1F, 
J = 244.9, 11.0 Hz), -105.6 (dq, 1F, J = 244.9, 8.7 Hz); HRMS (ESI+) m/z: [M + NH4]
+ calcd for 
C25H28F5N2O5S, 563.1634; found, 563.1623.  
 
N,N-bis(4-methoxybenzyl)-1,1-difluoro-2-hydroxy-2-methyl-2-phenylethanesulfonamide (2.76). 
Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 38 mg (0.32 
mmol) acetophenone and was obtained as a white solid after chromatography, eluting with 0 to 
100% DCM in hexane (65 mg, 49% yield). 1H NMR (CDCl3, 300 MHz): δ 7.66 (d, 2H, J = 7.7 
Hz), 7.43 (m, 3H), 7.1 (d, 4H, J = 8.5 Hz), 6.84 (d, 4H, J = 8.5 Hz), 4.37 (m, 4H), 3.9 (s, 1H), 
3.82 (s, 6H), 1.97 (s, 3H); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 139.0, 130.2, 128.4, 128.1, 
126.7, 122.7 (ap t, J = 293.6 Hz), 126.4, 114.0, 76.0 (dd, J = 22.3, 20.9 Hz), 55.3, 50.3, 24.7 (d, J 
= 2.7 Hz); 19F NMR (CDCl3, 282 MHz): δ -105.5 (d, 1F, J = 236.3 Hz), -108.0 (d, 1F, J = 236.4 
Hz); HRMS (ESI+) m/z: [M + NH4]
+ calcd for C25H31F2N2O5S, 509.1916; found, 509.1925. 
 
1,1-difluoro-1-(1-hydroxycyclohexyl)-N,N-bis(4-methoxybenzyl)methanesulfonamide (2.77). 
Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 32 mg (0.32 
mmol) of freshly distilled cyclohexanone and was obtained as a colorless oil after 





300 MHz): δ 7.14 (d, 4H, J = 8.7 Hz), 6.86 (d, 4H, J = 8.7 Hz), 4.37 (s, 4H), 3.83 (s, 6H), 2.77 
(s, 1H), 2.05 (m, 2H), 1.73 (m, 7H), 1.26 (m, 1H); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 
130.2, 126.7, 123.8 (ap t, J = 291.9 Hz), 113.9, 74.5 (ap t, J = 20.8 Hz), 55.2, 50.3, 30.5, 25.2, 
20.5; 19F NMR (CDCl3, 282 MHz): δ -111.1 (s); HRMS (ESI
+) m/z: [M + Na]+ calcd for 
C23H29F2NNaO5S, 492.1627; found, 492.1619. 
 
N,N-bis(4-methoxybenzyl)-1,1-difluoro-2-hydroxy-2-cyclopropylethanesulfonamide (2.78). 
Prepared according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 22 mg 
cyclopropanecarboxaldehyde (0.32 mmol) and was obtained as a colorless oil after 
chromatography, eluting with 10 to 40% EtOAc in hexane (81 mg, 68% yield). 1H NMR (CDCl3, 
300 MHz): δ 7.16 (d, 4H, J = 8.6 Hz), 6.87 (d, 4H, J = 8.7 Hz), 4.38 (s, 4H), 3.83 (s, 6H), 3.75 
(m, 1H), 2.9 (bs, 1H), 1.28 (m, 1H), 0.72 (m, 2H), 0.58 (m, 2H); 13C{1H} NMR (CDCl3, 75 
MHz): δ 159.4, 130.2, 126.6, 122.5 (dd, J = 289.9, 287.1 Hz), 114.0, 74.1 (dd, J = 23.9, 21.5 
Hz), 55.3, 50.2, 10.8 (ap t, J = 3.2 Hz), 3.0, 2.0; 19F NMR (CDCl3, 282 MHz): δ -108.2 (dd, 1F, J 
= 237.4, 5.8 Hz), -114.6 (dd, 1F, J = 237.3, 16.0 Hz); HRMS (ESI+) m/z: [M + Na]+ calcd for 
C21H25F2NnaO5S, 464.1314; found, 464.1302. 
 
N,N-bis(4-methoxybenzyl)-1,1-difluoro-2-hydroxy-3-methylbutanesulfonamide (2.79). Prepared 
according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 23 mg (0.32 mmol) of 
freshly distilled isobutyraldehyde and was obtained as a colorless oil after chromatography, 





7.15 (d, 4H, J = 8.7 Hz), 6.87 (d, 4H, J = 8.7 Hz), 4.40 (d, 2H, J = 15.4 Hz), 4.34 (d, 2H, J = 15.3 
Hz), 4.21 (ddd, 1H, J = 21.2, 9.0, 4.6 Hz), 3.83 (s, 6H), 2.78 (d, 1H, J = 5.4 Hz), 2.3 (s, 1H), 1.15 
(d, 3H, J = 6.9 Hz), 1.11 (d, 3H, J = 6.8 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 130.2, 
126.6, 123.3 (dd, J = 292.3, 288.7 Hz), 114.0, 73.3 (dd, J = 24.0, 19.9 Hz), 55.3, 50.2, 28.7, 20.2, 
16.2; 19F NMR (CDCl3, 282 MHz): δ -107.1 (dd, 1F, J = 236.1, 2.5 Hz), -113.8 (dd, 1F, J = 
236.1, 21.2 Hz); HRMS (ESI+) m/z: [M + Na]+ calcd for C21H27F2NnaO5S, 466.1470; found, 
466.1456. 
 
N,N-bis(4-methoxybenzyl)-1,1-difluoro-2-hydroxy pentanesulfonamide (2.80). Prepared 
according to general procedure 2.5 from 100 mg (0.27 mmol) 2.41 and 23 mg (0.32 mmol) of 
freshly distilled butyraldehyde and was obtained as a colorless oil after chromatography eluting 
with 10 to 30% EtOAc in hexane (52 mg, 43% yield). 1H NMR (CDCl3, 300 MHz): δ 7.13 (d, 
4H, J = 8.6 Hz), 6.85 (d, 4H, J = 8.6 Hz), 4.35 (s, 4H), 4.28 (m, 1H), 3.81 (s, 6H), 2.67 (s, 1H), 
1.73 (m, 3H), 1.49 (m, 1H), 1 (t, 3H, J = 7.2 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 
130.2, 126.5, 122.5 (dd, J = 289.6, 287.1 Hz), 114.0, 70.3 (dd, J = 24.5, 22.0 Hz), 55.3, 50.1, 
31.3, 18.5, 13.7; 19F NMR (CDCl3, 282 MHz): δ -108.8 (dd, 1F, J = 236.2, 5.4 Hz), -115.8 (dd, 









mg (0.32 mmol) of freshly distilled phenylacetaldehyde. The product was isolated by RP-HPLC 
using a C18 column (10 μm, 150 mm × 20 mm, 10 mL/min flow rate) using a gradient of 20 to 
100% acetonitrile in water over 60 min (RT = 45 min) yielding 9k as a colorless oil (15 mg, 11% 
yield). 1H NMR (CDCl3, 300 MHz): δ 7.36 (m, 5H), 7.17 (d, 4H, J = 8.6 Hz), 6.88 (d, 4H, J = 
8.7 Hz), 4.55 (m, 1H), 4.39 (s, 4H), 3.84 (s, 6H), 3.25 (d, 1H, J = 14.1 Hz), 2.98 (dd, 1H, J = 
14.1, 10.2 Hz), 2.7 (s, 1H); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.5, 136.4, 130.2, 129.5, 
128.6, 127.0, 126.5, 122.3 (dd, J = 290.6, 287.3 Hz), 114.0, 71.6 (dd, J = 25.0, 21.5, Hz), 55.3, 
50.2, 35.9; 19F NMR (CDCl3, 282 MHz): δ -108.6 (dd, 1F, J = 236.3, 5.0 Hz), -115.9 (dd, 1F, J = 
236.5, 17.2 Hz); HRMS (ESI+) m/z: [M + NH4]
+ calcd for C25H31F2N2O5S, 509.1916; found, 
509.1898. 
 When the reaction was performed at -128 °C in a mixture of 3:2 THF:Et2O the yield was 
increased to 52 mg (39% yield) and the product could be isolated by flash chromatography, 5% 
to 25% EtOAc in hexane.  
 When the reaction was performed at -128 °C in a mixture of 3:2 THF:Et2O using 130 mg 
(4 equiv) of freshly distilled phenylacetaldehyde and 1.08 mL (2 equiv) of 0.5 M KHMDS in 
toluene then the yield was increased to 84 mg (61% yield) and the product was isolated by flash 
chromatography, 5 to 25% EtOAc in hexane.  
 
tert-butyl (3S)-3-((2-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,2-difluoro-1-hydroxyethyl)amino)-
2-oxobutanoate (2.84). Boc-alanal (2.82) was prepared according to a literature procedure.114  
 2.41 (371 mg, 1 mmol, 1 equiv) and 2.82 (208 mg, 1.2 mmol, 1.2 equiv) were dissolved 





in 5 mL of 1:1 Et2O:THF, cooled to -114 °C, then transferred by cannula over a period of 4 min. 
The reaction was stirred for an additional 5 min then was quenched with 5 mL sat. NH4Cl. The 
mixture was warmed, diluted with 20 mL of water, and extracted twice with 20 mL ether. The 
combined ether layers were washed with brine, dried over MgSO4, filtered and concentrated. 
19F 
NMR using 3-fluorotoluene as internal standard indicated that this mixture contained a 1:1.2 
mixture of diastereomers in 26% yield. The mixture was subjected to several rounds of flash 
chromatography 0 to 12% EtOAc in 1:1 DCM: hexanes. 57 mg (10%) of the minor, more polar 
diastereomer was separated. None of the less polar, major diastereomer could be separated from 
unidentified impurities. 1H NMR (CDCl3, 300 MHz) σ: 7.10 (d, 4H, J = 8.4 Hz), 6.83 (d, 4H, J = 
8.5 Hz), 4.94 (d, 1H, J = 8.0 Hz), 4.51 (d, 1H, J = 21.7 Hz), 4.37 (d, 2H, J = 15.1 Hz), 4.27 (d, 
2H, J = 15.2 Hz), 4.20, (br, 1H), 3.80 (s, 6H), 3.64 (m, 1H), 1.45 (s, 9H), 1.30 (d, 3H, J = 6.7 
Hz); 13C{1H} NMR (CDCl3, 125 MHz) σ: 159.4, 155.6, 130.2, 126.5, 122.2 (dd, J = 293.4, 288.7 
Hz), 114.0, 80.0, 71.6 (dd, J = 24.2, 19.8 Hz), 55.3, 50.3, 47.1, 28.4, 15.2 19F NMR (CDCl3, 282 
MHz): δ -108.9 (d, 1F, J = 238.5 Hz), -115.5 (dd, 1F, J = 238.7, 21.9 Hz) HRMS-ESI+ (m/z) 
calcd for C25H34N2O7SF2Na
+
 (M + Na)
+ 567.19470, found 567.19584.  
Determination of the extent of epimerization in 2.84 
 Compound 2.84 (47 mg, 0.087 mmol, 1 equiv) was dissolved in 2 mL of 25% TFA in 
DCM. The mixture was stirred at room temperature for 2 h. The mixture was diluted with 20 mL 
of EtOAc then washed twice with 20 mL of 10% Na2CO3. The organic layer was dried over 
MgSO4, filtered, and concentrated, the residue was dissolved in 10 mL of DCM then divided into 
two flasks. To each was added HOAt (23 mg, 0.17 mmol, 4 equiv) EDC·HCl (33 mg, 0.17 
mmol, 4 equiv) and either D or L N-benzenesulfonyl proline. The resulting mixture was stirred 





mmol, 4 equiv). After stirring an additional 10 min the reaction was diluted with 50 mL of 
EtOAc washed twice with 20 mL 0.1 M HCl, once with 5 % NaHCO3 and once with brine. The 
organic layers was dried over magnesium sulfate, filtered and concentrated to give crude 2.86, 
derived from N-benzenesulfonyl-L-proline, and 2.87, derived from N-benzenesulfonyl-D-
proline.  
 The crude material was subjected to HPLC. Isocratic gradient 0.1% TFA 47% 
CH3CN:H2O. The retention time was 29.1 min for 2.87 and 31.1 min for 2.86. These compounds 
showed baseline separation on coinjection and in both cases there minor diastereomer was not 
observed (Figure 2.9).  
General procedure 2.6 for the reaction of 2.41 with N-PhF α-aminoaldehydes 
 See Chapter 3 for the preparation of amino aldehydes PhF-alanal (2.88), PhF-methioninal 
(2.94), N-PhF-O-(tBu)-Aspartal (2.95) and PhF-prolinal (2.96). 
 2.41 (0.4-1 mmol, 1.00 equiv) and PhF protected α-amino aldehyde (1.20 equiv) were 
dissolved in 10 mL of 1:1 THF:Et2O per mmol of 2.41 then cooled to -114 °C. Separately 
KHMDS (0.5 M in toluene, 1.2 equiv) was diluted in 1:1 THF:Et2O, 5 mL per mmol of 2.41, 
cooled to -114 °C. The KHMDS was transferred to the reaction flask dropwise by cannula over 
5-10 min. After the addition was complete the reaction was stirred for an additional 5 min before 
quenching with saturated NH4Cl solution and extraction three times with DCM. The combined 
organic layers are dried over magnesium sulfate, filtered, and concentrated to yield a mixture of 







butane-1-sulfonamide (2.89) and (2S,3S)-1,1-difluoro-2-hydroxy-N,N-bis(4-methoxybenzyl)-3-
((9-phenyl-9-fluorenyl)amino)butane-1-sulfonamide (2.90). Prepared according to general 
procedure 2.6 from 208 mg (0.56 mmol) of 2.41 and 211 mg (0.67 mmol) of 2.88. Flash 
chromatography, eluting with 5 to 25% EtOAc in hexane, yielded a mixture of 2.89 and 2.90, 
which were separated on a second column with a gradient of 0 to 5% EtOAc in 1:1 DCM 
hexane. Combined yield 335 mg (87%). 2.89 is slightly more polar than 2.90. 
 2.89 (syn isomer) was obtained as a white foam (285 mg, 74% yield). 1H NMR (CDCl3, 
300 MHz): δ 7.78 (d, 1H, J = 7.5 Hz), 7.73 (d, 1H, J = 7.4 Hz), 7.45-7.2 (m, 11H), 7.14 (d, 4H, J 
= 8.5 Hz), 6.86 (d, 4H, J = 8.5 Hz), 4.33 (s, 4H), 3.90 (dt, 1H, J = 20.1, 4.7 Hz), 3.80 (s, 6H), 
2.81 (m, 1H), 0.84 (d, 3H), J = 6.4 Hz); 13C{1H} NMR (CDCl3, 282 MHz): δ 159.3, 150.4, 
147.6, 144.6, 140.8, 140.1, 130.3, 128.7, 128.6, 128.2, 128.0, 127.5, 127.0, 122.8 (dd, J = 293.5, 
284.7 Hz), 125.9, 125.1, 120.3, 120.1, 113.9, 72.7 (dd, J = 26.1, 19.8 Hz), 72.5, 55.3, 50.3, 47.7, 
21.9; 19F NMR (CDCl3, 282 MHz): δ -109.0 (d, 1F, J = 238.5 Hz), -115.7 (dd, 1F, J = 238.4, 
19.8 Hz); HRMS (ESI+) m/z: [M + H]+ calcd for C39H39O5N2F2S, 685.2542; found, 685.2568.  
 2.90 (anti isomer) was obtained as a white foam (50 mg, 13% yield). 1H NMR (CDCl3, 
300 MHz): δ 7.66 (d, 1H, J = 7.6 Hz), 7.61 (d, 1H, J = 7.6 Hz), 7.33 (m, 3H), 7.24 (m, 4H), 7.17 
(m, 5H), 6.98 (d, 4H, J = 8.5 Hz), 6.72 (d, 4H, J = 8.6 Hz), 4.16 (s, 4H), 3.71 (m, 7H), 2.6 (m, 
1H), 0.85 (d, 3H, J = 6.7 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.3, 149.9, 148.6, 144.6, 





113.9, 72.7, 71.1 (dd, J = 25.4, 19.3 Hz), 55.3, 50.2, 49.2 (d, J = 1.7 Hz), 17.5; 19F NMR (CDCl3, 
282 MHz): δ -106.2 (d, 1F, J = 239.6 Hz), -113.3 (dd, 1F, J = 239.6, 22.2 Hz); HRMS (ESI+) 
m/z: [M + H]+ calcd for C39H39O5N2F2S, 685.2542; found, 685.2568. 
 
(2R,3S)-1,1-difluoro-2-hydroxy-N,N-bis(4-methoxybenzyl)-5-(methylthio)-3-((9-phenyl-9-
fluorenyl)amino)pentane-1-sulfonamide (2.97) and (2S,3S)-1,1-difluoro-2-hydroxy-N,N-bis(4-
methoxybenzyl)-5-(methylthio)-3-((9-phenyl-9-fluorenyl)amino)pentane-1-sulfonamide(2.100). 
Prepared according to general procedure 2.6 from 448 mg (1.20 mmol) of 2.94 and 371 mg (1.00 
mmol) of 2.41. Flash chromatography, eluting with 5 to 30% EtOAc in hexane, gave a mixture 
of 2.97 and 2.100 in a 5.5:1 ratio (693 mg, 93% combined yield).  
 The mixture was subjected to additional chromatography, eluting with 0 to 5% EtOAc in 
DCM, and a portion of 2.97 was separated as a colorless oil (460 mg, 60% yield). 2.97 and 2.100 
were not easily distinguished by TLC and fractions containing pure 2.100 were identified by 
19F NMR. 1H NMR (CDCl3, 300 MHz): δ 7.74 (d, 1H, J = 7.5 Hz), 7.70 (d, 1H, J = 7.4 Hz), 7.4-
7.2 (m, 11H), 7.10 (d, 4H, J = 8.6 Hz), 6.84 (d, 4H, J = 8.6 Hz), 4.29 (s, 4H), 4.05 (dt, 1H, J = 
20.6, 3.6 Hz), 3.80 (s, 6H), 2.87 (m, 1H), 2.15 (m, 2H), 1.83 (s, 3H), 1.40 (m, 2H); 13C{1H} 
NMR (CDCl3, 75 MHz): δ 159.4, 150.4, 147.6, 144.7, 140.6, 140.2, 130.2, 128.72, 128.65, 
128.5, 128.1, 128.0, 127.4, 126.8, 126.3, 125.9, 125.1, 120.3, 122.7 (dd, 293.1, 287.5 Hz), 120.0, 





MHz): δ-107.9 (d, 1F, J = 237.5 Hz), -113.5 (dd, 1F, J = 237.5, 20.6); HRMS (ESI+) m/z: [M + 
H]+ calcd for C41H43F2N2O5S2, 745.2576; found, 745.2593.  
  None of the minor diastereomer 2.97 was separated.  
 
tert-butyl(3S,4R)-5-(N,N-bis(4-methoxybenzyl)sulfamoyl)-5,5-difluoro-4-hydroxy-3-((9-phenyl-9-
fluorenyl)amino)pentanoate (2.98) and tert-butyl (3S,4S)-5-(N,N-bis(4-
methoxybenzyl)sulfamoyl)-5,5-difluoro-4-hydroxy-3-((9-phenyl-9-
fluorenyl)amino)pentanoate(2.101). Prepared according to general procedure 2.6 from 200 mg 
(0.480 mmol) of 2.95 and 149 mg (0.400 mmol) of 2.41. Flash chromatography, eluting with 5 to 
30% EtOAc in hexane, yielded awhite foam consisting of a mixture 2.98 and 2.101 in a 2.3:1 
ratio (295 mg, combined 94% yield).  
 The mixture was subjected to additional chromatography 0 to 7% EtOAc in DCM and a 
portion of 2.98 (syn isomer) was separated as a white solid (192 mg, 61% yield). 2.98 and 2.101 
were not easily distinguished by TLC and fractions containing pure 2.98 were identified by 
19F NMR. 1H NMR (CDCl3, 300 MHz): δ 7.76 (d, 1H, J = 7.5 Hz), 7.71 (d, 1H, J = 7.4 Hz), 7.34 
(m, 11H), 7.09 (d, 4H, J = 8.3 Hz), 6.82 (d, 4H, J = 8.4 Hz), 4.28 (s, 4H), 4.13 (m, 1H), 3.80 (s, 
6H), 2.84 (s, 1H), 2.05 (m, 1H), 1.82 (dd, 1H, J = 17.5, 4.7 Hz), 1.42 (s, 9H); 13C{1H} NMR 
(CDCl3, 75 MHz): δ 171.6, 159.3, 150.7, 147.3, 144.2, 140.5, 140.2, 130.2, 128.84, 128.80, 
128.5, 128.4, 128.1, 127.4, 127, 125.9, 125.8, 124.6, 122.6 (dd, J = 293.6, 282.9 Hz), 120.5, 





(CDCl3, 282 MHz): δ -107.9 (1F, d, J = 240.2 Hz), -116.5 (1F, dd, J = 240.1, 19.8 Hz); HRMS 
(ESI+) m/z: [M + H]+ calcd for C44H47N2O7SF2,
 785.3067; found, 785.3029.  
 None of the minor diastereomer (anti isomer) 2.101 was isolated.  
 
®-1,1-difluoro-2-hydroxy-N,N-bis(4-methoxybenzyl)-2-((S)-1-(9-phenyl-9-
fluoren144yrrolidinedin-2-yl)ethane-1-sulfonamide (2.99) and (S)-1,1-difluoro-2-hydroxy-N,N-
bis(4-methoxybenzyl)-2-((S)-1-(9-phenyl-9-fluoren144yrrolidinedin-2-yl)ethane-1-
sulfonamide(2.102). Prepared according to general procedure 2.6 from 291 mg (0.780 mmol) of 
2.41 and 320 mg (0.940 mmol) of 2.96. The diastereomers were separated by flash 
chromatography eluting with 0 to 10% Et2O in DCM. Combined yield 535 mg (96%) as a 5 to 1 
mixture of 2.99:2.102. Compound 2.102 is more polar than 2.99.  
 2.99 (syn isomer) was obtained as a white foam (445 mg, 80% yield). 1H NMR (CDCl3, 
300 MHz): δ 7.77 (d, 1H, J = 7.6 Hz), 7.61 (d, 1H, J = 7.3 Hz), 7.47 (m, 5H), 7.27 (m, 6H), 7.03 
(d, 4H, J = 8.5 Hz), 6.78 (d, 4H, J = 8.5 Hz), 5.99 (s, 1H), 4.20 (s, 4H), 3.78 (s, 6H), 3.57 (td, 1H, 
J = 18.3, 6.2 Hz), 3.30 (t, 2H, J = 7.3 Hz), 3.04 (t, 1H, J = 6.8 Hz), 1.87 (m, 1H), 1.75 (m, 1H), 
1.42 (m, 1H), 1.17 (m, 1H); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.2, 148.3, 146.9, 142.6, 
141.9, 139.0, 130.2, 129.2, 128.6, 128.5, 128.4, 127.7, 127.0, 126.0, 125.7, 122.4 (dd, J = 293.2, 
282.9 Hz), 120.5, 119.7, 113.8, 77.6, 69.7 (dd, J = 26.7, 19.5 Hz), 57.8, 55.3, 50.5, 50.2, 31.6, 
23.8; 19F NMR (CDCl3, 282 MHz): δ -112.4 (dd, 1F, J = 238.4, 4.4 Hz), -117.1 (dd, 1F, J = 





 2.102 (anti isomer) was obtained as a white foam (90 mg, 16% yield). 1H NMR (CDCl3, 
300 MHz): δ 7.76 (d, 1H, J = 7.4 Hz), 7.64 (d, 1H, J = 7.4 Hz), 7.49 (m, 5H), 7.25 (m, 6H), 7.02 
(d, 4H, J = 8.3 Hz), 6.78 (d, 4H, J = 8.4 Hz), 4.16 (s, 4H), 3.78 (s, 6H), 3.54 (m, 2H), 3.28 (m, 
2H), 2.92 (m, 1H), 2.00 (m, 1H), 1.78 (m, 1H), 1.62 (m, 2H); 13C{1H} NMR (CDCl3, 75 MHz): 
δ 159.2, 148.2, 146.6, 143.6, 142.2, 138.9, 130.2, 128.9, 128.7, 128.5, 127.9, 127.8, 127.3, 127.2, 
126.9, 126.3, 125.7, 122.6 (dd, J = 293.7, 283.3 Hz),120.2, 120.1, 113.8, 77.5, 69.8 (dd, J = 26.3, 
17.3 Hz), 59.0, 52.4, 50.2, 27.2, 25.6; 19F NMR (CDCl3, 282 MHz): δ 110.0 (1F, dd, J = 239.3, 
4.2 Hz), -114.1 (1F, dd, J = 239.2, 23.0 Hz); HRMS(ESI+) m/z: [M + H]+ calcd for 
C41H41F2N2O5S,
 711.2699; found, 711.2718. 
 When Using NaHMDS. The reaction was performed by dissolving 2.41 (100 mg, 0.27 
mmol, 1.00 equiv) and 2.96 (108 mg, 0.32 mmol, 1.2 equiv) in 5 mL of 3:2 THF:Et2O. The 
solution was cooled to -128 °C and then NaHMDS (1 M in THF, 594 µL, 2.20 equiv) was added 
dropwise. The mixture was stirred until complete by TLC (5 min) then was quenched with 2 mL 
of saturated NH4Cl. The mixture was diluted with water, extracted three times with DCM, the 
combined organic layers were dried over magnesium sulfate, filtered, and concentrated then the 
residue was purified by flash chromatography, 5 to 25% EtOAc in hexane, to yield a white solid 
consisting of 2.99 and 2.102 (96:4) (184 mg, 96% combined yield). 
 A crystal of 2.99 suitable for x-ray crystallography was obtained by dissolving pure 2.99 
in a 1:1 mixture of DCM:Et2O at room temperature. The solution was placed in a 7 mL vial and 
left open to air until completely evaporated. 
Determination of the extent of epimerization in 2.89 
 2.89 (68 mg, 0.1 mmol, 1 equiv) was dissolved in 10 mL of MeOH and 13 mg of 20 wt% 





complete by TLC. The reaction was filtered with a pad of celite and concentrated to give a crude 
mixture consisting of free amine 2.91 and 9-phenylfluorene. The crude material was dissolved in 
10 mL of DCM and divided into two flasks. To each was added HOAT (27 mg, 0.2 mmol, 4 
equiv), EDC·HCl (38 mg, 0.2 mmol, 4 equiv) and either D or L N-benzenesulfonyl proline. The 
reactions were stirred for 3 h then unreacted HOAt ester was destroyed by the addition of TAEA 
(30 µL, 0.2 mmol, 4 equiv) After stirring an additional 10 min the reaction was diluted with 50 
mL of EtOAc washed twice with 20 mL 0.1 M HCl, once with 5 % NaHCO3 and once with 
brine. The organic layers was dried over magnesium sulfate, filtered and concentrated to give 
crude 2.92, derived from N-benzenesulfonyl-L-proline, and 2.93, derived from N-
benzenesulfonyl-D-proline.  
 The crude material was subjected to HPLC. 10 to 90% CH3CN 0.1% TFA:H2O over 45 
min. The retention time was 34.5 min for 2.92 and 35.1 min for 2.93. Both were 
diastereomerically pure and could be separated by coinjection. (Figure 2.10).  
Synthesis of N-Benzyl-N-PhF-α-amino aldehydes 2.103-2.106 
 
N-Benzyl-N-(9-phenyl-9-fluorenyl)-alanine (2.140). Freshly lyophilized alanine (178 mg, 2.00 
mmol, 1.00 equiv) was placed in 5 mL of CH3CN and BSA (586 µL, 2.40 mmol, 1.2 equiv) was 
added. The mixture was heated to reflux for 5 min until completely dissolved. After cooling to 0 
°C, NMM (220 µL, 2.00 mmol, 1.00 equiv) and BnBr (237 µL, 2.00 mmol, 1.00 equiv) were 





equiv) and PhFCl (662 mg, 2.40 mmol, 1.20 equiv) and 10 mL CH3CN were added and the 
mixture cooled to 0 °C. AgNO3 (748 mg, 4.4 mmol, 2.2 equiv) was added as a solution in 7 mL 
of CH3CN. A white precipitate formed immediately, and the reaction was stirred at room 
temperature for 1 hour then was quenched with 5 mL of MeOH. The precipitate was filtered off 
and the filtrate was concentrated. The residue was purified by flash chromatography eluting with 
0 to 100% EtOAc in DCM to give (2.128) as a white foam (214 mg, 25% yield). 1H NMR 
(CDCl3, 300 MHz): δ 10.47 (br, 1H), 7.83 (d, 1H, J = 7.6 Hz), 7.75 (m, 1H), 7.68 (dd, 2H, J = 
7.5, 2.0 Hz), 7.57 (m, 2H), 7.44 (m, 5H), 7.32 (m, 7H), 4.38 (d, 1H, J = 13.3 Hz), 4.01 (d, 1H, J 
= 13.3 Hz), 3.34 (q, 1H, J = 7.1 Hz), 0.93 (d, 3H, J = 7.2 Hz); 13C{1H} NMR (CDCl3, 75 MHz): 
δ 177.2, 147.6, 145.7, 142.9, 141.1, 139.9, 138.2, 129.6, 129.1, 128.91, 128.87, 128.5, 128.3, 
128.0, 127.8, 127.6, 127.2, 127.0, 126.0, 120.8, 120.3, 79.7, 55.3, 50.6, 12.5; HRMS (ESI+) m/z: 
[M + Na]+ calcd for C29H25NO2, 419.1885; found, 442.1761.  
 329 mg of (9-phenyl-9-fluorenyl) alanine was also isolated (56% yield).  
N-Benzyl-N-(9-phenyl-9-fluorenyl)-alanal(2.103). Compound 2.140 (210 mg, 0.50 mmol, 1.00 
equiv) was dissolved in 5 mL of DCM and cooled to 0 °C then CDI (89 mg, 0.55 mmol, 1.10 
equiv) was added and the mixture was stirred for 1 hour until complete by TLC. After cooling to 
-78 °C DIBALH (1 M in toluene, 1.1 mL, 2.2 equiv) was added dropwise over 20 min and 
stirring was continued for two h at –78 °C before another portion of DIBALH (1 M in toluene, 
1.1 mL, 2.2 equiv) was added dropwise over 10 min. The mixture was stirred for an additional 2 
h and then was quenched with 1 mL of EtOAc then 1 mL of MeOH and then was concentrated 
on silica. This was purified by flash chromatography eluting with DCM to give 2.103 as a 
colorless oil (124 mg, 59% yield). 1H NMR (CDCl3, 300 MHz): δ 9.27 (s, 1H), 7.76 (m, 3H), 





13.2 Hz), 3.88 (d, 1H, J = 13.3 Hz), 3.17 (q, 1H, J = 6.7 Hz), 0.59 (d, 3H, J = 6.8 Hz); 13C{1H} 
NMR (CDCl3, 75 MHz): δ 202.5, 148.5, 146.9, 143.3, 140.9, 139.9, 138.5, 129.6, 128.8, 128.7, 
128.6, 128.4, 128.2, 128.0, 127.7, 127.5, 127.1, 126.8, 125.8, 120.6, 120.3, 78.9, 61.9, 50.1, 9.9; 
HRMS (ESI+) m/z: [M + H]+ calcd for C29H26NO, 404.2009; found, 404.1991. 
 
(S)-2-(benzylamino)-N-methoxy-N-methyl-4-(methylthio)butanamide (2.141). Methionine N,O-
dimethylhydroxamide hydrochloride (670 mg, 2.93 mmol, 1 equiv) was dissolved in 6 mL of 
methanol and powdered NaOH (117 mg, 2.93 mmol, 1 equiv) was added followed by 
benzaldehyde (1.02 mL 10.0 mmol, 3.41 equiv). The reaction was sealed and heated to 60 °C 
overnight then was cooled to 0 °C and added to a suspension of NaBH4 (975 mg, 25.0 mmol, 
8.53 equiv) in 10 mL of THF and 10 mL of methanol. The reaction was stirred for 3 h while 
warming to room temperature then was quenched with 1 mL AcOH. The volume was reduced to 
approximately 10 mL and the mixture was diluted with 30 mL of 10% Na2CO3. The pH was 
adjusted to 12 with 6 M NaOH then the mixture was extracted with 20 mL of DCM 5 times. The 
combined organic layers were dried over magnesium sulfate, filtered, concentrated and the 
residue was purified by flash chromatography eluting with 5 to 50% EtOAc in hexane to give 
2.141 as a viscous oil (552 mg, 67% yield). 1H NMR (CDCl3, 300 MHz): δ 7.35 (d, 2H, J = 7.3 
Hz), 7.3 (t, 2H, J = 7.4 Hz), 7.23 (t, 1H, J = 7.2 Hz), 3.83 (d, 1H, J = 13.1 Hz), 3.74 (m, 1H), 
3.58 (s, 3H), 3.56 (d, 1H, J = 13.2 Hz), 3.21 (s, 3H), 2.68 (m, 2H), 2.07 (s, 3H), 1.86 (m, 1H), 





32.5, 32.0, 30.7, 14.9; HRMS (ESI+) m/z: [M + H]+ calcd for C14H23N2O2S,
 283.1475; found, 
283.1503. 
 (S)-2-(benzyl(9-phenyl-9H-fluoren-9-yl)amino)-N-methoxy-N-methyl-4-(methylthio)-
butanamide(2.142). Compound 2.141 (500 mg, 1.77 mmol, 1.00 equiv), PhFCl (587 mg, 2.13 
mmol, 1.2 equiv) and NMM (235 µL, 2.13 mmol, 1.2 equiv) were dissolved in 10 mL of CH3CN 
and cooled to 0 °C then AgNO3 (362 mg, 2.13 mmol, 1.2 equiv) was added as a solution in 4 mL 
CH3CN. A white precipitate formed immediately which darkened to brown/purple over time. 
The mixture was stirred for 1 hour then was filtered and concentrated onto silica. Flash 
chromatography, eluting with 0 to 25% EtOAc in hexane, yielded 2.142 as a white foam (727 
mg, 79% yield). 1H NMR (CDCl3, 300 MHz): δ 7.7 (m, 8H), 7.27 (m, 10H), 5.06 (d, 1H, J = 
14.0 Hz), 4.29 (d, 1H, J = 14.6 Hz), 4.00 (m, 1H), 3.1 (s, 3H), 2.62 (s, 3H), 2.36 (m, 2H), 1.78 (s, 
3H), 1.51 (m, 2H);13C{1H} NMR (CDCl3, 75 MHz): δ 174.2, 148.8, 146.7, 144.5, 142.6, 141.0, 
140.6, 128.7, 128.4, 128.2, 127.9, 127.7, 127.6, 127.5, 127.2, 126.5, 126.2, 120.1, 120.0, 80.1, 
60.8, 54.8, 50.6, 31.8, 31.2, 30.8, 15.0; HRMS (ESI+) m/z: [M + H]+ calcd for C33H35N2O2S, 
523.2414; found, 523.2428. 
 N-benzyl-N-(9-phenyl-9-fluorenyl)methioninal (2.104). Compound 2.142 (261 mg, 0.5 
mmol, 1 equiv) was dissolved in 5 mL of THF and cooled to -78 °C. LiAlH4 (2 M in THF, 275 
µL, 0.550 mmol 1.1 equiv) was added and the reaction was stirred overnight at 0 °C. The 
reaction was quenched by dropwise addition of 1 mL of EtOAc followed by 1 mL of MeOH and 
finally 5 mL of silica then was concentrated. Flash chromatography, eluting with 2.5% to 15% 
EtOAc in hexane, gave 2.104 as a white solid (78 mg, 34% yield). 1H NMR (CDCl3, 300 MHz): 
δ 9.27 (s, 1H), 7.86 (m, 1H), 7.81 (d, 1H, J = 7.5 Hz), 7.69 (m, 3H), 7.51 (m, 3H), 7.44 (t, 1H, J 





Hz), 2.1 (t, 1H, J = 9.1 Hz), 1.72 (s, 3H), 1.68 (m, 2H), 1.22 (t, 1H, J = 8.3 Hz); 13C{1H} NMR 
(CDCl3, 75 MHz): δ 201.1, 148.2, 146.6, 143.2, 141.0, 139.9, 138.2, 129.7, 129.1, 128.8, 128.7, 
128.4, 128.3, 128.1, 127.8, 127.6, 127.1, 126.9, 125.7, 120.8, 120.4, 78.9, 65.6, 51.1, 32.4, 26.2, 
15.2; HRMS (ESI+) m/z: [M + Na]+ calcd for C31H29NOSNa, 486.1862, found, 486.1856.  
 
N-(9-phenyl-9-fluorenyl)-N-benzyl-O4-tbutyl-aspartol (2.143). N-benzyl-O4-tbutyl-aspartol was 
prepared according to a literature procedure.128 N-benzyl-O4-tbutyl-aspartol (480 mg, 1.81 
mmol, 1 equiv) was dissolved in 10 mL of CH3CN and BSA (530 µL, 2.17 mmol, 1.20 equiv) 
was added. The solution was refluxed for 15 min then cooled to 0 °C and NMM (239 µL, 2.17 
mmol, 1.2 equiv) and PhFCl (598 mg, 2.17 mmol, 1.20 equiv) were added followed by AgNO3 
(364 mg, 2.17 mmol, 1.20 equiv) in a solution of 4 mL CH3CN. A white precipitate formed 
immediately. The mixture was stirred for two h then the reaction was quenched with 5 mL of 
MeOH. The precipitate was filtered off and the filtrate was diluted with 100 mL EtOAc and 
washed with 100 mL 5% Na2CO3. The organic layer was concentrated then redissolved in 10 mL 
of THF and TBAF was added (1 M in THF, 4.5 mL, 2.48 equiv). After 1 hour the TMS ether 
was completely consumed by TLC and the reaction was diluted with 100 mL EtOAc and then 
washed with 50 mL of 5% Na2CO3 then 50 mL of water. The organic layer was dried over 
magnesium sulfate, filtered, and concentrated. Then the residue was purified by flash 
chromatography, eluting with 15 to 30% EtOAc in hexane, to yield 2.131 as a white foam (814 
mg, 89% yield). 1H NMR (CDCl3, 300 MHz): δ 7.68 (m, 6H), 7.33 (m, 12H), 4.17 (d, 1H, J = 





(m, 1H), 1.23 (s, 9H); 13C{1H} NMR (CDCl3, 75 MHz): δ 171.6, 147.9, 146.6, 143.5, 140.94, 
140.90, 140.1, 128.69, 128.66, 128.5, 128.4, 128.3, 128.0, 127.6, 127.35, 127.27, 127.1, 126.7, 
126.2, 120.6, 120.0, 80.3, 79.6, 64.9, 56.1, 50.7, 36.7, 27.8; HRMS (ESI+) m/z: [M + H]+ calcd 
for C34H36NO3, 506.2690; found, 506.2692. 
N-(9-phenyl-9-fluorenyl)-N-benzyl-O4-tbutyl-aspartal (2.105).  Oxallyl chloride (211 µL, 
2.42 mmol, 3 equiv) was dissolved in 10 mL of DCM and cooled to -78 °C. DMSO (345 µL, 
4.84 mmol, 6 equiv) was added dropwise and stirred for 10 min. 2.143 (408 mg, 0.81 mmol, 1.00 
equiv) was added as a solution of 5 mL DCM, dropwise, then stirred for 15 min. Triethylamine 
(1.03 mL, 7.27 mmol, 9 equiv) was added dropwise and stirred for 5 min before warming to 
room temperature. After an additional 30 min the reaction was quenched wit 30 mL of water and 
extracted twice with 20 mL of DCM. The combined organic layers were dried over magnesium 
sulfate, filtered, and concentrated. The residue was purified by flash chromatography, eluting 
with 0 to 30% EtOAc in hexane, to yield 2.105 as a white foam (227 mg, 56% yield). 1H NMR 
(CDCl3, 300 MHz): δ 9.28 (s, 1H), 7.92 (br, 2H), 7.76 (m, 4H), 7.50 (m, 3H), 7.4 (m, 9H), 4.30 
(d, 1H, J = 13.2 Hz), 3.87 (d, 1H, J = 3.7 Hz), 3.74 (d, 1H, J = 13.2 Hz), 2.29 (dd, 1H, J = 16.2, 
9.8 Hz), 1.83 (d, 1H, J = 15.3 Hz), 1.28 (s, 9H); 13C{1H} NMR (CDCl3, 75 MHz): δ 199.9, 
170.1, 147.8, 146.3, 142.9, 140.9, 140.3, 137.8, 129.7, 129.0, 128.9, 128.8, 128.6, 128.3, 127.9, 
127.6, 127.1, 126.5, 125.8, 120.8, 120.5, 80.2, 78.9, 63.1, 51.3, 31.8, 27.8, HRMS (ESI+) m/z: [M 
+ H]+ calcd for C34H34NO3,








N-benzyl valinol (2.115). Compound 2.114 (3.79 g, 10.0 mmol, 1.00 equiv) was dissolved in 50 
mL of DCM then benzoic anhydride (4.00 g, 17.7 mmol, 1.77 equiv) and triethylamine (2.02 g, 
20.0 mmol, 2.00 equiv) were added. The mixture was stirred until complete as determined by 
TLC (1 hour) then excess benzoic anhydride was destroyed by the addition of 1 mL of diamino 
propane and stirring for 15 min. The mixture was diluted with 200 mL of DCM then washed 
twice with 100 mL of 10% citric acid and once with 100 mL of 10% Na2CO3. The organic layer 
was dried over magnesium sulfate, filtered, and concentrated to give crude benzoyl valine benzyl 
ester which was used without further purification. The crude material was dissolved in 40 mL of 
THF then cooled to 0 °C. LiAlH4 (2 M in THF, 11 mL, 2.2 equiv) was added dropwise and 
stirred until the ester was completely reduced (15 min) then the reaction was heated to reflux 
until the amide was completely reduced (2 h). The reaction was cooled to 0 °C, diluted with 50 
mL of Et2O and then quenched with 1 mL of water, then 1 mL of 3 M NaOH, then 3 mL of 
water. The suspension was stirred for 15 min at room temperature then dried with magnesium 
sulfate, filtered, and concentrated. The residue was purified by reversed phase chromatography 
using a Biotage Isolera One Flash purification system including a C-18 reversed-phase 
preparative Biotage column (30 g) using a gradient of 10 to 100% methanol over 30 min at 25 
mL per minute (RT = 19 min) to give 2.115 as a colorless oil (1.88 g, 97% yield). 
1H NMR of 
this material was identical to previously reported spectra.129 
 N-(9-phenyl-9-fluorenyl)N-benzyl valinol (2.116). Compound 2.115 (1.88 g, 9.74 mmol, 





11.6 mmol, 1.20 equiv) was added and the mixture was heated to reflux for 20 min then cooled 
to 0 °C. PhF-Cl (3.23 g, 11.6 mmol, 1.20 equiv) and NMM (1.28 mL, 11.6 mmol, 1.20 equiv) 
were added followed by a solution of AgNO3 (1.98 g, 11.6 mmol, 1.20 equiv) in 20 mL of 
CH3CN. The mixture was warmed to room temperature and stirred for 1 hour and then 5 mL of 
methanol was added to quench the reaction. The mixture was filtered and concentrated to remove 
most of the CH3CN then was diluted with 100 mL of water then extracted 3 times with 100 mL 
of 1:1 Et2O:hexane. The combined organic layers were dried over MgSO4, filtered, and 
concentrated. The residue was dissolved 20 mL of THF then TBAF (1 M in THF, 11.6 mL, 11.6 
mmol, 1.2 equiv) was added and the colorless solution briefly turned a vibrant orange color 
which disappeared after 5 min. After 15 min the TMS ether was completely removed by TLC 
and the reaction was diluted with 100 mL of Et2O and washed three times with 100 mL of water, 
dried over MgSO4, filtered and concentrated. The residue was purified by flash chromatography, 
eluting with 1 to 15% EtOAc in hexane to give 2.116 as a white foam (3.82 g, 91% yield). 
1H NMR (CDCl3, 300 MHz): δ 7.82 (d, 2H, J = 7.6 Hz), 7.73 (m, 4H), 7.63 (d, 2H, J = 7.1 Hz), 
7.36 (m, 10H), 4.38 (d, 1H, J = 14.5 Hz), 4.27 (d, 1H, J = 14.6 Hz), 3.09 (m, 2H), 2.43 (m, 1H), 
1.67 (bs, 1H), 1.35 (m, 1H), 0.51 (m, 6H); 13C{1H} NMR (CDCl3, 75 MHz): δ 148.3, 148.2, 
144.5, 141.7, 140.7, 140.4, 128.6, 128.4, 128.3, 128.0, 127.7, 127.5, 127.4, 127.3, 127.1, 126.8, 
120.4, 120.3, 80.2, 65.0, 61.1, 51.8, 28.8, 23.1, 19.3; HRMS (ESI+) m/z: [M + H]+ calcd for 
C31H32NO,
 434.2478; found, 434.2480. 
 N-(9-phenyl-9-fluorenyl)N-benzyl valinal (2.106). 2.116 (3.72 g, 8.59 mmol, 1.00 equiv) 
was dissolved in 100 mL of DCM and water (186 µL, 10.3 mmol, 1.20 equiv) was added. The 
reaction was immersed in an ice bath as Dess-Martin reagent (3.93 g, 9.27 mmol, 1.07 equiv) 





most of the starting material had been consumed and an additional 250 mg of Dess-Martin 
reagent was added. After an additional 1 hour the reaction was complete by TLC and the mixture 
was diluted with 300 mL of Et2O and washed with 200 mL of 5% Na2S2O3. The organic layer 
was dried over magnesium sulfate, filtered, and concentrated then the residue was purified by 
flash chromatography, eluting with 1 to 10% EtOAc in hexane, to give 2.106 as a white solid 
(3.42 g, 92% yield). 1H NMR (CDCl3, 300 MHz): δ 8.96 (d, 1H, J = 2.2 Hz), 7.85 (d, 2H, J = 7.3 
Hz), 7.8 (d, 1H, J = 7.1 Hz), 7.72 (d, 1H, J = 6.9 Hz), 7.66 (d, 1H, J = 4.1 Hz), 7.63 (d, 1H, J = 
4.4 Hz), 7.49 (m, 3H), 7.32 (m, 9H), 4.39 (d, 1H, J = 13.9 Hz), 4.12 (d, 1H, J = 13.9 Hz), 2.75 
(dd, 1H, J = 10.0, 1.3 Hz), 1.38 (m, 1H), 0.81 (d, 3H, J = 6.6 Hz), 0.37 (d, 3H, J = 6.5 
Hz);13C{1H} NMR (CDCl3, 75 MHz): δ 204.9, 148.1, 147.6, 143.8, 140.7, 140.2, 139.9, 129.6, 
129.1, 128.8, 128.7, 128.1, 127.9, 127.8, 127.5, 127.4, 127.1, 126.9, 120.8, 120.3, 79.8, 72.3, 
52.6, 27.4, 21.0, 20.7; HRMS (ESI+) m/z: [M +Na]+ calcd for C31H29NNaO, 454.2141; found, 
454.2124. 
General procedure 2.7 for the reaction of 2.41 with N-Benzyl-N-PhF-α-amino aldehydes 
 A solution of 2.41 approximately (0.150 mmol, 1.00 equiv) and aldehyde 2.103 - 2.105 
(1.20 equiv) were dissolved in 4 mL of 3:2 THF:Et2O and cooled to -128 °C. NaHMDS (1 M in 
THF, 2.20 equiv) was added dropwise and the reaction was stirred until complete by TLC (5 
min). Then the mixture was quenched with 10 mL NH4Cl, extracted three times with DCM, dried 
over magnesium sulfate, filtered, and concentrated. The residue was purified by flash 







methoxybenzyl) butane-1-sulfonamide (2.107). Prepared according to general procedure 2.7 from 
2.41 (68 mg, 0.184 mmol, 1.00 equiv) and 2.103 (89 mg, 0.221 mmol, 1.20 equiv) as a white 
solid (115 mg, 81% yield). 1H NMR (CDCl3, 300 MHz) : δ 7.69 (m, 8H), 7.32 (m, 10H), 7.05 (d, 
4H, J = 8.2 Hz), 6.81 (d, 4H, J = 8.1 Hz), 4.55 (dd, 1H, J = 26.1, 4.4 Hz), 4.17 (m, 6H), 3.79 (s, 
6H), 3.39 (q, 1H, J = 6.7 Hz), 1.31 (d, 1H, J = 4.7 Hz), 0.84 (d, 3H, J = 6.9 Hz); 13C{1H} NMR 
(CDCl3, 125 MHz): δ 159.3, 147.7, 147.2, 143.6, 141.9, 140.8, 140.2, 130.2, 128.8, 128.5, 128.4, 
127.8, 127.53, 127.45, 127.4, 127.2, 126.9, 126.6, 122.3 (dd, J = 295.9, 285.5 Hz), 120.4, 120.1, 
113.9, 80.3, 74.8 (dd, J = 26.3, 19.4 Hz), 55.3, 52.4, 50.2, 50.1, 12.6; 19F NMR (CDCl3, 471 
MHz): δ -103.9 (d, 1F, J = 235.2 Hz), -117.6 (dd, 1F, J = 235.2, 26.2 Hz); HRMS (ESI+) m/z: [M 
+ H]+ calcd for C46H45F2N2O5S,
 775.3012; found, 775.2979. 
 
(2R,3S)-3-(benzyl(9-phenyl-9H-fluoren-9-yl)amino)-1,1-difluoro-2-hydroxy-N,N-bis(4-
methoxybenzyl)-5-(methylthio)pentane-1-sulfonamide (2.108). Prepared according to general 
procedure 2.7 from 2.41 (52 mg, 0.140 mmol, 1.00 equiv) and 2.104 (78 mg, 0.168 mmol, 1.20 
equiv) as a white solid (103 mg, 89% yield). 1H NMR (CDCl3, 500 MHz): δ 7.85 (m, 2H), 7.76 





Hz), 6.86 (d, 4H, J = 7.8 Hz), 4.42 (d, 1H, J = 13.9 Hz), 4.35 (d, 1H, J = 14.1 Hz), 4.27 (dd, 1H, 
J = 26.5, 4.1 Hz), 4.18 (s, 4H), 3.84 (s, 6H), 3.26 (d, 1H, J = 8.0 Hz), 2.67 (bs, 1H), 2.4 (br, 1H), 
2.33 (s, 1H), 1.8 (s, 3H), 1.6 (m, 1H), 1.35 (m, 1H); 13C{1H} NMR (CDCl3, 125 MHz): δ 159.4, 
147.6, 145.9, 144.3, 141.3, 141.1, 140.2, 130.2, 129.0, 128.47, 128.45, 128.3, 127.8, 127.72, 
127.70, 127.2, 127.0, 126.7, 126.6, 122.1 (dd, J = 289.2, 295.1 Hz), 120.6, 120.0, 113.9, 80.0, 
71.1 (dd, J = 25.4, 20.2 Hz), 56.9, 55.3, 52.0, 50.2, 31.4, 28.8, 14.7; 19F NMR (CDCl3, 471 
MHz): δ -102.6 (d, 1F, J = 232.9 Hz), -116.9 (dd, 1F, J = 232.8, 27.1 Hz); HRMS (ESI+) m/z: [M 
+ H]+ calcd for C48H49F2N2O5S2, 835.3046; found, 835.3029. 
 
tert-butyl (3S,4R)-3-(benzyl(9-phenyl-9H-fluoren-9-yl)amino)-5-(N,N-bis(4-methoxybenzyl)-
sulfamoyl)-5,5-difluoro-4-hydroxypentanoate (2.109). Prepared according to general procedure 
2.7 from 2.41 (61 mg, 0.167 mmol, 1.00 equiv) and 2.105 (100 mg, 0.20 mmol, 1.20 equiv) as a 
white solid (100 mg, 69% yield). A second species could be observed by 19F NMR comprising 
~3% of the mixture. This is presumed to be the minor, anti diastereomer and no attempt was 
made to isolate this material. 1H NMR (CDCl3, 300 MHz): δ 7.78 (d, 2H, J = 7.5 Hz), 7.71 (m, 
3H), 7.59 (d, 1H, J = 7.5 Hz), 7.47 (d, 2H, J = 7.1 Hz), 7.29 (m, 10H), 7.09 (d, 4H, J = 8.6 Hz), 
6.84 (d, 4H, J = 8.6 Hz), 4.21 (m, 6H), 3.96 (m, 2H), 3.81 (s, 6H), 2.73 (d, 1H, J = 6.8 Hz), 2.45 
(dd, 1H, J = 16.5, 8.5 Hz), 2.11 (dd, 1H, J = 16.6, 2.6 Hz), 1.34 (s, 9H); 13C{1H} NMR (CDCl3, 
75 MHz): δ 171.9, 159.3, 146.5, 146.3, 143.6, 140.8, 140.6, 140.5, 130.2, 128.8, 128.6, 128.50, 
128.46, 127.6, 127.5, 127.3, 127.19, 127.16, 127.1, 122.4 (dd, J = 294.8, 291.9 Hz), 120.3, 





(CDCl3, 282 MHz): δ (Major diastereomer) -101.9 (dd, 1F, J = 234.3 Hz), -117.2 (dd, 1F, J = 
234.3, 26.3 Hz); (minor diastereomer) -107.1 (d, 1F, J = 239.4 Hz), -119.8 (dd, 1F, J = 239.8, 
23.0 Hz); HRMS (ESI+) m/z: [M + H]+ calcd for C51H53F2N2O7S,
 875.3536; found, 875.3514. 
 When the reaction was performed using 1.2 equiv of KHMDS instead of NaHMDS then 
a yield of 70 % was estimated by 19F NMR and the presumed minor diastereomer comprised 4% 
of the crude.  
 
(2R,3S)-3-(benzyl(9-phenyl-9-fluorenyl)amino)-1,1-difluoro-2-hydroxy-N,N-bis(4-
methoxybenzyl)-4-methylpentane-1-sulfonamide (2.110). Compound 2.106 (2.90 g, 6.73 mmol, 
1.00 equiv) and 2.41 (2.50 g, 6.73 mmol, 1.00 equiv) were dissolved in 60 mL of THF and 40 
mL of Et2O then cooled to -128 °C. KHMDS (1 M in THF, 8.07 mL, 1.20 equiv), was added 
dropwise and the mixture was stirred for 10 min until complete by TLC then was quenched with 
10 mL of saturated NH4Cl, diluted with 100 mL of water and extracted three times with 100 mL 
of DCM. The combined organic layers were dried over magnesium sulfate, filtered, and 
concentrated then the residue was purified by flash chromatography, 5 to 20% EtOAc in hexane, 
to give 30 as a white solid (5.15 g, 96% yield). 1H NMR (CDCl3, 300 MHz): δ 7.77 (m, 4H), 
7.63 (m, 4H), 7.42 (m, 2H), 7.27 (m, 8H), 7.06 (d, 4H, J = 8.6 Hz), 6.85 (d, 4H, J = 8.6 Hz), 4.53 
(m, 2H), 4.18 (m, 5H), 3.84 (s, 6H), 2.96 (d, 1H, J = 9.5 Hz), 2.4 (bs, 1H), 1.55 (m, 1H), 1.11 (d, 
3H, J = 6.6 Hz), 0.67 (ap t, 3H, J = 6.4 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 147.7, 
145.9, 141.6, 141.0, 140.2, 130.3, 129.7, 128.9, 128.3, 128.2, 127.9, 127.8, 127.6, 127.4, 127.0, 





63.4, 55.4, 52.6, 50.2, 28.4, 23.4, 20.9, 20.7; 19F NMR (CDCl3, 282 MHz): δ -99.8 (d, 1F, J = 
229.3 Hz), -110.7 (dd, 1F, J = 227.5, 26.5 Hz); HRMS (ESI+) m/z: [M + H]+ calcd for 
C48H49F2N2O5S, 803.33248; found, 803.3296. 
 When 2.2 equiv NaHMDS was used instead of KHMDS then the isolated yield was 51%. 
Determination of the absolute relative stereochemistry of 2.89 and 2.110. 
 
(2R,3S)-3-amino-1,1-difluoro-2-hydroxy-N,N-bis(4-methoxybenzyl)-4-methylpentane-1-
sulfonamide (2.111). Compound 2.110 (4.95 g, 6.17 mmol) was dissolved in 100 mL of 1% TFA 
in MeOH. Pd/C 5 wt% (495 mg) and Pd(OH)2/C 20 wt% (125 mg) were added and the mixture 
was stirred under an H2 atmosphere overnight. The catalyst was removed by filtration with a pad 
of celite and the mixture was diluted with 300 mL of water and washed with 200 mL of hexane. 
Most of the methanol was evaporated from the aqueous layer and then Na2CO3 was added until a 
pH of 10 was achieved. The suspension was extracted 3 times with 100 mL of DCM. The 
combined DCM layers were dried over magnesium sulfate, filtered, and concentrated to give the 
free amine 2.111 as a white solid (2.69 g, 92% yield). 1H NMR (CDCl3, 500 MHz): δ 7.14 (d, 
4H, J = 8.3 Hz), 6.86 (d, 4H, J = 8.3 Hz), 4.42 (d, 2H, J = 15.1 Hz), 4.32 (m, 3H), 3.83 (s, 6H), 
2.89 (m, 1H), 2.1 (m, 1H), 1.05 (d, 3H, J = 6.6 Hz), 1.03 (d, 3H, J = 6.6 Hz); 13C{1H} NMR 
(CDCl3, 125 MHz): δ 159.3, 130.2, 126.8, 124.2 (dd, J = 293.5, 288.4 Hz), 113.9, 71.0 (dd, J = 
23.3, 20.2 Hz), 58.5, 55.2, 50.3, 29.4, 20.4, 17.5; 19F NMR (CDCl3, 471 MHz): δ -103.0 (d, 1F, J 
= 238.9 Hz), -112.1 (dd, 1F, J = 238.9, 20.6 Hz); HRMS (ESI+) m/z: M + H]+ calcd for 







sulfonamide (2.112). 2.111 (29 mg, 0.061 mmol, 1 equiv) was dissolved in 3 mL of DCM and 
cooled to 0 °C. DIPEA (27 µL, 0.153 mmol, 2.5 equiv) was added followed by triphosgene (9.1 
mg, 0.0307 mmol, 0.5 equiv) in a solution of 1 mL DCM. The reaction was stirred for two h then 
was applied to a column of silica eluted using a gradient of 0 to 20% EtOAc in DCM. 2.112 was 
obtained as a colorless oil (28 mg, 92% yield). The relative stereochemistry of this compound 
was assigned based on NOESY contacts between the protons of the valine side chain and the 
proton α to the alcohol, which indicated that the geometry in the ring was trans. 1H NMR 
(CDCl3, 500 MHz): δ 7.10 (ArH, d, 4H, J = 8.6 Hz), 6.82 (ArH, d, 4H, J = 8.7 Hz), 6.34 (NH, s, 
1H), 5.21 (HCO, dt, 1H, J = 20.9, 6.6 Hz), 4.36 (ArCH2, s, 4H), 3.94 (C
αH, t, 1H, J = 7.2 Hz), 
3.8 (OCH3, s, 6H), 2.31 (C
ßH m, 1H), 1.06 (C
γH3, d, 3H, J = 6.5 Hz), 1.03 (C
γH3, d, 3H, J = 6.5 
Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 157.6, 130.2, 126.5, 120.9 (dd, J = 297.6, 288.3 
Hz), 113.9, 75.2 (dd, J = 29.7, 20.3 Hz), 61.9, 55.3, 50.7, 27.6, 20.7, 18.8; 19F NMR (CDCl3, 471 
MHz) δ: -106.5 (dd, 1F, J = 244.2, 4.0 Hz), -112.6 (dd, 1F, J = 243.6, 20.8 Hz); HRMS (ESI+) 







HMQC Peak Coordinates for 2.112 (300 MHz, CDCl3) 
 1H 13C 
C1H3 3.80 55.3 
C3H 6.82 113.9 
C4H 7.1 130.2 
C6H2 4.36 50.7 
C8H 5.21 75.2 
C9H 3.94 61.9 
C10H 2.31 27.6 
C11H3 1.06 18.8 
C11H3 1.03 20.7 
  
COSY Peak Coordinates for 2.112 (300 MHz, CDCl3) 
H3-H4 7.11 – 6.84 
H8-H9 5.22 – 3.95 
H9-H10 3.95 – 2.33 
H10-H11 2.32 – 1.06 
  
NOESY Peak Coordinates for 2.112 (300 MHz, CDCl3) 
H3-H6 7.–9 - 4.36 
H4-H6 6.–2 - 4.36 
H3-H1 6.–2 - 3.78 
H13-H9 6.–4 - 3.93 
H8-H9 5.–9 - 3.92 
H8-H10 5.–9 - 2.29 
H8-H11 5.–9 - 1.01 
H9-H10 3.–3 - 2.29 
H9-H11 3.–3 - 1.03 
H10-H11 2.–0 - 1.02 











methanesulfonamide (2.113). 2.89 (50 mg, 0.073 mmol, 1.0 equiv) was dissolved in 5 mL of 1% 
TFA MeOH. 5 mg of 20 wt% Pd(OH)2 on carbon and 10 mg of 10 wt% Pd on carbon were added 
and the mixture was stirred under hydrogen atmosphere for 16 h. The mixture was filtered then 
diluted with 20 mL of water and washed with 20 mL of hexane. The aqueous layer was basified 
with Na2CO3 until pH 10 and then extracted 3 times with 10 mL DCM. The combined DCM 
layers were dried over magnesium sulfate, filtered and concentrated then the residue was 
redissolved in 5 mL DCM and cooled to 0 °C. DIPEA (32 µL, 0.18 mmol, 2.5 equiv) was added 
followed by a solution of triphosgene (11 mg, 0.037 mmol, 0.5 equiv) in 1 mL DCM. The 
reaction was stirred for two h then was applied to a silica column and eluted with a gradient of 0 
to 30% EtOAc in DCM to yield a colorless oil. 1H NMR (CDCl3 300 MHz) δ 7.04 (d, 4H, J = 8.4 
Hz), 6.77 (d, 4H, J = 8.4 Hz), 5.63 (s, 1H), 4.69 (ddd, 1H, J = 15.1, 8.3, 5.1 Hz), 4.28 (m, 5H), 
3.74 (s, 6H), 1.41 (d, 3H, J = 6.3 Hz); 13C{1H} NMR (CDCl3 75 MHz) δ 159.5, 156.6, 130.2, 
126.1, 120.0 (ap t, J = 288.2 Hz), 114.0, 79.4 (dd, J = 24.6, 20.5 Hz), 55.3, 50.4, 48.3, 21.8; 19F 
NMR (CDCl3 283 MHz) δ -111.6 (dd, 1F, J = 239.6, 8.2 Hz), -117.0 (dd, 1F, J = 239.5, 15.5 






HMQC Peak Coordinates for (2.113) (300 MHz, CDCl3) 
 1H 13C 
C2H2 4.29 47.79 
C3H3 1.41 21.97 
C4H4 4.70 79.32 
C5H5 4.28 50.65 
C6H6 7.04 130.41 
C7H7 6.78 113.98 
C8H8 3.74 54.95 
COSY Peak Coordinates for (2.113) (300 MHz, CDCl3) 
H6-H7 7.–4 - 6.78 
H4-H2 4.–0 - 4.29 
H2-H3 4.–8 - 1.41 
NOESY Peak Coordinates for (2.113) (300 MHz, CDCl3) 
H8-H7 6.–7 - 3.74 
H6-H5 7.–4 - 4.29 
 5.–4 - 4.28 
 5.–4 - 1.40 
H2-H3 4.–8 - 1.40 




Cbz-Val-OH (2.13 g, 8.49 mmol, 1.49 equiv) was dissolved in 50 mL of DCM and HOAt (1.15 
g, 8.49 mmol, 1.49 equiv) was added followed by EDC HCl (1.62 g, 8.49 mmol, 1.49 equiv) the 
resulting solution was stirred for 15 min then 31 (2.69 g, 5.70 mmol, 1 equiv) was added. The 
reaction was stirred overnight at room temperature then placed on a silica column and eluted 





(CDCl3, 300 MHz): δ 7.32 (s, 5H), 7.1 (d, 4H, J = 8.6 Hz), 6.83 (d, 4H, J = 8.7 Hz), 6.67 (d, 1H, 
J = 9.3 Hz), 5.65 (d, 1H, J = 8.8 Hz), 5.11 (s, 2H), 4.53 (d, 1H, J = 20.9 Hz), 4.33 (m, 6H), 4.09 
(dd, 1H, J = 8.8, 7.1 Hz), 3.8 (s, 6H), 2.24 (m, 2H), 0.96 (m, 12H); 13C{1H} NMR (CDCl3, 75 
MHz): δ 172.5, 159.4, 156.7, 136.1, 130.1, 128.5, 128.1, 127.9, 126.5, 123.0 (dd, J = 293.1, 
289.0 Hz), 113.9, 70.4 (ap t, J = 22.0 Hz), 67.1, 60.9, 55.4, 55.2, 50.3, 30.2, 28.7, 20.4, 19.4, 
17.84, 17.77; 19F NMR (CDCl3, 282 MHz): δ -105.6 (d, 1F, J = 239.1 Hz), -114.2 (dd, 1F, J = 




(2.118). 2.117 (3.63 g, 5.15 mmol, 1.00 equiv) was dissolved in 20 mL of MeOH and 182 mg of 
Pd(OH)2 20 wt% on carbon was added. The mixture was stirred under hydrogen for 1 hour until 
complete by TLC then filtered with a pad of celite and concentrated to dryness to give the crude 
amine. Separately, Boc-Phe-OH (2.05 g, 7.72 mmol, 1.50 equiv) was dissolved in 20 mL of 
DCM and HOAt (1.05 g, 7.72 mmol, 1.50 equiv) was added followed by EDC HCl (1.48 g, 7.72 
mmol, 1.50 equiv). The mixture was stirred for 15 min then added to the crude amine. After 
stirring for 6 h at room temperature the reaction was filtered and the volume was reduced to 
approximately 20 mL then was purified by flash chromatography, eluting with 0 to 30% EtOAc 
in DCM, to give 2.118 as a white foam (4.14 g, 98% yield). 
1H NMR (CDCl3, 300 MHz): δ 7.25 
(m, 3H), 7.19 (m, 2H), 7.09 (d, 4H, J = 8.7 Hz), 6.82 (d, 4H, J = 8.7 Hz), 6.68 (d, 1H, J = 8.0 
Hz), 6.48 (d, 1H, J = 8.3 Hz), 4.98 (d, 1H, J = 6.4 Hz), 4.52 (ddd, 1H, J = 20.9, 9.1, 4.8 Hz), 4.33 





9H), 0.87 (d, 3H, J = 6.8 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 172.8, 172.5, 159.2, 155.8, 
137.2, 130.2, 129.5, 128.3, 126.8, 126.5, 123.3 (ap t, J = 291.4 Hz), 113.8, 79.4, 70.4 (ap t, J = 
21.7 Hz), 59.7, 55.6, 55.2, 54.4, 50.3, 37.8, 30.4, 28.8, 28.4, 20.5, 19.3, 18.5, 17.4; 19F NMR 
(CDCl3, 282 MHz) : δ -106.9 (d, 1F, J = 239.5 Hz), -113.4 (dd, 1F, J = 238.4, 16.0 Hz); HRMS 
(ESI+) m/z: [M + H]+ calcd for C41H56F2N4O9s, 818.37361; found, 819.3799. 
 
(1R)-1-(Boc-Phe-Val-Valinolyl)-1,1-difluoromethanesulfonamide (2.119). To a solution of 2.118 
(2.00 g 2.44 mmol, 1.00 equiv) in 100 mL of CH3CN at 0 °C, CAN (5.35 g, 9.75 mmol, 4 equiv) 
in 20 mL of water was added dropwise over 20 min. The resulting solution was stirred at 0 °C 
for 3 h then additional CAN (5.35 g, 9.75 mmol, 4 equiv) in 20 mL of water was added dropwise 
over 20 min. After 6 h total stirring the reaction was diluted with 250 mL brine and 250 mL 10% 
citric acid then was extracted three times with 250 mL of EtOAc. The combined organic layers 
were concentrated and then purified by reversed phase chromatography using a Biotage Isolera 
One Flash purification system employing a C-18 reversed-phase preparative Biotage column (30 
g) on a gradient of 20 to 100% methanol over 30 min at 25 mL per minute (tr = 22 min), giving 
2.119 as a white powder (1.12 g, 79% yield). It was noted that an aqueous suspension of 2.119 
was extremely prone to bumping when concentrating on a rotary evaporator, therefore we 
recommend that fractions containing product be diluted with a large volume of 
isopropanol/toluene or another suitable solvent to azeotropically remove the water. 1H NMR 
(CDCl3, 300 MHz): δ 7.96 (d, 1H, J = 9.5 Hz), 7.26 (m, 5H), 4.3 (m, 4H), 3.14 (dd, 1H, J = 14.0, 
4.7 Hz), 2.81 (dd, 1H, J = 13.9, 9.9 Hz), 2.27 (m, 1H), 2.14 (m, 1H), 1.37 (s, 9H), 0.94 (m, 12H); 





= 291.7, 286.9 Hz), 80.6, 70.4 (ap t, J = 22.6 Hz), 60.0, 57.2, 54.1, 38.9, 31.7, 29.5, 28.6, 20.7, 
20.0, 18.1, 16.1; 19F NMR (CDCl3, 282 MHz): δ -105.6 (d, 1F, J = 242.4 Hz), -119.8 (ddd, 1F, J 




(2.120). CMBP was prepared according to a literature procedure.119 2.119 (289 mg, 0.50 mmol, 
1.0 equiv) was placed in 10 mL of dry toluene. 2-morpholinoethan-1-ol (98 mg, 0.75 mmol, 1.5 
equiv) was added followed by CMBP (0.5 M in toluene, 1.50 mL, 0.75 mmol, 1.5 equiv). The 
reaction was heated to 100 °C for 2 h then the reaction was concentrated. The residue was 
subjected to flash chromatography eluting with 0 to 30% MeOH in DCM. Fractions containing 
product were pooled and further purified by reversed phase chromatography using a Biotage 
Isolera One Flash purification system including two C-18 reversed-phase preparative Biotage 
columns (30 g) connected in series on a gradient of 40 to 75% methanol over 60 min at 25 mL 
per minute (tr product = 48 min, tr starting material = 40 min). 2.119 was obtained as a white 
solid (220 mg, 64% yield). 1H NMR (CDCl3, 500 MHz) : δ 7.3 (t, 2H, J = 7.2 Hz), 7.24 (m, 1H), 
7.18 (d, 2H, J = 7.2 Hz), 6.67 (s, 2H), 5.16 (br, 2H), 4.98 (s, 1H), 4.49 (d, 1H, J = 22.0 Hz), 4.35 
(q, 1H, J = 6.5 Hz), 4.22 (t, 1H, J = 5.8 Hz), 4.09 (m, 1H), 3.69 (t, 4H, J = 4.3 Hz), 3.36 (m, 2H), 
3.08 (m, 2H), 2.53 (t, 2H, J = 5.7 Hz), 2.46 (m, 4H), 2.24 (m, 1H), 2.14 (m, 1H), 1.39 (s, 9H), 
0.98 (d, 3H, J = 6.6 Hz), 0.94 (d, 3H, J = 6.6 Hz), 0.9 (d, 3H, J = 6.8 Hz), 0.84 (d, 3H, J = 6.9 
Hz); 13C{1H} NMR (CDCl3, 125 MHz): δ 172.4, 155.8, 136.7, 129.3, 128.5, 126.8, 122.5 (dd, J 





37.6, 30.1, 28.6, 28.3, 20.4, 19.3, 18.0, 17.8; 19F NMR (CDCl3, 471 MHz) : δ -106.7 (d, 1F, J = 
245.7 Hz), -115.7 (d, 1F, J = 245.0 Hz); HRMS (ESI+) m/z: [M +H]+ calcd for C31H52F2N5O8S, 
692.34992; found, 692.3559. 
 
1,1-difluoro-N,N-bis(4-methoxybenzyl)-2-(4-methoxyphenyl)-166yrrolidinedin-1-yl)ethane-1-
sulfonamide (2.125). 1-(4-methoxybenzylide166yrrolidinedin-1-ium perchlorate (2.122) was 
prepared according a literature procedure.130 2.41 (50 mg, 0.135 mmol, 1.0 equiv) and 2.122 (78 
mg, 0.27 mmol, 2 equiv) were dissolved in 2.7 mL of THF and 300 µL of DMF. The mixture 
was cooled to –98 °C and KHMDS (1 M in THF, 270 µL, 0.27 mmol, 2.0 equiv). was added 
dropwise. The mixture was stirred for 15 min then was quenched with 10 mL brine. The reaction 
was extracted three times with 10 mL of DCM dried over magnesium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography, 0 to 20% EtOAc hexane, to 
give 53 mg colorless oil (70% yield). This material existed as a mixture of rotamers ~93:7 
1H NMR (CDCl3, 300 MHz) : δ 7.38 (d, 2H, J = 8.3 Hz), 7.13 (d, 4H, J = 8.3 Hz), 6.95 (d, 2H, J 
= 8.4 Hz), 6.83 (d, 4H, J = 8.3 Hz), 4.61 (dd, 1H, J = 19.6, 12.8 Hz), 4.34 (s, 4H), 3.85 (s, 3H), 
3.82 (s, 6H), 2.69 (s, 4H), 1.72 (s, 4H); 13C{1H} NMR (CDCl3, 125 MHz): δ 159.7, 159.2, 131.9, 
130.1, 124.8 (dd, J = 292.9, 289.7 Hz), 127.2, 123.15, 123.13, 113.8, 113.5, 66.2 (dd, J = 23.3, 
18.3 Hz), 55.2, 50.4, 50.2, 23.2; 19F NMR (CDCl3, 282 MHz): δ (Major Rotamer) 100.6 (dd, 1F, 
J = 232.6, 12.7 Hz), -103.1 (dd, 3F, J = 232.6, 19.7 Hz), (minor rotamer)-103.7 (dd, 5F, J = 
261.5, 11.6 Hz), -106.1 (dd, 7F, J = 261.9, 18.9 Hz); HRMS (ESI+) m/z: [M +H]+ calcd for 








sulfinamide (2.123) was prepared according to a literature procedure.132 2.41 (50 mg, 0.135 
mmol, 1 equiv) and 2.123 (44 mg, 0.162 mmol, 1.2 equiv) were dissolved in 2 mL of THF and 1 
mL of Et2O. The mixture was cooled to -114 °C and NaHMDS (1 M in THF, 300 µL, 2.2 equiv) 
was added dropwise. The reaction was stirred for 15 min then was quenched with 10 mL sat. 
NH4Cl and extracted 3 times with 10 mL DCM. The combined organic layers were dried over 
magnesium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography, 10 to 40% EtOAc in hexane, to yield 87 mg (99% yield) of 2.126 as a white 
solid. The DR was estimated as 97:3 by 19F NMR. 1H NMR (CDCl3, 300 MHz): δ 7.64 (d, 2H, J 
= 8.1 Hz), 7.28 (d, 2H, J = 8.4 Hz), 7.24 (d, 2H, J = 8.1 Hz), 7.12 (d, 4H, J = 8.5 Hz), 6.87 (d, 
2H, J = 7.0 Hz), 6.84 (d, 4H, J = 7.0 Hz), 5.3 (m, 1H), 5.06 (d, 1H, J = 8.0 Hz), 4.43 (d, 2H, J = 
15.1 Hz), 4.26 (d, 2H, J = 14.9 Hz), 3.82 (s, 9H), 2.39 (s, 3H); 13C{1H} NMR (CDCl3, 75 MHz): 
δ 160.1, 159.4, 141.6, 141.2, 130.1, 129.9, 129.4, 126.5, 122.1 (dd, J = 290.0, 286.0 Hz), 125.9, 
125.8, 114.0, 113.9, 58.8 (dd, J = 25.7, 21.0 Hz), 55.3, 55.2, 50.2, 21.3; 19F NMR (CDCl3, 282 
MHz): δ (Major diastereomer) -103.2 (dd, J = 235.5, 8.5 Hz), -108.6 (dd, J = 235.6, 17.9 Hz), 
(Minor diastereomer) -104.6 (dd, J = 235.0, 7.7 Hz), -110.4 (dd, J = 234.9, 17.0 Hz); HRMS-
ESI+ (m/z) calcd for C32H35F2N2O6S2
+
 (M + H)
+ 645.1899, found 645.1886.  
 When the reaction was performed using 1.2 equiv KHMDS the DR was 92:8, the reaction 







sulfonamide (2.127). (R,E)-4-methyl-N-(2-methylpropylidene)benzenesulfinamide (2.124) was 
prepared according to a literature procedure.131  
 Compound 2.41 (50 mg, 0.135 mmol, 1.0 equiv) and 2.124 (34 mg, 0.16 mmol, 1.2 
equiv) were dissolved in 1.5 mL of THF and 1 mL of Et2O then cooled to -128 °C. NaHMDS (1 
M in THF, 300 µL, 2.2 equiv) was added dropwise and the reaction was stirred for 15 min before 
quenching with NH4Cl. The mixture was extracted three times with 10 mL of DCM then the 
organic layers were dried over magnesium sulfate, filtered, and concentrated. The residue was 
purified by flash chromatography using 5 to 30 % EtOAc in hexanes to yield 56 mg (72% yield) 
of 2.127 as a colorless oil. The DR was estimated at 97:3 by 19F NMR. 1H NMR (CDCl3, 300 
MHz): δ 7.8 (3, 2H, J = 8.2 Hz), 7.35 (3, 2H, J = 8.0 Hz), 7.16 (3, 4H, J = 8.6 Hz), 6.87 (3, 4H, J 
= 8.6 Hz), 4.29 (m, 6H), 3.83 (s, 6H), 2.55 (m, 1H), 2.43 (s, 3H), 1.21 (d, 3H, J = 6.9 Hz), 1.03 
(d, 3H, J = 6.8 Hz); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 142.6, 141.7, 130.2, 129.6, 123.6 
(ap. t, J = 288.6 Hz), 126.7, 125.8, 114.0, 62.8 (ap. t, J = 20.9 Hz), 55.3, 50.3, 27.7, 21.4, 20.7, 
16.7; 19F NMR (CDCl3, 282 MHz): δ (Major diastereomer) -104.2 (dd, F, J = 235.7, 11.2 Hz), -
105.2 (dd, F, J = 235.9, 14.4 Hz); (Major diastereomer) -96.3 (dd, 1F, J = 237.2, 8.6 Hz), -106.8 
(dd, F, J = 237.2, 19.3 Hz); HRMS-ESI+ (m/z) calcd for C28H35F2N2O5S2
+
 (M + H)
+ 581.1950, 









disulfonamide (2.128). Compound 2.41 (100 mg, 0.27 mmol, 1.00 equiv) and phenyl benzoate 
(64 mg, 0.324 mmol, 1.20 equiv) were dissolved in 5 mL of THF and cooled to – 78 °C. 
KHMDS (1 M in THF, 324 µL, 0.324 mmol, 1.2 equiv) was added dropwise and the reaction 
was stirred for 15 min. The reaction was quenched with 10 mL of sat. NH4Cl and extracted with 
10 mL of DCM three times. The combined organic layers were dried over magnesium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography eluting with 10 to 
60% EtOAc in hexane 41 mg white solid (35% yield). 1H NMR (CDCl3, 300 MHz): δ: 7.86 (m, 
2H), 7.49 (m, 3H), 7.04 (d, 8H, J = 8.6 Hz), 6.78 (d, 8H, J = 8.7 Hz), 4.97 (s, 1H), 4.26 (br, 8H), 
3.77 (s, 12H); 13C{1H} NMR (CDCl3, 75 MHz): δ 159.4, 130.2, 130.1, 129.9, 128.2, 128.0, 
126.3, 121.3 (ap t, J = 302.1 Hz), 113.9, 79.4 (ap t, J = 20.9 Hz), 55.3, 50.6; 19F NMR (CDCl3, 
283 MHz): δ -102.2 (d, 2F, J = 250.0 Hz); -103.3 (d, 2F, J = 251.7 Hz); HRMS (ESI+) m/z: [M + 
NH4]
+ calcd for C41H46N3O9S2F4, 864.2612; found, 864.2575. 
 
 N,N-bis(4-methoxybenzyl)-1,1-difluoro-1-benzoylmethanesulfonamide (2.37). Compound 
2.41 (74 mg, 0.2 mmol, 1 equiv) and benzoic anhydride (180 mg, 0.8 equiv, 4 equiv) were 
dissolved in 3 mL THF and 2 mL of Et2O. The mixture was cooled to -128 °C and then KHMDS 
(1 M in THF, 400 µL, 0.4 mmol, 2 equiv) was added dropwise. After stirring for 20 min the 
reaction was quenched with 10 mL of sat. NH4Cl and extracted twice with 10 mL of DCM. The 





residue was purified by flash chromatography to yield 62 mg (65% yield) of 2.37. 1H NMR and 
19F NMR of this material was identical to an authentic sample prepared by electrophilic 










Chapter 3 — Introduction of the 9‑Phenyl-9-fluorenyl Protecting Group 
into Amines, Acids, Alcohols, Sulfonamides, Amides, and Thiols 
3.1 — Introduction 
3.1.1 — Background 
 During the course of our work on ß-hydroxy-α-difluoromethane sulfonamides (Chapter 
2) we required α-amino aldehydes that were suitably protected for reaction with difluoromethane 
sulfonamide carbanions. Various N-protected α-aminoaldehydes have been reported.132 
Carbamate-protected α-aminoaldehydes are notoriously prone to racemization and are usually 
used immediately after they are prepared without purification.114 N,N-dibenzylamino aldehydes 
are less prone to racemization,133 but even these do racemize under basic conditions.134 Garner’s 
aldehyde provides excellent resistance to racemization, but it is limited to serine and threonine 
derivatives.135 The 9-phenyl-9-fluorenyl (PhF) group (Figure 3.1) provides greater resistance to 
racemization than dibenzylamines and is more general than Garner’s aldehyde so we decided to 
investigate this group for the protection of α-amino aldehydes.  
 






 The PhF group has been shown to preserve the configuration of α-amino aldehydes in the 
presence of silica, organic bases, and during nucleophilic additions.115 The first example of a PhF 
amine was published in the 1930’s,136 but the benefits of using it as a protecting group for amines 
weren’t realized until the 1980’s when Henry Rapoport and coworkers began using it for the 
synthesis and protection of compounds such as amino aldehydes.137,138 In addition to preventing 
racemization, the group is very useful in other situations where proton abstraction from the α-
carbon must be avoided. PhF protection avoids alkylation at the α-position during ß- or γ- 
alkylations of aspartate or glutamate derivatives,  (Scheme 3.1 a).139 This ability to selectively 
functionalize at the less hindered ester is also useful for the synthesis of ß,γ-unsaturated 
glutamates while avoiding the α,ß-unsaturation (Scheme 3.1 b).116 PhF protection also enables 
Mitsunobu reactions on serine derivatives while avoiding E2 eliminations which would lead to 
dehydroalanines (Scheme 3.1 c).140 Even benzylic alkylation of a benzyl ester without alkylation 
at the α-carbon is possible   (Scheme 3.1d).137 
 






 PhF deprotection can be accomplished using a variety of methods including using 
acidolysis,115 hydrogenolysis,141 TMSOTf and triethylsilane,142 I2 in methanol,
143 and Li or Na in 
ammonia.144 
 Both steric and electronic factors play a role in PhF protection. Sterically, the PhF group 
is similar to the trityl group which can also be used to shield the α-proton.145 The bulk of the PhF 
group forces the molecule into a conformation where the Cα-Hα bond is co-planer with the 
carbonyl, which is unfavorable for enolization (Figure 3.2). This has been shown in the crystal 
structure of PhF protected α-amino aldehydes.146  
 
Figure 3.2. The PhF protected α-amino aldehydes adopt a conformation where the α-proton and 
carbonyl are coplanar.  
 
 Electronically the PhF group differs from the trityl group. Whether the fluorenyl cation is 
antiaromatic or simply nonaromatic has been a matter of some debate. Although the 12-electron 
π system would indicate the cation is antiaromatic, not all measurements and calculations support 
this classification.147 Regardless of classification, the PhF cation is less stable than the trityl 
cation leading to increased reactivity and increased Lewis acidity. Therefore, PhF groups have 





 On the other hand, the PhF anion, with 14 electrons is aromatic and the negative charge is 
better stabilized than the trityl anion which is reflected in the pKa values of triphenylmethane 
(33) and 9-phenylfluorene (18.5).149 The highly stabilized anion is a reasonable leaving group 
and this gives PhF-protected α-amino aldehydes a tendency to eliminate rather than enolize 
(Scheme 3.2). Even this requires forcing conditions; (phenylfluorenyl)alanal has a half-life of 8 h 
when refluxing in THF with triethylamine, and under the same conditions no racemization is 
detected.115  
 
Scheme 3.2. Deprotonation of α-amino aldehydes leads to decomposition not epimerization. 
 Despite its usefulness, the PhF protecting group is not widely used, possibly due to the 
issues that are sometimes encountered during its installation. The procedure originally developed 
by Rapoport is still generally used (Scheme 3.3).150 In this procedure, an amino acid ester 3.1 is 
reacted with phenylfluorenyl bromide in the presence of potassium phosphate, which acts as a 
base, and Pb(NO3)2 which acts as a halide acceptor. The solvent is usually a mixture of 
chloroform and acetonitrile in which potassium phosphate and Pb(NO3)2 are insoluble; therefore, 
a Morton flask is used to facilitate mixing.151 Rapoport later reported that the reaction also 
proceeds in the absence of Pb(NO3)2 if the reaction is conducted in nitromethane, though this 





requiring several days and even then, yields of 3.2 can be variable.137 Once 3.2 is obtained, it is 
readily converted to amide 3.3, which is similar to a Weinreb’s amide, and can be reduced to the 
configurationally stable aldehyde 3.4. It is also possible to reduce 3.2 to the alcohol and then 
oxidize to 3.4 with standard methodologies.152 
 
Scheme 3.3. Nα-PhF protection of α-amino acids and their conversion to Nα-PhF protected of α-
aldehydes using the method of Rapoport. 
 
 We were interested in several aldehydes of type 3.4. which were needed for work 
discussed in Chapter 2. We applied Rapoport’s procedure to Weinreb’s amides 3.5-3.7. In our 
hands, these conditions were unsatisfactory as they provided protected amines 3.8-3.10 in poor to 
moderate yields after four days (Scheme 3.4). Therefore, we undertook a study to develop more 
efficient conditions for the installation of the PhF group.  
 






3.1.2 — Research objective 
 The drawbacks of the literature method for introducing the PhF group are long reaction 
times, variable yields, limited substrate scope, toxic reagents, and specialized glassware. The 
primary objective of the work described in this chapter was to develop a method to install a 9-
phenyl-9-fluorenyl protecting group which was superior to existing literature methods.  
3.2 — Results and discussion. 
 The reagent of choice for phenylfluorenation has been phenylfluorenyl bromide. This 
reagent is commercially available but is very expensive. It can be easily prepared from 9-
fluorenone in two steps (Scheme 3.5), however, we decided to use the chloride instead for three 
reasons. First, we expected the chloride to be more stable to extended storage and less sensitive 
to hydrolysis. Second, the PhF group is similar to the trityl group is some respects, and the 
majority of tritylations use trityl chloride, so we hoped to have similar success with 
176henylfluorenyl chloride (PhF-Cl). Finally, we found that the chloride was more easily 
prepared than the bromide. Both PhFBr and PhFCl are prepared from the corresponding alcohol. 
The bromide is prepared by treating the 176henylfluorenyl alcohol (PhFOH) with HBr for two 
days while the chlorination occurs after just one hour reflux with SOCl2 (Scheme 3.5). 
 






 We began our studies using amine 3.11 as a model substrate, AgOTf to activate PhFCl 
and precipitate out the chloride ion, N-methylmorpholine (NMM) to sequester the acid produced 
in the reaction, and chloroform as solvent. Under these conditions, at – 20 °C, the corresponding 
PhF derivative 3.12 was obtained in 29% yield after 1 h (Table 1 entry 1). Performing the 
reaction at -78 °C in DCM resulted in a substantially increased yield (entry 2). As AgOTf is 
expensive we examined the much less expensive AgNO3 as the activator. Using acetonitrile to 
help solubilize the silver nitrate and performing the reaction at 0 °C gave 3.12 in 92% yield 
(entry 3). Changing the base to triethylamine reduced the yield slightly and lead to increased 
unidentified side products (entry 4).  














1 AgOTf NMM CH3Cl -20 29 
2 AgOTf NMM DCM -78 65 
3 AgNO3 NMM CH3CN 0 92 
4 AgNO3 Et3N CH3CN 0 88 
 
 We noticed that small amounts of side products were formed in all of the above reactions 
including entry 3. In addition to the expected PhFOH, we isolated side products 3.13 and 3.14 
which were identified by comparison to authentic samples (Scheme 3.6). These compounds were 
also produced in a blank reaction containing only PhFCl, AgNO3 and NMM. Although the 
mechanism is unknown, 3.14 and 3.13 likely result from a radical process because if TEMPO is 





products remain. A radical mechanism is not unexpected because radical processes are known to 
be initiated by silver nitrate.153 During the synthesis of 3.13 (Scheme 3.6b) a red solution was 
briefly observed which we took to indicate formation of the PhF cation, and we recognized that 
this could be an alternative method for introducing the PhF group. 
 
Scheme 3.6. Side products from the phenylfluorenation reaction. 
3.2.1 — PhF protected α-amino aldehydes 
With effective conditions in hand, we turned to our main target, protected amino 
aldehydes (Table 3.2). Good to excellent yields of PhF-protected Weinreb amides of amino acids 
were obtained and the PhF-protected products could easily be isolated by chromatography (Table 
3.2). In most cases the amides could be easily reduced to the aldehydes using LiAlH4 in excellent 
yields (Table 3.3). The aspartate derivative (entry 3) was obtained in a modest yield of 42% due 
to competing reduction of the t-Bu ester. The isoleucine derivative (entry 7) was obtained in 83% 
yield, but only after overnight treatment with 2 equivalents of LiAlH4, presumably due to high 





Table 3.2. Introduction of the PhF Group into Weinreb’s Amides of Amino Acids. 
 
Entry Substrate Product Yield (%) 
1a H-Met-N(Me)OMe (3.5) PhF-Met-N(Me)OMe (3.8) 87 
2 H-Pro-N(Me)OMe (3.6) PhF-Pro-N(Me)OMe (3.9) 70 
3 H-Asp(OtBu)-N(Me)OMe (3.7) PhF-Asp(OtBu)-N(Me)OMe (3.10) 82 
4 H-Ala-N(Me)OMe (3.11) PhF-Ala-N(Me)OMe (3.12) 92 
5 H-Phe-N(Me)OMe (3.15) PhF-Phe-N(Me)OMe (3.18) 84 
6 H-Lys(Boc)-N(Me)OMe (3.16) PhF-Lys(Boc)-N(Me)OMe (3.19) 76 
7 H-Ile-N(Me)OMe (3.17) PhF-Ile-N(Me)OMe (3.20) 86 
aTosylate salt and 2.4 equiv NMM were used. 
 
Table 3.3. Reduction of PhF-protected Weinreb’s Amides of Amino Acids. 
 
Entry Substrate Product Yield (%) 
1 PhF-Met-N(Me)OMe (3.8) PhF-Met-H (3.21) 89 
2 PhF-Pro-N(Me)OMe (3.9) PhF-Pro-H (3.22) 87 
3 PhF-Asp(OtBu)-N(Me)OMe (3.10) PhF-Asp(OtBu)-H (3.23) 42 
4 PhF-Ala-N(Me)OMe (3.12) PhF-Ala-H (3.24) 89 
5 PhF-Phe-N(Me)OMe (3.18) PhF-Phe-H (3.25) 89 
6 PhF-Lys(Boc)-N(Me)OMe (3.19) PhF-Lys(Boc)-H (3.26) 92 
7 PhF-Ile-N(Me)OMe (3.20) PhF-Ile-H (3.27) 83a,b 
a2 equiv of LiAlH4 are used and the reaction is stirred overnight.  






 To verify that the aldehydes were prepared without loss of stereochemical integrity we 
derivatized aldehyde 3.24 by reducing it to the alcohol 3.28 and forming Mosher’s ester 3.29. A 
mixture of 3.29 epimers was prepared from D/L alanine methyl ester hydrochloride (Scheme 
3.7). 19F NMR analysis of the Mosher’s esters revealed that 3.29 was prepared as a single 
diastereomer from 3.24 which indicates that 3.24 was enantiomerically pure (Figure 3.3). 
 
Scheme 3.7. Preparation of Mosher’s esters. 
 
(a)       (b) 
 
Figure 3.3. (a) 19F NMR spectra of (R,R/S) 3.29 (b) 19F NMR spectra of (R) 3.29. 
 3.2.2 — Phenylfluorenation of amino acid methyl esters  
 Amino acid methyl esters are not available or stable as free amines but instead are stored 
as ammonium salts or Nα-protected compounds. Therefore, we decided to investigate protocols 
for the phenylfluorenation of phenylalanine methyl ester where the amine is obtained as a crude 
free amine or ammonium salt upon Nα-deprotection (Scheme 3.8) or from its commercially 





20 min from the crude free amine Phe-OMe obtained via hydrogenolysis of the Cbz group from 
Cbz-Phe-OMe (3.30) (Scheme 3.8a). The reaction with the TFA salt, generated after removal of 
the Boc group from Boc-Phe-OMe (3.31), was slightly slower than with the free amine and 
required 2.5 equiv NMM, but nevertheless proceeded in excellent yield (Scheme 3.8b). Using 2.5 
equiv of NMM and our usual conditions, the tosylate salt 3.32 also proceeded in outstanding 
yield in just 30 min (Scheme 3.8c). Under our usual conditions, the chloride salt 3.33 did not 
react, even in the presence of 2.5 equiv NMM, possibly because the silver salt reacts with the 
hydrochloride salt faster than it reacts with PhFCl (Scheme 3.8d). However, if the equiv of 
AgNO3 was increased to 2.4, then 3.34 was obtained in excellent yield after 30 min (Scheme 
3.8e). Alternatively, converting the hydrochloride salt to the free amine via a base wash and then 
subjecting it to our usual conditions also gave 3.34 in excellent yield after 30 min (Scheme 3.8f). 
We also attempted the reaction by generating the PhF cation using PhFOH and BF3·OEt2 
(Scheme 3.8g). This was unsuccessful so the reaction was repeated in the presence of a base, 
NMM would form a complex with BF3·OEt2 so we used K3PO4 instead (Scheme 3.8h). We 
reasoned that since K3PO4 is all but insoluble in acetonitrile it would not react with boron 
trifluoride to any significant extent; however, it should still react with the Brønsted acid 
byproduct and drive the reaction forward. This did not give the product in good yield and we 






Scheme 3.8. Installation of the PhF Group into Phe-OMe. 
3.2.3 — Phenylfluorenation of unprotected α-amino acids 
 Next, we turned to unprotected amino acids, and again phenylalanine served as a model 
substrate. The carboxylate requires temporary protection which can be accomplished by the in 
situ generation of a TMS ester which also serves to solubilize the substrate. First, we tried the 
conditions of Rapoport which involved refluxing a suspension of phenylalanine with TMS 
chloride in a mixture of chloroform and acetonitrile. This produces the hydrochloride salt of the 
TMS ester which, when subjected to our usual conditions, resulted in a low yield of the desired 
product 3.35 (Scheme 3.9 a). The yield was significantly improved by doubling the amount of 
silver nitrate and changing the solvent to acetonitrile, which improved the solubility of silver 





generated a neutral and halide free TMS ester which gave excellent yields of 3.35 under our 
normal conditions in just 15 minutes (Scheme 3.9 c). 
 
Scheme 3.9. Phenylfluorenation of phenylalanine TMS ester. 
 We applied these conditions to several other amino acids (Table 3.4). The reaction 
proceeded rapidly to give high yields of the products in all cases except for tryptophan (entry 7) 
which gave a complex and strongly colored mixture. The products could be cleanly extracted 
into dilute base, acidified, and back extracted into DCM to give the desired products. Additional 
purification was not necessary except in the case of proline (3.40, entry 6) where minor 





Table 3.4. Phenylfluorenation of amino acids. 
 
Entry Amino acid Yield (%)  
1 Phe 90 (3.35) 
2 Val 98 (3.36) 
3 Met 99 (3.37) 
4 Lys(Boc)OH 75 (3.38) 
5 Asp(OtBu)OH·H2Oa 98 (3.39) 
6 Pro 80 (3.40) 
7 Trpa 0b 
a2.4 equivalents of BSA were used.  
bA complex mixture was formed. 
 
3.2.4 — Phenylfluorenation of carboxylic acids 
 Encouraged by our success with amines we decided to try our conditions with other 
functional groups. The PhF group has usually been used for amine protection, but it has been 
used to protect carboxylic acids at least once in solution phase peptide synthesis154 and 
occasionally as a linker in SPPS.155 In these cases, PhF is useful due to its increased acid stability 
relative to the trityl group. We were pleased to find that our AgNO3/PhFCl/NMM conditions 
gave ester 3.41 rapidly and in high yield from Cbz-Phe-OH (Table 3.5 entry 1). If the base was 
omitted, then the yield was reduced, and unidentified side products formed (entry 2). Perhaps 
because the product is not stable in the presence of one equivalent of nitric acid which is 
generated as a byproduct. No product was produced using BF3·OEt2/PhFOH unless K3PO4 was 



















1 AgNO3 NMM PhFCl 1 84 
2 AgNO3 none PhFCl 1 13 
3 BF3·OEt2 none PhFOH 18 0 
4 BF3·OEt2 K3PO4 PhFOH 18 27 
  
3.2.5 — Phenylfluorenation of alcohols 
 Next, we attempted the protection of primary alcohols using 3.42 as a model substrate. 
The primary alcohol was rapidly protected in excellent yield under our usual conditions to give 
3.43 (Table 3.6). Only a modest reduction in the yield occurred if the base was omitted (entry 2) 
suggesting that the PhF ether is more acid-stable than the related PhF ester 3.41. Using 
BF3·OEt2/PhFOH (entries 3 and 4), 3.43 was obtained in good yields, regardless of the presence 
or absence of base, although the reaction was slower without base.  














1 AgNO3 NMM PhFCl 1 93 
2 AgNO3 none PhFCl 1 82 
3 BF3·OEt2 none PhFOH 18 76 






 The secondary alcohol in 3.44 proved to be a more challenging substrate than the primary 
alcohol (3.42) and gave only 56% of the desired 3.45 under our standard conditions (Scheme 
3.10). However, an excellent yield was obtained if the amount of AgNO3 and PhFCl was 
increased slightly, and the reaction was stirred overnight.  
 
Scheme 3.10. Phenylfluorenation of a secondary alcohol. 
3.2.6 — Phenylfluorenation of thiols 
 We expected that the reaction would be successful with thiols by analogy to alcohols; 
therefore, we were surprised that only 15% of 3.47 was obtained using our AgNO3/PhFCl/NMM 
conditions and 3.46 (Table 3.7). We suspected that this was due to precipitation of a silver 
mercaptan. It is known that the combination of phenylfluorenyl chloride and silver nitrate results 
in the formation of 9-phenyl-9-fluorenyl nitrate, a reactive solid.156 Therefore we prepared the 
PhF nitrate ex situ, filtered off the silver chloride byproduct, and repeated the phenylfluorenation 
of 3.46 with this solution. This led to a very good yield of 3.47 (entry 2). Using 
BF3·OEt2/PhFOH, 3.47 was obtained rapidly and in excellent yield which was decreased slightly 



















1 AgNO3 NMM PhFCl 1 15 
2 none none PhFNO3 1 86 
3 BF3·OEt2 none PhFOH 1 95 
4 BF3·OEt2 K3PO4 PhFOH 1 80 
 
3.2.7 — Phenylfluorenation of sulfonamides and amides 
 Trityl sulfonamides are rare and we are aware of only one example of a PhF 
sulfonamide.157 When we applied our AgNO3/PhFCl/NMM conditions to methane sulfonamide 
3.48 and p-toluene sulfonamide 3.49 none of the desired products 3.50 and 3.51 were obtained 
(Table 3.8 entries 1 and 2). The crude mixtures contained several side products, chiefly 
compounds 3.13 and 3.14. Under BF3·OEt2/PhFOH conditions, sulfonamide 3.50 was obtained 
in a fair yield (entry 3) and both sulfonamides could be obtained in good yields if potassium 





















1 3.48 AgNO3 NMM PhFCl 16 0a 
2 3.49 AgNO3 NMM PhFCl 16 0a 
3 3.49 BF3·OEt2 none PhFOH 16 55 
4 3.48 BF3·OEt2 K3PO4 PhFOH 16 84 
5 3.49 BF3·OEt2 K3PO4 PhFOH 16 78 
aPhFOH and PhFH were observed as the major side products 
 
 While the trityl group is commonly used to protect amides, PhF amides are almost 
unheard of. PhF acetamide was first reported in 1937 but we are unaware of any more complex 
phenylfluorenyl amides.136 We selected two simple aliphatic amides, acetamide (3.52) and 3-
chloropropanamide (3.53), and these were unreactive under our AgNO3/PhCl conditions (Table 
3.9, entries 1 and 2). Using BF3·OEt2 / PhFOH, the desired amides 3.54 and 3.55 were obtained 
in moderate yields (entries 3 and 4). When base was added only trace quantities of protected 





















1 3.52 AgNO3 NMM PhFCl 16 0 
2 3.53 AgNO3 NMM PhFCl 16 0 
3 3.52 BF3·OEt2 none PhFOH 16 45 
4 3.53 BF3·OEt2 none PhFOH 16 44 
5 3.52 BF3·OEt2 K3PO4 PhFOH 16 trace 
6 3.53 BF3·OEt2 K3PO4 PhFOH 16 trace 
 
 The sulfonamides were protected in higher yields when a base was added while the 
amides showed the opposite trend. One explanation is that the acid byproduct formed catalyzes 
the reaction with amides, meanwhile sulfonamides are more acid labile and decompose under the 
acidic conditions (vide infra).  
3.2.8 — Chemoselective phenylfluorenation 
 Having noticed differential reactivities in amines, alcohols, carboxylates, and thiols we 
next attempted to perform various phenylfluorenations chemoselectively. We chose a selection 
of substrates bearing two nucleophilic functional groups. In these experiments we used a small 
excess of the nucleophile, relative to the other reagents.  
 The primary alcohol in 3.56 could be protected in the presence of an ammonium salt to 
give 3.57 (Table 3.10, entry 1) using AgNO3/PhFCl in the absence of a base; however, if a base 





also be selectively protected using BF3·OEt2/PhFOH conditions, although the reaction is slower, 
and the yield lower (entry 3).  


















1 AgNO3 None  PhFCl 1 0 - rt 80 0 
2 AgNO3 NMMa PhFCl 4 -20 28 53 
3 BF3·OEt2 none PhFOH 16 0 - rt 69 0 
a2.4 equiv 
 Amines could not be chemoselectively protected in the presence of alcohols and in order 
to perform this transformation the alcohol must be temporarily protected. By reacting 
phenylalanol with BSA to produce the TMS ether in situ, the amine could be protected followed 
by TMS deprotection with TBAF to give alcohol 3.59 in good yield over three steps in a one-pot 
process (Scheme 3.11). Alternatively, alcohol 3.59 could be readily obtained from 3.58 by 
selective removal of the PhF ether (vide infra).  
 
Scheme 3.11. PhF protection of an amine in the presence of an alcohol. 
 Carboxylic acids also require base for efficient protection so alcohols can be protected in 
their presence. For example, Cbz serine can be protected selectively at the alcohol to give ether 





(entries 1 and 3, Table 3.11). On the other hand, if base is added then a moderate yield of the 
resulting ester 3.61 can be obtained, but this is contaminated with significant amounts of 3.60 
and the doubly protected 3.62 (entry 2).  





 (1 equiv) 
PhF source 
(0.83 equiv) 






1 AgNO3 None  PhFCl 1 77 0 0 
2 AgNO3 NMMa PhFCl 1 6 47 28 
3 BF3·OEt2 none PhFOH 18 57 0 0 
 
 Next, we attempted to selectively protect primary alcohols in the presence of secondary 
alcohols (Scheme 4.12). We used 1,3-butanediol and thymidine as diols. Under our 
AgNO3/PhFCl/NMM conditions, fair yields of the desired primary ethers 3.63 and 3.66 were 
obtained; however, the reactions also produced doubly-protected material (3.65 and 3.68) and 
secondary ethers (3.64 and 3.67). Almost no products could be obtained from the reactions using 
BF3·OEt2/PhFOH, possibly because the diols form a bidentate complex with the boron trifluoride 
which prevents further reaction. Thymidine derivative 3.66 was previously reported by Hidehiko 
et al., however, their synthesis required harsher conditions (8 h reflux in pyridine) and provided 






Scheme 3.12. Chemoselective PhF protection of primary alcohols in the presence of secondary. 
 Thiols reacted much faster than the other protecting groups using BF3·OEt2/PhFOH; 
therefore, we attempted to selectively protect thiols under these conditions. We selected cysteine 
ethyl ester hydrochloride and Fmoc cysteine as model substrates (Scheme 3.13). The thiol of 
Fmoc-Cys-OH was readily protected in excellent yield in the presence of the carboxylic acid to 
give 3.69 in just 1 h. The thiol of the cysteine ethyl ester was also protected in good yield, but the 
reaction was slower, requiring 24 h, likely due to the poor solubility of the substrate. The 
resulting product was difficult to isolate so the free amine was acylated to give 3.70 which could 
be readily purified by flash chromatography.  
 
Scheme 3.13. Selective PhF protection of thiols. 
3.2.9 — PhF deprotection. 
 There are a number of methods available for the deprotection of PhF amines (see 





been established. We found that all of the functional groups examined could be deprotected 
under acidic conditions (Table 3.12). The ethers and esters were very acid labile and could be 
cleaved by 1% TFA/1% TIPS in DCM in a few minutes. The sulfonamides and thiols were more 
stable and were cleaved after 30 minutes in 10% TFA/1%TIPS, the thiol deprotection cocktail 
also included 1% ethanedithiol to prevent dimerization. Finally, the amines and amides were the 
most acid stable and were deprotected in 95% TFA/2.5% water/2.5% TIPS after 30 minutes. 
Therefore, the order of acid stability is amine ~ amide > sulfonamide ~ sulfide > ether ~ ester. 
Table 3.12. Deprotection of PhF-protected functional groups. 





1% TFA/1% TIPS, DCM 
 






1% TFA/1% TIPS, DCM 
 






10% TFA/1% TIPS, DCM 
 






10% TFA/1% TIPS, 1% EDT, DCM 
 



















aTime for complete dissaperance of the starting material as judged by TLC bIsolated yield. cProduct was not isolated. 
 
 Due to their high acid lability, PhF ethers could be removed in the presence of other less 





minutes in DCM cleanly removed the PhF ether without affecting the Boc group. Under the same 
conditions the PhF ether of compound 3.58 was removed while leaving the other PhF group 
(bound to the amine) intact. 
 
Scheme 3.14. PhF ether deprotection in the presence of a PhF- or Boc-protected amine. 
3.3 — Conclusions and future studies 
 In summary, we have introduced new conditions for the installation of a phenylfluorenyl 
group. We have shown that amines, alcohols, and acids are protected rapidly in high yields using 
AgNO3/PhFCl/NMM. Furthermore, we have shown that thiols are protected rapidly in excellent 
yields using BF3·OEt2/PhFOH. These conditions also work for alcohols, sulfonamides and 
amides but the reaction is slower. These conditions are superior to the literature conditions which 
uses toxic Pb(NO3)2, requires very long reaction times, gives variable yields, and is limited in 
substrate scope. Our method allows for the chemoselective protection of alcohols or thiols in the 
presence of carboxylic acids or ammonium salts in excellent yields, and for protection of primary 
alcohols in the presence of secondary with fair selectivity. All of these functional groups can be 
deprotected under mild conditions with TFA and a cation scavenger, and ethers can be 
deprotected in the presence of moderately acid labile groups. We have demonstrated that 
protected α-amino aldehydes prepared with our method are configurationally stable and these 
served as building blocks for our work in Chapter 2. We believe that these protocols should 





adoption of this very useful protecting group. In particular, new applications for this group 
include side chain protections of most amino acids, C-terminal protection in solution phase 
peptide synthesis, and use as a lipophilic tag for group assisted purification of very polar 
molecules.  
3.4 — Experimental  
3.4.1. — General 
 All reagents and solvents were purchased from commercial suppliers and used without 
purification unless stated otherwise. Dimethylformamide (DMF) and acetonitrile were distilled 
from calcium hydride and stored over activated 4 Å molecular sieves. Tetrahydrofuran (THF) 
was distilled from sodium metal in the presence of benzophenone under nitrogen immediately 
before use. Dichloromethane was distilled from calcium hydride under nitrogen immediately 
before use. Benzene and toluene were distilled from sodium in the presence of benzophenone 
and stored over activated 4 Å molecular sieves. Potassium phosphate was dried by vigorous 
heating under vacuum with a Bunsen burner. Weinreb’s amides were prepared from the coupling 
of methylmethoxy amine with Cbz protected α-amino acids using EDC HCl/HOBt in 
dichloromethane followed by hydrogenolysis using palladium on carbon in dry acetonitrile under 
a hydrogen atmosphere. 
All 13C{1H} NMR spectra were proton decoupled. Chemical shifts (δ) for 1H NMRspectra run in 
CDCl3 are reported in ppm relative to the standard tetramethylsilane (TMS). Chemical shifts for 
13C{1H} NMR spectra run in CDCl3 are reported in ppm relative to the solvent residual carbon (δ 
77.16 for central peak). The samples for high-resolution positive ion electrospray ionization mass 





3.4.2. — Experimental procedures. 
 
 
9-Chloro-9-phenylfluorene (PhFCl).159 In a three necked flask equipped with an addition funnel, 
a condenser and a glass stopper was placed magnesium turnings (10.9 g, 450 mmol, 3 equiv) and 
iodine (381 mg, 1.50 mmol, 0.01 equiv). Bromobenzene (47 mL, 450 mmol, 3 equiv) was 
dissolved in THF (210 mL) and 25 mL of this solution was added and stirred 5 min until a gentle 
reflux was achieved, then the remaining solution was added dropwise over 1 h. When the 
addition was complete, the reaction was refluxed for an additional 1 h, until all of the magnesium 
turnings had reacted, and then cooled to 0 °C. 9-fluorenone (27.0 g, 150 mmol, 1 equiv) was 
dissolved in THF (120 mL) and added dropwise over 1 h. When the addition was complete the 
reaction was allowed to warm to rt and stirred until complete (30 min) as determined by TLC 
(5% ethyl acetate in hexanes). The mixture was poured into 1 L of ice/saturated ammonium 
chloride then extracted with dichloromethane (3 x 500 mL). The combined organic layers were 
washed with water (1 L), brine (1 L), then dried over magnesium sulfate, filtered, and 
concentrated to yield 9-phenyl-9-fluorenyl alcohol (PhFOH) as a white solid which was used 
without further purification. The alcohol was dissolved in benzene (450 mL) and thionyl chloride 
(32.6 mL, 450 mmol, 3 equiv) was added. The mixture was refluxed for 1 h then an aliquot was 
concentrated to dryness and dissolved in CDCl3. 
13C{1H} NMR determined that the reaction was 
complete based on the disappearance of the peak at 83 ppm and the appearance of a new peak at 





and gravity filtered. The filtrate was allowed to cool and evaporate slowly to yield 34 g (82% 
yield) of PhFCl as yellow crystals over 4 crops. 1H NMR(CDCl3, 300 MHz) δ: 7.70 (d, 2H, J = 
7.7 Hz), 7.49 -7.37 (m, 6H), 7.32-7.27 (m, 5H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 149.4, 
141.3, 138.9, 129.3, 128.67, 128.4, 128.0, 126.6, 125.6, 120.4, 74.8 HRMS (ESI+) m/z: [M - Cl]+ 
calcd for C19H13, 241.1012; found, 241.1013. 
 
9-phenylfluorene (3.13). Prepared according to the general method of Vougioukalakis et al.160 To 
a solution of PhFOH (516 mg, 2.00 mmol, 1 equiv) in dichloromethane (4 mL) cooled to 0 °C 
triethylsilane (637 µL, 4 mmol, 2 equiv) was added followed by BF3·OEt2 (490 µL, 4 mmol, 2 
equiv). The reaction was stirred until complete by TLC (5 min). The reaction was quenched with 
5% sodium carbonate (10 mL) and extracted with dichloromethane (3 x10 mL). The combined 
organic layers were dried over magnesium sulfate, filtered, and concentrated to dryness. The 
residue was purified by flash chromatography using hexane which gave 3.13 as a white powder 
(484 mg, 89% yield). 1H NMR(CDCl3, 300 MHz) δ: 7.89 (d, 2H, J = 7.5 Hz) 7.49-7.30 (m, 9H), 
7.18 (d, 2H, J = 7.3 Hz), 5.14 (s, 1H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 148.0, 141.7, 141.1, 
128.8, 128.4, 127.4, 126.9, 125.4, 119.9, 54.57; HRMS (ESI+) m/z: [M - H-]+ calcd for C19H13, 
241.1012; found, 241.1010. 
 
N-(9-phenyl-9-fluorenyl)morpholine (3.14). PhFCl (276 mg, 1.00 mmol, 1 equiv) and 





°C. AgNO3 (170 mg, 1.00 mmol, 1 equiv) was added as a solution in acetonitrile (4 mL) and the 
reaction was stirred for 2 h at ambient temperature. The mixture was filtered through a 3 cm 
silica plug and eluted with dichloromethane (50 mL) then concentrated to dryness. The residue 
was purified by flash chromatography using a gradient of 100% hexane to 10% ethyl acetate in 
hexane, which gave 3.14 as a white powder (279 mg, 85% yield). 1H NMR(CDCl3, 300 MHz) δ: 
7.73 (d, 2H, J = 7.4 Hz), 7.57 (m, 2H), 7.45-7.36 (m, 4H), 7.31-7.25 (m, 5H), 3.72 (t, 4H, J = 
4.4 Hz), 2.50 (t, 4H, J = 4.0 Hz); 13C{1H} NMR (CDCl3, 75 MHz) δ: 146.6, 142.4, 140.7, 128.4, 
128.2, 127.4, 127.3, 127.2, 126.2, 119.9, 78.1, 67.8, 48.1; HRMS (ESI+) m/z: calcd for 
C23H22NO, 328.1696; found, 328.1692. 
General procedures for the phenylfluorenation of functional groups.  
 Unless otherwise specified, reactions were worked up by filtration through a short plug of 
silica (~5 cm for 1 mmol scale reactions) which was rinsed with ~50 mL of EtOAc. The eluent 
was concentrated under reduced pressure then purified by flash chromatography as specified.  
General Procedure 3.1 for the phenylfluorenation of functional groups.  
To a solution of acetonitrile at 0 °C containing substrate (0.166 M, 1 equiv), NMM (0.2 M, 1.2 
equiv) and PhFCl (0.2 M, 1.2 equiv) a solution of silver nitrate (0.3 M, 1.2 equiv) in CH3CN was 
added. The cooling bath was removed, and the white suspension was stirred until complete by 
TLC or a negative ninhydrin test (usually 1 h).  
General procedure 3.2 for the phenylfluorenation of functional groups.  
To a solution of acetonitrile at 0 °C containing substrate (0.166 M, 1 equiv), and PhFCl (0.2 M, 





was removed, and the white suspension was stirred until complete by TLC or a negative 
ninhydrin test (usually 1 h).  
General procedure 3.3 for the phenylfluorenation of functional groups.   
To a solution of acetonitrile at 0 °C containing substrate (0.1 M, 1 equiv) and PhFOH (0.12 M, 
1.2 equiv) BF3•OEt2 (1.2 equiv) was added. The cooling bath was removed, and the reaction was 
stirred until complete or for 16 h. 
General procedure 3.4 for the phenylfluorenation of functional groups.  
To a suspension of acetonitrile at 0 °C containing substrate (0.1 M, 1 equiv) PhFOH (0.12 M, 1 
equiv), and K3PO4 (1.2 equiv) was added BF3•OEt2 (1.2 equiv). The cooling bath was removed, 
and the reaction was stirred until complete or for 16 h.  
 
 
PhF-methionine methyl(methoxy)amide (3.8). According to General procedure 3.1 except that 
the tosylate salt of the methionine methyl(methoxy)amide (3.5) and 2.4 equiv of NMM were 
used. Obtained as a colorless oil 375 mg (87% yield) from (364 mg, 1.00 mmol) of 3.5. 1H 
NMR(CDCl3, 300 MHz) δ: 7.68 (d, 2H, J = 7.2 Hz), 7.39 (m, 3H), 7.28 (m, 8H), 3.51 (br, 1H), 
2.94 (d, 1H, J = 6.5 Hz), 2.85 (s, 3H), 2.83 (s, 3H), 2.67 (m, 1H), 2.45 (m, 1H), 1.95 (s, 3H), 
1.53 (m, 2H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 176.1, 149.8, 148.9, 145.0, 141.4, 139.8, 
128.3, 128.1, 128.1, 127.3, 127.1, 126.0, 125.8, 119.6, 119.5, 73.1, 60.3, 51.5, 34.2, 31.9, 30.9, 
15.1; HRMS (ESI+) m/z: [M + H]+ calcd for C26H29N2O2S,






PhF-proline methyl(methoxy)amide (3.9). According to general procedure 3.1 3.9 was obtained 
as a white amorphous solid (277 mg, 70% yield) from 3.6 (158 mg, 1.00 mmol). 1H 
NMR(CDCl3, 300 MHz) δ: 7.68 (d, 1H, J = 7.3 Hz), 7.60 (m, 4H), 7.44 (d, 1H, J = 7.4 Hz), 7.38 
(t, 1H, J = 7.43 Hz), 7.31-7.13 (m, 8H), 3.67 (m, 1H), 3.28 (m, 1H), 2.90 (m, 7H), 1.93-1.59 (m, 
4H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 177.3, 148.8, 148.0, 144.3, 141.1, 139.9, 128.3, 128.2, 
128.1, 127.7, 127.6, 127.5, 127.1, 127.0, 126.6, 119.7, 119.5, 77.2, 60.3, 57.8, 50.3, 32.2, 31.9, 
24.9; HRMS (ESI+) m/z: [M + H]+ calcd for C26H27O2N2, 399.2067; found, 399.2078. 
 
N2-PhF-O4-(t-butyl)aspartic acid methyl(methoxy)amide (3.10). According to General procedure 
3.1 3.10 was obtained as a white amorphous solid (389 mg, 82% yield) from 3.7 (232 mg, 1.00 
mmol). 1H NMR(CDCl3, 300 MHz) δ: 7.64 (d, 1H, J = 6.9 Hz), 7.62 (d, 1H, J = 6.9 Hz), 7.41-
7.13 (m, 11H), 3.33 (br, 1H), 2.96 (s, 3H), 2.75 (s, 3H), 2.33 (dd, 1H, J = 14.2, 8.2 Hz), 2.17 (dd, 
1H, J = 3.3, 14.2 Hz), 1.45 (s, 9H), the NH proton was not observed; 13C{1H} NMR (CDCl3, 75 
MHz) δ: 169.9, 149.2, 148.6, 145.1, 141.4, 139.7, 128.3, 128.2, 128.0, 127.3, 127.1, 127.0, 
126.2, 126, 119.5, 119.4, 80.3, 72.9, 60.4, 50.0, 41.7, 32.0, 28.2; HRMS (ESI+) m/z: [M + H]+ 






PhF-alanine methyl(methoxy)amide (3.12). According to General procedure 3.1 3.12 was 
obtained as a crystalline white solid (343 mg, 92% yield) from 3.11 (132 mg, 1.00 mmol). 1H 
NMR(CDCl3, 300 MHz) δ: 7.86 (d, 2H, J = 7.47 Hz), 7.48-7.42 (m, 3H), 7.35–7.17 (m, 8H), 
3.59 (s, 1H), 2.86 (m, 7H), 1.08 (d, 3H, J = 7.05 Hz); 13C{1H} NMR (CDCl3, 75 MHz) δ: 177.1, 
150.3, 149.4, 144.9, 141.2, 139.9, 128.23, 128.20, 128.10, 128.06, 127.5, 127.1, 126.8, 126.1, 
125.4, 119.7, 119.6, 73.3, 60.3, 48.3, 31.9, 21.9; HRMS (ESI+) m/z: [M + H]+ calcd for 
C24H25N2O2, 373.1911; found, 373.1915. 
 
PhF-phenylalanine methyl(methoxy)amide (3.18). According to General procedure 3.1 3.18 was 
obtained as an amorphous white solid (376 mg, 84% yield) from 3.15 (208 mg, 1.00 mmol). 1H 
NMR(CDCl3, 300 MHz) δ: 7.6 (d, 1H, J = 7.2 Hz), 7.54 (d, 1H, J = 7.5 Hz), 7.4-7.1 (m, 14H), 
6.8 (t, 1H, J = 7.02 Hz), 6.5 (d, 1H, J = 7.2 Hz), 3.33 (br, 1H), 3.05 (d, 1H, J = 6.6 Hz), 2.87 (s, 
3H), 2.84 (s, 3H), 2.6 (m, 2H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 176.1, 149.4, 149.3, 148.9, 
145.4, 141.4, 139.4, 138.9, 128.2, 128.1, 128.0, 127.9, 127.7, 127.3, 127.0, 126.2, 125.5, 119.4, 
119.0, 73.1, 60.3, 54.5, 41.4, 31.9; HRMS (ESI+) m/z: [M + H]+ calcd for C30H29N2O2, 449.2224; 
found, 449.2230. 
 
N2-PhF-N6-(boc)-lysine methyl(methoxy)amide (3.19). According to General procedure 3.1 3.19 





1H NMR(CDCl3, 300 MHz) δ: 7.61 (d, 1H, J = 6.9 Hz), 7.62 (d, 1H, J = 7.4 Hz), 7.41 (m, 3H), 
7.31-7.17 (m, 8H), 4.41 (br, 1H), 3.44 (s, 1H), 3.01 (m, 2H), 2.81 (m, 7H), 1.43 to 1.13 (m, 
15H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 176.6, 155.9, 149.9, 149.0, 145.01, 141.2, 139.8, 
128.2, 128.0, 127.8, 126.0, 119.4, 78.8, 73.1, 60.1, 51.8, 40.4, 34.5, 31.8, 29.4, 28.4, 22.8; 
HRMS (ESI+) m/z: [M + H]+ calcd for C32H40N3O4, 530.3013; found, 530.3039. 
 
PhF-isoleucine methyl(methoxy)amide (3.20). According to General procedure 3.1 3.20 was 
obtained as a colorless oil (356 mg, 86% yield) from 3.17 (174 mg, 1.00 mmol). 1H 
NMR(CDCl3, 300 MHz) δ: 7.55 (m, 2H), 7.35 (m, 3H), 7.3-7.1 (m, 8H), 3.25 (s, 1H), 2.77 (s, 
3H), 2.71 (s, 1H), 1.6-1.15 (m, 4H), 0.70 (t, 3H, J = 7.36 Hz), 0.65 (d, 2H, J = 6.76 Hz); 
13C{1H} NMR (CDCl3, 125 MHz) δ:176.35, 149.6, 149.0, 145.7, 141.4, 139.8, 128.2, 128.04, 
127.95, 127.7, 127.6, 127.0, 126.5, 126.1, 119.3, 73.1, 59.8, 56.4, 39.4, 31.7, 23.9, 16.3, 11.6; 
HRMS (ESI+) m/z: [M + H]+ calcd for C27H31O2N2, 415.2380; found, 415.2381. 
General procedure 3.5 for the reduction of PhF protected α-amino Weinreb amides. 
 To a solution of Weinreb’s amide in THF at a concentration of 0.1 M at -20 °C LiAlH4 (2 
M in THF, 1.1 equiv) was added dropwise. The reaction was stirred until complete by TLC (1 h) 
then was diluted with two volumes of cold diethyl ether and quenched with 50 µL of water 
followed by 150 µL of 1 M NaOH for ever 1 mmol of LiAlH4 used. This was stirred for 15 
minutes at 0 °C then dried over magnesium sulfate, filtered, and concentrated to dryness. The 







PhF-methioninal (3.21). 230 mg (89%) as a yellow oil was obtained from 300 mg (0.694 mmol) 
of 3.8 according to General procedure 3.5. 1H NMR(CDCl3, 300 MHz) δ:9.31 (s, 1H), 7.70 (d, 
2H, J = 7.5 Hz), 7.48 (m, 2H), 7.39-7.24 (m, 9H), 3.21 (br 1H), 2.76 (t, 1H, J = 5,6 Hz), 2.50 
(m, 2H), 1.97 (s, 3H), 1.63 (m, 2H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 202.1, 149.2, 149.1, 
144.4, 141.0, 140.2, 128.8, 128.6, 128.4, 128.1, 128.0, 127.4, 126.2, 126.1, 26.1, 125.5, 125.3, 
120.1, 119.9, 72.9, 61.3, 30.9, 29.9, 15.4; HRMS (ESI+) m/z: [M + H]+ calcd for C24H24ONS; 
374.15731 found; 374.15753. 
 
PhF-prolinal (3.22). 297 mg (87%) as a white solid as obtained from 398 mg (1 mmol) of 3.9 
according to General procedure 3.5. 1H NMR(CDCl3, 300 MHz) δ: 9.14 (d, 1H, J = 4.3 Hz), 
7.74 (d, 1H, J = 7.5 Hz), 7.63-7.39 (m, 6H), 7.35-7.2 (m, 5H), 7.13 (t, 1H, J = 7.5 Hz), 3.34 (m, 
1H), 3.00 (m, 1H), 2.72 (m 1H), 1.82-1.6 (m, 4H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 201.7, 
149.2, 145.7, 142.9, 142, 139.4, 129, 128.8, 128.5, 127.8, 127.7, 127.5, 127.4, 126.4, 125.9, 
120.2, 120.1, 76.3, 66.3, 50.8, 28.4, 24.9 HRMS (ESI+) m/z: [M + MeOH + H]+ calcd for 








N2-PhF-O4-(t-butyl)aspartaldehyde (3.23). 112 mg (43%) as a white solid was obtained from 
300 mg (0.63 mmol) of 3.10 according to General procedure 3.5. 1H NMR(CDCl3, 500 MHz) δ: 
946 (s, 1H), 7.72 (d, 2H, J = 7.4 Hz), 7.48-7.25 (m, 11H), 3.59 (s, 1H), 2.51 (dd, 1H, J = 15.9, 
3.2 Hz), 2.09 (dd, 1H, J = 15.8, 5.8 Hz), 1.49 (3H, s); 13C{1H} NMR (CDCl3, 125 MHz) δ:201.8, 
170.4, 149.5, 149.1, 144.6, 141.1, 140.0, 128.8, 128.7, 128.4, 128.3, 128.2, 127.4, 126.2, 125.6, 
125.3, 120.2, 120.0, 81.41, 72.9, 59.3, 38.2, 28.2; HRMS (ESI+) m/z: [M + H]+ calcd for 
C27H28O3N; 414.20637 found; 414.20665. 
 
PhF-alaninal (3.24). 808 mg (89%) was obtained as a white solid from 1.08 g (2.9 mmol) of 
3.12 according to General procedure 3.5. The NMR spectra were identical to literature data.115  
 
PhF-phenylalinal (3.25) 155 mg (89%) was obtained as a white solid from 200 mg (0.45 mmol) 
of 3.18 according to General procedure 3.5. 1H NMR(CDCl3, 300 MHz) δ: 9.26 (d, 1H, J = 2.2 
Hz), 7.67 (m, 2H), 7.4-7.2 (m, 12H), 7.07 (t, 1H, J = 7.5 Hz), 6.96 (m, 2H), 6.63 (d, 1H, 7.6 Hz), 
2.7-2.6 (m, 4H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 202.8, 148.6, 148.6, 144.2, 140.6, 140.6, 
136.4, 129.5, 128.9, 128.7, 128.4, 128.3, 128.0, 127.8, 127.3, 126.9, 126.1, 125.7, 124.9, 120.0, 





390.18591. This compound became discolored on standing and should be prepared immediately 
before use.  
 
N2-PhF-N6-Boc-lysinal (3.26). 245 mg (92%) was obtained as a white solid from 300 mg (0.567 
mmol) of 3.19 according to General procedure 3.5. 1H NMR(CDCl3, 300 MHz) δ: 9.20 (d, 1H, J 
= 1.8 Hz), 7.68 (d, 1H, J = 5.1 Hz), 7.65 (d, 1H, J = 5.2 Hz), 7.45 (m, 2H), 7.35-7.19 (m, 9H), 
4.47 (br, 1H), 3.00 (m, 3H), 2.57 (m, 1H), 1.43 (s, 9H), 1.25 (m, 6H); 13C{1H} NMR (CDCl3, 75 
MHz) δ: 203.3, 156.0, 149.3, 149.1, 144.5, 140.8, 140.5, 128.8, 128.5, 128.4, 128.0, 127.9, 
127.4, 126.2, 125.6, 125.1, 120.1, 112.0, 79.1, 72.9, 61.6, 40.1, 30.8, 29.8, 22.1; HRMS (ESI+) 
m/z: [M + H]+ calcd for C30H35O3N2; 471.2642 found; 471.2660. 
 
PhF-isoleucinal (3.27). Prepared according to General procedure 3.5 except that 2 equiv of 
LiAlH4 was used and the reaction was stirred overnight at 0 °C. 36 mg (83%) was obtained as a 
colorless oil from 50 mg of 3.20. 1H NMR (CDCl3, 300 MHz) δ: 9.31 (s, 1H), 7.65 (d, 2H, J = 
7.3 Hz), 7.48 (m, 2H), 7.36-7.15 (m, 9H), 3.02 (br, 1H), 2.51 (m, 1H), 1.49 (m, 1H), 1.26 (m, 
2H), 0.82 (d, 2H, J = 6.9 Hz), 0.65 (t, 3H, J = 7.4 Hz); 13C{1H} NMR (CDCl3, 75 MHz) δ: 
204.6, 149.2, 149.0, 144.7, 140.8, 140.4, 128.6, 128.4, 128.3, 127.74, 127.70, 127.28, 126.2, 
125.7, 125.6, 119.87, 119.77, 72.9, 65.3, 38.8, 25.3, 15.8, 11.6; HRMS-ESI+ (m/z) calcd for 
C25H26ON






PhF-alanol (3.28). Was prepared as an enantiomerically pure sample from 3.24 according to the 
method of Lubell and Rapoport.115 Additionally a racemic sample was prepared as follows. To a 
suspension of (DL)-alanine methyl ester hydrochloride (139 mg, 1.00 mmol, 1 equiv) in 
acetonitrile (6 mL) was added PhFCl (331 mg, 1.20 mmol, 1.2 equiv) and NMM (263 µL, 2.40 
mmol, 2.4 equiv). The solution was cooled to 0 °C and AgNO3 (408 mg, 2.40 mmol, 2.4 equiv) 
was added as a solution in acetonitrile (4 mL). The resulting suspension was stirred until 
complete as determined by a negative ninhydrin test (1 h), and then filtered through a short pad 
of silica and eluted with DCM. The mixture was concentrated to dryness and then dissolved in 
dry THF (10 mL) and cooled to -20 °C. LiAlH4 (2 M in THF, 700 µL, 1.40 mmol, 1.4 equiv) 
was added dropwise and the reaction was stirred until complete by TLC (1 h). The reaction was 
diluted with diethyl ether (20 mL) and quenched by the addition of 150 µL of water then 450 µL 
of 1 M NaOH. The resulting suspension was stirred for 15 min then dried over magnesium 
sulfate, filtered, and concentrated to dryness. The residue was purified by flash chromatography 
using a gradient of 5% to 45% ethyl acetate in hexane, which gave (R/S) 3.28 (231 mg, 73 % 
yield). 1H NMR of both samples was identical to literature data.115 
 
Preparation of the Mosher’s Esters of (L)- and (DL)-N-(9-phenyl-9-fluorenyl)phenylalanol 
(3.29). (S)-3.28 (15 mg, 0.048 mmol, 1 equiv) 4-dimethylaminopyridine (9 mg, 0.08 mmol, 1.6 





equiv) and EDC HCl (14 mg, 0.075 mmol, 1.6 equiv) were dissolved in DCM (2 mL) and stirred 
at ambient temperature for 18 h. The mixture was then filtered through a short pad of silica and 
eluted with DCM. The filtrate with concentrated to dryness and used without further purification. 
19F NMR (CDCl3, 282 MHz) δ: 71.77 (s, 3H). (R/S)-3.29 was prepared in an identical manner 
from (R/S)-3.28. 19F NMR (CDCl3, 282 MHz) δ: 71.69 (s, 1.5H), 71.77 (s, 1.5H). 
 
PhF-Phe-OMe (3.34). 
Method i. Cbz-Phe-OMe (3.30, 313 mg, 1.00 mmol, 1 equiv) was dissolved in acetonitrile (6 
mL) and Pd/C (10 wt.%, 30 mg) was added. The reaction was stirred under an atmosphere of 
hydrogen for 30 min until complete by TLC, then filtered through celite, the filtrate was 
subjected to General procedure 3.1.  
Method ii. BocPheOMe (3.31, 279 mg, 1.00 mmol, 1 equiv) was dissolved in DCM (5 mL) and 
cooled to 0 °C. TFA (5 mL) was added and the reaction was stirred for 30 min until complete by 
TLC. The reaction was concentrated to dryness and the residue dissolved in water (10 mL) and 
then lyophilized to a white powder. The powder was dissolved in acetonitrile (6 mL) and PhFCl 
(331 mg, 1.20 mmol, 1.2 equiv) and NMM (262 µL, 2.4 mmol, 2.4 equiv) were added. The 
mixture was cooled to 0 °C and then a solution of AgNO3 (204 mg, 1.20 mmol, 1.2 equiv) in 
acetonitrile (4 mL) was added. The cooling bath was removed, and the reaction was stirred until 
complete by ninhydrin test (2 h).  
Method iii. Phenylalanine methyl ester tosylate (3.32, 351 mg, 1.00 mmol, 1 equiv) was 





Method iv. Phenylalanine methyl ester hydrochloride (3.33, 215 mg, 1.00 mmol, 1 equiv) was 
subjected to General procedure 3.1 except that 2.4 equiv of NMM were used. 
Method v. Phenylalanine methyl ester hydrochloride (3.33, 215 mg, 1.00 mmol, 1 equiv) was 
dissolved in acetonitrile (6 mL) and PhFCl (331 mg, 1.20 mmol, 1.2 equiv) and NMM (262 µL, 
2.4 mmol, 2.4 equiv) were added. The solution was cooled to 0 °C and then a solution of AgNO3 
(408 mg, 2.4 mmol, 2.4 equiv) in acetonitrile (8 mL) was added. The cooling bath was removed, 
and the reaction was stirred 30 min until complete by ninhydrin test.  
Method vi. Phenylalanine methyl ester hydrochloride (3.33, 215 mg, 1.00 mmol, 1 equiv) was 
dissolved in 5% aqueous sodium carbonate (20 mL) and extracted three times with 
dichloromethane (10 mL). The combined organic layers were dried over magnesium sulfate, 
filtered, and concentrated. Residual water was removed by concentration from dry acetonitrile 
(10 mL). The residue was subjected to General procedure 3.1. 
Method vii. Phenylalanine methyl ester hydrochloride (3.33, 215 mg, 1.00 mmol, 1 equiv) was 
washed as in Method ii then the residue was subjected to General procedure 3.3.  
Method viii. Phenylalanine methyl ester hydrochloride (3.33, 215 mg, 1.00 mmol, 1 equiv) was 
washed as in Method ii then the residue was subjected to General procedure 3.4.  
In all cases the residue was purified by flash chromatography using 2.5% ethyl acetate/97.5% 
hexane and silica gel which had been treated with hexane containing 1% triethylamine then 
rinsed with 2-3 column volumes of 2.5% ethyl acetate/97.5% hexane. 3.34 was obtained as a 
white amorphous solid. 76% (method i), 95% (method ii), 94% (method iii), 0% (method iv), 
95% (method v), 96% (method vi), 0% (method vii), 13% (method viii). 1H NMR(CDCl3, 300 
MHz) δ: 7.67 (d, 1H, J = 7.6 Hz), 7.63 (d, 1H, J = 7.6 Hz), 7.37-7.17 (m, 12H), 7.06 (m, 2H), 





NMR (CDCl3, 75 MHz) δ: 176.2, 148.7, 148.5, 144.6, 141.0, 139.9, 137.6, 129.8, 128.3, 128.2, 
128.1, 128.0, 127.8, 127.2, 127.1, 126.4, 126.3, 126.1, 125.1, 119.8, 119.7, 72.9, 57.6, 51.4, 
41.4; HRMS (ESI+) m/z: [M + H]+ calcd for C29H26NO2, 420.1958; found, 420.1963. 
General procedure 3.6 for the synthesis of PhF protected amino acids. 
To a mixture of the amino acid (1 mmol) in acetonitrile (2 mL) was added N,O-
bis(trimethylsilyl)acetamide (BSA, 295 µL, 1.20 mmol, 1.2 equiv). The mixture was heated to 
reflux with stirring until a clear solution formed (generally 15 min). If necessary, an additional 
1.2 equiv BSA was added and reflux continued until all the solids dissolved. The solution was 
diluted with acetonitrile (4 mL), cooled to 0 °C, then NMM (131 µL, 1.20 mmol, 1.2 equiv) and 
PhFCl (331 mg, 1.20 mmol, 1.2 equiv) were added followed by a solution of AgNO3 (204 mg, 
1.20 mmol, 1.2 equiv) in acetonitrile (4 mL). A white precipitate of AgCl formed immediately 
and the reaction was stirred at ambient temperature until complete as determined by a negative 
ninhydrin test, generally less than 30 min. Methanol (1 mL) was added and the reaction was 
stirred an additional 15 min. The precipitate was filtered off, the solution was diluted with 
diethyl ether (50 mL) then extracted with sodium hydroxide (0.1 N, 3 x 20 mL). The combined 
aqueous layers are acidified with citric acid (6 g). Sodium chloride (6 g) was added and then the 
mixture was extracted with dichloromethane (3 x 25 mL). The combined dichloromethane layers 
were dried over magnesium sulfate, filtered, and concentrated to yield pure product. Further 
purification was not necessary unless otherwise noted. 
 
PhF-Phe-OH (3.35). Obtained as a white amorphous solid (365 mg, 90% yield) from 





MHz) δ: 7.68 (d, 1H, J = 7.1 Hz), 7.66 (d, 1H, J = 7.1 Hz), 7.34 – 7.00 (m, 16H), 6.64 (d, 1H, J 
= 7.6 Hz), 2.88–2.78 (m, 2H), 2.67 (m, 1H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 177.4, 148.1, 
147.0, 143.5, 140.6. 140.5, 136.2, 129.6, 128.9, 128.8, 128.5, 128.1, 127.9, 127.5, 127.1, 126.0, 
125.9, 124.6, 120.2, 119.9, 72.7, 57.0, 39.6; HRMS (ESI+) m/z: [M + H]+ calcd for C28H23NO2, 
406.1802; found, 406.1807. 
 
PhF-Val-OH (3.36). Obtained as a white powder (348 mg, 98% yield) from valine (117 mg, 1.00 
mmol) according to general procedure 3.6. 1H NMR(CDCl3, 300 MHz) δ: 7.69 (d, 1H, J = 7.12 
Hz), 7.68 (d, 1H, J = 7.28 Hz), 7.50 (m, 2H), 7.38-7.16 (m, 9H), 2.38 (d, 1H, J = 2.4 Hz), 1.80 
(m, 1H), 1.00 (d, 3H, J = 6.7 Hz), 0.86 (d, 3H, J = 6.7 Hz); 13C{1H} NMR (CDCl3, 75 MHz) δ: 
180.3, 148.5, 148.1, 144.5, 141.1, 140.4, 128.6, 128.5, 128.4, 127.8, 127.5, 127.4, 126.4, 126.2, 
125.7, 120.0, 119.9, 72.8, 61.1, 32.6, 19.2, 18.7; HRMS (ESI+) m/z: [M + H]+ calcd for 
C24H24NO2, 358.1813; found, 358.1800. 
 
PhF-Met-OH (3.37). Obtained as a white amorphous solid (389 mg, 99% yield) from methionine 
(149 mg, 1.00 mmol) according to general procedure 3.6. 1H NMR(CDCl3, 300 MHz) δ: 7.90 
(br, 2H), 7.70 (m, 1H), 7.45 (m, 3H), 7.38 (m, 2H), 7.30-7.18 (m, 6H), 2.81 (t, 1H, J = 6.0 Hz), 
2.49 (m, 2H), 1.97 (s, 3H), 1.75 (m, 2H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 178.2, 147.6, 





120.2, 120.1, 73.0, 55.4, 33.2, 30.3, 15.2; HRMS (ESI+) m/z: [M + H]+ calcd for C24H24NO2S, 
390.1533; found, 390.1521. 
 
PhF-Lys(Boc)-OH (3.38). Obtained as a white amorphous solid (368 mg, 75% yield) from Boc-
Lys-OH (246 mg, 1.00 mmol) according to general procedure 3.6. 1H NMR(CDCl3, 300 MHz) δ: 
7.67 (m, 2H), 7.38-7.00 (m, 13 H), 5.55 and 4.54 (br, 1H), 2.98 (m, 2H), 2.58 (t, 1H, J = 5.3 Hz), 
1.41–1.24 (m, 15H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 178.1, 156.2, 148.62, 147.5, 143.7, 
140.8, 140.6, 128.8, 128.7, 128.5, 128.0, 127.8, 127.5, 126.1, 126.0, 125.2, 120.1, 120.0, 79.2, 
73.0, 55.6, 40.0, 33.6, 29.6, 28.4, 22.2; HRMS (ESI) m/z: [M + H]+ calcd for C30H35N2O4, 
487.2602; found, 487.2607. 
 
PhF-Asp(OtBu)-OH (3.39). Obtained as a white amorphous solid (420 mg, 98% yield) from 
Asp(tBu)OH (207 mg, 1.00 mmol) according to general procedure 3.6. 1H NMR(CDCl3, 300 
MHz) δ: 7.73 (d, 1H, J = 7.59 Hz), 7.69 (d, 1H, J = 7.59 Hz), 7.45-7.20 (m, 11H), 2.80 (dd, 1H, 
J = 5.0, 3.3 Hz), 2.67 (dd, 1H, J = 3.3, 17.3 Hz), 1.89 (dd, 1H, J = 17.3, 5.0), 1.41 (s, 9H); 
13C{1H} NMR (CDCl3, 75 MHz) δ: 175.5, 170.8, 148.8, 147.2, 143.3, 140.6, 140.3, 129.1, 
129.0, 128.6, 128.5, 128.2, 127.6, 125.8, 125.2, 124.8, 120.5, 120.3, 81.7, 72.5, 52.8, 37.4, 28.1; 
HRMS-ESI+ m/z: calcd for C27H28NO4
+
 [M + H]






PhF-Pro-OH (3.40). Obtained as a white amorphous solid (285 mg, 80% yield) from proline 
(115 mg, 1.00 mmol) according to the General procedure 3.6 except that the reaction was stirred 
for 2 h and the crude product was purified by flash chromatography, using a gradient of 10% to 
100% ethyl acetate in hexane. 1H NMR(CDCl3, 300 MHz) δ: 10.24 (br, 1H), 7.75 (d, 1H, J = 7.5 
Hz), 7.64 (d, 1H, J = 7.64 Hz), 7.56 (d, 1H, J = 7.5 Hz), 7.49-7.15 (m, 11H), 3.41 (m, 1H), 3.24 
(dd, 1H, J = 2.5, 9.1 Hz), 3.06 (dd, 1H, J = 8.3, 18.8 Hz), 1.95 (m, 1H), 1.7 (m, 3H); 13C{1H} 
NMR (CDCl3, 75 MHz) δ: 175.0, 146.1, 144.8, 141.6, 140.7, 139.4, 129.5, 129.2, 128.8, 128.2, 
128.0, 127.0, 126.1, 125.9, 120.5, 120.2, 77.0, 62.7, 50.9, 31.1, 25.0; HRMS (ESI+) m/z: [M + 
H]+ calcd for C24H22NO2, 356.1656; found, 356.1646. 
 
Cbz-Phe-OPhF (3.41). All reactions used 299 mg (1 mmol) of Cbz-Phe-OH as the substrate and 
were purified by flash chromotography using a gradient of 0 to 25% ethyl acetate in hexane. 
Methods i-iv correspond to entries 1 to 4 in Table 3.5. Method i: Using General procedure 3.1, 
454 mg (84%) of 3.41 was obtained after 1 h. Method ii: Using General procedure 3.2, 74 mg 
(13%) of 3.41 was obtained after 1 h. Method iii: Using General procedure 3.3, no product was 
obtained after 18 h. Method iv: Using General procedure 3.4, 149 mg (27%) of 3.41 was 
obtained after 18h. The product was a white solid. 1H NMR(CDCl3, 300 MHz) δ: 7.70 (d, 1H, J 





Hz), 3.1 (d, 2H, J =6.2 Hz); 13C{1H} NMR{1H}(CDCl3, 75 MHz) δ: 169.2, 155.6, 146.1, 145.9, 
140.6, 140.4, 136.2, 135.7, 129.4, 129.3, 129.3, 128.56, 128.54, 128.4, 128.2, 128.1, 128.0, 
127.7, 127.0, 125.0, 124.6, 120.24, 120.21, 89.9, 66.8, 55.0, 38.2; HRMS (ESI+) m/z: [M + 
NH4]
+ calcd for C36H33N2O4, 557.2435; found, 557.2453.  
 
Cbz-O1-PhF-phenylalanol (3.43). All reactions used 285 mg (1 mmol) of Cbz-phenylalanol 
(3.42) as the substrate and were purified by flash chromotography using a gradient of 10 to 25% 
ethyl acetate in hexane. Methods i-iv correspond to entries 1-4 in table 3.6 Method i: Using 
General procedure 3.1, 490 mg (93%) of 3.43was obtained after 1 h. Method ii: Using General 
procedure 3.2, 428 mg (82%) of 3.43 was obtained after 1 h. Method iii: Using General 
procedure 3.3 400 mg (76%) of 3.43 was obtained after 18 h. Method iv: Using General 
procedure 3.4 412 mg (78%) of 3.43 was obtained after 4 h. The product was a white solid 1H 
NMR(CDCl3, 300 MHz) δ: 7.70 (d, 1H, J = 7.6 Hz), 7.69 (d, 1H, J = 7.5 Hz), 7.43-7.22 (m, 
21H), 5.21 (d, 1H, J = 8.8 Hz), 5.1 (s, 2H), 3.96 (br, 1H), 3.01 (m, 4H); 13C{1H} NMR (CDCl3, 
75 MHz) δ: 155.7, 146.9, 146.7, 143.3, 140.9, 140.6, 138.0, 136.7, 129.5, 129.3, 129.2, 128.57, 
128.39, 128.28, 128.23, 128.11, 127.3, 126.4, 125.6, 125.3, 125.2, 120.1, 120.0, 88.6, 66.5, 63.3, 
52.4, 38.2; HRMS (ESI+) m/z: [M + Na]+calcd for C36H31NO3Na








Boc-Thr(PhF)-OBn (3.45). Method i: Using General procedure 3.1, 306 mg (56%) of 3.45 was 
obtained after 1 h from 309 mg (1 mmol) of Boc-Thr-OBn (3.44). Method ii: To a solution of 
3.44 (309 mg, 1.00 mmol, 1 equiv) in acetonitrile (6 mL) PhFCl (470 mg, 1.7 mmol, 1.7 equiv) 
and NMM (131 µL, 1.20 mmol, 1.2 equiv) were added. The solution was cooled to 0 °C and then 
a solution of AgNO3 (289 mg, 1.7 mmol, 1.7 equiv) in acetonitrile (4 mL) was added. A white 
precipitate of AgCl formed immediately. The mixture was stirred for 16 h while slowly warming 
to ambient temperature. The reaction was filtered through a short plug of silica and eluted with 
ethyl acetate then concentrated to dryness. The residue was purified by flash chromatography 
using a gradient of 5% to 25% ethyl acetate in hexane to give 3.45 as a white solid (541 mg, 98% 
yield). 1H NMR(CDCl3, 300 MHz) δ: 7.67 (m, 2H), 7.41-7.21 (m, 14H), 7.09 (t, 1H, J = 7.4 Hz), 
6.97 (d, 1H, J = 7.4 Hz), 5.53 (d, 1H, J = 9.7 Hz), 5.22 (d, 1H, J = 12.3 Hz), 5.08 (d, 1H, J = 
12.3 Hz), 4.20 (d, 1H, J = 9.7 Hz), 4.05 (m, 1H), 1.49 (s, 9H), 0.72 (d, 3H, J = 6.1 Hz); 13C{1H} 
NMR (CDCl3, 75 MHz) δ: 171.1, 156.2, 148.6, 145.8, 143.8, 140.5, 140.2, 135.3, 129.3, 129.2, 
128.5, 128.4, 128.3, 128.15, 128.13, 128.12, 128.0, 127.1, 126.3, 126.2, 125.5, 120.1, 120.0, 
88.0, 79.9, 71.0, 67.1, 59.7, 28.4, 19.5; HRMS (ESI+) m/z: [M + Na]+ calcd for C35H35NNaO5, 






Fmoc-Cys(PhF)-OMe (3.47). All reactions were purified by flash chromotography using 0 to 
40% ethyl acetate in hexane to give 3.47 as a white solid. Methods i to iv correspond to entries 1 
to 4 in Table 3.7 Method i: Using General procedure 3.1, 53 mg (15%) of 3.47 was obtained 
from 165 mg (0.6 mmol) of Fmoc-Cys-OMe (3.46). Method ii: PhFCl (165 mg, 0.6 mmol, 1.2 
equiv) was dissolved in acetonitrile (2.5 mL) and AgNO3 (102 mg, 0.6 mmol, 1.2 equiv) in 
acetonitrile (2.5 mL) was added at 0 °C. The mixture was stirred for 10 minutes then the white 
precipitate was filtered off and the filtrate was added to a solution of 3.46 (178 mg, 0.5 mmol, 1 
equiv) and NMM (66 µL, 0.6 mmol, 1.2 equiv) in acetonitrile (5 mL). The reaction was stirred at 
ambient temperature until complete by TLC (1 h). The mixture was filtered through a short silica 
plug and eluted with ethyl acetate then concentrated to dryness. flash chromotography yielded 
255 mg (86%) of 3.47. Method iii: Using General procedure 3.3, 286 mg (95%) of 3.47 was 
obtained after 1 h from 175 mg (0.5 mmol) of 3.46. Method iv: Using General procedure 3.4, 
236 mg, (80%) of 3.47 was obtained after 1 h from 175 mg (0.5 mmol) of 3.46. 1H NMR(CDCl3, 
300 MHz) δ: 7.77-7.67 (m, 4H), 7.59-7.21 (m, 17H), 5.17 (d, 1H, J = 8.1 Hz), 4.33-4.19 (m, 
4H), 3.61 (s, 3H), 2.29 (d, 2H, J = 5.1 Hz); 13C{1H} NMR (CDCl3, 75 MHz) δ: 170.9, 155.6, 
148.7, 144.0, 141.4, 141.2, 139.9, 139.7, 128.7, 128.49, 128.47, 128.44, 128.3, 127.8, 127.7, 
127.2, 126.95, 125.62, 125.56, 125.3, 125.201, 120.20, 120.14, 120.07, 67.2, 63.5, 52.6, 47.2, 
31.8; HRMS (ESI+) m/z: [M + Na]+ calcd for C38H31NO4NaS
+, 620.1866; found, 620.1867. 
 
N-(9-phenyl-9-fluorenyl)methanesulfonamide (3.50). Method i: Using General procedure 3.4, 
247 (74%) mg of 3.50 was obtained from 95 mg (1 mmol) of methanesulfonamide (3.48) as a 





acetate in hexane. Method ii: Using General procedure 3.1 no product was obtained. 1H 
NMR(CDCl3, 300 MHz) δ: 7.74 (d, 2H, J = 7.5 Hz), 7.49-7.26 (m, 11H), 5.38 (s, 1H), 2.46 (s, 
3H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 147.1, 142.3, 140.1, 129.5, 128.8, 128.4, 128.0, 125.9, 
125.8, 120.6, 71.5, 42.9; HRMS (ESI+) m/z: [M + Na]+ calcd for C20H17O2NNaS, 358.0872; 
found, 358.0882. 
 
N-(9-phenyl-9-fluorenyl)toluenesulfonamide (3.51). All reactions used 171 mg (1.00 mmol) of p-
toluene sulfonamide (3.49) as a substrate and were purified by flash chromotography using 5 to 
25% ethyl acetate in hexane. Method i: no product was obtained using General procedure 3.1. 
Method ii: Using General procedure 3.3, 346 mg (84%) of 3.51 was obtained after 16 h. Method 
iii: Using General procedure 3.4, 190 mg (55%) of 3.51 was obtained after 16 h. 1H 
NMR(CDCl3, 300 MHz) δ: 7.40 (d, 2H, J = 7.6 Hz), 7.25-7.08 (m, 9H), 6.96 (m, 4H), 6.76 (d, 
2H, 8.0 Hz), 5.9 (br, 1H), 2.19 (s, 3H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 146.2, 142.8, 142.5, 
140.1, 137.7, 128.8, 128.7, 128.6, 127.9, 127.7, 127.1, 126.0, 125.7, 119.8, 71.3, 21.5; HRMS 
(ESI+) m/z: [M + NH4]
+ calcd for C26H25N2O2S, 429.1631; found, 429.1636.  
 
N-(9-phenyl-9-fluorenyl)acetamide (3.54). All reactions used 59 mg (1.00 mmol) of acetamide 
(3.52) as a substrate. Method i: No product was observed using general procedures 1 or 4. 
Method ii: Using General procedure 3.3, 139 mg (45%) of 3.54 was obtained as a white solid 
after 16 h reaction time and flash chromotography using 0 to 50% ethyl acetate in hexane. 1H 





7.31 Hz), 7.27 (m, 7H), 6.42 (s, 1H), 1.90 (s, 3H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 169.8, 
148.9, 141.4, 139.9, 128.8, 128.5, 128.3, 127.2, 125.8, 125.2, 120.0, 70.0, 23.9; HRMS-(ESI+) 
m/z: [M + Na]+ calcd for C21H17ONNa, 322.1202; found, 322.1209. 
 
3-Chloro-N-(9-phenyl-9-fluorenyl)propanamide (3.55). All reactions used 107 mg (1.00 mmol) 
of 3-chloropropanamide (3.53) as a substrate. Method i: No product was observed using general 
procedures 1 or 4. Method ii: Using General procedure 3.3, 151 mg (44%) of 3.55 was obtained 
as a white powder after 16 h reaction time and flash chromotography using 0 to 50% ethyl 
acetate in hexane. 1H NMR(DMSO-d6, 300 MHz) δ: 8.87 (s, 1H), 7.84 (d, 2H, J = 7.5 Hz), 7.58 
(d, 2H, J = 7.5 Hz), 7.39 (t, 2H, J = 7.5 Hz), 7.3-7.15 (m, 7H), 3.75 (t, 2H, J = 6.1 Hz), 2.71 (t, 
2H, J = 6.2 Hz); 13C{1H} NMR (DMSO-d6, 75 MHz) δ: 169.1, 148.9, 142.5, 139.3, 128.3, 
128.1, 127.8, 126.7, 125.6, 125.0, 120.0, 69.3, 41.0, 38.2; HRMS (ESI+) m/z: [M + K]+ calcd for 
C22H18ONClK, 386.0709; found, 386.0723. 
 
O1-(9-phenylfluoren-9-yl)phenylalanol (3.57). Method i: Compound 3.56 (162 mg, 0.600 mmol, 
1.2 equiv) was dissolved in minimal acetonitrile (8 mL) with gentle heating then cooled to 0 °C. 
PhFCl (138 mg, 0.500 mmol, 1 equiv) was added followed by a solution of AgNO3 (85 mg, 0.50 
mmol, 1 equiv) in acetonitrile (2 mL). The reaction warmed to room temperature and stirred for 





chromatography using ethyl acetate and silica gel which was previously equilibrated with 2% 
NH4OH in ethyl acetate. Compound 3.57 was obtained as a white amorphous solid (156 mg, 
80% yield). Method ii: Compound 3.56 (387 mg, 1.20 mmol, 1.2 equiv) was dissolved in 
acetonitrile (15 mL) with gentle heating. PhFOH (256 mg, 1.00 mmol, 1 equiv) was added 
followed by BF3•OEt2 (122 µL, 1.00 mmol, 1 equiv). The resulting solution was stirred for 18 h 
at room temperature. The mixture was diluted with ethyl acetate (30 mL) and washed with 5% 
Na2CO3 (30 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated 
to dryness. The residue was purified by flash chromatography which gave 3.57 as a white 
amorphous solid (269 mg, 69% yield). 1H NMR(CDCl3, 300 MHz) δ: 7.67 (d, 2H, J = 6.9 Hz), 
7.4-7.1 (m, 16H), 3.15 (br, 1H), 2.95 (m, 2H), 2.82 (m, 1H), 2.45 (m, 1H), 1.40 (s, 2H); 13C{1H} 
NMR (CDCl3, 75 MHz) δ: 147.2, 147.1. 143.6, 140.8, 140.7, 139.2, 129.3, 129.1, 128.42, 
128.31, 128.25, 128.19, 127.23, 126.2, 125.6, 125.43, 125.36, 120.04, 120.02, 88.5, 67.7, 52.9, 
40.8 HRMS (ESI+) m/z: [M + H]
+ calcd for C28H26NO, 392.2009; found, 392.2013.  
 
N,O1-bis(9-phenyl-9-fluorenyl)phenylalanol (3.58). To a solution of 3.56 (387 mg, 1.20 mmol, 
1.0 equiv) in acetonitrile (16 mL) PhFCl (276 mg, 1.00 mmol, 0.833 equiv) and NMM (316 µL, 
2.88 mmol, 2.4 equiv) were added then cooled to -20 °C. AgNO3 (170 mg, 1.00 mmol, 0.833 
equiv) was added as a solution in acetonitrile (4 mL) and the reaction was stirred for 4 h. The 
mixture was filtered through a short plug of silica and eluted with ethyl acetate then concentrated 
to dryness. The residue was purified by flash chromatography, using a gradient of 0% to 30% 
ethyl acetate in hexane, to give 3.58 as a white solid (168 mg, 53% yield). 1H NMR(CDCl3, 300 





6.71 (m, 3H), 2.86 (dd, 1H, J = 13.0, 8.6 Hz), 2.49 (m, 4H), 2.10 (m, 1H); 13C{1H} NMR 
(CDCl3, 75 MHz) δ: 150.4, 149.9, 147.6, 147.1, 145.5, 143.8, 140.9, 140.6, 140.4, 140.3, 139.9, 
129.5, 129.0, 128.9, 128.3, 128.21, 128.18, 128.08, 128.06, 127.9, 127.7, 127.6, 127.2, 127.0, 
126.2, 125.8, 125.7, 125.6, 125.5, 125.2, 125.1, 119.9, 119.7, 119.6, 88.3, 73.0, 65.1, 54.7, 40.9; 
HRMS (ESI+) m/z: [M + H]+ calcd for C47H38NO, 632.2959; found, 632.2940. 109 mg (28%) of 
compound 3.57 was also obtained from this reaction.  
 
N-(9-phenyl-9-fluorenyl)phenylalanol (3.59). To a solution of Cbz-protected phenylalanol (285 
mg, 1.00 mmol, 1 equiv) in MeOH (10 mL) 10 wt. % Pd/C (30 mg) was added. The mixture was 
stirred until complete by TLC (1 h) then filtered through a pad of Celite and concentrated to 
dryness. The residue was dissolved in acetonitrile (3 mL). BSA (414 µL, 1.70 mmol, 1.7 equiv) 
was added and the mixture was heated to reflux for 30 min. The solution was cooled to 0 °C and 
diluted with acetonitrile (4 mL). PhFCl (331 mg, 1.20 mmol, 1.2 equiv) and NMM (131 µL, 1.20 
mmol, 1.2 equiv) were added followed by a solution of AgNO3 (204 mg, 1.20 mmol, 1.2 equiv) 
in acetonitrile (4 mL). The reaction was stirred at room temperature until complete as determined 
by a negative ninhydrin test (20 min). The reaction was filtered through a short plug of silica and 
eluted with ethyl acetate and then concentrated to approximately 10 mL. Tetrabutylammonium 
fluoride (1.20 mL, 1 M in THF, 1.2 equiv) was added and the reaction stirred until the TMS 
group was completely removed by TLC (10 min). The reaction was diluted with ethyl acetate (10 
mL) then washed with 5% sodium carbonate, (2 x 20 mL), and aq. hydrochloride acid (0.1 M, 20 
mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated. The 





hexane, to give 3.59 as a white foam (303 mg, 77% yield). 1H NMR(CDCl3, 300 MHz) δ: 7.64 
(d, 1H, J = 7.6 Hz), 7.58 (d, 1H, J = 7.5 Hz), 7.26 (m, 5H), 7.10 (m, 8H), 6.74 (m, 2H), 6.66 (d, 
2H, J = 7.6 Hz), 2.99 (dd, 1H, J = 10.7, 2.9 Hz), 2.68 (dd, 1H, J = 3.7, 10.7 Hz), 2.56 (m, 2H), 
2.48-2.18 (m, 3H); 13C{1H} NMR (CDCl3, 75 MHz) δ: 149.7, 149.5, 145.0, 141.0, 139.9, 138.8, 
129.4, 128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.3, 126.3, 125.9, 125.2, 125.1, 120.1, 119.8, 
72.8, 63.2, 55.7, 40.3; HRMS (ESI+) m/z: [M + H]+ calcd for C28H26NO, 392.2020; found, 
392.2009. 
 
Cbz-Ser(OPhF)OH (3.60). Method i: Cbz-Ser-OH (239 mg, 1.00 mmol, 1 equiv) and PhFCl 
(230 mg, 0.833 mmol, 0.833 equiv) were dissolved in acetonitrile (6 mL) and cooled to 0 °C. A 
solution of AgNO3 (141 mg, 0.833 mmol, 0.833 equiv) in acetonitrile (4 mL) was added. The 
reaction was stirred at room temperature for 1 h, and then filtered through a short plug of silica 
and eluted with ethyl acetate and concentrated. The residue was purified by flash 
chromatography, using dichloromethane then 1% acetic acid, 30% ethyl acetate, 69% 
dichloromethane, which gave 3.60 as a white foam (308 mg, 77% yield). Method ii: Cbz-Ser-
OH (287 mg, 1.20 mmol, 1.2 equiv) was dissolved in acetonitrile (10 mL). PhFOH (256 mg, 
1.00 mmol, 1 equiv) was added followed by BF3•OEt2 (122 µL, 1.00 mmol, 1 equiv). The 
resulting solution was stirred overnight at room temperature. The reaction was concentrated in 
the presence of silica and purified by flash chromatography which gave 3.60 as a white foam 
(271 mg, 57% yield). 1H NMR(CDCl3, 300 MHz) δ: 9.89 (br, 1H), 7.71 (m, 2H), 7.40-7.18 (m, 





(m, 2H), 4.48 (major rotamer, d, 0.8H, J = 8.6 Hz), 4.43 (minor rotamer, br, 0.2H), 3.53 (dd, 1H, 
J = 2.3, 8.9 Hz), 3.32 (dd, 1H, J =3.0, 9.4 Hz); 13C{1H} NMR (CDCl3, 75 MHz) δ: 175.8, 156.1, 
146.1, 142.7, 141.0, 140.6, 136.2, 129.53, 129.47, 128.6, 128.52, 128.47, 128.3, 128.3, 128.2, 
127.4, 125.5, 125.4, 125.3, 120.2, 120.1, 88.8, 67.3, 63.5, 54.4; HRMS (ESI+) m/z: [M + Na]+ 
calcd for C30H25O5NNa, 502.1636; found, 502.1612.  
 
Cbz-Ser-OPhF (3.61) and Cbz-Ser(PhF)-OPhF (3.62). Cbz-Ser-OH (287 mg, 1.20 mmol, 1.0 
equiv) NMM (131 µL,1.20 mmol, 1.0 equiv) and PhFCl (276 mg, 1.0 mmol, 0.833 equiv) were 
dissolved in acetonitrile (6 mL) and cooled to 0 °C. A solution of AgNO3 (170 mg, 1.00 mmol, 
0.833 equiv) in acetonitrile (4 mL) was added. The reaction was stirred for 2 h then filtered 
through a plug of silica and eluted with ethyl acetate then evaporated to dryness. The residue was 
subjected to flash chromatography, using a gradient of 0% to 100% ethyl acetate in hexane 
which separated 3.60, 3.61, and 3.62.  
 3.60 was obtained as a white solid (29 mg, 6 % yield). 
 3.61 was obtained as a white amorphous solid (225 mg, 47% yield). 1H NMR(CDCl3, 300 
MHz) δ: 7.71 (d, 2H, J = 7.5 Hz), 7.32 (m, 16H), 5.68 (d, 1H, J =7.3 Hz), 5.09 (s, 2H), 4.52 (m, 
1H), 4.04 (d, 1H, J = 9.2 Hz), 3.92 (d, 1H, J = 9.8 Hz), 2.42 (br, 1H); 13C{1H} NMR (CDCl3, 75 
MHz) δ: 168.2, 156.3, 146.1, 146.0, 140.8, 140.5, 140.4, 136.1, 129.4, 128.6, 128.5, 128.4, 
128.2, 128.1, 127.9, 125.1, 124.7, 124.6, 120.2, 120.2, 90.1, 67.1, 63.4, 56.6; HRMS (ESI+) m/z: 
[M + NH4]





 3.62 was obtained as a free flowing white solid (99 mg, 28% yield). 1H NMR(CDCl3, 300 
MHz) δ: 7.74 (d, 2H, J = 7.7 Hz), 7.68 (d, 2H, J = 7.5 Hz), 7.40-7.15 (m, 26H), 6.97 (d, 1H, J = 
7.4 Hz), 5.64 (major rotamer, d, 0.9H, J = 8.6 Hz), 5.46 (minor rotamer, d, 0.1H, J = 7.0 Hz), 
5.06 (m, 2H), 4.46 (major rotamer, d, 0.9H, J = 8.6 Hz), 4.26 (minor rotamer, d, 0.1H, J = 6.4 
Hz), 3.70 (major rotamer, d, 0.9H, J = 8.1 Hz), 3.62 (minor rotamer, d, 0.1H, J = 9.5 Hz), 3.20 
(d, 1H, J = 9.0 Hz); 13C{1H} NMR (CDCl3, 75 MHz) δ: 168.0, 155.7, 146.29, 146.26, 146.2, 
146.1, 142.5, 140.9, 140.8, 140.7, 140.5, 140.3, 136.3, 129.5, 129.4, 129.3, 128.53, 128.49, 
128.33, 128.27, 128.1, 128.1, 128.0, 127.7, 127.2, 125.6, 125.4, 125.1, 125.1, 120.1, 120.1, 
120.0, 90.1, 88.6, 66.9, 63.8, 54.8; HRMS (ESI+) m/z: [M + K]+ calcd for C49H37O5NK
+, 
758.2314; found, 758.2290. 
 
Phenylfluorenation of 1,3-butanediol (3.63, 3.64 and 3.65). Method i: PhFCl (276 mg, 1.00 
mmol, 1 equiv) was dissolved in acetonitrile (6 mL) and cooled to 0 °C. NMM (110 µL, 1.00 
mmol, 1 equiv) and 1,3-butane diol (107 µL, 1.20 mmol, 1.2 equiv) were added, followed by a 
solution of AgNO3 (170 mg, 1.00 mmol, 1 equiv) in acetonitrile (4 mL). A white precipitate 
formed immediately. The cooling bath was removed and the reaction was stirred for 1 h at rt. 
The mixture was then filtered through a short plug of silica and eluted with dichloromethane. 
The mixture was subjected to flash chromatography using a gradient of 0 to 25% ethyl acetate in 
hexane.  
 3.63 (Rf = 0.15 in 10% ethyl acetate/90% hexane) was obtained as a colorless oil (179 





1H), 3.16–3.01 (m, 2H), 2.95 (s, 1H), 1.65-1.42 (m, 2H), 1.04 (d, 3H, J = 6.1 Hz); 13C{1H} 
NMR (CDCl3, 75 MHz) δ: 147.0, 146.9, 143.2, 140.9, 140.7, 129.23, 129.21, 128.39, 128.30, 
128.28, 127.3, 125.5, 125.3, 125.2, 120.1, 120.0, 89.0, 67.5, 62.2, 38.4, 23.2 HRMS (ESI+) m/z: 
[M + Na]+ calcd for C23H22O2Na, 353.1512; found, 353.1533.  
 3.64 (Rf = 0.1, 10% ethyl acetate/90% hexane) was obtained as a colorless oil (30 mg, 
9%). 1H NMR(CDCl3, 300 MHz) δ: 7.61 (m, 2H), 7.35-7.10 (m, 11H), 3.74 (m, 1H), 3.53 (m, 
1H), 3.37 (sextet, 1H, J = 5.9 Hz), 2.22 (br, 1H), 1.52 (m, 2H), 0.89 (d, 3H, J = 6.3 Hz); 13C{1H} 
NMR (CDCl3, 75 MHz) δ: 148.3, 147.4, 143.9, 141.3, 140.4, 129.4, 129.1, 128.3, 128.2, 128.1, 
127.3, 126.4, 126.12, 125.6, 120.2, 120.1, 88.7, 69.8, 60.1, 39.8, 21.9 HRMS (ESI+) m/z: [M + 
Na]+ calcd for C23H22O2Na, 353.1512; found, 353.1515.  
 3.65 (Rf = 0.6, 10% ethyl acetate/90% hexane) was obtained as a white solid (66 mg, 
23%). 1H NMR(CDCl3, 300 MHz) δ: 7.57 (m, 4H), 7.3-6.9 (m, 22H), 3.22 (sextet, 1H, J = 6.2 
Hz), 2.85 (dd, 2H, J = 5.8, 7.3 Hz), 1.67 (m, 1H), 1.37 (m, 1H), 0.60 (d, 3H, J = 6.2 Hz); 
13C{1H} NMR (CDCl3, 75 MHz) δ:148.5, 147.8, 147.66, 147.6, 144.2, 143.6, 140.75, 140.73, 
140.70, 128.91, 128.87, 128.78, 128.13 128.05, 128.02, 127.95, 127.85, 126.93, 126.90, 126.3, 
126.0, 125.7, 125.6, 125.3, 125.2, 119.9, 119.8, 88.38, 88.36, 68.1, 60.6, 38.7, 21.7; HRMS 
(ESI+) m/z: [M + Na]+ calcd for C42H34O2Na, 593.2451; found, 593.2458.  
 Method ii: 1,3-butane diol (129 µL, 1.44 mmol, 1.2 equiv) was dissolved in acetonitrile 
(10 mL) and cooled to 0 °C. PhFOH (309 mg, 1.20 mmol, 1 equiv) and K3PO4 (256 mg, 1.20 
mmol, 1 equiv) were added followed by BF3•OEt2 (142 µL, 1.20 mmol, 1 equiv). The resulting 
suspension was stirred for 18 h at room temperature. The reaction was concentrated in the 





mg, 2% yield), 3.63 was obtained as a colorless oil (104 mg, 26% yield). 3.65 was obtained as a 
white solid (15 mg, 4% yield).  
 
Phenylfluorenation of thymidine (3.66, 3.67, 3.68). Thymidine (290 mg, 1.20 mmol, 1.2 equiv) 
was dissolved in DMF (6 mL) and cooled to 0 °C. PhFCl (276 mg, 1.00 mmol, 1 equiv), NMM 
(110 µL, 1.00 mmol, 1 equiv) and acetonitrile (6 mL) were added. A solution of AgNO3 in 
acetonitrile (4 mL) was added dropwise and the reaction stirred at ambient temperature. After 4 h 
a white precipitate of AgCl was filtered off and the reaction was concentrated to dryness. The 
residue was subjected to flash chromatography using a gradient of 10 to 80% ethyl acetate in 
hexane.  
 3.66 (Rf = 0.2, 50% ethyl acetate/50% hexane) was obtained as a white solid (281 mg, 
58% yield). 1H NMR(CDCl3, 500 MHz) δ: 7.85 (s, 1H), 7.75 (d, 1H, J = 7.4 Hz), 7.70 (d, 1H, J 
= 7.4 Hz), 7.45 (t, 1H, J = 7.2 Hz), 7.35–7.20 (m, 10H), 6.49 (t, 1H, J = 6.4 Hz), 4.61 (s, 1H), 
4.00 (s, 1H), 3.36 (d, 1H, J = 8.7), 3.18 (d, 1H, J = 9.0 Hz), 2.47 (m, 2H), 1.48 (s, 3H); 13C{1H} 
NMR (CDCl3, 125 MHz) δ: 164.4, 151.0, 146.4, 145.8, 143.0, 141.2, 140.3, 136.2, 129.7, 129.4, 
128.6, 128.5, 128.4, 127.7, 125.5, 125.4, 124.8, 120.3, 111.3, 89.2, 86.5, 85.1, 72.9, 63.6, 41.2, 
11.8; HRMS (ESI+) m/z: [M + Na]+ calcd for C29H26N2NaO5, 505.1734; found, 505.1728.  
 3.67 (Rf = 0.25, 50% ethyl acetate/50% hexane) was obtained as a white solid (38 mg, 
8% yield). 1H NMR(CDCl3, 300 MHz) δ: 8.58 (s, 1H), 7.68 (m, 2H), 7.4-7.24 (m, 12H), 7.08 (s, 





3.04 (d, 1H, J = 11.4 Hz), 2.16 (ddd, 1H, J = 13.6, 6.0, 2.9 Hz), 1.77 (s, 3H); 13C{1H} NMR 
(CDCl3, 125 MHz) δ: 163.5, 150.2, 147.1, 147.0, 142.4, 141.0, 140.6, 136.4, 129.7, 129.6, 128.5, 
128.3, 128.2, 127.0, 125.9, 125.7, 125.6, 120.3, 120.2, 111.0, 89.0, 86.3, 86.2, 73.0, 61.8, 39.3, 
12.4; (HRMS (ESI+) m/z: [M + Na]+ calcd for C29H26N2NaO5, 505.1734; found, 505.1737.  
 3.68 (Rf = 0.6, 50% ethyl acetate/50% hexane) was obtained as a white solid (66 mg, 
19%). 1H NMR(CDCl3, 500 MHz) δ: 8.66 (s, 1H), 7.78 (d, 1H, J = 7.6 Hz), 7.70 (d, 1H, J = 7.6 
Hz), 7.67 (d, 1H, J = 7.6 Hz), 7.59 (d, 1H, J = 7.5 Hz), 7.56 (s, 1H), 4.79 (m, 1H), 7.42 (m, 2H), 
7.36-7.05 (m, 21H), 6.95 (d, 1H, J = 7.6 Hz), 6.40 (dd, 1H, J = 5.9, 8.3 Hz), 4.03 (d, 1H, J = 1.9 
Hz), 3.89 (d, 1H, J = 6.2 Hz), 3.00 (dd, 1H, J = 10.3, 1.8 Hz), 2.39 (dd, 1H, J = 10.3, 2.0 Hz), 
2.34 (dd, 1H, J = 13.6, 5.7 Hz), 1.87 (m, 1H), 1.38 (s, 3H); 
13C{1H} NMR (CDCl3, 125 MHz) δ: 
163.7, 150.3, 147.1, 146.9, 146.1, 145.7, 143.0, 142.5, 141.1, 140.6, 140.5, 134.0, 135.8, 129.54, 
129.51, 129.3, 129.0, 128.6, 128.5, 128.4, 128.3, 128.23, 128.18, 127.6, 127.0 126.0, 125.6, 
125.3, 124.5, 120.2, 120.12, 120.10, 111.1, 89.1, 88.8, 85.8, 84.9, 74.4, 62.9, 40.4, 11.5; HRMS 
(ESI+) m/z: [M + Na]+ calcd for C48H38N2NaO5, 745.2673; found, 745.2642. 
 
FmocCys(PhF)OH (3.69). FmocCysOH (230 mg, 0.671 mmol, 1.2 equiv) was dissolved in 
acetonitrile (10 mL) and PhFOH (142 mg, 0.554 mmol, 1 equiv) was added. The solution was 
cooled to 0 °C and BF3•OEt2 (68 µL, 0.56 mmol, 1 equiv) was added dropwise. The resulting 
solution was stirred at 0 °C until complete by TLC (1 h). The mixture was diluted with ethyl 
acetate (30 mL) then washed twice with 10% citric acid (20 mL). The organic layer was dried 
over magnesium sulfate, filtered, and concentrated to dryness. The residue was purified by flash 





Compound 3.69 was obtained as a white solid (358 mg, 92% yield). 1H NMR(CDCl3, 300 MHz) 
δ: 7.76 (d, 2H, J = 7.2 Hz), 7.67 (m, 2H), 7.59 (d, 2H, J = 6.9 Hz), 7.5-7.1 (m, 15H), 5.08 (d, 
1H, J = 7.6 Hz), 4.32 (m, 2H), 4.19 (m, 1H), 4.07 (m, 1H), 2.33 (m, 2H); 13C{1H} NMR (CDCl3, 
75 MHz) δ: 175.1, 155.8, 148.6, 148.4, 143.8, 143.6, 141.2, 141.0, 139.7, 139.6, 128.6, 128.4, 
128.3, 127.7, 127.6, 127.1, 126.8, 125.6, 125.4, 125.2, 125.1, 120.1, 112.0, 67.2, 63.5, 52.7, 47.0, 
31.4; HRMS (ESI+) m/z: [M + NH4]
+ calcd for C37H33N2O4, 601.2156; found, 601.2166. 
 
AcCys(PhF)OEt (3.70). HCl·H-Cys-OEt (222 mg, 1.20 mmol, 1.2 equiv) was suspended in 
acetonitrile (25 mL) and PhFOH (256 mg, 1.00 mmol, 1 equiv) was added followed by BF3•OEt2 
(126 µL, 1.00 mmol, 1 equiv). The suspension immediately became clear and new precipitates 
formed after stirring for 24 h. After 24 h the reaction was quenched with methanol (1 mL), 
filtered, and concentrated. The residue was dissolved in 30 mL ethyl acetate (30 mL) and washed 
three times with 10% Na2CO3 (15 mL). The organic layer was dried over magnesium sulfate, 
filtered, and concentrated to dryness. The crude material was subjected to Ac2O:pyridine:DCM 
(1:1:8, 10 mL) for 1 h. The mixture was diluted with dichloromethane (50 mL) and washed with 
10% Na2CO3 (20 mL) and 10% citric acid (2 x 20 mL). The organic layer was dried over 
magnesium sulfate, filtered, and concentrated to dryness. The residue was purified by flash 
chromatography using a gradient of 0% to 40% ethyl acetate in hexane. Compound 3.70 was 
obtained as a white solid (329 mg, 76% yield). 1H NMR(CDCl3, 300 MHz) δ: 7.70 (d, 2H, J = 
7.5 Hz), 7.5-7.2 (m, 11H), 5.78 (d, 1H, J = 7.7 Hz), 4.44 (dt, 1H, J = 7.9, 4.9 Hz), 4.08 (m, 2H), 





Hz);13C{1H} NMR (CDCl3, 75 MHz) δ:170.3, 169.5, 148.6, 148.5, 141.0, 139.6, 139.5, 128.43, 
128.32, 128.25, 128.2. 128.1, 127.5, 126.7, 125.4, 125.3, 120.1, 112.0, 77.6, 77.1, 76.7, 63.2, 
61.5, 51.0, 31.6, 22.8, 13.9; HRMS (ESI+) m/z: [M + Na]+ calcd for C26H25N2O3Na
+,454.1447; 
found, 454.1451. 
Procedures for the deprotection of PhF groups 
Deprotection of PhF ester 3.61. To a solution of 3.61 (50 mg, 0.11 mmol) in dichloromethane (5 
mL) triisopropylsilane (50 µL), and trifluoroacetic acid (50 µL) were added. The mixture was 
stirred until complete by TLC (5 min). The reaction was then diluted with hexane (15 mL) and 
extracted with aq. NaOH (0.1 N, 10 mL). The combined aqueous layers were acidified with 
hydrochloride acid (1 N, 5 mL), saturated with sodium chloride, then extracted with 
dichloromethane (3 x 10 mL). The combined dichloromethane layers were dried over 
magnesium sulfate, filtered, then concentrated which gave Cbz-Ser-OH as a white solid (20.6 
mg, 86% yield) whose 1H NMRspectrum was identical to an authentic commercial sample. 
Deprotection of PhF ether 3.43. To a solution of 3.43 (100 mg, 0.190 mmol) in dichloromethane, 
10 mL. triisopropylsilane (100 µL) and trifluoroacetic acid (100 µL) were added. A red color 
appeared briefly and disappeared after a few seconds. The colorless solution was stirred for five 
min until complete by TLC then the mixture was applied directly to a silica gel column and 
eluted with a gradient of dichloromethane to ethyl acetate to yield Cbz-phenylalanol (3.42, 50 
mg, 93% yield).  
Deprotection of PhF sulfonamide 3.51. Compound 3.51 (120 mg, 0.292 mmol) was dissolved in 
dichloromethane (9 mL) and triisopropylsilane (100 µL), and trifluoroacetic acid (1 mL) were 
added. The reaction was stirred until complete by TLC (15 min) and then concentrated to dryness 





100% hexane to 100% ethyl acetate, which gave p-toluenesulfonamide (3.49) as a white solid 
(49 mg, 98% yield).  
Deprotection of PhF sulfide 3.47. Compound 3.47 (100 mg, 0.167 mmol) was dissolved in DCM 
(5 mL) then 50 µL each of triisopropylsilane and ethanedithiol were added followed by 500 µL 
of TFA. The reaction was stirred for 30 minutes until complete at ambient temperature. The 
mixture was diluted with DCM (30 mL) and washed with monosodium citrate (0.5 M, 30 mL) 
then dried over magnesium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography to yield Fmoc-Cys-Ome (3.46) as a white solid (58 mg, 97%).  
Deprotection of PhF amide 3.55. Compound 3.55 (10 mg, 0.029 mmol) was dissolved in a 
mixture of trifluoroacetic acid, triisopropylsilane and water (95:2.5:2.5) (1 mL) and stirred at 
room temperature. The reaction was followed by TLC (UV, 20% ethyl acetate in hexane) until 
the starting material has been completely consumed (10 min). The product was not isolated. 
Deprotection of PhF amine 3.34. Compound 3.34 (10 mg, 0.042 mmol) was dissolved in a 
mixture of trifluoroacetic acid, triisopropylsilane and water (95:2.5:2.5, 1 mL) and stirred at 
room temperature. The reaction was followed by TLC (UV, 20% ethyl acetate in hexane) until 
the starting material has been completely consumed (30 min). The product was not isolated.  
Deprotection of PhF ether 3.45. Compound 3.45 (100 mg, 0.182 mmol) was dissolved in DCM 
(10 mL) then triisopropylsilane (100 µL) and trifluoroacetic acid (100 µL), were added. The 
reaction was stirred at ambient temperature until complete by TLC (15 min) then concentrated in 
the presence of silica. The product was isolated by flash chromatography using gradient elution 
10% to 60% ethyl acetate in hexane to yield Boc-Thr-OBn (29 mg, 98%).  
Partial deprotection of PhF ether 3.58. Compound 3.58 (50 mg, 0.079 mmol) was dissolved in 





reaction was stirred at ambient temperature until complete by TLC (1 h) then concentrated in the 
presence of silica. The residue was subjected to flash chromatography, using a gradient of 0% to 










Chapter 4 — Synthesis of peptidomimetic substrates and inhibitors of 
IgA1 protease. 
4.1 — Introduction. 
 This chapter concerns the synthesis of a series of potential inhibitors and substrates of the 
IgA1 protease produced by Haemophilus influenzae (H. influenzae). These studies could result in 
the development of antivirulence factors for the treatment of bacterial infections. Before these 
potential inhibitors and substrates can be introduced, a discussion of virulence factors and 
antivirulence therapy is warranted, beginning with the need for antivirulence therapy which is 
brought on by the growing threat of antibiotic resistance. 
4.1.1 — Antibiotics and antibiotic resistance. 
 Among the first antibiotics deployed were the sulfa drugs during the 1930’s, but the most 
well-known antibiotic is, without a doubt, penicillin, for which Alexander Fleming received one 
third of a Nobel prize in 1945. During his Nobel lecture, Fleming warned of the threat of 
widespread resistance to antibiotics that would result from the overuse, and the misuse of 
antibiotics.161,162 
 It would appear that history is slowly bearing out Fleming’s fear: in 2010, the World 
Health Organization (WHO) declared antibiotic resistance one of the three greatest threats to 
human health and the Infectious Disease Society of America called for the development of 10 





approved in the 21st century, resistance quickly follows. Table 4.1 shows the year in which major 
antibiotics were first deployed on a large scale alongside the date at which resistance to said 
antibiotic was observed clinically.1,164-170 Resistance has been observed to every major class of 
antibiotics deployed in the clinic so far. 
Table 4.1. Emergence of antibiotic resistance over time. 
Antibiotic Year Deployed Clinical resistance observed 
Sulfonamides 1930s 1940s 
Penicillins 1943 1946 
Streptomycin 1943 1959 
Chloramphenicol 1947 1959 
Tetracycline 1948 1953 
Erythromycin 1952 1988 
Vancomycin 1956 1988 
Methicillin 1960 1961 
Ampicillin 1961 1973 
Quinolones 1967 1969 
Cephalosporins 1960s 1960s 
Linezolid (oxazolidinones) 2000 2001 
Daptomycin (lipodepsipeptides) 2003 2005 
Retapamulin (pleuromutilins) 2007 2014 
Fidaxomicin (Tiacumicins) 2011 2019 
Bedaquiline (Diarylquinolines) 2012 2014 
 
 The selective pressure imposed by antibiotics is easily understood as the classical targets 
for antibiotics are inhibition of the synthesis of DNA, RNA, proteins, folate, or the cell wall, and 
depolarization of the membrane.1 All of these are necessary for the viability of bacteria in vitro; 
therefore, any resistant mutants which neutralize or otherwise avoid these antibiotics will have an 
enormous fitness advantage whenever the antibiotic is present. Even if a significant tradeoff 
exists in which the resistant mutants have reduced fitness in some other area, non-resistant 






 Research into novel classes of antibiotics has been declining among large pharmaceutical 
companies.171  The reason for this sluggish and limited development may be economic rather 
than scientific. The cost of bringing new drugs to market is extraordinary, and for antibiotics the 
potential return on investment is low. Antibiotics are generally administered over a short period 
of time meaning that only a small number of doses are needed. Furthermore, good stewardship of 
our antibiotic arsenal dictates that new drugs be held in reserve and used only when existing 
drugs have failed. Therefore, for any new class, particularly in the first few years, total sales will 
be low. This issue, combined with the short time-period between deployment and resistance, 
leads to a low return on investment for antibiotics. 
 Unfortunately, even with the most diligent antibiotic stewardship, resistance cannot be 
completely avoided because it exists at low levels in the general population of bacteria.164 We 
should expect that antibiotic resistance would predate modern antibiotics in light of the fact that 
most antibiotics, particularly early examples, are either natural products or derivatives thereof. 
Antibiotics have been produced by organisms for their own defense for millions of years and 
antibiotic resistance should evolve concurrently.173 
 Toxicity is also a concern with most antibiotics. For example, high toxicity has prevented 
the A54145 family of lipodepsipeptides from seeing clinical use.174  Unfortunately, toxicity may 
be unavoidable given the importance of the human microbiome, which is also vulnerable to 
antibiotics. 
 It is clear that greater efforts should be made toward the continued development of new 
drugs to combat the threat of antibiotic resistance. However, given that resistance appears to be 
an inevitable consequence of antibiotic use, and that antibiotics are, by their nature, prone to 





4.1.2 — Virulence factors and antivirulence therapy. 
 Due to the toxicity of certain antibiotics, the rapid appearance of resistance, and the need 
to constantly produce novel drugs, alternative approaches are attractive. One such approach is 
antivirulence therapy. Before this can be introduced, a brief discussion of virulence factors is 
warranted. Virulence is a measure of the severity or harmfulness of a disease. Virulence factors 
can be defined as bacterial products which are not necessary for viability in vitro and not 
necessarily beneficial to the bacterium in vitro or in vivo, but which cause disease either by 
preventing an immune response or damaging host tissues.175,176  Virulence factors are usually not 
produced by bacteria unless they have infected the host, this is the result of tight gene regulation 
and reflects the high metabolic cost of virulence.177  
 Virulence factors include adhesins which allow bacteria to adhere to specific surfaces and 
form biofilms, toxins which may cause cell death in host cells or the microbiome, effectors 
which mimic host proteins, siderophores which sequester iron from the blood, any mechanism 
that allows for immune system evasion, specialized secretory systems which allow delivery of 
effector molecules directly to eukaryotic cells, and quorum sensing systems which lead to the 
activation of virulent genes.1,177  Critically none of these are necessary for the viability of the 
bacterium in vitro which is in sharp contrast to the targets of antibiotics. 
 An ideal antivirulence therapy would be one which deactivates one of the aforementioned 
factors, but which has no effect on the viability or growth rate of bacterium in vivo. In other 
words, the therapy is neither bactericidal nor bacteriostatic. In specific cases, virulence therapy 
would not induce resistance (vide infra). Potential other benefits are reduced toxicity to the host 
and to the microbiome, the harmlessness of inappropriate or prophylactic use, low transfer of 





 The mechanism by which antivirulence therapies could avoid resistance is critical and 
warrants careful consideration because this is not equally true for all virulence factors. In a 2014 
review, Allen et al. divide virulence factors into 3 categories: (1) those which are not beneficial; 
(2) those which are beneficial to the bacterial community as a whole and; (3) those which are 
beneficial to the individual bacterium.178 
 The first category, virulence factors which confer no benefit to pathogens, uselessly 
consume energy and should be selected against over time.179 
 An example of the second class is a toxin (Figure 4.1a). Clostridium difficile releases 
toxins which damage the host or microbiome cells. This leads to diarrhea which helps to spread 
the disease which benefits the bacterial community. The condition can be treated with 
Bezlotoxumab, which is a monoclonal antibody that binds to one of these toxins and prevents 
damage to the epithelial cells and colitis.180 We shall assume that some small fraction of bacteria 
in the infection are resistant, which in this case means that they produce a mutant version of the 
toxin which is not neutralized by Bezlotoxumab. Since the fraction of resistant bacteria is 
assumed to be small, only a small quantity of toxin is produced which is not harmful to the host. 
Resistance should not increase for 2 reasons: first, increasing transmissibility gives no particular 
advantage to the bacterium which produce the mutant toxin, rather it affects the community as a 
whole. Second, the treatment is not bactericidal, therefore nonresistant bacteria will remain in the 
niche, preventing the exponential growth of resistant bacteria through competition. In this 
example, any mutants which produce no toxin at all will have a competitive advantage because 
the production of toxins is metabolically expensive. This treatment will select against virulence 





 An example of the third category is an adhesin (Figure 4.1b). Urinary tract infections 
caused by E. coli can form biofilms through adherence to bladder cells using structures known as 
pili and the assembly of pili can be inhibited with pilicides.181 Although the pili are not essential 
for the survival of the bacteria, if they are not present then the bacteria cannot adhere to the 
urinary tract and are flushed out with the normal stream of urine. Resistant bacteria are those 
which produce mutant pili whose construction is not inhibited by pilicides. Resistance will 
increase for three reasons. First, resistant bacteria will remain in the urinary tract and the 
susceptible bacteria will not, which provides a clear fitness advantage to resistant bacterium on 
an individual level. Second, the resistant bacteria can grow exponentially in the now empty 
niche. Thirdly, horizontal gene transfer of resistance is very likely because a large variety of 
bacteria display pili. This is not to say that the approach is useless, but simply that it does not 
offer any special advantage to avoid bacterial resistance over traditional antibiotics. 
 
Figure 4.1. Generalized bacterial infections producing virulence factors. (a) Bacteria produce 
harmful toxins. Treatment with antitoxin does not cause resistance. (b) Bacteria adhering to the 
epithelium using pili. Treatment with pilicides causes resistance.  
 
 Because antivirulence therapy is neither bacteriostatic nor bactericidal, it would be 
expected to be less toxic than traditional antibiotics which can harm the host microbiome. 





clear an infection and the treatment may need to continue for a very long time to maintain low 
virulence.178,182 Therefore, the main use of antivirulence is simply to avoid the damaging 
symptoms of bacterial infections until it can be cleared either by the immune system or using 
traditional therapies. This is not necessarily a limitation, since antivirulence therapy could be 
given prophylactically to high-risk individuals, such as those who have had surgery. The 
antibiotic is held in reserve until an infection is confirmed so that there is no risk of promoting 
resistance through inappropriate antibiotic use.182  
4.1.3 — The IgA1 antibody 
 The IgA1 antibody is produced in humans and other great apes. It is one of the primary 
antibodies used for defense against invasive bacteria. IgA is the most abundant class of antibody 
expressed by humans and consists of two subclasses: IgA1 and IgA2. IgA1 is the primary 
antibody expressed in serum and on mucosal surfaces. The solution state structure of IgA1 was 
studied in 1999 by Boehm et al. and it is best understood in the context of related antibodies 
IgA2 and IgG.183,184  
 IgA1 is often produced as a dimer, however for simplicity only the structure of the 
monomer is shown (Figure 4.2). In their monomeric form, IgA1, IgA2, and IgG all consist of two 
antigen binding fragments or Fab fragments and one Fc fragment or crystallizable fragment 
(Figure 4.2). Each fragment consists of a total of four domains for a total of twelve domains per 
antibody. 
 Each antibody contains 4 polypeptide chains, two heavy and two light. The light chains 
contain one constant domain and one variable domain, each light chain makes up half of a Fab 
fragment. The heavy chains also contain a constant and variable domain making up the other half 





Together the additional constant domains of the two heavy chains make up the Fc fragment. The 
function of the Fab fragments is to carry the hypervariable antigen binding region which binds to 
foreign substances such as pathogenic bacteria. Meanwhile the function of the Fc fragment is to 
bind to effector cells and initiate a response. 
 
Figure 4.2. Structure of common antibodies. (a) Structure of the IgA1 antibody; (b) Structure of 
IgA2 antibody; (c) Structure of IgG antibody. 
 
 The antibodies differ from each other in how the chains are joined. In IgA1 the heavy 
chains are linked by disulfide bonds in the CH2 domain, and each heavy chain is linked to a light 
chain by a disulfide bond between the CH1 and CL domains. The hinge region is 23 amino acids 
long and very mobile allowing for a 23 nm separation between the antigen binding regions and 
gives the molecule an overall ‘T’ shape. In IgA2 the heavy chains are also linked by disulfide 
bonds in the CH2 domains, but the heavy chains are linked to the light chains by noncovalent 
interactions. The light chains are linked to each other through disulfide bonds in the CL domains 
and this, combined with a hinge region that is only ten residues long gives the molecule an 
overall ‘Y’ shape. Finally, in IgG the heavy chains are linked through disulfide bonds in the 





and CL domains. Although the hinge region is 22 residues long, the disulfide bonds restrict 
mobility and result in an overall ‘Y’ shape for the molecule. 
 It is evident from the overall shape of the antibodies that the hinge region of IgA1 is the 
most accessible to attack from proteases and therefore it is rich in prolines and contains five 
glycosylations that are not present in the IgA2 and IgG. 185 These features make IgA1 resistant to 
hydrolysis by most mammalian and bacterial proteases. Boehm et al. suggest that the greater 
mobility the Fab regions in IgA1 allow for a binding to a greater range of antigens.184  
4.1.4 — The IgA1 protease 
 In 1973 Mehta and coworkers were interested in studying the Fc domain of IgA1, but 
common proteolytic enzymes either did not hydrolyze the antibody or did so nonspecifically, 
destroying the Fc domain. An enzyme was eventually isolated from human feces that specifically 
attacked the hinge region and yielded the intact Fc domain. This marked the first isolation of an 
IgA1 protease.186   
 IgA1 proteases are a polyphyletic group of proteinases which all cleave the hinge region 
of human IgA1 after a proline and generally have a very narrow substrate scope. IgA1 proteases 
have been isolated from a wide range of bacteria including Gram-positive and Gram-negative 
examples, and are either serine, cysteine, or metalloproteases. This striking example of 
convergent evolution suggests that the cleavage of this antibody must convey significant 
selective advantage to the bacteria that produce IgA1 proteases. Each protease cleaves the hinge 
region in one of several locations, those which cleave after a single proline are designated type 1 
and those which cleave after two prolines are designated type 2, the cleavage sites are 





STPPTPSP-) and enzymes that cleave at one position in the octameric repeat do not cleave at the 
analogous position in the other repeat. 
 
Figure 4.3. Cleavage sites of various IgA1 proteases produced by different bacteria. The sequence 
of the hinge region is shown with the glycosylated residues underlined.185 The bacteria are 
numbered according to the position which they hydrolyze. 
 
 H. influenzae produces both type 1 and type 2 IgA1P; the crystal structure of the type 1 
enzyme (IgA1PHinf1) was obtained by Holyoak and coworkers in 2009.
188  Using this structure 
(Figure 4.4) Holyoak was able to shed light on the mechanism of action of the enzyme and how 
it is able to cleave IgA1 with such remarkable specificity. 
 IgA1PHinf1 is a serine protease and consists of a large ß-helical domain which supports the 
other domains. The protease domain is chymotrypsin-like (see Section 1.1.2 for a general 
mechanism). A unique D-loop extends over the catalytic site. This D-loop is normally in a closed 
position which prevents substrates from entering the active site. Meanwhile, additional domains 
2, 3, and 4 extend away from the ß-helical domain and provide a binding site for the antibody. 
The largest of these, domain 2, forms one side of a large binding pocket (Figure 4.4). Holyoak  
and coworkers performed docking simulations which predict that first the Fc domain interacts 
with both the protease domain and domain 2, this stabilizes loop D in an open conformation and 





protease domain. The hinge region can then insert into the active site cleft. The correct 
positioning is aided by domains 3 and 4 and by the binding of the Fab fragment to the reverse 
side of the protease domain which ensures that the glycosylations of the hinge region are facing 
away from the active site. Hydrolysis can then occur, and one Fab fragment is separated. This 
complex method of substrate recognition reduces the degrees of freedom of the mobile antibody 
and allows for cleavage of a glycosylated hinge. Hydrolysis of the second hinge region occurs 
through the same mechanism independently of the first.189   
 
Figure 4.4. The Crystal structure of the type 1 IgA1 protease from H. influenzae as viewed from 
various angles showing the relative position of domain 2 and the active site. Images from the 
RCSB PDB (rcsb.org) of PDB ID H309.188  
 
 One additional important substrate exists. The enzyme produced by H. influenzae and 
some other species is produced as a proenzyme. The proenzyme contains a large C-terminal 
domain which inserts into the outer membrane and creates a pore which allows the remainder of 
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the enzyme to translocate. Once in the extra cellular space, the enzyme can cleave itself at an 
autoproteolytic site and be released from the cell.190 The hydrolysis may also occur 
intermolecularly.191 This site is cleaved in the absence of the long-range interactions with the 
IgA1 antibody which are normally necessary to stabilize the enzyme active site in an open 
position which has implications for the design of small molecule inhibitors. 
4.1.5 — IgA1 Protease and Virulence 
 IgA1P is a virulence factor because it allows bacteria to colonize areas of the body they 
otherwise could not. The enzyme is not necessary for the survival of the bacteria in vitro, and 
closely related strains of bacteria that do not produce this enzyme are not pathogenic.192,193  
 IgA1P causes disease by allowing bacteria to evade the immune system. Following 
hydrolysis of IgA1, the Fab and Fc fragments remain intact, and the Fab fragment can still bind 
to antigens, including IgA1 producing bacteria, but this can no longer be communicated to 
effector cells through the Fc domain so the antibody is neutralized. This has two additional 
important effects. The first effect is that the bacterium can become coated in these Fab fragments 
which reduces the ability of other, intact antibodies to detect the bacterium.194 The second effect 
stems from the Fab fragments having a net positive charge which can promote adherence of 
bacterium to host cells electrostatically.195  
 IgA1P should be most effective in environments where IgA1 is the most prevalent 
antibody, such as in serum.183 The enzyme is secreted into the serum where it benefits the entire 
community of bacteria by targeting IgA1 antibodies preventing the detection of bacteria by the 
immune system. If a hypothetical antiviral therapeutic is applied which inhibits IgA1P then 
bacteria cells will once again be identified for destruction. As before, we should assume that a 





not inhibited by the hypothetical antivirulence drug. In this case a small amount of resistant 
enzyme is produced which neutralizes only a small amount of IgA1, but since the serum is well 
mixed there is still enough intact IgA1 remaining to be effective. Critically, the resistant IgA1P 
provides no benefit to the resistant individuals over the nonresistant individual, assuming that the 
environment is well mixed.178 Furthermore, mutants which produce no IgA1P will have a 
selective advantage since the secretion of the enzyme is metabolically expensive. In this 
example, once the hypothetical antivirulence therapy is applied, then the immune system can 
clear the infection meaning that there is no need for an additional bactericidal or bacteriostatic 
drug and resistance should not increase. This makes IgA1P an ideal target for antivirulence 
therapy. 
4.1.6 — Assays of IgA1 protease activity 
 The study of IgA1P has been limited by the lack of a convenient assay. To the best of our 
knowledge three assays have been developed that have been used to screen IgA1P inhibitors. 
The earliest method of assaying the enzyme involves using the IgA1 antibody labeled with a 
radioactive isotope of iodine, usually 131I or 125I. The iodine is incorporated into the antibody 
using a general method developed by Hunter and Greenwood: radioactive iodide is oxidized with 
chloramine T to give iodine monochloride in the presence of the antibody, then any of the 
aromatic residues can react through electrophilic aromatic substitution to give the labeled 
enzyme (Scheme 4.1).196 Several studies have used this method to assay IgA1P.187,189,197 Once 
labeled the antibody is incubated with the enzyme where it is cleaved into the Fab and Fc 
domains which is analyzed by SDS-PAGE and quantified by autoradiograph. The intact light 
chain is separated from the cleaved heavy chain under the denaturing conditions of SDS-PAGE. 





substrate is isolated from human myeloma plasma and is commercially available but very 
expensive. Secondly radioactive iodine requires specialized precautions and equipment and is 
also expensive. Finally, throughput is low, SDS-PAGE is slow and precludes monitoring the 
reaction in real time. This limits the search for inhibitors in the above studies to only a few, 
rationally designed compounds. For decades this was the only available assay for IgA1P which 
limited the study of the enzyme. 
 
Scheme 4.1. Early Assay for IgA1 protease activity using 131I labeled antibody. 
 The next assay was developed by Garner et al. in 2013.198 Briefly, gold nanoparticles 
were modified with citrate so that they bore a negative charge. These are red when fully 
dispersed but undergo a blueshift when aggregated. The enzyme and antibody are incubated for 
18 hours and then the nanoparticles are added. After IgA1 is cleaved enzymatically the Fab 





leading to aggregation and a blue shift in the spectrum (Scheme 4.2). Using this method Garner 
et al. were able to screen approximately 100 compounds for IgA1P inhibition. Several inhibitors 
were identified; however, these were only tested against enzyme produced by S. pneumoniae, 
which is a type 2 metalloprotease. This assay represents an improvement over the previously 
discussed method as it can be performed in a 96 well plate and the use of radioactive material is 
eliminated. However, the assay still requires overnight incubation and uses considerable 
quantities of the antibody. 
 
Scheme 4.2. Assay of IgA1P activity based on aggregation of the FAB domain with charged gold 
nanoparticles. 
 
 The final assay is based on FRET and was independently developed by the Kritzer group 
concurrently with the nanoparticle assay.199  This is the first assay to use an artificial substrate, 
4.1. The peptide is cleaved by IgA1P, separating the FRET donor accepter pair and the change in 
fluorescence can be measured (Scheme 4.3). Unlike the previous two assays, the measurement is 
non-destructive so multiple readings from the same experiment can be obtained more easily 
which allows for higher throughput. The artificial substrate was designed to mimic the 
autoproteolytic site of IgA1PNgon2. Surprisingly, the probe was effective with several different 
proteases produced by different species including both the type 1 and type 2 enzymes, and both 





2019, this group was able to use this probe to perform a high throughput screening of 47 000 
small molecules as inhibitors of IgA1PHinf1.
200  
 
Scheme 4.3. Assay of IgA1 protease activity based on cleavage of an artificial substrate resulting 
in loss of FRET. 
 
 Currently there is no assay available which can monitor the activity of the enzyme in real 
time using an easily accessible chromogenic substrate, such as a p-nitrophenyl ester or amide. 
4.1.7 — Inhibitors of the IgA1 protease 
 The first small molecule inhibitors for any IgA1P were short peptides based on the hinge 
region of IgA1 that were reported in 1988. These included either one or two copies of the 
octameric repeat and several modifications thereof.187  In particular, Burton et al. were interested 
in replacing the hydroxyl containing amino acids with cysteine and dimerizing these with 





the enzyme binds to only one hinge region at a time. This result agrees with later docking 
simulations.188 The best inhibitor was an octapeptide with an IC50 of 50 µM using IgA1PNgon1 and 
200 µM using IgA1PNgon2 (Figure 4.5). 
 
Figure 4.5. Early peptide inhibitor of IgA1P which mimics the IgA1 hinge region. 
 This octapeptide was not a substrate of the enzyme. Perhaps because the peptides bind in 
the binding cleft, but in the absence of the Fc fragment, the D-loop is not stabilized in an open 
conformation and the inhibitors cannot insert deeply in the active site, even if the length of the 
peptide was extended to 25 residues only a very poor substrate was obtained.199 Substrates can be 
obtained if peptides are based on the autoproteolytic site. This was demonstrated in 1991 by 
Wood and Burton using decapeptides derived from the self-cleavage site of IgA1PNgon2 to 
produce the first synthetic substrate of any IgA1 protease.201 Since the self-cleavage site is 
naturally hydrolyzed in the absence of the IgA1 antibody it is not surprising that these peptides 
were better substrates than those derived from the hinge region. However, this was only 
demonstrated using enzymes derived from N. gonorrhoeae and not H. influenzae. 
 The first small molecule inhibitors of IgA1PHinf1 were small peptidyl boronic acids that 
were prepared by Bachovchin et al. in 1990 (Table 2).197  The C-terminal carboxylate is replaced 
by a boronic acid. Boronic acids are well known serine protease inhibitors which bind in the 
active site as transition state analogs.202 These effectively inhibited types 1 and 2 IgA1PHinf and 





All four of the susceptible proteases were inhibited at submicromolar levels and this is the first 
series of potent IgA1P inhibitors. 
Table 4.2. Peptidyl boronic acid inhibitors of serine IgA1 proteases. 
 N. gonorrhoeae H. influenzae S. sanguis 
 Type 1 Type 2 Type 1 Type 2 Type 2 
Hinge-cleavage site PTP TPP PSP TPP TPP 
Self-cleavage site APP RPP DVP DVP  
Entry Inhibitors Ki (µM) 
1 H-boroPro-OH a a b b 33 
2 Ac-boroPro-OH a 18 65 12 55 
3 H-Ala-boroPro-OH a 14 80 73 7.2 
4 Boc-Ala-boroPro-OH 3.7 1.2 18 4.5 26 
5 Ac-Ala-Pro-boroPro-OH 0.016 0.004 1.3 0.013 b 
6 Boc-Ala-Pro-boroPro-OH 0.063 0.035 5.9 0.03 b 
7 H-Ala-Pro-boroPro-OH 62 85 b 47 b 
8 H-Ala-Pro-boroVal-OH c a c c c 
9 Boc-Pro-Thr-boroPro-OH 13 a 3.2 a b 
10 Boc-Pro-Thr(OBn)-boroPro-OH (4.2) 3.2 a 0.25 50 b 
11 MeO-Suc-Ala-Ala-Pro-boroPro-OH 0.052 0.028 7 0.019 b 
12 MeO-Suc-Ala-Ala-Pro-boroVal-OH c a a 25 b 
a Ki >100 µM. bno inhibition at 1000 µM. cnot determined. 
 Much can be learned from the structure of the molecules in Table 4.2. First, α-amino 
boronic acids alone are not sufficient to inhibit as shown by the mono and dipeptides which are 
at best, marginal inhibitors (entries 1-4). Only those peptides with a C-terminal proline showed 
good inhibition and those with a C-terminal valine substitution were less active (entries 8 and 
12). Furthermore, entries with a free N-terminus were poor inhibitors (entries 1,3,7, and 8), the 
cation evidently is not accommodated by the active site. 
 Both type 2 enzymes cleave the hinge in the second octameric repeat after the double 





enzymes (Entries 5, 6 and 11). These were also potent inhibitors of the IgA1PNgon1, but not for 
IgA1PHinf1. This can be explained by examining the self-cleavage sites of these enzymes: both 
type 1 and 2 IgA1PNgon enzymes self-cleave after a double proline while both IgA1PHinf enzymes 
self-cleave after an aspartate-valine-proline site.193,199 The aspartate-valine-proline boronic acid 
was not prepared which would presumably be a potent inhibitor for both IgA1PHinf1 and 
IgA1PHinf2. 
 The best inhibitor of IgA1PHinf1 was boronic acid 4.2 (entry 10) which closely resembles 
the hinge-cleavage site of this enzyme. If the threonine were exchanged for a serine it would be 
even more similar and might be a better inhibitor. In the hinge region of IgA1, this serine would 
be glycosylated, the glycosylation is mimicked by the benzyl ether in 4.2 and, removal of this 
ether resulted in a moderate loss of activity (entry 9). 
 The discovery of additional inhibitors has been slow due to the lack of a convenient assay 
however recently a high throughput screening of chemical libraries has identified 85 inhibitors of 
IgA1PHinf1 (Figure 4.6).
200 Ester 4.3 was identified as a lead compound which was a potent 
inhibitor, although still more than 20-fold less potent than boronic acid 4.2. Analogs of 4.3 were 
prepared and begin to show structure activity relationships that make this a promising starting 






Figure 4.6. Analogs of an IgA1P inhibitor identified by high throughput screening. 
 
4.1.8 — Research Objective 
 The principal objectives of the research described in this chapter are to prepare a series of 
peptides or peptidomimetics based on the hinge region or autoproteolysis site of IgA1PHinf1, 
which we anticipate will serve either as substrates or inhibitors of the IgA1PHinf1. 
Peptidomimetics corresponding to the cleavage sites in the hinge or autoproteolysis sites and 
bearing the ß-keto and ß-hydroxy α,α-difluorosulfonamide groups, were prepared. Since peptides 
containing boronic acid,197 or trifluoromethyl ketone19 groups are known to be good inhibitors of 
serine proteases, we also prepared potential peptide-based inhibitors bearing these 
functionalities. Additionally, since a simple colorimetric assay for the enzyme would be helpful 
for screening inhibitors and for kinetic studies, peptides containing C-terminal p-nitrophenyl 
esters and p-nitroanilides were also prepared. When we began this study, the Holyoak group was 
investigating the production of IgA1PHinf1 using a yeast expression system. We wished to prepare 
as many candidate inhibitors and substrates as possible in advance, which could be investigated 





4.2 — Results and discussion 
4.2.1 — p-Nitrophenyl ester based IgA1P substrates 
 Early on, we realized that our studies of the IgA1P enzyme would be facilitated by the 
development of a chromogenic assay based on the hydrolysis of a 4-nitrophenyl ester. To that 
end we sought to prepare two candidate molecules (Figure 4.7). We believed that these were 
strong candidates for enzyme substrates based on their similarity to known boronic acid 
inhibitors of IgA1PHinf1 (see Table 4.2). Ester 4.4 contains the DVP sequence which corresponds 
to the three residues that are immediately towards the N-terminus to the autoproteolytic cleavage 
site and Ester 4.5 contains a PSP sequence which corresponds to the three residues that are 
immediately towards the N-terminus to the site of hydrolysis in the hinge region. 
 
Figure 4.7. Structure of 4-nitrophenyl ester candidate substrates. 
 We began the synthesis of these compounds using standard solution phase peptide 
synthesis techniques (Scheme 4.4). Tripeptide 4.7 was prepared through two peptide couplings 
from proline benzyl ester hydrochloride. After removing the C-terminal benzyl ester by 
hydrogenolysis, we attempted to form the 4-nitrophenyl ester on the resulting acid, 4.8, using 
DIC/4-nitrophenol in pyridine. Pyridine has previously been used as a solvent for the synthesis 





inseparable mixture with N-acyl urea 4.10. The mixture was subjected to TFA to remove the side 
chain t-butyl ester to give 4.4 which was separated from the N-acyl side product by HPLC. 
 
Scheme 4.4. Synthesis of 4-nitrophenyl ester 4.4. 
 We attempted to prepare ester 4.5 using a similar approach (Scheme 4.5). Tripeptide 4.11 
was prepared with standard peptide couplings then deprotected to give 4.12. We attempted to 
form 4-nitrophenyl ester 4.5 with DIC and 4-nitrophenol in DMF using DMAP as a nucleophilic 
catalyst; however, none of the desired product was observed in the mass spectrum of the crude 
material. Instead diketopiperazine 4.13 was isolated. When the side chain of serine was protected 
with a TBS group, then the esterification could be performed using 4-nitrophenyl 





was subjected to the esterification conditions which provided 4.14, albeit in very poor yield. The 
TBS group could then be removed with TFA and 4-nitrophenyl ester 4.5 was isolated. 
Unfortunately, 4.5 was unstable and existed only long enough to characterize by 1H NMR and 
HRMS. The NMR sample slowly turned yellow and TLC analysis showed that this was 
decomposing to yield 4.13 and 4-nitrophenol. 
 






 Given that 4.14 was more stable than 4.5, we suspected that a benzyl ether would also 
slow the rate of DKP formation (Scheme 4.6). A benzyl ether was thought to mimic a 
glycosylation in the boronic acid inhibitors discussed in Table 4.2; therefore, we suspected that 
this modification would also lead to a better substrate. Tripeptide 4.16 was prepared from proline 
tert-butyl ester. Following deprotection with TFA, the 4-nitrophenol group was installed using 4-




Scheme 4.6. Synthesis of 4-nitrophenyl ester 4.17. 
 We next investigated the stability of 4.4 and 4.17 (Figure 4.8). When these esters were 
placed in buffer at pH 7.5, an increase in the absorbance at 405 nm was observed over a period 
of two hours which indicated the production of 4-nitrophenol. However, the rate of increase was 
far greater with PSP derivative 4.17 than with the DVP derived 4.4, and we concluded that ester 





produced due to DKP formation and hypothesized that this side reaction could be minimized by 
N-methylation of the serine residue. 
 Initial attempts to prepare Ac-Pro-N-MeSer(Bn)-Pro-OpNP (4.24 in Scheme 4.7) were 
hindered by the propensity of the N-methyl serine proline dipeptide esters to undergo DKP 
formation which is a common occurrence with N-methylated dipeptide esters.204 In order to 
circumvent this problem we elected to begin the synthesis by reducing Cbz proline to alcohol 
4.18 which was protected with a TBS group giving 4.19. Tripeptide 4.21 was then constructed by 
standard peptide coupling techniques without the possibility of DKP formation. The TBS group 
was removed by treatment with mild acid and the carboxylic acid was restored by a TEMPO 
bleach oxidation to give 4.23. Finally, the pNP ester was installed using 4-nitrophenyl 
trifluoroacetate in pyridine. The rate of p-nitrophenol production in buffer at pH 7.5 was much 
slower with N-methylated 4.24 compared to the unmethylated 4.17 (Figure 4.8). Therefore, we 






Scheme 4.7. Synthesis of Ac-Pro-MeSer(Bn)-Pro-OpNP 4.24. 
  
 
Figure 4.8. Hydrolysis of 4-nitrophenyl esters in buffer over time. A 200 µM solution of the ester 
in 20 mM TRIS 50 mM EDTA at pH 7.5 is incubated at 37 °C for 2 h in triplicate and 
absorbance at 405 nm is recorded every 2 minutes. 
4.2.2 — p-Nitroanilide based IgA1P substrates 
 Although esters 4.4 and 4.24 were more stable than 4.17, we were concerned that these 
might still be too labile for enzyme studies. The IgA1PHinf1 is produced with a 6 histidine C-
terminal tag which aids in purification.188 The imidazole side chains of this tag might catalyze 
the hydrolysis of the 4-nitrophenyl esters, or the ester might react with any other surface exposed 
nucleophilic amino acid.205,206 To mitigate the possibility of hydrolysis or attack by nucleophilic 
residues (other than the catalytic serine) we decided to prepare the more stable 4-nitroanilides. 
 Two series of 4-nitroanilides were prepared according to the Fmoc solid phase method of 
Abbenante (Scheme 4.8).207 The syntheses were performed on polystyrene-supported 2'-
chlorotrityl resin which was loaded with 1,4-diaminobenzene to give 4.25. The peptide chain was 





















DIC/HOBt and Fmoc deprotection was performed using 20% 4-methylpiperidine in DMF. This 
was repeated as necessary to give peptides of type 4.27. Some of the peptides contained amino 
acid side chains that required protection. tert-Butyl groups were used to protect Thr or Asp 
residues and trityl groups was used to protect Asn residues, Gln was used without protection. 
Serine residues had a permanent O-benzyl group on its side chain. The N-terminus was capped 
with acetic anhydride and the peptides were cleaved from resin using 1% TFA to give 4-
aminoanilides 4.29. Oxidation to nitro anilides 4.30 was accomplished with Oxone® and final 
deprotection was performed using TFA for those peptides bearing temporary protecting groups 
to give the final peptides 4.31. These were subjected to normal-phase flash chromatography 






Scheme 4.8. Synthesis of 4-nitroanilides based substrates. 
 
Similar to the 4-nitrophenyl esters, we prepared the Ac-Asp-Val-Pro and Ac-Pro-
Ser(Bn)-Pro C-terminal 4-nitroanilide derivatives (entries 1 and 2 in Table 4.3). We also 
extended these peptides with the residues found in the hinge region and self-cleavage site to 
yield peptides with 4 to 7 residues for a total of 10 peptides (entries 3-10, Table 4.3). We 
anticipated that there would be a tradeoff between longer peptides which could mimic the natural 
substate to a greater extent and smaller peptides which could more easily enter bypass the active 
site lid, but we were unsure what the optimal length would be. The analytical HPLC 
chromatograms of peptides 4.32 and 4.37-4.40 showed single peaks. Peptides 4.33-4.36 showed 





material. We were unable to achieve baseline separation by HPLC and this minor product was 
not separated. No additional peptides could be identified by HRMS. It is possible that these 
additional peaks arise from epimers; however, peptides that are proline-rich sequences are 
known to give rise to multiple cis-trans conformers, and such conformers have been reported to 
be separable by HPLC in some cases.208 Therefore, it is possible that the extra peak in the HPLC 
chromatograms of compounds 4.33-4.36 is due to a conformational isomer. One method to 
distinguish between epimers and conformational isomers would be to analyze these peptides by 
HPLC at increased temperatures. Finally, the presence of peptide 4.41 was confirmed by HRMS; 
however, after subjecting the crude material to flash chromatography, several peaks were 
observed in the HPLC chromatograph and we were unable to obtain this compound in high 
enough purity for enzyme studies (see the Appendix for copies of HPLC and HRMS data). The 
compounds in Table 4.3 were prepared by Yishu Zang, an undergraduate student in the Taylor 





Table 4.3. Yield, retention times, and mass spectrometric analyses of p-nitroanilides 4.32-4.41. 
Entry Peptide Retention 
time(min)a 
Yield(%) m/z (calc.) m/z (obs.) 
1 Ac-Pro-Ser(Bn)-Pro-pNA (4.32) 26.0 46 552.2453(M+H) 552.2474 
2 Ac-Thr-Pro-Ser(Bn)-Pro-pNA (4.33) 24.5  57 653.2930(M+H) 653.2925 
3 Ac-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.34) 24.5 31 750.3457(M+H) 772.3295 
4 Ac-Pro-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.35 25.0 30 853.4067(M+Li) 853.4104 
5 Ac-Thr-Pro-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.36) 24.5 27 948.4462(M+H) 948.4459 
6 Ac-Asp-Val-Pro-pNA (4.37) 21.5 11 492.2089(M+H) 492.2089 
7 Ac-Ala-Asp-Val-Pro-pNA (4.38) 25.5 12 585.2279(M+Na) 585.2289 
8 Ac-Gln-Ala-Asp-Val-Pro-pNA (4.39) 22.5 28 691.3046(M+H) 691.3072 
9 Ac-Ile-Gln-Ala-Asp-Val-Pro-pNA (4.40) 28.5 14 826.3706(M+Na) 826.3747 
10 Ac-Asn-Ile-Gln-Ala-Asp-Val-Pro-pNA (4.41) - trace 918.4316(M+H) 918.44299 
aGradient: 5:95 MeCN:H2O (+0.1% TFA) to 95:5 MeCN:H2O (+ 0.1% TFA) over 40 min. 
 To determine the stability of the 4-nitrophenyl amides in aqueous solution, peptide 4.37 
was dissolved in 20 mM Tris, 50 mM EDTA buffer at pH 7.5 and incubated at 37 °C for 24 
hours (Figure 4.9). The absorbance was recorded at 380 nm (the λmax of 4-nitroaniline) and no 
significant increase was observed over that time period.  
 
Figure 4.9. Hydrolysis of 4-nitrophenyl esters in buffer over time. A 250 µM solution of 4.37 in 
20 mM TRIS, 50 mM EDTA at pH 7.5 was incubated at 37 °C for 24 h and the absorbance at 
380 nm was recorded every 10 minutes. 




















4.2.3 — Boronic acid based IgA1P inhibitors 
 The first potential inhibitors that we prepared were peptidyl boronic acids. There were 
several reasons for this. First, it had already been demonstrated that small peptides with C-
terminal boronic acids act as inhibitors of IgA1 proteases (Table 4.2).197 Additionally, peptidyl 
boronic acids and esters are well-known inhibitors of other serine proteases and some are found 
in FDA approved medications.209,210 Finally, boronic acids have been used as ligands for affinity 
chromatography.211-213 It occurred to us that a potent boronic acid inhibitor of an IgA1P could be 
used to prepare an affinity column which would facilitate purification of the enzyme. 
 Bachovchin had already demonstrated that Boc-Pro-Thr(OBn)-boroPro-OH was a good 
inhibitor of IgA1PHinf1 (Table 4.2).
197 However, this molecule is more similar to the cleavage site 
of other IgA1 proteases. The cleavage site of IgA1PHinf1 has a -Pro-Ser-Pro- sequence, therefore; 
we anticipate that peptide 4.42, which contains a serine in place of the threonine, would be a 
better inhibitor (Figure 4.10). The self-cleavage site of IgA1PHinf1 occurs after an Asp-Val-Pro 
sequence, therefore 4.43 would also be a candidate inhibitor. 
 
Figure 4.10. Tripeptides bearing C-terminal boronic acids as potential inhibitors of IgA1PHinf1. 
 It has been observed that the purification of boronate esters by chromatography can often 
be problematic due to over absorption on silica gel which leads to tailing, poor resolution, and 
low recovery.214 Therefore, it was desirable that the synthesis of the tripeptides be done with as 





method of Wityak (Scheme 4.9).215 Amine 4.44 was cyclized in the presence of DIPEA with 
potassium iodide added as a nucleophilic catalyst (Scheme 4.10). The reaction mixture was 
cooled to -15 °C, and then a dipeptide, activated as a mixed anhydride with isobutyl 
chloroformate and NMM, was added to the mixture. The resulting tripeptides were purified by 
flash chromatography. Deprotection was performed in two steps using TFA to remove the 
tert-butyl protecting groups, followed by transesterification with phenyl boric acid which gave 
4.47 and 4.58 as well as phenylboronic acid pinanediol ester, which partitioned into hexane. The 
final tripeptides were purified by RP HPLC. Tripeptide 4.47 was acylated with 4-nitrophenyl 
acetate to give the candidate inhibitor 4.43. Peptide 4.48 will be acylated in the near future. 
 
Scheme 4.9. Synthesis of boronic acid tripeptides. 
  Tripeptides 4.47 and 4.48 were also loaded onto Sepharose solid support column using a 





the amount of bound tripeptide was estimated removing an aliquot of the loading cocktail and 
determining the amount of tripeptide remaining by RP HPLC and comparing this to a standard of 
known concentration. The loading step was repeated three times until there was no change in the 
concentration of tripeptide, giving a total of approximately 20 µmols of tripeptide per gram of 
resin. This resulted in resins 4.49 and 4.50 which are potential affinity columns which may be 
useful in the isolation of active IgA1P, assuming that 4.42 and 4.43 are inhibitors of IgA1P. 
 
 Scheme 4.10. Loading of boronic acid tripeptides onto a solid support. 
4.2.4 — Trifluoromethyl alcohol and ketone based IgA1P inhibitors 
 The next class of potential inhibitors that were preprared were peptidyl trifluoromethyl 
ketones as these types of compounds have been shown to be good inhibitors of serine proteases 
(See Section 1.1.2 for details). We also prepared the corresponding trifluoromethyl alcohols as 
peptidyl trifluoromethyl alcohols are also known to be inhibitors of serine proteases, although 
they tend to be less potent than the corresponding ketones.217 All of the inhibitors were prepared 
from trifluoromethyl alcohol 4.53 (Scheme 4.11).218 Trifluoromethyl alcohols 4.51 and 4.52 were 
prepared from Boc prolinal (Scheme 4.11). Diastereomers were separated by flash 
chromatography. Only 4.52, the major isomer, was carried forward. The Boc group in 4.52 was 






Scheme 4.11. Synthesis of trifluoromethyl prolinol 4.53. 
 Tripeptides containing 4.53 were prepared using standard solution phase peptide 
chemistry (Scheme 4.12). Dipeptides 4.54 and 4.56 were found to be single diastereomers which 
indicated that no epimerization of the α-carbon occurred in the trifluoromethylation of Boc-
prolinal. These were extended by acidic deprotection of the Boc groups followed by acylation 
with Pfp esters of the next amino acid. Multiple conformers are expected for peptides containing 
multiple prolines.208 The NMR spectrum of tripeptide 4.55 indicated that it existed as a mixture 
of several rotamers. The peaks corresponding to the various rotamers coalesced to a single set of 
peaks corresponding to one of the rotamers upon heating to 100 °C. The N-terminal acylation of 
4.57 was performed using 4-nitrophenyl acetate which avoided O-acylation at the trifluoromethyl 






Scheme 4.12. Preparation of trifluoromethyl alcohol tripeptides. 
 
 Next, the tripeptides were oxidized to the trifluoromethyl ketones. Trifluoromethyl 
alcohols are reported to resist oxidation with DMSO or metal-based reagents, and Dess-Martin 
reagent is the method of choice, although even this typically requires an excess of the oxidant.218 
This approach successfully yielded the PSP derivative 4.59, which was obtained as a mixture of 
isomers which may arise from epimerization of the proline α-carbon or from conformational 
isomers (Scheme 4.13). 19F NMR spectroscopy indicated that the 4.59 existed primarily in the 







Scheme 4.13. Dess Martin oxidation of trifluoromethyl alcohol 4.55. 
 Unfortunately, the same transformation failed on alcohol 4.58 (Scheme 4.14 a). However, 
the transformation was successful if a benzyl ester protecting group on the aspartate side chain 
was present (Scheme 4.14 b). Ketone 4.62 was obtained from 4.61 as a single isomer as judged 
by 19F NMR; however, after hydrogenolysis of the benzyl group, the final ketone 4.60 was 
obtained as a mixture of isomers, presumably due to epimerization of the proline α-carbon 
 
Scheme 4.14. Synthesis of Ac-Asp-Val-Pro trifluoromethyl ketone 4.60. 
 
4.2.5 — Sulfonamide based IgA1P inhibitors 
 Unlike the trifluoromethyl compounds and boronic acids that were prepared above, ß-
keto-α,α-difluorosulfonamides can be incorporated into peptidomimetics at an interior position 
rather than strictly at the C-terminus. Therefore, we began our studies of sulfonamide-based 
inhibitors by considering artificial substrate 4.1. The termini of 4.1 are labeled with a FRET pair, 





Although 4.63 is derived from the cleavage site of IgA1PNgon2, this was a substrate for proteases 
from several different species, including IgA1PHinf1, which all cleaved in the same location 
between proline and alanine (Figure 4.11).200 We reasoned that we could create an analog by 
substituting a ß-keto-α,α-difluorosulfonamide into the structure to give 4.64 which we 
hypothesized would be able to enter the active site of the enzyme and form a covalent adduct 
with the active site serine. We further reasoned that since 4.1 was a general substrate of IgA1 
proteases then 4.64 might be a general inhibitor. 
 
 Figure 4.11. Proposed General IgA1P inhibitor derived from an artificial substrate. 
 We envisioned that 4.64 would be prepared by extension of peptide 4.65 using standard 
peptide couplings (Scheme 4.15). 4.65 would be prepared by condensation of fragments 4.66 and 
4.67 meanwhile 4.67 could be assembled by solution phase peptide synthesis while fragment 






Scheme 4.15. Retrosynthesis of 4.64. 
 The first step was to prepare fragment 4.67 (Scheme 4.16). BocTyr(Bn)OBn was 
deprotected with TFA followed by acylation with the Pfp ester of Boc-Phe to give dipeptide 
4.68. Similar conditions with the Pfp ester of Boc-Val gave the C-terminal tripeptide 4.69. 
Deprotection with HCl in dioxane gave amine 4.67 which was ready to be coupled to the central 
fragment 4.66. 
 
Scheme 4.16. Synthesis of peptide fragment 4.67. 
 The synthesis of 4.66 began with the installation of an OBO protecting group on Cbz-
proline. This was accomplished in two steps using the general method of Zhdanko and 





which tolerates strong bases and nucleophiles without risk of epimerization. Next, the Cbz-
protecting group was removed by hydrogenolysis to furnish 4.72. The mesyl group was installed 
with MsCl giving 4.73. 
 With the OBO group successfully installed, the most acidic site in 4.73 is the sulfonamide 
methyl group. We expected 4.73 to be slightly less acidic than a methyl sulfone which would 
mean a pKa in the range of 25 to 30.
221,222 The lithium salt of 4.73 reacted with alloc-Pro-OMe to 
give 4.74 The alloc group is selected here because OBO group removal requires treatment with 
acid followed by base, and because it can be removed in the presence of the benzyl groups used 
to protect fragment 4.67. 
 OBO deprotection was accomplished according to a literature procedure using mild 
aqueous acid to give ester 4.75, which was not isolated and was hydrolyzed under basic 
conditions to give acid 4.76.220 Electrophilic fluorination of 4.76 using Selectfluor and CsF gave 
4.66 in modest yield. The yield was significantly improved if 4.76 was not isolated in which case 
4.66 was obtained in 78% yield from 4.74. Sulfonamide 4.66 is similar to a dipeptide; however, 
it contains a central sulfonamide group rather than an amide. Therefore, there is little risk of 
epimerization at this step since sulfonamides do not form oxazolones, which is a problem 
frequently encountered with amides.223 Coupling of fragments 4.66 and 4.67 using DCC/HOAt 






Scheme 4.17. Synthesis of peptidiomimetic 4.65. 
 The next step was to remove the N-terminal alloc protecting group. Coupling tripeptide 
Cbz-Pro-Arg(NO2)-Pro-OH followed by hydrogenolysis would yield 4.64. However, before we 
attempted this transformation, we wanted to test the conditions on a simpler substrate to 
determine if dipeptides could be prepared from ß-keto-α,α-difluorosulfonamides derived from α-





that we would be able to remove the alloc group with Pd(PPh3)4 and phenylsilane and then obtain 
dipeptide 4.79 using a Pfp ester (Scheme 4.18a). Unfortunately, we found that 4.79 was not 
observed in the crude reaction mixture which consisted of numerous side products, one of which 
was amide 4.78 as determined by HRMS. When we attempted the reaction using Fmoc-Pro-OH 
and EDC/HOBt, we observed a small amount of 4.79 by HRMS, but the crude reaction mixture 
was still dominated by unidentified side products including 4.78 (Scheme 4.18b). We also 
prepared Boc protected 4.80 (see Table 1.5, entry 17) and attempted the transformation (Scheme 
4.18c). In this case the dominant product was 4.81; however, the reaction contained fewer 






Scheme 4.18. Attempted synthesis of ß-keto-α,α-difluorosulfonamide dipeptides. 
 
 The side reaction to produce 4.81 obviously involves the production of amino 
diphenylmethane, which might arise by hydrolysis of the sulfonamide. However, similar 
products were also observed under anhydrous conditions (Scheme 4.18a and b), furthermore ß-
keto-α,α-difluorosulfonamides have been shown to hydrolyze under basic aqueous conditions to 
give difluoromethanesulfonamides, not amines (Chapter 2 Section 2.2.1). A plausible mechanism 
that explains the side product is shown in Scheme 4.19. First TFA deprotection yields an 
ammonium salt, which does decompose in solution as determined by 19F NMR. When base is 





dioxide, difluorocarbene, carbon monoxide and an imine. Sheehan and Frankenfeld proposed a 
similar mechanism to explain the base promoted decarbonylation of an α-amino acid yielding an 
imine, carbon monoxide and toluene sulfonic acid.224 Despite some experimentation, we were 
unable to perform the desired transformation cleanly and turned to the synthesis of sulfonamide-
based inhibitors derived from the Pro-Ser-Pro and Asp-Val-Pro tripeptides. 
 
Scheme 4.19. Proposed mechanism for the decomposition of 4.80. 
 We began with proline derivative 4.82 (See Table 2.8 entry 4). The diastereomers of 4.82 
were readily separable by flash chromatography but only the major (R,S) isomer was used (see 
chapter 2 for details). Various methods were investigated to remove the PhF protecting group 
(Table 4.4). Hydrogenolysis under a hydrogen atmosphere was sluggish in EtOAc/EtOH even if 
acid was added (entries 1 and 2). 10% Pd(OH)2/C, H2, DCM/MeOH, 1% TFA gave a complex 
mixture (entry 3). In chapter 3, the use of 95:2.5:2.5 TFA:H2O:TIPS was effective for 
deprotecting a PhF amine, but in this case led to partial loss of the PMB protecting groups before 
PhF deprotection was complete (entry 4). Employing 2 equiv of I2 in refluxing MeOH did not 
produce any reaction even after 16 h (entry 5). Triethylsilane in DCM/MeOH in the presence or 
absence of TFA were also unsuccessful (entries 6 and 7). However, performing the reaction with 
triethylsilane and cat. Pd/C in DCM/MeOH was effective (entry 8) and the reaction rate was 





Table 4.4. Optimization of PhF deprotection from sulfonamide 4.82. 
 
Entry Conditions Result 
1 10 wt. % of 20% Pd(OH)2/C, H2, EtOAc/EtOH (2:3), rt, 16 h Trace product 
2 EtOAC/EtOH/AcOH (12:8:1), H2, rt, 16 h Trace product 
3 10% Pd(OH)2/C, H2, DCM/MeOH, 1% TFA Unknown side reactions 
4 95% TFA, 2.5% TIPS, 2.5% water, rt, 16 h Partial loss of PMB groups 
5 2 equiv I2,
 
MeOH, reflux, 16 h No reaction 
6 DCM:MeOH:TES (1:1:1), 16 h No reaction 
7 DCM:MeOH:TES (1:1:1), 3% TFA, 16 h No reaction 
8 DCM:MeOH:TES (1:1:1), 10 wt. % of 10% Pd/C Complete after 16 h 
9 DCM:MeOH:TES (1:1:1), 10 wt. % of 10% Pd/C, 3% TFA Complete after 30 min 
  
 Next a fragment coupling was performed between Ac-Pro-Ser(Bn)-OH and amine 4.83 
using a variety of coupling reagents on a small scale (Table 4.5). Yields were estimated by 
HPLC, and all of the coupling reagents except for DPPA showed some degree of epimerization 






Table 4.5. Optimization of the coupling conditions for tripeptide 4.84. 
 







 (yield 2 h) 
4.84  
(yield 2 h) 
4.85  
(yield 24 h) 
4.84  
 (yield 24 h) 
1 DEPBT DIPEA THF - 17% 52%   
2 DEPBT K2CO3 THF - 0% 8% 7% 75% 
3 DPPA DIPEA DMF - 0% 33% 0% 72% 
4 DPPA K2CO3
 DMF - 0% 28% 0% 33% 
5 HATU DIPEA DMF - 11% 16%   
6 HCTU DIPEA DMF - 19% 17%   
7 PyAOP DIPEA DMF - 8% 31%   
8 HATU DIPEA DMF HOAt 25% 17%   
9 HCTU DIPEA DMF HOAt 24% 17%   
10 PyAOP DIPEA DMF HOAt 15% 17%   
aReactions were performed with 10 mg of 4.83 and the indicated base, additives, and dipeptide in 
1.4 mL of solvent. The mixture was cooled to -40 °C then the activating agent was added in 100 
µL of solvent then the mixture was warmed to 0 °C. 
 
 When the reaction was scaled up, 4.84 was obtained in good yield without detectable 
epimerization as determined by HPLC (Scheme 4.20). Various methods have been reported for 
the deprotection of PMB-protected sulfonamides including, AgSbF6 and trimethoxybenzene,
226 
FeCl3·6H2O in DCM or DCE at 60 °C,
227,228 KBr and Oxone in nitromethane,229 or titanium 
chloride;230 however, none of these were successful in our hands. CAN or TFA have also been 
used.10 TFA required high temperatures and prolonged reaction times which resulted in 
competing loss of the benzyl ether. Cerium ammonium nitrate successfully removed the PMB 





purification by flash chromatography. This material was judged to be homogenous by 
HPLC/HRMS (see Appendix Figures A.23 and A.24) but the presence of at least four 
conformers made characterization by NMR challenging. 
 
Scheme 4.20. Synthesis of tripeptide 4.86 by fragment coupling with DPPA and oxidative 
debenzylation. 
 
 Unfortunately, the fragment coupling between amine 4.83 and Ac-Asp(OtBu)-Val-OH 
led to epimerization; therefore, this tripeptide was prepared by stepwise couplings using 
EDC·HCl and HOAt which provided tripeptide 4.88 albeit in low yields (Scheme 4.21). The N-
terminal Cbz group was removed by catalytic hydrogenation however acylation using 4-
nitrophenyl acetate failed to provide any product. Therefore, we employed Ac2O and base, which 
resulted in acylation of the amine as well as partial acylation of the α-difluoro alcohol. The crude 
mixture was hydrolyzed with lithium hydroxide followed by TFA to remove the O-acylation as 
well as the t-butyl ester giving 4.89. PMB deprotection proceeded smoothly giving 4.90 using 







Scheme 4.21. Synthesis of 4.90 by stepwise peptide synthesis followed by oxidative 
debenzylation. 
 The next step would be to oxidize the ß-hydroxylsulfonamides to ketones using the Dess-
Martin reagent; however, during preliminary studies with this reaction we encountered 
difficulties in analyzing the reaction mixtures. Specifically, the ketones appeared to give extreme 
tailing when analyzed by RP-HPLC. This phenomenon, combined with the presence of multiple 
conformers, the possibility of keto/hydrate mixture, and the high likelihood of epimerization of 
the carbonyl α-carbon, made assessment of purity challenging. Additional work will be required 






4.3 — Conclusions and Future Studies. 
 In this chapter we have described the synthesis of some potential substrates and inhibitors 
of the type 1 IgA1 protease derived from H. influenzae. These were designed to mimic the 
cleavage site in the hinge region of the IgA1 antibody, or the autoproteolytic site which is 
hydrolyzed by IgA1P during its secretion. 
 We successfully prepared three tripeptides as potential chromogenic substrates bearing C-
terminal 4-nitrophenyl esters. However, these were hydrolytically unstable; therefore, we also 
prepared nine peptides of varying length bearing the more stable 4-nitroanilide group. Future 
studies with these compounds will determine which, if any, can be hydrolyzed by IgA1PHinf1. 
The studies with 4-nitroanilides will also determine the optimal length of the substrate peptides 
which will influence the rational design of future inhibitors. 
 A number of potential inhibitors were prepared that consist of tripeptides bearing various 
non-hydrolyzable groups on the C-terminus. In particular, we investigated C-terminal boronic 
acids, trifluoromethyl alcohols, trifluoromethyl ketones and ß-hydroxyl-α,α-
difluorosulfonamides. The preparation of ß-keto-α,α-difluorosulfonamide tripeptides is 
underway. We have shown that the boronic acids are readily loaded on to a solid support 
providing a potential affinity column for IgA1P. 
 The synthesis of octapeptide 4.64 was attempted, but was unsuccessful due to difficulties 
extending the chain from the ß-keto-α,α-difluorosulfonamide residue. It should be possible to 
overcome this side reaction by protecting the ketone (Scheme 4.22). A suitable protecting group 
would be the 2,2-dimethyl-propane-1,3-diol acetal which as previously been used in peptide 







Scheme 4.22. Proposed synthesis of peptide 4.64 utilizing ketone protection. 
 Future investigations on the inhibition of IgA1PHinf1 will determine which of these 
candidate molecules are inhibitors of the enzyme. Should some of these compounds be 
inhibitors, then the x-ray crystal structure of these inhibitors bound to IgA1PHinf1 will be obtained 
in collaboration with the Holyoak group. Overall, these studies could lead to the development of 
new antivirulence therapies for treating bacterial infections. 
4.4 — Experimental 
4.4.1 — General experimental 
 All reagents and solvents were purchased from commercial suppliers and used without 
purification unless stated otherwise. Dimethylformamide (DMF) and acetonitrile were distilled 
from calcium hydride and stored over activated 4 Å molecular sieves. Tetrahydrofuran (THF) 
was distilled from sodium metal in the presence of benzophenone under nitrogen immediately 
before use. Dichloromethane was distilled from calcium hydride under nitrogen immediately 





and stored over activated 4 Å molecular sieves. 1,4-diaminobenzene was recrystallized from hot 
ethanol and stored under argon. 
 All 13C NMR spectra were proton decoupled. Chemical shifts (δ) for 1H NMR spectra run 
in CDCl3 are reported in ppm relative to the standard tetramethylsilane (TMS). Chemical shifts 
for 13C NMR spectra run in CDCl3 are reported in ppm relative to the solvent residual carbon (δ 
77.16 for central peak). The samples for high-resolution positive ion electrospray ionization mass 
spectrometry (HRMS-ESI+) (ion trap) were prepared in 1:1 MeOH/H2O + 0.1% formic acid. 
 Analytical HPLC was accomplished with a reversed-phase C18 column (10 μm, 250 mm 
× 4.6 mm, 1 mL/min flow rate). Preparative HPLC was accomplished using a C18 column (10 
μm, 150 mm × 20 mm, 10 mL/min flow rate). 
4.4.2 — Experimental procedures for synthesized compounds 
 Cbz-prolinol was prepared according to a literature procedure.232 Dipeptides Boc-Pro-
Ser(Bn)-OH, Boc-Asp(OtBu)-Val-OH, and Ac-Pro-Ser(Bn)-OH were prepared by the reaction of 
the appropriate Pfp ester with H-Ser(Bn)-OH or valine. Alloc-N-methyl-O3-benzyl-serine was 
prepared according to method of Zhang.233  
 
Ac-Asp(OtBu)-Val-Pro benzyl ester (4.7). Boc-Val-OH (1.08 g, 5 mmol, 1.25 equiv), HOAt 
(680 mg, 5 mmol, 1.25 equiv), and DCC (1.03 g, 5 mmol, 1.25 equiv) were dissolved in 30 mL 
of DCM at 0 °C and stirred for 10 min. Proline benzyl ester hydrochloride (966 mg, 4 mmol, 1 
equiv) and DIPEA (870 µL, 5 equiv, 1.25 equiv) were added. The mixture was stirred at room 





for 10 minutes until the unreacted HOAt ester was consumed then cooled to 0 °C and allowed to 
stand 30 minutes to encourage precipitation of DCU. The suspension was filtered through a pad 
of celite and rinsed with 70 mL of DCM. The filtrate was washed twice with 100 mL of 10% 
citric acid, twice with 100 mL of saturated NaHCO3 and once with 100 mL of brine. The organic 
layer was dried over MgSO4, filtered, and concentrated. The crude dipeptide was dissolved in 5 
mL of DCM, 15 mL of TFA was added and stirred for 1 hour at room temperature then the 
solvent was evaporated. 
 Separately Ac-Asp(OtBu)-OH (1.16 g, 5 mmol, 1.25 equiv) HOAt (680 mg, 5 mmol, 
1.25 equiv), and DCC (1.03 g, 5 mmol, 1.25 equiv) were dissolved in 30 mL of DCM at 0 °C 
and stirred for 10 min. The dipeptide TFA salt from above was added along with DIPEA (870 
µL, 5 mmol, 1.25 equiv) and the mixture stirred overnight at room temperature. TAEA (295 µL, 
2 mmol, 0.5 equiv) was added and the mixture stirred for 10 minutes until the unreacted HOAt 
ester was consumed then cooled to 0 °C and allowed to stand 4 hours to encourage precipitation 
of DCU. The suspension was filtered through a pad of celite and rinsed with 70 mL of DCM. 
The filtrate was washed twice with 100 mL of 10% citric acid, twice with 100 mL of saturated 
NaHCO3 and once with brine. The organic layer was dried over MgSO4, filtered, and 
concentrated. The residue was purified by flash chromatography 50 to 100% EtOAc in hexane to 
give 4.7 as 1.27 g of white foam (62% yield). 1H NMR (CDCl3, 500 MHz): δ 7.32 (m, 5H), 7.05 
(d, 1H, J 8.6 Hz), 6.87 (d, 1H, J = 8.27 Hz), 5.16 (d, 1H, J = 12.3 Hz), 5.09 (d, 1H, J = 12.3 
Hz), 4.67 (m, 1H), 4.53 (m, 2H), 3.74 (m, 1H), 3.64 (m, 1H), 2.85 (dd, 1H, J = 16.8, 4.6 Hz), 
2.54 (dd, 1H, J = 16.9, 5.9 Hz), 2.18 (m, 1H), 2.01 (m, 7H), 1.42 (s, 9H), 0.95 (d, 3H, J = 6.7 
Hz), 0.88 (d, 3H, J = 6.8 hz); 13C {1H} NMR (CDCl3, 125 MHz): δ, 171.84, 171.49, 170.43, 





31.46, 29.09, 28.09, 25.00, 23.33, 19.35, 17.61; HRMS-ESI+ (m/z) calcd for C27H40N3O7
+
 (M + 
H)+ 518.2872, found, 518.2861. 
 
Ac-Asp(OtBu)-Val-Pro 4-nitrophenyl ester (4.9). Tripeptide 4.7 (1.27 g, 2.46 mmol, 1 equiv) was 
dissolved in 30 mL of methanol and Pd(OH)2, 20 wt% on carbon (127 mg, 0.136 mmol, 10 
mol%) was added was added. The reaction was stirred under a hydrogen atmosphere overnight 
then filtered through a pad of celite. The solution was concentrated to give 970 mg of crude 4.8 
as a white solid which was dissolved in 60 mL of pyridine and cooled to 0 °C. p-Nitrophenol 
(640 mg, 4.60 mmol, 1.9 equiv) was added followed by DIC (400 µL, 2.56 mmol, 1.05 equiv) 
the solution was warmed to rt and stirred overnight then concentrated in the presence of silica 
and subjected to flash chromatography on a gradient of 0 to 100% EtOAc in DCM. This yielded 
1.2 g of a mixture of the desired p-nitrophenyl ester and an N-acyl urea side product which was 
carried forward to the next reaction, however a small portion of analytically pure 4.9 was found 
in some fractions. (CDCl3, 500 MHz): δ 8.28 (d, 2H, J = 8.9 Hz), 7.32 (d, 2H, J = 8.9 Hz), 7.11 
(d, 1H, J = 8.4 Hz), 6.90 (d, 1H, J = 8.1 Hz), 4.81 (m, 1H), 4.69 (dd, 1H, J = 7.8, 5.7 Hz), 4.58 
(t, 1H, J = 7.7 Hz), 3.90 (m, 1H), 3.74 (m, 1H), 2.91 (dd, 1H, J = 16.9, 4.6 Hz), 2.58 (dd, 1H, J 
= 16.9, 5.9 Hz), 2.45 (m, 1H), 2.13 (m, 7H), 1.47 (s, 9H), 1.01 (d, 3H, J = 6.7 Hz), 0.94 (d, 3H, J 
= 6.7 Hz); 13C {1H} NMR (CDCl3, 125 MHz): δ 171.7, 170.62, 170.59, 170.3, 170.0, 155.5, 
145.6, 125.4, 122.4, 82.0, 59.3, 56.0, 49.6, 47.4, 36.8, 31.4, 29.2, 28.1, 25.4, 23.4, 19.3, 17.7; 
HRMS-ESI+ (m/z) calcd for C26H37N4O9
+
 (M + H)






Ac-Asp(OtBu)-Val-Pro 4-nitrophenyl ester (4.4). A mixture of 1.2 g of crude 4.9 and side 
product 4.10 were dissolved in 12 mL of DCM and 12 mL of TFA was added. The reaction was 
stirred for one hour and then concentrated. The reside was subjected to flash chromatography, 0 
to 10% MeOH in DCM with 1% AcOH. Fractions containing product were further purified by 
HPLC using a gradient of 25 to 40% CH3CN in water (0.1% TFA) over 40 min to yield 392 mg 
of white solid (32% in three steps from 1.27 g of 4.7). 1H NMR (CDCl3, 300 MHz): δ 11.66 (br, 
1H), 8.24 (d, 2H, J = 7.5 Hz, ), 7.83 (d, 1H, J = 6.0 Hz), 7.40 (br, 1H), 7.26 (d, 2H, J = 7.9 Hz), 
4.91 (m, 1H), 4.69 (m, 1H), 4.55 (m, 1H), 3.96 (m, 1H), 3.73 (m, 1H), 2.91 (d, 1H, J = 15.2 Hz), 
2.72 (d, 1H, J = 14.3 Hz), 2.41 (m, 1H), 2.07 (m, 7H), 0.95 (d, 3H, J = 5.7 Hz), 0.90 (d, 3H, J = 
5.2 Hz); 13C {1H} NMR (CDCl3, 75 MHz): δ 173.9, 171.9, 171.5, 171.0, 169.5, 155.2, 145.5, 
125.3, 122.3, 59.4, 56.4, 49.6, 47.8, 36.1, 31.0, 29.1, 25.1, 22.6, 18.9, 18.0; HRMS-ESI+ (m/z) 
calcd for C22H49N4O9
+
 (M + H)
+ 493.1929, found 493.1930. 
 
Ac-Pro-Ser(Bn)-Pro benzyl ester (4.11). Experimental procedure. Boc-Ser(Bn)-OH (1.48 g, 5.00 
mmol, 1.25 equiv), HOAt (680 mg, 5.00 mmol, 1.25 equiv), DIPEA (870 µL, 5.00 mmol, 1.25 





mixture was stirred for 15 minutes and then H-Pro-OBn·HCl (940 mg, 4 mmol, 1 equiv) was 
added as a solution in 10 mL of DCM and the reaction was stirred 90 minutes at room 
temperature. The mixture was cooled to 0 °C then filtered through celite, rinsed with 100 mL of 
DCM then the filtrate was washed 3 times with 50 mL of 0.1 M HCl, 3 times with 50 mL of 5% 
NaHCO3, and once with 50 mL of brine. The organic layer was dried over MgSO4, filtered, and 
concentrated to give crude dipeptide. The residue was suspended in 5 mL of DCM at 0 °C and 15 
mL of TFA was added. The reaction was stirred until complete removal of the Boc group was 
observed by TLC then concentrated. 
 Separately acyl proline (785 mg, 5.00 mmol, 1.25 equiv), HOAt (680 mg, 5.00 mmol, 
1.25 equiv), DIPEA (870 µL, 5.00 mmol, 1.25 equiv), and DCC (1.03 g, 5.00 mmol, 1.25 equiv) 
were dissolved in 30 mL of DCM at 0 °C and stirred for 15 minutes before adding the 
deprotected dipeptide TFA salt as a solution in 10 mL of DCM. The reaction was stirred 
overnight at room temperature. The mixture was cooled to 0 °C then filtered through celite, 
rinsed with 100 mL of DCM then the filtrate was washed 3 times with 50 mL of 0.1 M HCl, 3 
times with 50 mL of 5% NaHCO3, and once with 50 mL of brine. The organic layer was dried 
over MgSO4, filtered, and concentrated. The residue was purified by flash chromatography 1 to 
10% MeOH in DCM to yield 4.11 as a white foam, 1.25 g (60% yield). 1H NMR (CDCl3, 300 
MHz): δ 7.3 (m, 11H), 5.16 (d, 1H, J = 12.6 Hz), 5.07 (d, 1H, J = 12.5 Hz), 4.86 (m, 1H), 4.4 
(m, 4H), 3.53 (m, 6H), 2.3-1.8 (m, 11H); 13C {1H} NMR (CDCl3, 75 MHz): δ 171.6, 171.3, 
170.5, 168.8, 138.0, 135.7, 128.5, 128.3, 128.2, 128.1, 127.7, 127.6, 73.2, 70.0, 66.8, 59.7, 59.1, 
51.2, 48.2, 47.1, 29.0, 28.3, 24.9, 24.9, 22.5; HRMS-ESI+ (m/z) calcd for C29H36N3O6
+
 (M + H)
+ 







(4.13). Benzyl ester 4.11 (1.23 g, 2.36 mmol, 1.00 equiv) was dissolved in 20 mL of MeOH and 
Pd(OH)2 (20 wt% on carbon, 123 mg) was added. The suspension was stirred under a hydrogen 
atmosphere for 2 hours. The mixture was the filtered through celite and concentrated to give 4.12 
which was used without further purification. 
 The residue was dissolved in 20 mL of DMF and 4-nitrophenol (1.3 g, 9.3 mmol, 4 
equiv), DIC (550 µL, 443 mg, 3.52 mmol, 1.49 equiv) and DMAP (25 mg, 0.20 mmol, 0.086 
equiv) were added. The mixture was stirred for four hours and TLC analysis showed that this 
consisted of a mixture of 4.12 and 4.13 but not 4.5. The mixture was concentrated, and the 
residue was subjected to flash chromatography with a gradient of 0 to 15% MeOH in DCM to 
give 400 mg of 4.13 as a white solid (52% yield). 13C{1H} NMR showed that this compound 
existed as a mixture of rotamers in DMSO-d6 which coalesced when heated to 100 °C. 
1H NMR 
(MeOD, 300 MHz): δ 3.17-2.90 (m, 4H), 2.77 (t, 1H, J = 7.4 Hz), 2.12-1.92 (m, 4H), 1.81 (m, 
1H), 0.8-0.5 (m, 11H); 13C {1H} NMR (CDCl3, 125 MHz, DMSO-d6 100 °C): δ 171.1, 168.2, 
167.8, 162.5, 62.3, 57.9, 53.8, 53.7, 46.6, 44.2, 28.2, 27.4, 23.6, 21.3, 21.1; HRMS-ESI+ (m/z) 
calcd for C15H22N3O5
+
 (M + H)
+ 324.1554, found 324.1555. 
 
Ac-Pro-Ser(TBS)-Pro 4-nitrophenyl ester (4.14). Tripeptide 4.12 (906 mg, 2.66 mmol, 1.0 equiv) 





TBSCl (1.2 g, 7.9 mmol, 3.0 equiv), and N-methylimidazole (1.34 mL, 1.38 g, 16.8 mmol, 6.0 
equiv) were added. The reaction was stirred for 3 hours at room temperature. The mixture was 
concentrated in the presence of silica and subjected to flash chromatography, 1% AcOH, 0 to 
10% MeOH in DCM. This provided the TBS ether as a mixture with inseparable impurities 
which was dissolved in 20 mL of pyridine and 4-nitrophenyl trifluoroacetate (1.25 g, 5.3 mmol, 
2.0 equiv) was added. The mixture was stirred overnight at room temperature and then was 
diluted with 100 mL of EtOAc and washed three times with 100 mL of 0.1 M HCl, 3 times with 
100 mL of 5% Na2CO3, and once with 50 mL of brine The organic layer was dried over MgSO4, 
filtered, and concentrated then the residue was purified by flash chromatography (0 to 6%) 
MeOH in DCM to give 200 mg of an amorphous white solid (14% yield for two steps). 1H NMR 
(CDCl3, 300 MHz): δ 8.15 (d, 2H, J = 9.1 Hz), 7.31 (m, 1H), 7.21 (d, 2H, J = 9.1 Hz), 4.74 (m, 
3H), 3.74 (m, 4H), 3.49 (m, 1H), 3.36 (m, 1H), 2.02 (m, 11H), 0.74 (s, 9H), -0.08 (s, 3H), -0.1 (s, 
3H); 13C {1H} NMR (CDCl3, 75 MHz): δ 171.2, 170.6, 169.6, 169.6, 155.5, 145.3, 125.0, 122.4, 
63.3, 59.6, 59.3, 52.8, 48.2, 47.2, 29.1, 28.0, 25.7, 25.1, 24.9, 22.4, 18.1, -5.7, -5.8; HRMS-ESI+ 
(m/z) calcd for C27H41N4O8Si
+ (M + H)+ 577.2688, found 577.2687. 
 
Ac-Pro-Ser-Pro 4-nitrophenyl ester (4.5). Compound 4.14 (190 mg, 0.33 mmol) was dissolved 
in 4 mL of TFA and stirred for 1 hour. The reaction was quenched 30 mL of ice water saturated 
with NaHCO3. 30 mL of brine was added and the mixture was extracted 5 times with a 3:1 





concentrated. Working quickly, the residue was purified by flash chromatography 0 to 10% 
MeOH in DCM to give a colorless oil (Rf = 0.1 in 5% MeOH in DCM). The product was 
immediately examined by 1H NMR and HRMS which confirmed the identity of the material. 
However the solution gradually turned yellow and after several hours TLC analysis showed that 
a significant amount of the product had decomposed by DKP formation releasing 4-nitrophenol 
and 4.13. 1H NMR (CDCl3, 300 MHz): δ 8.2 (d, 2H, J = 8.8 Hz), 7.41 (d, 1H, J = 7.7 Hz), 7.28 
(d, 2H, J = 8.8 Hz), 4.8 (m, 1H, J = 6.9 Hz), 4.67 (m, 1H, J = 4.2 Hz), 4.4 (dd, 1H, J = 7.3, 3.5 
Hz), 3.79 (s, 4H), 3.6-3.4 (m, 2H, J = 9.1 Hz), 2.5-1.8 (m, 11H); This compound decomposed 
before a carbon NMR could be obtained. HRMS-ESI+ (m/z) calcd for C21H27N4O8
+ (M + H)+ 
463.1823, found 463.1823. 
 
 
Ac-Pro-Ser(Bn)-Pro t-butyl ester (4.16). H-Ser(Bn)-OH (1.00 g, 5.10 mmol, 1.00 equiv) and 
NaOH (205 mg, 5.10 mmol, 1.00 equiv) were dissolved in 20 mL of water and 25 mL of THF 
and cooled to 0 °C. Allyl chloroformate (653 µL, 6.1 mmol, 1.2 equiv) was added dropwise and 
stirred for 5 hours until complete. The THF was removed by evaporation under reduced pressure 
and the mixture was adjusted to pH 12 with 1 M NaOH then washed with 30 mL of DCM. The 
aqueous layer was acidified to pH 1 with 1 M HCl and then extracted three times with 30 mL of 
DCM and the combined organic layers were dried over MgSO4, filtered, and concentrated. The 





mL, 12.8 mmol, 2.5 equiv), EDC·HCl (1.2 g, 6.1 mmol, 1.2 equiv) and H-Pro-OtBu·HCl (1.04 g, 
6.1 mmol, 1.2 equiv) were added. The reaction was stirred overnight then diluted with 200 mL of 
EtOAc and washed twice with 50 mL of 10% Na2CO3 twice with 50 mL of 10% citric acid and 
once with 50 mL of brine. The organic layer was dried over MgSO4, filtered, and concentrated to 
give crude 4.15. 
 The crude dipeptide was dissolved in 35 mL of DCM. DMBA (780 mg, 5.00 mmol, 1.00 
equiv) and Pd(PPh3)4 (92 mg, 0.08 mmol, 1.6 mol%) were added the mixture was stirred for 2 
hours until complete allyl deprotection was observed by TLC. The reaction was extracted three 
times with 30 mL of 0.1 M HCl. Then the combined aqueous layers were adjusted to pH 12 and 
saturated with NaCl then back extracted five times with 30 mL of 3:1 CH2Cl2:iPrOH. The 
combined organic layers was dried over MgSO4, filtered and concentrated. 
 Separately acyl proline (942 mg, 6.00 mmol, 1.50 equiv), HOAt, (816 mg, 6.00 mmol, 
1.50 equiv) and EDC·HCl (1.15 g, 6.00 mmol, 1.50 equiv) were dissolved in 30 mL of DCM at 0 
°C and stirred for 30 minutes before adding the deprotected dipeptide as a solution in 10 mL of 
DCM. The reaction was stirred for 30 minutes until complete then was diluted with 200 mL of 
EtOAc and washed with 50 mL of 10% Na2CO3, twice with 50 mL of 10% citric acid, and once 
with 50 mL of brine. The organic layer was dried over MgSO4, filtered, and concentrated. The 
residue was purified by flash chromatography, 0 to 10% MeOH in EtOAc, to give 4.16 as 1.19 g 
of white foam (45% yield). 4.16 existed as a mixture of rotamers in CDCl3. 
1H NMR (CDCl3, 
300 MHz): δ 7.27 (m, 5H), 6.95 (m, 1H), 4.84 (m, 1H), 4.44 (m, 4H), 3.53 (m, 6H), 1.96 (m, 
11H), 1.38 (s, 9H); 13C {1H} NMR (CDCl3, 75 MHz): δ (major rotamer) 171.3, 170.8, 170.4, 
168.4, 138.0, 128.2, 127.6, 127.5, 81.1, 73.2, 69.9, 59.8, 59.7, 51.2, 48.1, 47.0, 32.1, 30.6, 29.0, 





81.4 71.2 69.3 61.9 59.9 50.7 46.7 46.4 32.2 30.7 28.9 28.4 27.8 22.8 22.4 22.2; HRMS-ESI+ 
(m/z) calcd for C26H38N3O6
+(M + H)+ 488.2755, found 488.2745. 
 
Ac-Pro-Ser(Bn)-Pro 4-nitrophenyl ester (4.17). t-Butyl ester 4.16 (487 mg, 1.00 mmol, 1.00 
equiv) was dissolved in 10 mL of TFA and stirred for 30 minutes, until complete by TLC, then 
concentrated. The residue was dissolved in 3 mL of pyridine and 4-nitrophenyltrifluoroacetate 
(352 mg, 1.50 mmol, 1.50 equiv) was added and the reaction was stirred for 3 hours. The 
solution was diluted with 100 mL of EtOAc then washed twice with 10% citric acid and four 
times with 1% Na2CO3 the organic layer was dried over MgSO4, filtered, and concentrated. The 
residue was purified by flash chromatography, 0 to 20% MeOH in EtOAc, to give 250 mg of 
4.17 as a white foam (45% yield). 1H NMR (CDCl3, 300 MHz): δ 8.17 (d, 2H, J = 8.8 Hz), 7.42 
(d, 1H, J = 7.1 Hz), 7.23 (m, 5H), 4.92 (m, 1H), 4.65 (m, 1H), 4.47 (m, 3H), 3.78 (m, 2H), 3.69 
(m, 2H), 3.52 (m, 1H), 3.40 (m, 1H), 2.12 (m, 11H); 13C {1H} NMR (CDCl3, 75 MHz): δ 171.5, 
170.7, 169.8, 169.3, 155.4, 145.4, 137.7, 128.3, 127.6, 127.5, 125.1, 122.4, 73.4, 69.9, 59.7, 59.4, 
51.1, 48.2, 47.3, 29.1, 28.3, 25.2, 24.9, 22.5; HRMS-ESI+ (m/z) calcd for C28H33N4O8
+
 (M + H)
+ 
553.2293, found 553.2290. 
 
O-tert-butyldimethylsilyl Cbz-prolinol (4.19). Cbz-prolinol (884 mg, 4.00 mmol, 1.00 equiv) was 





mmol, 1.5 equiv) were added and stirred overnight. The mixture was diluted with 100 mL of 
ether and washed three times with 100 mL of 0.1 M HCl and once with 100 mL of 10% Na2CO3. 
The organic layer was dried over MgSO4, filtered, and concentrated. The residue was purified by 
flash chromatography, 20% EtOAc in hexane to yield 1.00 g of colorless oil (71%). 4.19 existed 
as a 1:1 mixture of rotamers in CDCl3 as determined by 2D-EXSY NMR which showed chemical 
exchange between the peaks at 3.5 and 3.75 ppm. 1H NMR (CDCl3, 300 MHz): δ 7.36 (m, 5H), 
5.19 (m, 2H), 3.92 (m, 1H), 3.60 (m, 4H), 1.95 (m, 4H), 0.92 (m, 9H), 0.07 (m, 6H); 13C {1H} 
NMR (CDCl3, 75 MHz): δ 154.8, 137.1 and 136.8, 128.4, 128.1 and 127.9, 127.8 and 127.7, 66.8 
and 66.5, 63.8 and 63.1, 59.0 and 58.4, 47.2 and 46.9, 28.3 and 27.5, 25.9 and 25.7, 23.9 and 
22.9, 18.2, -3.5 -5.5 HRMS-ESI+ (m/z) calcd for C19H32NO3Si
+
 (M + H)




oxopropan-2-yl)(methyl)carbamate (4.20). Compound 4.19 (350 mg, 1.00 mmol, 1.00 equiv) 
was dissolved in 5 mL of MeOH and Pd(OH)2 20 wt% on carbon (35 mg, 0.05 mmol, 5 mol%) 
was added. The mixture was stirred under a hydrogen atmosphere for 1 hour until complete then 
was filtered through a pad of celite and concentrated. 
 Separately alloc-N-methyl-O-benzyl serine (293 mg, 1.00 mmol, 1.00 equiv) was 
dissolved in 10 mL of DCM and Oxyma (142 mg, 1 mmol, 1 equiv) and DIPEA (176 µL, 1 
mmol, 1 equiv) were added followed by COMU (428 mg, 1 mmol, 1 equiv) the mixture was 





reaction was stirred for 2 hours then was diluted with 50 mL of EtOAc and washed with 50 mL 
of 10% citric acid then 50 mL of 10% Na2CO3. The organic layer was dried over MgSO4, 
filtered, and concentrated. The residue was purified by flash chromatography 5 to 30% EtOAc in 
hexane to yield 355 mg of a colorless oil (72% yield). 4.20 existed as a mixture of rotamers in 
CDCl3 as determined by 2D-EXSY NMR which showed chemical exchange between the peaks 
at 4.97 and 5.15. 1H NMR (CDCl3, 300 MHz): δ 7.28 (s, 5H), 5.89 (m, 1H), 5.21 (m, 3H), 4.55 
(m, 4H), 4.09 (s, 1H), 3.65 (m, 6H), 2.91 (m, 3H), 1.93 (m, 4H), 0.84 (m, 9H), -0.02 (m, 6H); 13C 
{1H} NMR (CDCl3, 75 MHz): δ (major rotamer) 167.8, 156.8, 137.9, 132.8, 128.3, 127.7, 127.6, 
117.3, 72.9, 66.7, 66.3, 62.3, 58.8, 56.1, 47.3, 29.7, 26.9, 25.8, 24.2, 18.1, -5.7; (minor rotamer) 
167.2, 156.0, 137.9, 132.7, 128.3, 127.7, 127.6, 117.8, 73.2, 67.0, 66.4, 62.3, 58.9, 57.0, 46.9, 
30.1, 26.9, 25.8, 24.2, 18.1, -5.7; HRMS-ESI+ (m/z) calcd for C26H43N2O5Si
+




 O-tert-butyldimethylsilyl-(Ac-Pro-N-methylSer(Bn)-prolinol) (4.21). Dipeptide 4.20 (355 
mg, 0.724 mmol, 1 equiv), Pd(PPh3)4 (8 mg, 7 µmol, 1 mol%), and DMBA (126 mg, 0.81 mmol, 
1.1 equiv) were dissolved in 5 mL of DCM and stirred for 30 minutes until complete by TLC. 
Separately Ac-Pro-OH (345 mg, 2.20 mmol, 3.00 equiv), HOAt (299 mg, 2.2 mmol, 3.00 equiv), 
DIPEA (390 µL, 2.2 mmol, 3.00 equiv) and EDC·HCl (422.4 mg, 2.2 mmol, 3 equiv) were 
dissolved in 5 mL of DCM at 0 °C and stirred for 15 minutes. Then the entire mixture was 
transferred to the alloc deprotection reaction and stirred overnight. TAEA (150 µL, 1 mmol) was 
added to the reaction and stirred 15 min to destroy unreacted HOAt ester and the mixture was 





Na2CO3. The organic layer was dried over MgSO4, filtered and concentrated. The residue was 
purified by flash chromatography, 0 to 10% MeOH in EtOAc, to yield 355 mg of a colorless oil 
(88% yield). 4.21 existed as a mixture of rotamers in CDCl3 as determined by 2D-EXSY NMR 
which showed chemical exchange between the peaks at 5.61 and 5.41 and the peaks for the N-
protons at 3.1 ppm. 1H NMR (CDCl3, 300 MHz): δ 7.29 (m, 5H), 5.61 (m) and 5.41 (t, J = 7.1 
Hz)(1H), 4.84 (m, 1H), 4.53 (m, 2H), 4.10 (m, 1H), 3.65 (m, 8H), 3.12 (m, 3H), 1.97 (m, 11H), 
0.85 (m, 9H), 0.00 (m, 6H); 13C {1H} NMR (CDCl3, 75 MHz): δ (major rotamer) 172.5, 169.0 
168.3, 137.9, 128.3, 127.8, 127.6, 72.9, 66.9, 62.3, 58.6, 56.7, 54.9, 48.0, 47.3, 31.6, 31.1, 28.8, 
26.8, 25.8, 24.7, 24.2, 22.3, -5.48, -5.50; (minor rotamer) 172.4, 169.4, 167.4, 137.3, 128.5, 
127.9, 127.6, 73.0, 66.0, 62.1, 58.7, 56.5, 54.3, 47.5, 46.7, 30.6, 30.4, 28.8, 26.9, 25.8, 24.5, 24.4, 
22.1, -5.48, -5.50 HRMS-ESI+ (m/z) calcd for C29H48N3O5Si
+
 (M + H)
+ 546.3358, found 
546.3354. 
 
 Ac-Pro-N-methylSer(Bn)-prolinol (4.22). Tripeptide 4.21 (355 mg, 0.651 mmol) was 
dissolved in 5 mL of 1:3:1 THF:AcOH:H2O and stirred overnight at rt then concentrated. The 
residue was purified by flash chromatography, 0 to 10% MeOH in DCM, to give 160 mg of a 
white foam (57% yield). 1H NMR (CDCl3, 300 MHz): δ 7.31 (m, 5H), 5.37 (t, 1H, J = 6.7 Hz), 
4.80 (dd, 1H, J = 8.0, 3.9 Hz), 4.57 (d, 1H, J = 12.0 Hz), 4.49 (d, 1H, J = 11.9 Hz), 4.15 (m, 
1H), 3.64 (m, 8H), 3.17 (m, 3H), 1.96 (m, 11H); 13C {1H} NMR (CDCl3, 75 MHz): δ 172.6, 
170.8, 169.3, 137.6, 128.4, 127.8, 127.8, 73.3, 67.5, 66.4, 61.3, 56.7, 55.1, 48.1, 47.9, 32.0, 28.7, 
28.1, 24.6, 22.2, 20.7; HRMS-ESI+ (m/z) calcd for C23H34N3O5
+
 (M + H)







Ac-Pro-N-methylSer(Bn)-proline (4.23). Tripeptide 4.22 (80 mg, 0.18 mmol, 1.0 equiv) was 
dissolved in 1.5 mL of acetone then cooled to 0 °C. 1.5 mL of 5% NaHCO3 was added followed 
by potassium bromide (28 mg, 0.18 mmol, 1.0 equiv), TEMPO (28 mg, 0.18 mmol, 1.0 equiv), 
and 6% sodium hypochlorite (825 µL, 0.74 mmol, 4.0 equiv). The mixture was stirred for 90 
minutes at room temperature then was diluted with 20 mL of water and washed with 20 mL of 
ether. The aqueous layer was adjusted to pH 1 with 1 M HCl and the extracted 3 times with 20 
mL of 10% MeOH in DCM. The organic layer was dried over MgSO4, filtered, and 
concentrated. The residue was purified by flash chromatography, 1% AcOH, 10% MeOH, 89% 
DCM to give 4.23 as 78 mg of a white foam (94% yield). 1H NMR (CDCl3, 300 MHz): δ 10.88 
(br, 1H), 7.24 (s, 5H), 4.97 (m, 2H), 4.47 (m, 3H), 3.63 (m, 6H), 3.08 (m, 3H), 1.99 (m, 11H); 
13C {1H} NMR (CDCl3, 75 MHz): δ 172.4, 171.3, 170.1, 137.4, 128.5, 127.9, 73.2, 66.7, 57.4, 
57.2, 48.4, 47.4, 28.6, 28.0, 24.9, 24.4, 21.5; HRMS-ESI+ (m/z) calcd for C23H31N3O6Na
+
 (M + 
Na)+ 468.2111, found 468.2107. 
 
 Ac-Pro-N-methylSer(Bn)-proline 4-nitrophenyl ester (4.24). Tripeptide 4.23 (38 mg, 0.085 
mmol, 1.0 equiv) was dissolved in 2 mL of pyridine and p-nitrophenyltrifluoroacetate (60 mg, 
0.26 mmol, 3.0 equiv) was added and the mixture was stirred for 1 hour at rt. The reaction was 





with 20 mL of 10% Na2CO3. The organic layer was died over MgSO4, filtered and concentrated 
to dryness. The residue was purified by HPLC using 40% CH3CN in water to yield 4.24 as a 
colorless oil, 23 mg (48% yield). 1H NMR (CDCl3, 300 MHz): δ. 8.14 (m, 2H), 7.20 (m, 7H), 
5.32 (m, 1H), 4.84 (m, 1H), 4.48 (m, 3H), 3.70 (m, 6H), 3.11 (m, 3H), 2.03 (m, 11H); 13C {1H} 
NMR (CDCl3, 75 MHz): δ 172.5, 169.9, 169.4, 169.1, 155.4, 145.4, 137.7, 128.3, 127.67, 
127.66, 125.1, 122.3, 73.2, 67.3, 59.3, 56.7, 55.7, 48.1, 47.0, 32.5, 28.9, 28.7, 25.2, 24.7, 22.2; 
HRMS-ESI+ (m/z) calcd for C29H35N4O8 (M + H)
+ 567.2449, found 567.2461. 
 
Resin-bound 1,4-diaminobenzene (4.25). Polystyrene supported 2-chlorotrityl resin (1.00 g, 1.50 
mmol, 1.00 equiv) was swelled in dry DCM under reflux for 15 minutes. Thionyl chloride (392 
µL, 5.4 mmol, 3.6 equiv) was added followed by DMF (22 µL, 0.30 mmol, 0.2 equiv). and the 
suspension was refluxed for 4 hours. The resin was transferred to a disposable polyethylene 
cartridge for peptide synthesis and rinsed with DMF (3 x 3 min) and DCM (3 x 3 min). A 
solution of 1,4-diamino benzene (1.3 g, 12 mmol, 1.5 equiv) and DIPEA (2.1 mL, 12 mmol, 1.5 
equiv) in 8 mL of DMF was added. And the mixture was stirred overnight at room temperature. 
After rinsing with DMF (3 x 3 min) and DCM (3 x 3 min) a solution of 9:1 DCM methanol was 
added and stirred for 30 minutes to cap any unreacted sites. Then the resin was rinsed DCM (3 x 
3 min) and dried under vacuum. 
General procedure for amino acid coupling on a solid support. 
 The resin was swelled in DMF for 15 minutes then Fmoc-AA-OH (4 equiv), HOBt (4 
equiv), and DIC (4 equiv) 0.5 M in DMF were added. The cartridge was mixed for 4 hours at 
room temperature and the cartridge was drained then the resin was rinsed with DMF (3 x 3 min) 





General procedure for Fmoc deprotection. 
 Fmoc groups were removed by two 5-minute treatments with 20% 4-methylpiperidine in 
DMF followed by rinsing with DMF (3 x 3 min) and DCM (3 x 3 min). 
General procedure for the synthesis of peptides 4.32-4.41 
 Peptides 4.32 to 4.41 were synthesized from 100 mg, 0.15 mmol, of resin 4.25 according 
to the general procedures for Fmoc SPPS. Once all amino acid residues were added the N-
terminal amine was capped with a solution of 2:3 acetic anhydride: pyridine with mixing for 30 
min. The acylated peptides were rinsed with DMF (3 x 3 min) and DCM (3 x 3 min) followed by 
cleavage with 1% TFA in DCM for 1 hour. The solvent was removed and the crude 4-
aminoalilide peptides were dissolved in 6 mL of 1:1 CH3CN:H2O with 12 equiv of Oxone
® and 
the mixture stirred overnight at room temperature. Brine was added and the mixture was 
extracted with 9:1 DCM:MeOH three times. The combined organic layers were dried over 
MgSO4, filtered and concentrated then purified by flash chromatography 1 to 10% MeOH in 
DCM. 
 For peptides which bore side t-butyl side chain protecting groups, deprotection was 
accomplished with 95:2.5:2.5 TFA:H2O:TIPS for 1 hour followed by concentration under 
reduced pressure. This was followed by a second round of flash chromatography 1 to 10% 
MeOH in DCM. 
 The purified 4-nitroanilides (Table 4.3) were analyzed by analytical HPLC and HRMS. 








dioxaborol-2-yl)butyl)chloro-l4-azane (4.44). Compound 4.44 was prepared according to a 
literature procedure.215  
 
Ac-Asp(OtBu)-Val-boroPro pinanediol boronate ester (4.45). Compound 4.44 (100 mg, 0.273 
mmol, 1.0 equiv) was dissolve in 2 mL of THF and potassium iodide (45 mg, 0.27 mmol, 1.0 
equiv) and DIPEA (95 µL, 0.55 mmol, 2.0 equiv) were added. White precipitates formed and the 
mixture was stirred for 1 hour at room temperature before cooling to -15 °C. A negative 
ninhydrin test indicated that cyclization was complete. 
 Separately Ac-Asp(OtBu)-Val-OH (132 mg, 0.34 mmol, 1.25 equiv) and NMM (31 µL, 
0.31 mmol, 1.125 equiv) were dissolved in 2 mL of THF and cooled to -15 °C. iso-Butyl 
chloroformate (40 µL, 0.31 mmol, 1.125 equiv) was added as a solution in 1 mL of THF and the 
mixture was stirred for 10 minutes before being transferred by cannula to the flask containing the 
crude amine. The mixture is stirred for 6 hours while warming slowly. Then the reaction was 
concentrated on silica and purified by flash chromatography, gradient elution 0 to 100% EtOAc 





δ 6.96 (d, 1H, J = 9.1 Hz), 5.63 (d, 1H, J = 8.7 Hz), 4.47 (t, 1H, J = 8.3 Hz), 4.37 (br, 1H), 4.23 
(m, 1H), 3.72 (t, 1H, J = 7.9 Hz), 3.43 (m, 1H), 3.10 (dd, 1H, J = 10.0, 6.9 Hz), 2.81 (dd, 1H, J 
= 16.7, 5.3 Hz), 2.54 (dd, 1H, J = 16.7, 5.1 Hz), 2.3-1.7 (m, 10H), 1.4-1.3 (m, 25H), 0.91 (d, 3H, 
J = 6.7 Hz), 0.87 (d, 3H, J = 6.7 Hz), 0.79 (s, 3H); 11B NMR (CDCl3, 96 MHz): δ 30.74 (br) and 
21.81 (br); 13C {1H} NMR (CDCl3, 75 MHz): δ 171.0, 170.5, 169.2, 155.4, 85.8, 81.3, 80.2, 
77.8, 55.5, 51.2, 46.8, 39.5, 39.4, 38.1, 37.1, 35.4, 31.4, 28.6, 28.3, 28.0, 27.3, 27.2, 27.1, 26.2, 
24.0, 19.0, 17.7; Note that a signal for the R2HC-B(OR)2 carbon was not observed due to 
quadrupolar coupling effects. However, the chemical shift of the unobserved peak can be 
determined by examination of the HMQC spectrum which shows a cross peak for Cα-Hα of 44.7-
3.09 ppm. HRMS-ESI+ (m/z) calcd for C32H55N3O8B
+
 (M + H)
+ 620.4078, found 620.4089. 
 
Boc-Pro-Ser(Bn)-boroPro pinanediol boronate ester (4.46). Compound 4.44 (400 mg, 0.8 mmol, 
1.0 equiv) was dissolve in 10 mL of THF and potassium iodide (132 mg, 0.8 mmol, 1 equiv) and 
DIPEA (279 µL, 1.6 mmol, 2 equiv) were added. White precipitates formed and the mixture was 
stirred for 1 hour at room temperature before cooling to -15 °C. A negative ninhydrin test 
indicated that cyclization was complete. 
 Separately Boc-Pro-Ser(Bn)-OH (392 mg, 1 mmol, 1.25 equiv) and NMM (99 µL, 0.9 
mmol, 1.125 equiv) were dissolved in 8 mL of THF and cooled to -15 °C. iso-Butyl 
chloroformate (116 µL, 0.9 mmol, 1.125 equiv) was added as a solution 4 mL of THF and added 
to the dipeptide and the mixture was stirred for 10 minutes before being transferred by cannula to 





to room temperature then concentrated on silica and purified by flash chromatography, 0 to 
100% EtOAc in hexane, 450 mg of 4.46 as a white foam (66% yield). 1H NMR (CDCl3, 300 
MHz): δ 7.28 (m, 5H), 7.07-6.71 (m, 1H), 4.93 (br, 1H), 4.53 (d, 1H, J = 11.8 Hz), 4.43 (d, 1H, J 
= 11.8 Hz), 4.24 (d, 1H, J = 7.6 Hz), 3.6-3.4 (m, 6H), 3.12 (t, 1H, J = 8.21 Hz), 2.3-1.8 (m, 
13H), 1.39 (s, 9H), 1.37 (s, 3H), 1.29 (d, 1H), 1.23 (s, 3H), 0.79 (s, 3H); 11B NMR (CDCl3, 96 
MHz): δ 32.3 (br); 13C {1H} NMR (CDCl3, 75 MHz): δ 172.2, 167.7, 154.2, 138.0, 128.4, 128.1, 
127.5, 85.7, 80.3, 73.1, 70.3, 60.7, 51.2, 50.0, 46.8, 44.5, 39.5, 38.1, 35.4, 30.9, 28.5, 28.2, 27.2, 
27.0, 26.1, 24.5, 24.0, 23.6; HRMS-ESI+ (m/z) calcd for C34H51N3O7B
+




Asp-Val-boroPro (4.47). Boronate ester 4.45 (118 mg, 0.19 mmol, 1.0 equiv) was dissolved in 2 
mL of DCM then 2 mL of TFA was added. The reaction was stirred for 1 hour and then the 
solvent was removed under a stream of N2 gas. The residue was dissolved in 3 mL of water and 
phenyl boronic acid (24 mg, 0.2 mmol, 1.05 equiv) was added. Hexane, 3 mL was added and 
stirred 30 minutes before being discarded, this washing was repeated a total of three times and 
the aqueous layer was purified by HPLC using a gradient of 10:90 CH3CN:H2O (0.1% TFA) to 
30:70 CH3CN:H2O (0.1% TFA) which yielded 49 mg of a white solid (75% yield). 
1H NMR 
(D2O, 300 MHz): δ 4.29 (m, 2H), 3.66 (t, 1H, J = 8.7 Hz), 3.39 (m, 1H), 2.85 (m, 3H), 1.96-1.78 
(m, 4H), 1.54 (m, 1H), 0.81 (m, 6H); 11B NMR (D2O, 96 MHz): δ 19.4 (s); 
13C {1H} NMR (D2O, 
75 MHz): 172.5, 170.0, 168.2, 57.0, 49.3, 47.4, 34.9, 29.4, 26.9, 26.6, 18.2, 17.1; Note that a 
signal for the R2HC-B(OR)2 carbon was not observed due to quadrupolar coupling effects. 





HMQC spectrum which shows a cross peak for Cα-Hα of 48.6-2.85 ppm. HRMS-ESI+ (m/z) calcd 
for C13H23N3O5B
+
 (M -H2O + H)
+ 312.1725, found 312.1723. 
 
Pro-Ser(Bn)-boroPro (4.48). Boronate ester 4.46 (88 mg, 0.14 mmol, 1.0 equiv) was dissolved in 
2 mL of DCM then 2 mL of TFA was added. The reaction was stirred for 1 hour and then the 
solvent was removed under a stream of N2 gas. The residue was dissolved in 3 mL of water and 
phenyl boronic acid (18.3 mg, 0.15 mmol, 1.07 equiv) was added. Hexane, 3 mL, was added and 
stirred 30 minutes before being discarded, this washing was repeated a total of three times and 
the aqueous layer was purified by HPLC using a gradient of 10:90 CH3CN:H2O (0.1% TFA) to 
30:70 CH3CN:H2O (0.1% TFA) which yielded 25 mg of a white solid (45% yield). 
1H NMR 
(D2O, 300 MHz): δ 7.42 (m, 5H), 4.64 (d, 1H, J = 11.8 Hz), 4.59 (d, 1H, J = 11.9 Hz), 4.39 (dd, 
1H, J = 8.2, 6.2 Hz), 3.87 (dd, 1H, J = 10.8, 4.8 Hz), 3.75 (m, 2H), 3.41 (m, 3H), 3.01 (dd, 1H, J 
= 10.8, 6.8 Hz), 2.43 (m, 1H), 2.04 (m, 6H), 1.65 m, 1H); 11B NMR (D2O, 96 MHz): δ 30.2 (br) 
and 19.5 (s); 13C {1H} NMR (D2O, 75 MHz): δ 169.3, 167.7, 136.7, 128.7, 128.5, 128.4, 73.1, 
67.5, 59.4, 51.9, 47.3, 46.4, 29.7, 26.7, 26.6, 23.6; Note that a signal for the R2HC-B(OR)2 
carbon was not observed due to quadrupolar coupling effects. However, the chemical shift of the 
unobserved peak can be determined by examination of the HMQC spectrum which shows a cross 
peak for Cα-Hα of 48.5-2.97 ppm. HRMS-ESI+ (m/z) calcd for C`9H27N3O4B
+
 (M -H2O + H)
+ 








Ac-Asp-Val-boroPro (4.43). Compound 4.47 (50 mg, 0.112 mmol, 1.0 equiv) was dissolved in 3 
mL of water. The solution was buffered with NaHCO3 (29 mg, 0.336 mmol, 3.0 equiv) and 
Na2CO3 (36 mg, 0.336 mmol, 3.0 equiv) and then 4-nitrophenyl acetate (61 mg, 0.336 mmol, 3.0 
equiv) was added. The reaction was stirred at room temperature for 1 hour until complete as 
determined by ninhydrin test and then 50 mL of 0.2 M HCl was added. The solution was washed 
3 times with 50 mL of DCM then the aqueous layer was neutralized with minimum ammonium 
acetate and concentrated. The residue was purified by RP HPLC, 1 to 10% CH3CN in H2O over 
40 minutes, RT = 40 min. This yielded 18 mg of a white solid (43% yield). 1H NMR (D2O, 300 
MHz): δ 4.55 (dd, 1H, J = 7.6, 6.1 Hz), 4.27 (dd, 1H, J = 8.1 Hz), 3.65 (ap t, 1H, J = 8.9 Hz), 
3.42-3.30 (m, 1H), 2.8 (dd, 1H, J = 11.2, 6.6 Hz), 2.73 (m, 1H), 2.64 (dd, 1H, J = 16.8, 7.7 Hz), 
2.00-1.75 (m, 7H), 1.52 (m, 1H), 0.79 (dd, 3H, J = 5.2 Hz), 0.77 (dd, 3H, J = 5.3 Hz); HRMS-
ESI+ (m/z) calcd for C15H26BN3NaO7
+
 (M + Na) 394.1756 found 394.1759. This compound was 
not soluble enough in D2O or DMSOd6 to obtain a 
13C NMR. 
 
Boc-(S,R)-prolinolyl trifluoromethane (4.51) and Boc-(S,S)-prolinolyl trifluoromethane (4.52). 
Compounds 4.51 and 4.51 were prepared according to the method of Podichetty,234 except that 
the mixture of diastereomers was separated by flash chromatography, 0 to 5% EtOAc in DCM 
(4.52 is more polar than 4.51). Both diastereomers gave NMR spectra that were identical to 






(S,S)-prolinolyl trifluoromethane hydrochloride (4.53). Compound 4.52 (836 mg, 3.11 mmol) 
was dissolved in 8.5 mL of 4 M HCl in dioxane and stirred at room temperature. After 30 
minutes the solution was concentrated to dryness then dissolved in 30 mL of water and the pH 
was adjusted to 12 with NaOH. The solution was extracted 3 times with 30 mL of 3:1 
CHCl3:iPrOH and the organic layers were concentrated. The free amine was dissolved in 0.1 M 
HCl and concentrated to dryness to give 4.53 as a grey powder 459 mg (72% yield). 1H NMR 
((CD3)2SO, 300 MHz): δ 9.56 (br, 2H), 7.10 (br, 1H), 4.60 (m, 1H), 3.69 (m, 1H), 3.14 (m, 2H), 
1.93 (m, 4H); 13C {1H} NMR ((CD3)2SO, 125 MHz): δ 124.5 (q, J = 283.1 Hz), 66.7 (q, J = 30.1 
Hz), 57.67, 45.14, 24.29, 23.29; 19F NMR ((CD3)2SO, 282 MHz): δ -75.9 (d, J = 7.17 Hz); 
HRMS-ESI+ (m/z) calcd for C6H11NOF3
+
 (M + H)
+ 170.0787, found 170.0787. 
 
Boc-Pro-Ser(Bn)-Prolinolyl trifluoromethane (4.55). Compound 4.53 (822 mg, 4.00 mmol, 1.00 
equiv) was placed in 30 mL of DCM and Boc-Ser(Bn)-OPfp (2.3 g, 5.00 mmol, 1.25 equiv) was 
added followed by DIPEA (1.29 g, 10 mmol, 2.5 equiv) the mixture was stirred until complete 
by TLC (8 h) and then the unreacted Pfp ester was destroyed by the addition of 225 µL of Tris(2-
aminoethyl)amine. This mixture was stirred for 30 minutes then was diluted with 200 mL of 
EtOAc and washed twice with 100 mL of 10% citric acid, twice with 100 mL of NaHCO3 and 





to give 4.54 which was used without further purification. 1H NMR (CDCl3, 500 MHz): δ 7.32 
(m, 5H), 5.59 (d, 1H, J = 7.9 Hz), 4.72 (m, 1H), 4.53 (m, 3H), 4.41 (m, 1H), 4.31 (m, 1H), 3.78 
(m, 1H), 3.69 (m, 1H), 3.61 (m, 1H), 3.42 (m, 1H), 2.11 (m, 1H), 2.01 (m, 2H), 1.79 (m, 1H), 
1.43 (s, 9H); 13C {1H} NMR (CDCl3, 125 MHz): δ 170.2, 155.4, 137.3, 128.5, 128.0, 127.8, 
124.4 (q, J = 256.8 Hz), 80.0, 73.5, 70.4, 68.8 (q, J = 29.1 Hz), 58.4, 52.4, 48.3, 28.3, 24.9; 19F 
NMR (CDCl3, 471 MHz): δ -75.3 (d, 3F, J = 6.9 Hz); HRMS-ESI
+ (m/z) calcd for 
C21H30O5N2F3
+
 (M + H)
+ 447.2101, found 447.2100. 
 The dipeptide 4.54 was dissolved in 10 mL of TFA and stirred for 20 minutes until 
complete by TLC and then was concentrated. The residue was dissolved in 30 mL of DCM and 
Ac-Pro-OPfp (1.60 g, 5.00 mmol, 1.25 equiv) was added followed by DIPEA (1.29 g, 10 mmol, 
2.5 equiv). The reaction was stirred overnight then was diluted with 200 mL of EtOAc and 
washed twice with 100 mL of 10% citric acid, twice with 100 mL of NaHCO3 and once with 100 
mL of brine. The organic layer was dried over MgSO4, filtered and concentrated. The residue 
was purified by flash chromatography, 0 to 10% MeOH in EtOAc, to give 1.3 g of 4.55 as a 
white solid (67% yield). This existed as a mixture of rotamers which coalesced by heating the 
compound in DMSO to 100 °C. 1H NMR (CDCl3, 500 MHz): δ 7.52 (d, 1H, J = 7.0 Hz), 7.31 
(m, 5H), 4.89 (dd, 1H, J = 12.5, 6.2 Hz), 4.5 (m, 5H), 4.31 (m, 1H), 3.71 (m, 3H), 3.55 (m, 1H), 
3.41 (m, 2H), 2.23 (m, 1H), 2.03 (m, 9H), 1.78 (m, 1H); 13C {1H} NMR (DMSO-d6, 100 °C, 125 
MHz): δ 172.0, 169.3, 169.0, 138.8, 125.8 (q, J = 288.7 Hz), 128.5, 127.8, 127.8, 73.0, 70.4, 
68.4, 59.8, 57.2, 51.8, 48.1, 47.4, 32.2, 29.2, 25.2, 24.7, 24.0, 22.3; 19F{1H} NMR (DMSO-d6, 
100 °C, 471 MHz): δ -75.04 (s, 3F); HRMS-ESI+ (m/z) calcd for C23H31O5N3F3
+
 (M + H)
+ 






Boc-Val-Prolinolyl trifluoromethane (4.56). Boc-Val-OH (217 mg, 1.00 mmol, 2 equiv), HOAt 
(136 mg, 1.00 mmol, 2 equiv) and DIPEA (172 µL, 1 mmol, 2 equiv) were dissolved in 10 mL 
of DCM and cooled to 0 °C then DCC (206 mg, 1.00 mmol, 2 equiv) was added. The mixture 
was stirred for 15 minutes before adding 4.53 (103 mg, 0.50 mmol, 1 equiv) the reaction was 
stirred overnight at room temperature and then filtered through a pad of celite and rinsed with 
100 mL of EtOAc. The filtrate was washed 50 mL of each of water, twice with 10% citric acid, 
twice with 10% Na2CO3 and brine. The organic layer was dried over MgSO4, filtered, and 
concentrated and the residue was purified by flash chromatography, 20 to 30% EtOAc in hexane 
to give 4.56 as 154 mg of white foam (84% yield). 1H NMR (CDCl3, 300 MHz): δ 5.42 (d, 1H, J 
= 6.5 Hz), 5.25 (d, 1H, J = 9.2 Hz), 4.32 (m, 3H), 3.81 (m, 1H), 3.40 (m, 1H), 1.94 (m, 5H), 
1.38 (s, 9H), 0.93 (d, 3H, J = 6.7 Hz), 0.85 (d, 3H, J = 6.7 Hz); 13C {1H} NMR (CDCl3, 75 
MHz): δ, 172.9, 156.0, 124.8 (q, J = 283.2 Hz), 79.7, 70.3 (q, J = 28.8 Hz), 58.9, 57.1, 48.2, 
31.1, 28.3, 25.7, 24.8, 19.5, 16.9; 19F NMR (CDCl3, 282 MHz): δ -75.1 (d, J = 6.6 Hz); HRMS-
ESI+ (m/z) calcd for C16H27N2O4F3Na
+
 (M + Na)
+ 391.1821, found 391.1814. 
 
Cbz-Asp(OBn)-Val-Prolinolyl trifluoromethane (4.57). Compound 4.56 (965 mg, 2.50 mmol, 1 
equiv) was dissolved in 10 mL of DCM and cooled to 0 °C then 10 mL of TFA was added and 
the reaction was stirred for 1 hour at rt until complete by TLC then concentrated to dryness. The 
residue was dissolved in 25 mL of DCM and DIPEA (871 µL, 5.00 mmol, 2 equiv) was added 





hour until complete as determined by a negative ninhydrin test. The mixture was washed with 25 
mL of 0.5 M HCl then 25 mL of brine then the organic layer was dried over MgSO4, filtered, and 
concentrated to dryness. The residue was purified by flash chromatography, gradient elution: 25 
to 60% EtOAc in hexane, to give 4.57 1.35 g of a white foam (89% yield). 1H NMR (CDCl3, 300 
MHz): δ 7.31 (m, 10H), 7.23 (d, 1H, J = 8.8 Hz), 6.02 (d, 1H, J = 8.9 Hz), 5.30 (d, 1H, J = 7.4 
Hz), 5.10 (m, 4H), 4.61 (m, 2H), 4.42 (t, 1H, J = 6.9 Hz), 4.31 (m, 1H), 3.81 (m, 1H), 3.41 (m, 
1H), 3.05 (dd, 1H, J = 16.9, 4.3 Hz), 2.74 (dd, 1H, J = 17.1, 5.8 Hz), 2.03 (m, 4H), 1.78 (m, 1H), 
0.92 (d, 3H, J = 6.7 Hz), 0.85 (d, 3H, J = 6.7 Hz); 13C {1H} NMR (CDCl3, 75 MHz): δ 172.0, 
171.5, 170.3, 156.1, 135.9, 135.3, 128.6, 128.4, 128.3, 128.25, 128.20, 124.9 (q, J = 283.9 Hz), 
70.3 (q, J = 28.8 Hz), 67.4, 66.9, 59.1, 56.2, 51.3, 48.4, 36.2, 31.2, 25.9, 24.7, 19.5, 17.1; 19F 
NMR (CDCl3, 282 MHz): δ -75.1 (d, J = 7.3 Hz); HRMS-ESI
+ (m/z) calcd for C30H36N3O7F3
+
 
(M + H)+ 608.2578, found 608.2577. 
 
.Ac-Asp-Val-Prolinolyl trifluoromethane (4.58). Compound 4.57 (930 mg, 1.53 mmol, 1 equiv) 
was dissolved in 50 mL of MeOH and Pd(OH)2 20 wt% on carbon (93 mg, 0.13 mmol, 0.086 
equiv) was added. The mixture was stirred under a hydrogen atmosphere for 3 hours then was 
filtered through celite and concentrated. The residue was dissolved in 20 mL of DMF and K2CO3 
(422 mg, 3.06 mmol, 2 equiv) and p-nitrophenyl acetate (554 mg, 3.06 mmol, 2 equiv) were 
added. The mixture was stirred for 1 hour then was concentrated. The residue was purified by 
flash chromatography with 1% AcOH, 10% MeOH and 89% EtOAc to give 4.58 as 437 mg of 
white foam (67%). 1H NMR (D2O, 300 MHz): δ 4.58 (dd, 1H, J = 7.4, 6.0 Hz), 4.48 (qd, 1H, J = 





(s, 2H), 2.74 (dd, 1H, J = 16.9, 5.7 Hz), 2.64 (dd, 1H, J = 16.8, 7.8 Hz), 1.9 (m, 8H), 0.80 (d, 
6H, J = 6.6 Hz); 13C {1H} NMR (D2O, 75 MHz): δ 74.0, 173.8, 172.2, 171.6, 124.6 (q, J = 282.8 
Hz), 67.4 (q, J = 29.3 Hz), 57.3, 56.8, 50.0, 48.8, 48.5, 35.3, 30.2, 24.6, 23.6, 21.6, 18.1, 17.3; 
19F NMR (D2O, 282 MHz): δ -76.66 (d, J = 7.2 Hz); HRMS-ESI
+ (m/z) calcd for C17H27N3O6F3
+
 
(M + H)+ 426.1847, found 426.1845. 
 
Ac-Asp-Val-Prolinyl trifluoromethane (4.59). Alcohol 4.55 (610 mg, 1.23 mmol, 1.00 equiv) was 
added to a solution of Dess Martin reagent (1.30 g, 3.08 mmol, 2.50 equiv) in 13 mL of DCM. 
The clear solution was stirred at room temperature for 3 hours then quenched with 10 mL of sat. 
sodium thiosulfate. 50 mL of EtOAc was added and the mixture was washed twice with 50 mL 
of sat. NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated. The residue 
was purified by flash chromatography using 40% acetone in DCM to give 380 mg (62% yield). 
NMR showed that this existed as a mixture of isomers, approximately 3:7. These did not 
coalesce upon heating in DMSO and may result from epimerization of the carbonyl α-carbon. 1H 
NMR (D2O, 300 MHz): δ 8.07-7.70 (m, 1H), 7.36 (s, 5H), 4.9 (dd, 0.3H, J = 7.6, 4.6 Hz), 4.83 
(ap t, 0.7H, J = 5.8 Hz), 4.55 (s, 2H), 4.51-4.47 (m, 1H), 4.38-4.25 (m, 1H), 3.81-3.38 (m, 6H), 
2.17-1.79 (m, 11H); 13C {1H}NMR (4:1CD3CN:D2O, 75 MHz): δ (major isomer) 173.3, 172.9, 
171.5, 137.8, 128.4, 127.9, 127.8, 123.5 (q, J = 288.0 Hz), 73.0, 68.9, 62.7, 59.7, 51.5, 48.8, 
48.2, 29.4, 25.9, 24.3, 24.0, 21.5; (minor isomer) 173.1, 172.8, 171.6, 137.7, 128.4, 127.9, 127.8, 
123.5 (q, J = 288.0 Hz), 72.9, 68.8, 62.6, 61.2, 51.6, 48.8, 46.8, 31.7, 26.0, 24.1, 22.5, 21.4 (the 






NMR (4:1CD3CN:D2O, 283 MHz): δ Hydrate (Major isomer-80.8), (Minor isomer)-80.9. Minor 
peaks (<5%) are also observed at -76.4 and -77.5 for the keto form. 
 
Ac-Asp(OBn)-Val-Prolinolyl trifluoromethane (4.61). Compound 4.56 (153 mg, 0.42 mmol, 1 
equiv) was dissolved in 4 mL of 4 M HCl in dioxane and stirred for 1 hour then concentrated. A 
mixture of Ac-Asp(OBn)-OH (222 mg, 0.84 mmol, 2.0 equiv), HOAt (114 mg, 0.84 mmol, 2.0 
equiv), DIPEA (61 mg, 0.84 mmol, 2.0 equiv) and DIC (106 mg, 0.84 equiv, 2.0 equiv) were 
added as a solution of 10 mL of DCM. The mixture was stirred overnight then the unreacted 
HOAt ester was destroyed by the addition of 270 µL of tris(2-aminoethyl)amine. After stirring a 
further 10 minutes the mixture was diluted with 100 mL of EtOAc and was washed twice with 
50 mL of 10% citric acid and twice with 50 mL of 10% Na2CO3 then the organic layer was dried 
over MgSO4, filtered and concentrated. The residue was purified by flash chromatography, 70 to 
100% EtOAc in hexane, to give 106 mg of 4.61 as a white foam (49% yield). 1H NMR (CD3CN, 
300 MHz): δ 7.35 (s, 5H), 7.19-7.09 (m, 1H), 6.98-6.92 (m, 1H), 5.09 (s, 2H), 4.78-4.68 (m, 1H), 
4.61-4.50 (m, 3H), 4.22 (t, 1H, J = 7.1 Hz), 3.73 (m, 1H), 3.38 (dd, 1H, J = 16.6, 7.8 Hz), 2.82 
(dd, 1H, J = 16.4, 6.4 Hz), 2.71 (dd, 1H, J = 16.6, 6.5 Hz), 2.13-1.74 (m, 8H), 0.91 (d, 3H, J = 
6.8 Hz), 0.85 (d, 3H, J = 6.7 Hz); 13C {1H} NMR (CD3CN, 75 MHz): δ (major rotamer)170.4, 
170.3, 170.0, 169.9, 136.0, 125.0 (q, J = 283.0 Hz), 128.2, 127.8, 127.6, 67.7 (q, J = 28.5 Hz), 
65.8, 56.8, 55.6, 49.4, 47.5, 35.2, 30.6, 24.5, 23.6, 21.6, 18.5; (minor rotamer) 170.4, 170.3, 
170.0, 169.9, 136.0, 124.9 (q, J = 282.7 Hz), 128.2, 127.8, 127.7, 67.7 (q, J = 28.4 Hz), 65.8, 





MHz): δ major rotamer -76.96 minor rotamer -76.98 HRMS-ESI+ (m/z) calcd for C24H33F3N3O6
+
 
(M + H)+ 516.2316, found 516.2317. 
 
Ac-Asp(OBn)-Val-Prolinyl trifluoromethane (4.62). Alcohol 4.61 (350 mg, 0.67 mmol, 1 equiv) 
was dissolved in 3.5 mL of DCM and then Dess Martin reagent (0.2 M in DCM, 5.9 mL, 1.18 
mmol, 1.75 equiv) was added. The mixture was stirred for 2 hours until complete by 19F NMR. 
Then 25 mL of DCM was added and the mixture was washed twice with 25 mL of 5% Na2CO3. 
The organic layer was dried over MgSO4 and the residue was purified by flash chromatography 
with 100 EtOAc to give 260 mg of a colorless oil (75% yield). 1H NMR (2:1 Acetone-d6:D2O, 
300 MHz): δ 7.28 (s, 5H), 5.05 (s, 2H), 4.79 (m, 1H), 4.5 (t, 1H, J = 8.0 Hz), 4.37 (m, 1H), 3.96 
(m, 1H), 3.44 (m, 1H), 2.87 (dd, 1H, J = 16.1, 6.3 Hz), 2.72 (dd, 1H, J = 16.3, 8.6 Hz), 2.03-
1.89 (m, 7H), 1.75 (m, 1H), 0.88 (d, 3H, J = 6.5 Hz), 0.83 (d, 3H, J = 6.6 Hz); 13C {1H}NMR 
(2:1 Acetone-d6:D2O, 75 MHz): δ 175.1, 171.8, 171.1, 170.7, 135.9, 123.7 (q, J = 289.6 Hz), 
128.5, 128.0, 95.0 (q, J = 29.7 Hz), 66.4, 62.4, 56.6, 49.7, 49.0, 35.9, 30.5, 26.0, 24.1, 21.8, 18.6, 
17.3; 19F NMR (2:1 Acetone-d6:D2O, 283 MHz): δ -82.1 HRMS-ESI
+ (m/z) calcd for 
C24H31F3N3O6
+ (M + H)+ 514.2159, found 514.2161. 
 
Ac-Asp-Val-Prolinyl trifluoromethane (4.60). Compound 4.62 (260 mg, 0.5 mmol) was dissolved 
in 9.5 mL of MeOH and 0.5 mL of AcOH. 26 mg of Pd(OH)2, 20 wt % on carbon was added and 
the mixture was stirred under a hydrogen atmosphere for 16 hours. Then the catalyst was 





was purified by preparative TLC using 1% AcOH in EtOAc. The product was collected and 
lyophilized to give 96 mg of a white powder (44% yield). 19F NMR indicated that the compound 
existed primarily as a hydrate in D2O and as a 1:1 mixture of two isomers, additionally a small 
amount, <10%, of the ketone was present. 1H NMR (D2O, 500 MHz): δ 4.64 (m, 1H), 4.48 (m, 
2H), 3.91 (m, 1H), 3.5 (m, 1H), 2.79-2.70 (m, 2H), 2.05-2.00 (m, 7H), 1.79 (m, 1H), 0.91-0.81 
(m, 6H); 13C {1H} NMR (D2O, 125 MHz): δ 175.01, 174.98, 174.1, 172.45, 123.02 (q, J = 288.6 
Hz), 94.8 (q, J = 30.9 Hz), 61.68 and 61.63, 57.21 and 57.17, 50.18 and 50.16, 49.17, 35.9 and 
35.5, 30.26 and 30.25, 25.62, 23.86, 21.66 and 21.61, 18.26 and 18.25, 17.06 and 17.04; 19F 
NMR (D2O, 471 MHz): δ (Hydrate) Mixture of isomers -82.21, -82.23 (Ketone) -75.8; HRMS-
ESI+ (m/z) calcd for C17H27F3N3O7
+
 (M + H2O + H)
+ 442.1796, found 442.1796. 
 
Boc-Val-Phe-Tyr(Bn)OBn (4.67). Boc-Tyr(Bn)-OBn (507 mg, 1.10 mol, 1.10 equiv) was 
dissolved in 10 mL of TFA. 1 mL of anisole was added as a t-butyl scavenger. This was stirred 
for 30 minutes until complete by TLC. The reaction was concentrated than redissolved in 30 mL 
of 10% Na2CO3 and extracted three times with 30 mL of EtOAc. The combined organic layers 
were dried over MgSO4s, filtered, and concentrated. The residue was dissolved in 10 mL of 
DCM and Boc-Phe-OPfp (431 mg, 1.00 mmol, 1.00 equiv) was added followed by 10 mL of 5% 
NaHCO3 the mixture was stirred for 2 hours. Then unreacted Pfp ester was destroyed by the 
addition of tris(2-aminoethyl)amine (1 mmol, 150 µL, 1.00 equiv) and stirring for 5 minutes. The 
organic layer was separated, and the aqueous layer was extracted with 20 mL of EtOAc. The 





were dried over MgSO4, filtered, and concentrated. This yielded crude Boc-Phe-Tyr(Bn)-OBn 
which was used without further purification. 
 The crude dipeptide was dissolved in 10 mL of TFA. 1 mL of anisole was added as a t-
butyl scavenger. This was stirred for 30 minutes until complete by TLC then was concentrated 
then redissolved in 30 mL of 10% Na2CO3 a extracted three times with 30 mL of EtOAc. The 
combined organic layers were dried over MgSO4s, filtered and concentrated. This was 
redissolved in 10 mL of DCM and Boc-Val-OPfp (421 mg, 1.1 mmol, 1.1 equiv) was added 
followed by 10 mL of 5% NaHCO3. The reaction was stirred for 16 hours then unreacted Pfp 
ester was destroyed by the addition of Tris(2-aminoethyl)amine (1 mmol, 150 µL, 1.00 equiv) 
and stirring for 5 minutes. The reaction was diluted with 100 mL of EtOAc and then washed 3 
times with 100 mL of 1 M HCl and 3 times with 10% Na2CO3. The organic layer was dried over 
MgSO4, filtered, and concentrated. The residue was purified by flash chromatography, 20 to 40% 
EtOAc in hexane, to give 460 mg of 4.67 as a white solid (65% yield). 1H NMR (CDCl3, 300 
MHz): δ 7.3 (m, 15H), 6.76 (s, 4H), 6.45 (d, 1H, J = 4.9 Hz), 6.09 (d, 1H, J = 5.0 Hz), 5.09 (s, 
2H), 5.00 (s, 2H), 4.88 (d, 1H, J = 7.2 Hz), 4.71 (dd, 1H, J = 13.2, 6.1 Hz), 4.61 (dd, 1H, J = 
13.3, 6.6 Hz), 3.88 (t, 1H, J = 6.8 Hz), 3.1 (dd, 1H, J = 13.6, 5.8 Hz), 2.96 (m, 2H), 2.09 (m, 
1H), 1.44 (s, 9H), 0.88 (d, 3H, J = 6.8 Hz), 0.79 (d, 3H, J = 6.3 Hz); 13C {1H} NMR (CDCl3, 75 
MHz): 171.6, 170.7, 170.2, 157.9, 155.9, 137.0, 136.3, 135.1, 130.3, 129.4, 128.7, 128.6, 128.5, 
128.0, 127.7, 127.5, 127.0, 114.9, 80.0, 69.9, 67.2, 60.0, 54.2, 53.6, 38.3, 37.1, 30.8, 28.4, 19.3, 
HRMS-ESI+ (m/z) calcd for C42H49N3O7Li
+
 (M + Li)






Cbz-proline (3-methyloxetan-3-yl)methyl ester (4.70). (3-methyloxetan-3-yl)methanol (490 mg, 
4.80 mmol, 1.2 equiv) and DMAP (5 mg, 0.04 mmol, 0.01 equiv) were dissolved in 6 mL of 
DCM and cooled to 0 °C. DIC (555 mg, 475 µL, 4.40 mmol, 1.10 equiv) was added followed by 
Cbz-Pro-OH (1.00 g, 4.00 mmol, 1 equiv). After stirring for 2 hours, an additional 150 µL of 
DIC was added. After stirring for 3 hours in total the reaction was diluted with 50 mL of DCM 
and washed with 50 mL of 0.1 M HCl then 50 mL of brine. The organic layer was dried over 
MgSO4, filtered and concentrated. The residue was purified by flash chromatography, 40 to 60% 
EtOAc in hexane to give 4.70 as a colorless oil, 1.00 g, (75% yield). 1:1 mixture of rotamers. 1H 
NMR (CDCl3, 500 MHz): δ 7.34 (m, 5H), 5.13 (m, 2H), 4.53 (d, 0.5H, J = 6.0 Hz), 4.50 (d, 
0.5H, J = 6.0 Hz), 4.45 (dd, 0.5H, J = 8.6, 3.5 Hz), 4.40 (dd, 0.5H, J = 8.7, 3.6 Hz), 4.36 (m, 
2H), 4.28 (dd, 1H, J = 5.8, 3.8 Hz), 4.25 (d, 0.5H, J = 11.2 Hz), 4.21 (d, 0.5H, J = 11.1 Hz), 
4.10 (d, 0.5H, J = 11.1 Hz), 4.00 (d, 0.5H, J = 11.1 Hz), 3.58 (m, 2H), 2.3 (m, 1H), 1.98 (m, 
3H), 1.33 (s, 1.5H), 1.22 (s, 1.5H); 13C {1H} NMR (CDCl3, 125 MHz): δ 172.9, 172.7, 154.8, 
154.2, 136.7, 136.5, 128.5, 128.4, 128.0, 128.0, 128.0, 127.9, 79.4, 79.4, 79.2, 79.2, 68.9, 68.9, 
67.1, 67.0, 59.3, 58.9, 46.9, 46.4, 39.2, 39.0, 31.0, 30.0, 24.4, 23.5, 21.1, 20.9; HRMS-ESI+ (m/z) 
calcd for C18H24O5N
+
 (M + H)
+ 334.1649, found 334.1648. 
 
Cbz-Pro-OBO (4.71). Ester 4.70 (5.93 g, 17.8 mmol, 1.00 equiv) was dissolved in 40 mL of 
DCM and BF3·OEt2 (252 mg, 220 µL, 1.78 mmol, 0.1 equiv) was added. The reaction was stirred 
at room temperature for 6 hours then was quenched by adding 400 µL of triethyl amine and 
stirring an additional 30 minutes. The solution was concentrated then dissolved in 120 mL of 





once with 100 mL of brine. The organic layer was dried over MgSO4, filtered, and concentrated 
to give 5.41 g of a white solid that was used without further purification (91% yield). 1H NMR 
(CDCl3, 300 MHz): δ 7.39 (d, 2H, J = 7.3 Hz), 7.33 (t, 2H, J = 7.4 Hz), 7.28 (m, 1H), 5.21 
(broad doublet, 1H, J = 8.5 Hz), 5.07 (d, 1H, J = 12.4 Hz), 4.18 (m, 1H), 3.86 (s, 6H), 3.55 (m, 
1H), 3.39 (m, 1H), 2.08 (m, 2H), 1.76 (m, 2H), 0.77 (s, 3H); 13C {1H} NMR (CDCl3, 75 MHz):, 
δ, 155.7, 137.2, 128.3, 127.8, 127.7, 109.8, 72.6, 66.7, 60.4, 47.1, 30.5, 26.4, 23.8, 14.5; HRMS-
ESI+ (m/z) calcd for C18H24NO5
+
 (M + H)
+ 333.1649, found 334.1646. 
 
Pro-OBO (4.72). Compound 4.71 (260 mg, 0.78 mmol) was dissolved in 18 mL of MeOH and 
42 mg of Pd 10 wt% on carbon was added. The suspension was stirred under a hydrogen 
atmosphere for 16 hours then was filtered through a pad of celite and concentrated. The residue 
was purified by flash chromatography, 0 to 10% triethylamine in EtOAc to give 127 mg of a 
yellow solid (82% yield). 1H NMR (CDCl3, 300 MHz): δ 3.75 (s, 6H), 3.06 (t, 1H, J = 6.9 Hz), 
2.84 (m, 1H), 2.7 (m, 1H), 1.95 (s, 1H), 1.56 (m, 4H), 0.64 (s, 3H); 13C {1H} NMR (CDCl3, 75 
MHz): δ 109.5, 72.6, 61.5, 46.9, 30.5, 26.0, 25.5, 14.4 HRMS-ESI+ (m/z) calcd for C10H18NO3
+
 
(M + H)+ 200.1281, found 200.1282. 
 
Mesyl-Pro-OBO (4.73). Compound 4.72 (1.95 g, 9.80 mmol, 1.00 equiv) was dissolved in 50 mL 
of DMF and DIPEA (3.10 g, 4.30 mL, 24 mmol, 2.40 equiv) was added followed by 
methanesulfonyl chloride (1.14 g, 930 µL, 12.0 mmol, 1.2 equiv) the reaction was stirred for 90 





flash chromatography, 60% EtOAc in hexane to give 2.4 g of light brown solid (89% yield). 1H 
NMR (CDCl3, 300 MHz): δ4.07 (dd, 1H, J = 8.2, 2.5 Hz), 3.86 (s, 6H), 3.66 (m, 1H), 3.2 (m, 
1H), 2.97 (s, 3H), 1.92 (m, 4H), 0.78 (s, 3H); 13C {1H} NMR (CDCl3, 75 MHz): δ 109.4, 72.6, 
62.2, 48.7, 40.9, 30.6, 27.4, 24.8, 14.4; HRMS-ESI+ (m/z) calcd for C11H19NO5S (M + H)
+ 
278.1058, found 278.1057. 
 
allyl (S)-2-(2-(((R)-2-(4-methyl-2,6,7-trioxabicyclo[2.2.2]octan-1-yl)pyrrolidin-1-yl)sulfonyl)-
acetyl)pyrrolidine-1-carboxylate (4.74) Compound 4.73 (1.22 g, 4.40 mmol, 2.10 equiv) was 
dissolved in 30 mL of THF and cooled to – 78 °C. BuLi (2.5 M in hexane, 1.76 mL, 4.40 mmol, 
2.1 equiv) was added dropwise and the mixture was stirred for 30 minutes before adding alloc-
Pro-OMe (446 mg, 2.09 mmol, 1.00 equiv) as a solution in 5 mL of THF over a period of 5 
minutes. The reaction was stirred for an additional 40 minutes until complete by TLC then was 
quenched with sat. NH4Cl, 50 mL. The reaction was extracted 3 times with 50 mL of DCM then 
the combined organic layers were dried over MgSO4, filtered, and concentrated, flash 
chromatography, 40 to 50% EtOAc in hexane gave 775 mg 4.74 as a colorless oil (81% yield). 
1H NMR (CDCl3, 500 MHz): δ 5.93 (m, 1H), 5.3 (d, 1H, J = 17.4 Hz), 5.21 (d, 1H, J = 10.4 Hz), 
4.62 (m, 4H), 4.33 (m, 1H), 4.18 (m, 1H), 3.92 (s, 6H), 3.73 (dd, 1H, J = 15.1, 8.2 Hz), 3.58 (m, 
2H), 3.35 (m, 1H), 2.21 (m, 3H), 1.96 (m, 5H), 0.81 (s, 3H); 13C {1H} NMR (CDCl3, 75 MHz): δ 
(Major Rotamer) 199.2, 154.6, 132.7, 117.1, 109.1, 72.3, 65.7, 64.8, 62.3, 49.0, 46.7, 30.4, 28.7, 





47.1 30.4 29.5 27.1 24.5 23.3 14.1 HRMS-ESI+ (m/z) calcd for C20H31N2O8S
+
 (M + H)
+ 
459.1796, found 459.1773. 
 
N-(alloc-prolinyl)methanesulfonyl proline (4.76). Compound 4.74 (652 mg, 1.42 mmol) was 
dissolved in a mixture of 24 mL of DCM, 600 µL of water and 150 µL of TFA. The reaction was 
stirred at room for 30 minutes until complete by TLC then was concentrated. The residue was 
dissolved in 6 mL of THF and 18 mL of 0.5 M NaOH was added. This was stirred at room 
temperature for 1 hour until complete by TLC and then was diluted with 15 mL of 1 M HCl and 
extracted three times with 15 mL of 3:1 CHCl3:iPrOH. The combined organic layers were dried 
over MgSO4, filtered, and concentrated. The residue was purified by flash chromatography, 80% 
EtOAc, 19% hexane, 1%AcOH, to give 478 mg of a white solid (89% yield). 1H NMR (CDCl3, 
300 MHz): δ 10.75 (s, 1H), 5.8 (m, 1H), 5.14 (m, 2H), 4.36 (m, 6H), 3.44 (m, 4H), 2.04 (m, 8H); 
13C {1H} NMR (CDCl3, 75 MHz): δ (major rotamer) 198.8 175.6 155.2 132.4 117.5 66.3 65.7 
60.9 59.3 48.5 46.8 30.8 28.2 24.7 24.2 (minor rotamer) 198.6, 175.6, 154.4, 132.4, 118.0, 66.4, 
65.6, 60.9, 58.9, 48.6, 47.2, 30.9, 29.2, 24.7, 23.4; HRMS-ESI+ (m/z) calcd for C15H23N2O7S1
+
 
(M + H)+ 375.1221, found 375.1217. 
 
N-(alloc-prolinyl)difluoromethanesulfonyl proline (4.66). Compound 4.74 (400 mg, 0.87 mmol, 
1 equiv) was dissolved in 16 mL of DCM then 400 µL of water and 100 µL of TFA were added. 
The mixture was stirred for 30 minutes until complete by TLC and then evaporated to dryness. 





was stirred for 1 hour and then acidified to pH 1 and diluted with 40 mL of brine. This was 
extracted three times with 40 mL of 3:1 CHCl3;iPrOH. The combined organic layers were dried 
over MgSO4, filtered, and concentrated. The residue was dissolved in 20 mL of DMF and cesium 
fluoride (800 mg, 5.2 mmol, 6.0 equiv) was added followed by Selectfluor (1.85 g, 5.2 mmol, 6.0 
equiv). After stirring 1 hour the reaction was diluted with 100 mL of EtOAc and washed twice 
with 100 mL of 0.1 M HCl. The combined aqueous layers were back extracted with 100 mL of 
3:1 CHCl3;iPrOH, then the combined organic layers were dried over MgSO4, filtered and 
concentrated. The residue was purified by flash chromatography, 47.5:2.5:50 
EtOAc:AcOH:hexane to give 278 mg of a white solid (78% yield). 1H NMR (CDCl3, 300 MHz): 
δ 8.21 (broad singlet, 1H), 5.87 (m, 1H), 5.23 (m, 2H), 4.94 (dd, 1H, J = 8.3, 4.7 Hz), 4.54 (m, 
3H), 3.63 (m, 4H), 2.15 (m, 8H); 13C {1H} NMR (CDCl3, 75 MHz): δ 194.6 (t, J = 26.0 Hz), 
174.7, 154.1 (m), 132.5, 117.4, 66.3, 61.4, 61.2, 49.6, 46.6, 30.8, 29.2, 24.2, 23.3; 19F NMR 
(CDCl3, 282 MHz): δ (major rotamer) -106.7 (d, J = 250.6 Hz), -108.6 (d, J = 251.2 Hz); (minor 
rotamer) -107.7 (apparent singlet); HRMS-ESI+ (m/z) calcd for C15H21N2O7SF2
+
 (M + H)
+ 
411.1032, found 411.1018. 
 
N-(alloc-prolinyl)difluoromethanesulfonyl Pro-Val-Phe-Tyr(Bn)-OBn (4.65). Tripeptide 4.67 (50 
mg, 0.071 mmol, 1 equiv) was dissolved in 3 mL of 4 M HCl in dioxane with 1 mL of anisole 
added as a t-butyl scavenger. The reaction was stirred for 30 minutes and then concentrated and 





combined organic layers were dried over MgSO4, filtered, and concentrated then redissolved in 3 
mL of DMF. HOAt (50 mg, 0.37 mmol, 5.2 equiv) and 4.66 (30 mg, 0.73 mmol, 1.0 equiv) were 
added and the mixture cooled to 0 °C. DCC (50 mg, 0.364 mmol, 5.1 equiv) was added and then 
the mixture was stirred overnight. The suspension was then filtered through a pad of celite, 
diluted with 50 mL of EtOAc, then washed with 50 mL of water then 50 mL of brine. The 
organic layer was dried over MgSO4, filtered, and concentrated then the residue was purified by 
flash chromatography, 50 to 70% EtOAc in hexane, to give 58 mg of 4.65 as a white solid (81% 
yield). This was judged to be >95% pure by analytical RP-HPLC. HRMS-ESI+ (M/z): calcd for 
C52H60O11N5F2S
+ [M +H]+, 1000.3973; found 1000.3975. See Appendix Figure A21 and A22 for 
copies of data. 
 
Boc-Ala-diphenylmethylamide (4.81). Sulfonamide 4.80 (50 mg, 0.1 mmol, 1 equiv) was 
dissolved in 4.5 mL of toluene and 500 µL of TFA was added. The reaction was stirred for 1 
hour until complete by TLC then 5 mL of 10% Na2CO3 was added. Boc-Ala-OPfp (50 mg, 0.13 
mmol, 1.1 equiv) was added dissolved in 1 mL of toluene. The reaction was stirred for 90 
minutes at room temperature then diluted with 20 mL of EtOAc and washed twice with 20 mL of 
saturated NaHCO3 and twice with 20 mL of 0.05 M HCl. The organic layer was dried over 
MgSO4, filtered, and concentrated. The residue was purified by flash chromatography to give 








(4.84). Sulfonamide 4.82 (305 mg, 0.42 mmol, 1 equiv) and 30 mg of palladium 10 wt% on 
carbon were placed in 1 mL of DCM, 4 mL of MeOH and 1 mL of TES. The mixture is cooled 
to 0 °C and TFA (77 µL, 114 mg, 1.00 mmol, 2.4 mmol) was added dropwise. The mixture was 
stirred for 30 minutes until complete by TLC and then filter with a plug of celite. 10 mL of 10% 
Na2CO3 was added and then the reaction was extracted three times with DCM. The combined 
organic layers were dried over MgSO4, filtered and concentrated. The residue was dissolved in 
10 mL of DMF and DIPEA (261 µL, 1.5 mmol, 3.6 equiv) and Ac-Pro-Ser(Bn)-OH (258 mg, 
0.75 mmol, 1.8 equiv) were added. The mixture was cooled to – 40 °C and then DPPA (160 µL, 
0.75 mmol, 1.8 equiv) was added. The reaction was stirred for 16 hours while warming slowly to 
0 °C. The reaction was quenched with 20 mL of 10% citric acid and the mixture was extracted 5 
times with 20 mL of EtOAc. The combined organic layers were dried over MgSO4, filtered, and 
concentrated. The residue was purified by flash chromatography, 10 to 90% EtOAc in hexane to 
give 280 mg of a white solid (83% yield). 19F NMR showed that a minor rotamer accounted for 
approximately 10% of the mixture. 1H NMR (CDCl3, 300 MHz): δ 7.44 (d, 1H, J = 7.2 Hz), 7.29 
(s, 5H), 7.09 (d, 4H, J = 8.6 Hz), 6.79 (d, 4H, J = 8.6 Hz), 5.1 (d, 1H, J = 7.5 Hz), 4.9 (m, 1H), 
4.78 (m, 1H), 4.49 (m, 3H), 4.32 (s, 4H), 4.11 (m, 1H), 3.77 (s, 6H), 3.55 (m, 6H), 2.02 (m, 
11H); 13C {1H}NMR (CDCl3, 75 MHz): δ 173.0, 171.4, 170.7, 159.2, 137.6, 130.2, 128.4, 127.7, 
127.7, 127.0, 122.6 (dd, J = 292.4, 287.6 Hz), 113.8, 73.7 (dd, J = 23.7, 21.3 Hz), 73.4, 70.0, 





δ (major rotamer) -104.3 (d, 1F, J = 241.4 Hz), -114.8 (dd, 1F, J = 241.5, 18.0 Hz); (minor 
rotamer) -104.8 (dd, 1F, J = 242.0, 20.0 Hz), -113.2 (dd, 1F, J = 243.2, 18.5 Hz); HRMS-ESI+ 
(m/z) calcd for C39H49F2N4O9S
+ (M + H)+ 787.3183, found 787.3192. 
 
(Ac-Pro-O3-benzyl-Ser(Bn)-Prolinolyl)difluoromethanesulfonamide (4.86). Sulfonamide 4.84 
(78 mg, 0.1 mmol, 1.0 equiv) was dissolved in 10 mL of CH3CN and cooled to -20 °C then CAN 
(438 mg, 0.80 mmol, 8.0 equiv) was added as a solution in 4 mL of water. The mixture was 
stirred overnight at 0 °C then was quenched with 50 mL of brine and 50 mL of 10% citric acid. 
The product was extracted 3 times with 50 mL of EtOAc then the combine organic layers were 
dried over MgSO4, filtered and concentrated. The residue was purified by flash chromatography 
to give 51 mg of a white foam (93% yield). This was judged to be > 90% pure by analytical RP-
HPLC HRMS-ESI+ (m/z) calcd for C23H31F2N4O7S
+ (M + H)+ 545.1876, found 545.2045. See 
Appendix Figures A23 and A24 for copies of data. 
 
N,N-bis(4-methoxybenzyl)-1-(Val-prolinyl)-1,1-difluoromethanesulfonamide (4.87). Sulfonamide 
4.82 (710 mg, 1 mmol, 1 equiv) was dissolved in 10 mL of DCM, 10 mL of MeOH and 4 mL of 
triethylsilane were added followed by 71 mg Pd 10 wt% on carbon. The mixture was cooled in 





mixture was then stirred at room temperature for 30 minutes until complete by TLC (20% EtOAc 
in hexane) and filtered using a pad of celite. 20 mL of 5% Na2CO3 was added and the mixture 
was extracted three times with 10 mL of DCM. The combined organic layers were dried over 
MgSO4 filtered and concentrated yielding solid which consisted of the desired free amine and 9-
phenylfluorene. Separately Z-Val-OH (3 mmol, 753 mg, 3 equiv) and HOAt (408 mg, 3 mmol, 3 
equiv) were dissolved in 30 mL of DCM and EDC·HCl (576 mg, 3 mmol, 3 equiv) was added 
the mixture was stirred for 15 minutes at room temperature yielding a clear colorless solution 
which was added to the free amine. This was stirred until complete by TLC (1h) then 400 µL of 
Tris(2-aminoethyl)amine was added and stirred for 15 minutes to destroy excess activated ester. 
The mixture was then diluted with 200 µL of EtOAc and washed with 100 mL of 10% citric 
acid, 100 mL of 5% Na2CO3 and 100 mL of brine then dried over MgSO4 filtered and 
concentrated. The residue was purified by flash chromatography using a gradient of 20 to 80% 
EtOAc in hexane to give 410 mg of a white foam (58% yield). 1H NMR (CDCl3, 300 MHz): δ 
7.35 (m, 5H), 7.12 (d, 4H, J = 8.7 Hz), 6.82 (d, 4H, J = 8.7 Hz), 5.50 (d, 1H, J = 8.7 Hz), 5.08 
(m, 3H), 4.80 (m, 1H), 4.35 (m, 5H), 4.15 (m, 1H), 3.82, (m, 1H), 3.80 (s, 6H), 3.59 (m, 1H), 
2.04 (bs, 5H), 1.03 (d, 3H, J = 6.7 Hz), 0.96 (d, 3H, J = 6.7Hz); 13C {1H} NMR (CDCl3, 75 
MHz): δ ν(F1) [ppm] 175.3, 159.3, 156.5, 136.4, 130.2, 128.5, 128.1, 127.9, 126.9, 12.6 (dd, J = 
292.9, 288.0 Hz), 113.9, 74.0 (dd, J = 23.1, 21.7 Hz), 66.8, 57.9, 57.8, 55.2, 50.5, 47.6, 31.3, 
27.8, 27.8, 24.3, 19.3, 17.7; 19F NMR (CDCl3, 282 MHz): δ -114.0 (dd, 1F, J = 241.0Hz, 17.7 
Hz), -104.5 (d, 1F, J = 241.1 Hz); HRMS-ESI+ (m/z) calcd for C35H44N3O8SF2
+
 (M + H)
+ 







(4.88). Dipeptide 4.87 (251 mg, 0.357 mmol, 1 equiv) was dissolved in 10 mL of MeOH and 25 
mg of Pd(OH)2 20 wt% on carbon was added. The mixture was stirred under hydrogen 
atmosphere for one hour, then was filtered with a pad of celite and concentrated. Separately, 
Cbz-Asp(OtBu)-OH (345 mg, 1.07 mmol, 3 equiv) and HOAt (145 mg, 1.07 mmol, 3 equiv) 
were placed in 15 mL of DCM and cooled to 0 °C. EDC·HCl (205 mg, 1.07 mmol, 3 equiv) and 
the mixture was stirred for 15 minutes, then added to the free amine. This reaction was stirred for 
2 hours at room temperature then 250 µL of Tris (2-aminoethyl)amine was added and stirred 5 
minutes to destroy any unreacted HOAt ester. The reaction was diluted with 100 mL of EtOAc 
and washed with 50 mL of 10% citric acid, 50 mL of 10% Na2CO3, 50 mL of brine, then the 
organic layer was dried over MgSO4, filtered, and concentrated. The residue was purified by 
flash chromatography, 50 to 100% EtOAc in hexane. To give 4.88 as 125 mg of a white solid 
(40% yield). A minor epimer or rotamer was observed by 19F NMR which comprised 6% of the 
mixture. 1H NMR (CDCl3, 300 MHz): δ 7.38 (m, 5H), 7.14 (m, 5H), 6.84 (d, 4H, J = 8.7 Hz), 
6.06 (d, 1H, J = 8.7 Hz), 5.16 (s, 2H), 5.11 (d, 1H, J = 8.1 Hz), 4.8 (m, 1H), 4.59 (m, 2H), 4.41 
(d, 2H, J = 15.0 Hz), 4.32 (d, 2H, J = 15.1 Hz), 4.17 (m, 1H), 3.81 (s, 6H), 3.60 (m, 1H), 2.96 
(dd, 1H, J = 17.1, 4.3 Hz), 2.63 (dd, 2H, J = 17.1, 5.8 Hz), 2.07 (m, 2H), 1.44 (s, 9H), 1.01 (d, 
3H, J = 6.7 Hz), 0.94 (d, 3H, J = 6.7 Hz); 13C {1H} NMR (CDCl3, 75 MHz): δ 174.6, 171.1, 
170.5, 159.3, 156.1, 136.0, 130.2, 128.6, 128.3, 128.2, 126.9, 122.5 (dd, J = 292.7, 287.7 Hz), 
113.9, 81.8, 74.3 (apparent triplet, J = 22.3 Hz), 67.3, 57.7, 56.0, 55.2, 51.4, 50.4, 47.6, 37.1, 
31.5, 27.9, 27.9, 24.3, 19.3, 17.5; 19F NMR (CDCl3, 282 MHz): δ (Major)-104.4 (d, 1F, J = 





112.0 (dd, 3F, J = 242.7, 16.5 Hz), HRMS-ESI+ (m/z) calcd for C43H56F2N4NaO11S
+(M + Na)+ 
897.3527, found 897.3504. 
 
N,N-bis(4-methoxybenzyl)-1-(Ac-Asp-Val-prolinyl)-1,1-difluoromethanesulfonamide (4.89). 
Tripeptide 4.88 (251 mg, 0.287 mmol, 1 equiv) was dissolved 10 mL of MeOH and 25 mg of 10 
wt % Pd(OH)2 on carbon was added. The mixture was stirred under an atmosphere of hydrogen 
until complete by TLC then was filtered through a pad of celite and concentrated. The residue 
was dissolved in 10 mL of DCM and 200 µL of acetic anhydride. After two hours no reaction 
had occurred as judged by TLC and an additional 200 µL of acetic anhydride was added 
followed by 300 µL of Et3N. The mixture was stirred overnight and then the reaction mixture 
was placed on a silica column and eluted with EtOAc and concentrated to give a mixture of 
mono- and di- acylated material as judged by LRMS. (the second acylation occurring on the 
hydroxyl group which is ß-to the sulfonamide). The undesired acylation was removed by 
treatment with 10 mL of a 0.1 M solution of LiOH in 1:1 H2O:THF for 6 hours at room 
temperature. The crude material was then neutralized with minimal 1 M HCl and concentrated. 
The residue was dissolved in 5 mL of 95:5:5 TFA:TIPS:H2O at 0 °C and stirred for 1 hour then 
was diluted in 50 mL of heptane and concentrated. The residue was subjected to flash 
chromatography, 0 to 10% MeOH in EtOAc (1% AcOH). Fractions containing product were 
further purified by RP-HPLC using a gradient of 30 to 70% CH3CN in 0.1% TFA:H2O over 50 
minutes (retention time = 35 min). This gave 103 mg of 4.89 as a white solid (49% yield). A 





12% of the mixture. 1H NMR (CDCl3, 500 MHz): δ 7.15 (d, 1H, J = 6.1 Hz), 6.78 (d, 1H, J = 
5.7 Hz), 6.62 (d, 4H, J = 6.4 Hz), 6.4 (d, 4H, J = 6.4 Hz), 4.95 (m, 1H), 4.81 (m, 1H), 4.67 (t, 
1H, J = 6.1 Hz), 4.5 (m, 4H), 4.14 (m, 1H), 4.08 (s, 6H), 3.93 (bs, 1H), 3.4 (dd, 1H, J = 12.7, 3.5 
Hz), 3.28 (dd, 1H, J = 12.6, 4.5 Hz), 2.74 (m, 8H), 1.92 (d, 3H, J = 5.0 Hz), 1.89 (d, 3H, J = 4.9 
Hz); 13C {1H} NMR (CDCl3, 125 MHz): δ 174.2, 174.1, 171.2, 171.0, 159.3, 130.2, 126.9, 122.8 
(dd, J = 293.4, 287.1 Hz), 113.9, 72.2 (dd, J = 23.6, 20.8 Hz), 58.3, 56.6, 55.3, 50.5, 49.7, 47.8, 
36.5, 31.1, 27.1, 24.1, 22.9, 19.2, 18.0; 19F NMR (CDCl3, 483 MHz): δ (major rotamer) -104.6 
(d, 1F, J = 240.3 Hz), -114.6 (dd, 1F, J = 240.4, 18.9 Hz); (minor rotamer) -104.8 (dd, 1F, J = 
239.6, 26.9 Hz), -111.9 (dd, 1F, J = 242.7 Hz); HRMS-ESI+ (m/z) calcd for C33H45F2N4O10S
+
 (M 
+ H)+ 727.2819, found 727.2800. 
 
1-(Ac-Asp-Val-prolinyl)-1,1-difluoromethanesulfonamide (4.90). Tripeptide 4.89 (103 mg, 
0.1412 mmol, 1 equiv) was dissolved in 10 mL of acetonitrile and cooled to –20 °C then CAN 
(621 mg, 1.13 mmol, 8 equiv) was added as a solution in 4 mL of water. The mixture was stirred 
overnight at 0 °C then 25 mL of 10% citric acid and 25 mL of brine were added. The mixture 
was extracted 5 times with EtOAc. The combined organic layers were dried over MgSO4, 
filtered, and concentrated. The residue was purified by RP-HPLC, 10 to 50% CH3CN in water 
over 50 minutes, retention time = 28 min, yielding 55 mg of a white solid (78% yield). A minor 
rotamer or epimer was observed in 19F NMR which comprised approximately 20% of the 
mixture. Experimental procedure. 1H NMR (MeOD, 300 MHz): δ 7.4 (m, 2H), 4.98 (d, 1H, J = 





16.5, 7.4 Hz), 2.05 (m, 8H), 0.97 (m, 6H); 13C {1H} NMR (MeOD, 75 MHz): δ (major rotamer) 
172.9, 172.4, 172.0, 171.6, 121.1 (dd, J = 291.7, 286.3 Hz), 70.4 (dd, J = 24.5, 20.4 Hz), 58.0, 
56.5, 50.0, 44.9, 35.1, 30.5, 26.6, 23.5, 21.0, 18.4, 16.8, (minor rotamer) 172.5, 172.3, 172.1, 
170.8, 120.8 (ap t, J = 287.1 Hz), 70.9 (t, J = 23.1 Hz), 56.9, 56.4, 50.2, 42.5,, 35.2, 32.6, 
28.7,21.0, 20.5, 17.9, 17.0; 19F NMR (MeOD, 282 MHz): δ (major rotamer) -106.6 (d, 1F, J = 
242.3 Hz), -119.0 (dd, 1F, J = 242.3, 20.6 Hz); (minor rotamer) -101.9 (2, 1F, J = 254.3, 11.6 
Hz), -111.7 (2, 1F, J = 255.5, 6.9 Hz); HRMS-ESI+ (m/z) calcd for C17H29N4O8SF2
+
 (M + H)
+ 
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Appendix — HPLC/HRMS Data of compounds 4.32-4.41, 4.65, and 4.86. 
 
Figure A1. HPLC Chromatogram of Ac-Pro-Ser(Bn)-Pro-pNA (4.32). Gradient 5:95 CH3CN:H2O 
(0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
Figure A2. HRMS data for Ac-Pro-Ser(Bn)-Pro-pNA (4.32). The peak at m/z = 552.24736 
corresponds to the M + H species (m/z) calcd for C28H34N5O7
+ = 552.2453. The peak at m/z 
590.20170 corresponds to the M+K species (m/z) calcd for C28H33KN5O7






Figure A3. HPLC Chromatogram of Ac-Thr-Pro-Ser(Bn)-Pro-pNA (4.33). Gradient 5:95 
CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
Figure A4. HRMS data for Ac-Thr-Pro-Ser(Bn)-Pro-pNA (4.33). The peak at m/z = 653.29248 
corresponds to the M+H species (m/z) calcd for C32H41N6O9
+ = 653.2930. The peak at m/z = 
675.27448 corresponds to the M+Na species (m/z) calcd for C32H40N6NaO9







Figure A5. HPLC Chromatogram of Ac-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.34). Gradient 5:95 
CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
 
Figure A6. HRMS data for Ac-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.34). The peak at m/z = 750.34760 
corresponds to the M+H peak (m/z) calcd for C37H48N7O10
+ = 750.3457. The peak at m/z = 
772.32947 corresponds to the M + Na species (m/z) calcd for C37H47N7NaO10
+ = 772.3277. The 








Figure A7. HPLC Chromatogram of Ac-Pro-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.35). Gradient 5:95 
CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
Figure A8. HRMS data for Ac-Pro-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.35). The peak at m/z = 
853.41042 corresponds to the M+Li species (m/z) calcd for C42H54LiN8O11







Figure A9. HPLC Chromatogram of Ac-Thr-Pro-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.36). Gradient 5:95 
CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
Figure A10. HRMS data for Ac-Thr-Pro-Pro-Thr-Pro-Ser(Bn)-Pro-pNA (4.36). The peak at m/z = 
948.45538 corresponds to the M+H species (m/z) calcd for C46H62N9O13
+= 948.4462. The peak at 








Figure A11. HPLC Chromatogram of Ac-Asp-Val-Pro-pNA (4.37). Gradient 5:95 CH3CN:H2O 
(0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
 
Figure A12. HRMS data for Ac-Asp-Val-Pro-pNA (4.37). The peak at m/z = 492.20948 corresponds 
to the M+H species (m/z) calcd for C22H30N5O8
+ = 492.2089. The peak at m/z = 493.2146 
corresponds to the M+D species (m/z) calcd for C22H29DN5O8+ = 493.2152. The peak at m/z = 
514.195 corresponds to the M+Na species (m/z) calcd for C22H29N5NaO8
+ = 514.1908. The peak 









Figure A13. HPLC Chromatogram of Ac-Ala-Asp-Val-Pro-pNA (4.38). Gradient 5:95 CH3CN:H2O 
(0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
Figure A14. HRMS data for Ac-Ala-Asp-Val-Pro-pNA (4.38). The peak at m/z = 585.22894 
corresponds to the M+Na species (m/z) calcd for C25H34N6NaO9







Figure A15. HPLC Chromatogram of Ac-Gln-Ala-Asp-Val-Pro-pNA (4.39). Gradient 5:95 
CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
Figure A16. HRMS data for Ac-Gln-Ala-Asp-Val-Pro-pNA (4.39). The peak at m/z = 691.30719 
corresponds to the M+H species (m/z) calcd for C30H43N8O11







Figure A17. HPLC Chromatogram of Ac-Ile-Gln-Ala-Asp-Val-Pro-pNA (4.40). Gradient 5:95 
CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
Figure A18. HRMS data for Ac-Ile-Gln-Ala-Asp-Val-Pro-pNA (4.40). The peak at m/z = 826.37467 
corresponds to the M+Na species (m/z) calcd for C36H53N9NaO12







Figure A19. HPLC Chromatogram of the attempted synthesis of Ac-Asn-Ile-Gln-Ala-Asp-Val-Pro-
pNA (4.41). Gradient 5:95 CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 40 
min. (λ = 220 nm). 
 
Figure A20. HRMS data for Ac-Asn-Ile-Gln-Ala-Asp-Val-Pro-pNA (4.41). The peak at 940.42493 
corresponds to the M+Na species (m/z)calcd for C40H59N11NaO14






Figure A21. HPLC Chromatogram of compound 4.65. Gradient 50:50 CH3CN:H2O (0.1% TFA) to 
100:0 CH3CN:H2O over 40 min. (λ = 220 nm). 
 
Figure A22. HRMS data for compound 4.65. The peak at m/z = 1000.39754 corresponds to the 
M+H species (m/z) calcd for C52H60F2N5O11S
+ = 1000.3973. The peak at m/z = 1018.40771 
corresponds to the M+H2O+H species (m/z) calcd for C52H62F2N5O12S
+ = 1018.4078. The peak 
at m/z = 1022.37921 corresponds to the M+Na species (m/z) calcd for C52H59F2N5NaO11S
+ = 
1022.3792. The peak at m/z = 1038.35333 corresponds to the M+K species (m/z) calcd for 
C52H59F2N5O11SK
+ = 1038.3531. The peak at m/z = 1056.36431 corresponds to the M+H2O+K 
species (m/z) calcd for C52H61F2N5O12SK







Figure A23. HPLC Chromatogram of compound 4.86. Gradient 10:90 CH3CN:H2O (0.1% TFA) to 
90:10 CH3CN:H2O (0.1% TFA) over 40 min. (λ = 220 nm). 
 
Figure A24. HRMS data for compound 4.86. The peak at m/z = 547.20450 corresponds to the 
M+H species (m/z) calcd for C23H33F2N4O7S
+= 547.2033. The peak at m/z = 459.18618 
corresponds to the M+Na species (m/z) calcd for C23H32F2N4O7NaS
+= 569.1852. 
 
